Annual Reports in
MEDICINAL CHEMISTRY VOLUME
44 Sponsored by the Division of Medicinal Chemistry of the American Chemical Society Editor-in-Chief
JOHN E. MACOR Neuroscience Discovery Chemistry Bristol-Myers Squibb Wallingford, CT, United States Section Editors ROBICHAUD STAMFORD BARRISH MYLES PRIMEAU LOWE DESAI
Amsterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore Sydney Tokyo Academic Press is an imprint of Elsevier
ACADEMIC PRESS
Academic Press is an imprint of Elsevier Linacre House, Jordan Hill, Oxford OX2 8DP, UK 84 Theobald’s Road, London WC1X 8RR, UK Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA
First edition 2009 Copyright r 2009 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email:
[email protected]. Alternatively you can submit your request online by visiting the Elsevier web site at http://www.elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. ISBN: 978-0-12-374766-2 ISSN: 0065-7743 For information on all Academic Press publications visit our web site at www.elsevierdirect.com
Printed and bound in USA 09 10 11 12 13
10 9 8 7 6 5 4 3 2 1
CONTRIBUTORS
Neel K. Anand
339
James N. Leonard
149
Jan D. Andersson
501
Shawn Maddaford
27
Subhash C. Annedi
27
Ju¨rgen Maibaum
105
Gregory S. Bisacchi
379
Carl L. Manthey
211
Robert M. Borzilleri
301
Dennis J. McCarthy
501
Bruce D. Car
555
Nicholas A. Meanwell
397
Karen Miller-Moslin
323
Terry W. Moore
443
Bernard P. Murray
535
379
John M. Nuss
339
Charles S. Elmore
515
Brian T. O’Neill
David L. Feldman
105
Stefan Peukert
323
William R. Foster
555
M. Edward Pierson
501
Robert G. Gentles
3
William J. Pitts
247
Christer Halldin
501
Mark R. Player
211
Sangdon Han
227
Mimi L. Quan
189
51
Suman Rakhit
27
Jotham W. Coe John Gaetano D’Angelo Gene M. Dubowchik Jacques Dumas
Simon N. Haydar
71 359 3
71
Shridhar Hegde
577
Jailall Ramnauth
27
Christopher Paul Hencken
359
Hans Rollema
71
Warren D. Hirst
51
Stefan U. Ruepp
555
Shuanghua Hu
3
Thomas Ryckmans
129
Arthur T. Sands
475
397
Michelle Schmidt
577
Alvin Solomon Kalinda
359
Paul M. Scola
397
Rao Kalla
265
Joanne M. Smallheer
189
John A. Katzenellenbogen
443
Roland G.W. Staal
Robert M. Jones John F. Kadow
149, 227
51
xv
xvi
Contributors
Nicole van Straten
171
Dolatrai M. Vyas
281
Jayant Thatte
227
Stephen T. Wrobleski
247
Thomas N. Thompson
459
Mark D. Wittman
281
Marco Timmers
171
Heedong Yun
51
Amy Lew Tsuhako
339
Jeff Zablocki
265
Upender Velaparthi
281
Brian P. Zambrowicz
475
Gregory D. Vite
301
PREFACE
Annual Reports in Medicinal Chemistry has reached Volume 44. I hope that it continues to be the review resource for medicinal chemists. Volume 44 continues the traditions of Annual Reports in Medicinal Chemistry with 28 chapters covering the themes of central nervous system disease, cardiovascular and metabolic diseases, inflammation/pulmonary/gastrointestinal (GI), oncology, infectious disease, topics in biology, topics in drug design and discovery and finally our review of new drugs introduced in 2008 in the ‘‘To Market, To Market’’ section. I am particularly pleased that Volume 44 contains three case histories detailing the discovery and development of varenicline for smoking cessation, aliskerin for hypertension and ixabepilinone for cancer. We will continue to seek case histories for future volumes because I believe these successes are some of the most instructive stories in medicinal chemistry. It is also gratifying to see the breadth of the sources of the reviews in Volume 44. My colleagues at Bristol-Myers Squibb continue to embrace the series with seven contributions in Volume 44. Scientists from Pfizer and AstraZeneca each contributed three chapters to Volume 44, while Arena Pharmaceuticals and Novartis each contributed two chapters. Wyeth, Neuraxon, Schering-Plough, Johnson&Johnson, CV Therapeutics, Exelixis, Lexicon Pharmaceuticals and Gilead scientists each contributed one chapter to Volume 44. Finally, chapters from Alfred University, the University of Illinois and an individual consultant completed the line up for Volume 44. I will continue to look to increase the diversity of contributing organizations and urge those organizations with significant medicinal chemistry resources who have not contributed recently to ‘‘step up to the plate’’ and contribute to this community resource known as Annual Reports in Medicinal Chemistry. Although we all worry about the mergers and resulting contractions of medicinal chemistry departments, we remain a vibrant science, and I am confident that Annual Reports in Medicinal Chemistry will continue to receive the quality contributions that have defined this series for over 40 years. Putting together Annual Reports in Medicinal Chemistry is a team effort of volunteers, starting with the chapter authors themselves. I thank the contributors to Volume 44 for their dedication and talent. Helping bring
xvii
xviii
Preface
this all together are the Section Editors: Joel Barrish, Manoj Desai, John Lowe, David Myles, John Primeau, Albert Robichaud and Andrew Stamford. I thank them for yet another seamless quality effort. Helping them and me were a team of reviewers/proof readers that have done a spectacular job behind the scenes as well. I acknowledge these reviewers/proof readers by listing their names below as a demonstration of our appreciation for their time and effort. AstraZeneca — Mike Barbachyn and Brian Sherer Bristol-Myers Squibb — Stephen Adams, Joanne Bronson, James Corte, Andrew Degnan, Murali Dhar, Douglas Dischino, James Duan, Carolyn Dzierba, Rick Ewing, Matthew Hill, John Hynes, George Karageorge, Lawrence Marcin, Ivar McDonald, Harold Mastalerz, Michael Miller, Natesan Murugesan, Richard Olson, Kenneth Santone, Michael Sinz, Lawrence Snyder, John Starrett, Drew Thompson, Dolatrai Vyas, Michael Walker and Christopher Zusi Gilead Sciences — Randall Halcomb, Richard Mackman and Will Watkins Novartis — Lawrence Hamann Pfizer — Joe Brady and Joel Morris Schering-Plough — Brian McKittrick Wyeth — Jonathan Gross, Steven O’Neil and Dane Springer Finally, I also acknowledge Shridhar Hedge and Michelle Schmidt for compiling the ‘‘To Market, To Market’’ review once again. I see that section as one of the consistent highlights of the book. And last, I also thank Ms. Catherine Hathaway, my Administrative Assistant, who always keeps things on an even keel. In summary, I hope that Volume 44 of Annual Reports in Medicinal Chemistry continues to be a key reference for your medicinal chemistry pursuits. As Editor-in-Chief, I continue to look for ways to optimize, improve and evolve the series. Please do not hesitate to contact me with suggestions for improving the series (
[email protected]). Thank you. John E. Macor Bristol-Myers Squibb, R&D, Wallingford, CT, USA
CHAPT ER
1 Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer’s Disease Robert G. Gentles, Shuanghua Hu and Gene M. Dubowchik
Contents
1. 2. 3. 4.
Introduction Etiology of Alzheimer’s Disease Principal Functions of GSK-3 Additional Neuroprotective Indications for GSK-3 Inhibition 5. Selective Functional Inhibition of GSK-3 6. GSK-3 Isoforms 7. GSK-3 Crystal Structures 8. Challenges in the Development of Effective GSK-3 Inhibitors 9. Advances in GSK-3 Inhibitors 9.1 Indirubins 9.2 Maleimides 9.3 Organometallic GSK-3 inhibitors 9.4 Thiadiazolidinones: noncompetitive GSK-3 inhibitors 9.5 Established drugs with GSK-3 inhibitory properties 9.6 Miscellaneous chemotypes 10. Conclusion References
3 4 5 7 8 9 9 9 10 11 13 14 18 19 20 22 22
Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04401-7
r 2009 Elsevier Inc. All rights reserved.
3
4
Robert G. Gentles et al.
1. INTRODUCTION Alzheimer’s disease (AD) is the seventh leading cause of death in the United States and the fifth leading cause of mortality in people over the age of 65. Currently more than 5 million suffer from the condition and this number is expected to grow significantly with progressive aging of the population, rising to between 11 and 16 million affected individuals by 2050 [1]. It is estimated that the cost of treating AD and other dementias currently exceeds $148 billion annually in direct and indirect costs, and this is expected to increase dramatically with projected demographic changes. Current therapies are mostly palliative [2], and there exists a significant unmet medical need in the treatment of this devastating condition. AD is a dementia characterized symptomatically by progressive agerelated memory loss and cognitive impairment. Histopathologically, the disease is defined by neuronal loss, the presence of intracellular neurofibrillary tangles (NFTs), the formation of extracellular senile plaques [3], and the occurrence of cerebral amyloid angiopathy (CAA) [4]. NFTs are composed of aggregated hyperphosphorylated forms of the microtubule-associated protein tau [5]. This aggregation is thought to impair intracellular transport mechanisms [6] and may result in neuronal dystrophy [7]. Extracellular plaques are composed of precipitated amyloid beta-peptide (Ab) and are frequently associated with activated microglia, inflammation, and neuronal atrophy [8]. In CAA, Ab is deposited in cerebral arteries where it is associated with increased risk of hemorrhagic stroke [9,10].
2. ETIOLOGY OF ALZHEIMER’S DISEASE The most long-considered theory on the cause of AD is the ‘‘amyloid cascade hypothesis’’ [3,11]. This posits that Ab overproduction leads directly to the formation of senile plaques and CAA [12,13]. The presence of significant degenerative neuronal processes in the area of plaques, and the death of smooth muscle cells in the vicinity of the Ab deposits in cerebral arteries, is highly suggestive of the toxicity of the Ab peptide [14,15]. Additionally, areas of the brain most significantly affected in AD show co-localization between Ab plaques and neuronal cell death [16]. There has been much discussion on the exact form of Ab that may be noxious [17]. Experiments have shown that under some conditions fibrillation of Ab is required to observe neurotoxic effects [18,19]. However, at present, the exact toxic species of Ab has yet to be unambiguously identified.
Recent Advances in the Discovery of GSK-3 Inhibitors
5
An additional aspect of Ab pathology is its induction of hyperphosphorylation of tau [20]. This is thought to be primarily mediated through the activation of glycogen synthase kinase-3 (GSK-3), which has been shown to be responsible for the phosphorylation of key tau epitopes known to be relevant in AD [21,22]. Hyperphosphorylated tau disengages from microtubules, resulting in their structural destabilization with concomitant negative effects on intracellular structures and transport mechanisms [6]. In addition, the uncomplexed hyperphosphorylated tau assembles into paired helical filaments (PHFs) that aggregate to produce the stereotypic intracellular NFTs associated with AD [23,24]. It should be noted that other kinases such as CDK5 are also known to hyperphosphorylate tau and have also been pursued as therapeutic targets [25]. A recently proposed alternative theory to the amyloid cascade hypothesis postulates that GSK-3 may play a more instigative role in the etiology of AD [26]. It has been suggested that aberrant wnt or insulin signaling results in increased GSK-3 function [27–29] and this is responsible for the observed hyperphosphorylation of tau and the formation of PHFs and NFTs. In addition, elevated GSK-3 activity may induce increased Ab formation through its action on g-secretase [30,31], and thereby give rise to the primary stereotypic pathology observed in AD. GSK-3 has also been demonstrated to be involved in mechanisms underlying memory and learning, and dysregulation of GSK-3 function may explain some of the early cognitive deficiencies observed in AD [26]. However, some recent research has suggested the potential for the induction of behavioral deficits if constitutive GSK-3 activity is overly suppressed [32]. While these hypotheses continue to be challenged, refined, and even reconsidered, there are currently no definitive refutations of either theory. Consequently, it seems reasonable to pursue therapeutic approaches focused both on the direct modulation of Ab levels and on the inhibition of GSK-3. Ultimately, the successful treatment of AD may require that multiple treatment options be explored in different patient populations, and that differently targeted therapeutics be exploited either sequentially or in combination.
3. PRINCIPAL FUNCTIONS OF GSK-3 GSK-3 is a proline-directed serine/threonine kinase. It effects the phosphorylation of a range of substrates and is involved in the regulation of numerous diverse cellular functions, including metabolism [33,34], differentiation, proliferation, and apoptosis [35]. GSK-3 is constitutively active, with its basal level of activity being positively modulated by
6
Robert G. Gentles et al.
phosphorylation on Tyr216 [36]. GSK-3 has a unique substrate selectivity profile that is distinguished by the strong preference for the presence of a phosphorylated residue optimally located four amino acids C-terminal to the site of GSK-3 phosphorylation [37]. Most commonly, GSK-3 activity is associated with inducing a loss of substrate function, such that GSK-3 inhibition will frequently result in increased downstream activity. GSK-3 is widely distributed in the brain [38,39] and as discussed above, a principal consequence of its dysregulation is the hyperphosphorylation of the microtubule-associated protein tau [20], as depicted in the bottom-right panel of Figure 1. This function of GSK-3 has been demonstrated both in cell culture [40] and in in vivo studies looking at tau phosphorylation [41] and NFT formation [22,42]. The exact form of GSK3 (complexed or free) responsible for the phosphorylation of tau has not been characterized.
GSK-3: Discrete Cellular Pools Wnt Pathway Non-Stimulated
P
P
P
P
P
P
β-Catenin P
IRS
P
P
AXIN
P
P
CK1
GSK-3
P P
β-Catenin β-Catenin β-Catenin
Z
Glycogen Z Synthase
APC
AXIN
P
GSK-3 Glycogen Synthase
Tau
PKB
Z Phosphatases
Phosphorylation of Tau
Microtubule
P
GSK-3 FRAT
PDK1
PI3K
APC
GSK-3
P
Wnt Pathway Stimulated
Insulin Signaling Pathway
Insulin
β-Catenin
GSK-3
P
Microtubule
Microtubule
P
P
CK1 Disassembles
PHF’s
NFT’s
Figure 1 Key elements in the primary cellular pathways involving GSK-3 discussed in this review. APC, adenomatous polyposis coli; CK1, casein kinase 1; IRS, insulin receptor substrate; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PDK1, phosphoinositide-dependent kinase-1. (See Color Plate 1.1 in Color Plate Section.)
Recent Advances in the Discovery of GSK-3 Inhibitors
7
GSK-3 is also known to play a key role in glucose metabolism, and was first identified as the enzyme responsible for effecting the inhibitory phosphorylation of glycogen synthase [43], the result of which is to reduce the rate of conversion of glucose to glycogen, giving rise to elevations in blood glucose levels. This function of GSK-3 is controlled by insulin, operating through the signaling pathway [44] shown in the topright panel of Figure 1. The net effect of this cellular cascade is inhibition of GSK-3 by a process that exploits features of the substrate selectivity mechanism described above. Binding of insulin to its receptor leads indirectly to the activation of protein kinase B (PKB) and subsequent phosphorylation of a key serine residue in the N-terminal domain of GSK-3 [45]. The phosphorylated N-terminus functions as a pseudosubstrate, folding in a manner such that it occupies the substrate-binding cleft [46,47]. This conformation is stabilized by interactions between the phosphorylated serine and residues on the enzyme that constitute the substrate selectivity pocket. An unrelated mechanism of GSK-3 inhibition operates in the wntsignaling cascade, a cellular pathway involved in controlling cell-fate, differentiation, and proliferation [48,49]. In this system, GSK-3 is complexed with APC, axin, and b-catenin, as well as other proteins [50], as depicted in the top-left panel of Figure 1. This protein assembly is occasionally termed the ‘‘destruction complex’’. When the wnt system is in a non-stimulated state, GSK-3 phosphorylates axin and APC, the effect of which is to create a more tightly associated complex. CK1, which is also associated with this protein assembly, functions in one capacity as a priming kinase for GSK-3 by performing an initial phosphorylation of b-catenin [51]. This protein is then poly-phosphorylated by GSK-3, resulting in its dissociation from the complex and its subsequent ubiquitination and destruction by the proteosome [52], thereby regulating cellular levels of b-catenin [53,54]. However, following binding of wnt ligands to their receptors, axin is displaced from the complex with GSK-3 as a result of binding of the latter to FRAT (frequently rearranged in advanced T-cell lymphomas) peptide [55], see bottom-left panel of Figure 1. This leads to the dissociation of the destruction complex, the consequence of which is that b-catenin is no longer effectively phosphorylated and degraded. Consequently, intracellular concentrations of the protein rise, and there is increased trafficking of b-catenin to the nucleus [56] where it interacts with transcription factors that induce increased expression of wnt regulated genes, which, among other things, are operative in certain neoplastic transformations. It is interesting to note that no crossover in these inhibition mechanisms is thought to occur: GSK-3 mediated phosphorylation of axin and b-catenin is not inhibited by a phosphorylated hexapeptide that is effective at inhibiting GSK-3 phosphorylation of primed substrates
8
Robert G. Gentles et al.
[37], suggesting that N-terminal serine phosphorylation is not operative in controlling GSK-3 activity within the destruction complex. In addition, wnt signaling does not affect the phosphorylation state of uncomplexed GSK-3 [57]. Correspondingly, the effects of insulin or wnt signaling would appear to be limited to discrete cellular pools of GSK-3, the significance of which is discussed below.
4. ADDITIONAL NEUROPROTECTIVE INDICATIONS FOR GSK-3 INHIBITION GSK-3 has been demonstrated to be involved in apoptosis regulation, and it has been suggested that its inhibition can have neuroprotective effects distinct from prevention of tau hyperphosphorylation. Mitochondria, for example, have been found to be susceptible to unregulated GSK-3 activity, resulting in Parkinson’s disease (PD)-like effects [58]. In addition, GSK-3 inhibition can attenuate apoptosis resulting from MPP+ and rotenone challenges that mimic PD neuronal pathology [58]. GSK-3 inhibition has also been implicated as a target for amyotrophic lateral sclerosis (ALS). Highly phosphorylated tau protein, along with upregulated GSK-3 has been observed in ALS with cognitive impairment [59]. A recent study has shown that chronic lithium dosing (vide infra) to ALS patients (2 150 mg/day) significantly delayed disease progression and increased survival time in comparison with those taking riluzole, a neuroprotective agent. In addition, lithium was shown by the same group to be protective in a mutant superoxide dismutase 1 (SOD1) model of ALS [60]. Clinical trials with lithium (alone, and in combination with riluzole) in ALS are ongoing [61].
5. SELECTIVE FUNCTIONAL INHIBITION OF GSK-3 It is apparent that inhibition of GSK-3 may be associated with significant mechanism-based toxicities, potentially ranging from hypoglycemia to tumorigenesis. To successfully develop a GSK-3 inhibitor it may be necessary to identify agents that can selectively inhibit specific cellular functions of GSK-3. How might this be realized? One potential mechanism could involve targeting or obviating the inhibition of the discrete cellular pools described above. It is conceivable that this could be achieved by exploiting subtle differences in the structures of GSK-3 that might arise when the enzyme is associated within different protein assemblies, or when the enzyme is in an uncomplexed form. Alternatively, if inhibitors can be identified that interact in the vicinity of
Recent Advances in the Discovery of GSK-3 Inhibitors
9
the ATP-binding site it may be possible to achieve substrate-selective inhibition as has been observed in the development of gamma secretase inhibitors [62]. Hypothetically, the identification of allosteric inhibitors [63] could afford very different and potentially unique functionally selective inhibition profiles [63], as could the development of isoform-selective GSK-3 inhibitors (vide infra). To date, the primary literature is devoid of such information but it might safely be assumed that acquisition of data of this type is a feature of many preclinical programs.
6. GSK-3 ISOFORMS GSK-3 exists in two isoforms, GSK-3a (51 kDa) and GSK-3b (47 kDa), that share 84% overall identity and greater than 98% identity within their respective catalytic domains [64,65]. A minor splice variant of GSK-3b, denoted as GSK-3b2, has been reported [66]. This isoform has a 13-amino-acid insert within its kinase domain and displays reduced activity toward tau protein. It has been found by immunohistochemistry to be localized predominantly in cell soma, unlike GSK-3b that is found extensively in neuronal processes. Both primary isoforms are ubiquitously expressed [67,68], with particularly high levels observed in the brain and testes. In most brain areas, GSK-3b is the predominant isoform and has become of primary interest as a CNS target. However, it should be noted that some studies suggest that GSK-3a and GSK-3b share very similar, if not entirely redundant functions in a number of cellular processes [69]. Therefore, the utility of an isoform-selective inhibitor could be determined by the particular cellular function targeted, as well as the relative isoform expression levels in the tissue of interest.
7. GSK-3 CRYSTAL STRUCTURES The crystal structure of GSK-3 has been reported [46], as have structures of GSK-3 complexed to components of the wnt-signaling pathway [50]. All these data have provided insight into the mechanism of action of this kinase, the nature of its substrate selectivity, and the unique mechanism of inhibition effected through phosphorylation of the N-terminal serine residue [70]. In addition, a number of co-crystal structures have been published of GSK-3 bound to a diverse set of active site inhibitors [71–73]. These data have been exploited in improving the intrinsic potency of these ligands, as well as suggesting pathways for improved kinase selectivity profiles. More recently, these crystal structures have
10
Robert G. Gentles et al.
been employed in a variety of virtual screening protocols directed at the identification of novel GSK-3 inhibitors [74,75].
8. CHALLENGES IN THE DEVELOPMENT OF EFFECTIVE GSK-3 INHIBITORS In common with all kinase-targeted therapeutics, a key issue to be addressed relates to selectivity. This must be sufficient to avoid off-target toxicities, and this may be more important for CNS-targeted drugs than compounds designed for use in oncology, where targeting multiple kinases can occasionally be advantageous. In general, the broader the kinase counter screen used in determining selectivity, the greater the confidence that this problem can be adequately assessed. However, in the extant GSK-3 literature, limited selectivity data are disclosed beyond that related to phylogenetically related kinases. Historically, this can be attributed to technological limitations in large-scale parallel kinase screening. However, recent developments [76] have largely eliminated such restrictions and more extensive kinase counter-screening data are now beginning to be disclosed [77]. A specific issue for the use of GSK-3 inhibitors in AD is the need to access the CNS compartment. Given the polar nature of many kinase inhibitors it would be desirable to include early assessments of blood brain barrier (BBB) permeability and P-glycoprotein (Pgp) substrate potential. In addition, having suitable brain-to-plasma ratios may be a determinant in achieving an adequate therapeutic index by limiting the peripheral exposure required to drive CNS efficacy. Again, few data in this area have been offered, and most reports are limited to the discussion of biochemical activities with limited disclosures of in vivo studies. With regard to mechanism-based toxicities, the primary concern for GSK-3-targeted therapeutics relates to their potential to induce transformation of nonmalignant cells or exacerbate preexisting malignancies through their actions on b-catenin (vide supra). It is worth recalling however, that lithium has been used as a standard therapeutic for the treatment of bipolar disorder since the 1950’s. This agent is a weak GSK-3 inhibitor, exerting its effect through a mixed mechanism of direct inhibition [78] and activation of PKC-a [79], the latter of which leads to increased GSK-3 Ser9/21 phosphorylation. At therapeutic doses, lithium is estimated to achieve B25% inhibition of total GSK-3 activity, and this degree of inhibition has not yet been associated with increased levels of tumorigenesis or deaths from cancer. This is perhaps the most compelling argument for the potential safety of GSK-3 inhibitors.
Recent Advances in the Discovery of GSK-3 Inhibitors
11
9. ADVANCES IN GSK-3 INHIBITORS Over the past 20 years a number of chemical classes of GSK-3 inhibitors have been discovered [80]. More recently, the structural diversity of compounds reported in this area has expanded considerably, especially in the patent literature. However, in light of the preceding discussion we limit ourselves here to a review of GSK-3 inhibitors on which additional data beyond that of the primary enzyme activity have been disclosed, such that the utility of these compounds in the treatment of AD might be better assessed.
9.1 Indirubins The indirubins are a class of natural product bis-indoles that can be isolated from a variety of plant and animal sources, or alternatively, can be relatively easily synthesized from appropriately functionalized indoles and isatins. They have been demonstrated to possess potent kinase inhibition activities, and considerable efforts over a number of years have resulted in the identification of GSK-3-selective analogs [81]. An issue constraining their biological evaluation is their characteristically low aqueous solubility. Recent work has focused on addressing this limitation while attempting to maintain required potency and selectivity profiles. A number of co-crystal structures of indirubins complexed with various kinases have been reported. These have proved valuable in understanding the molecular features that determine affinity and selectivity, and have contributed to the prioritization of vectors that could be exploited for the modulation of off-target and physicochemical properties. In the case of the co-crystal structure of 6-bromo-indirubin-3u-oxime (6BIO) with GSK-3, the principal interactions between the ligand and the enzyme have been identified [82,83]. From the extant structure activity relationship (SAR) data, it is known that bromine at the 6-position of the indirubin core can be a key determinant of selectivity for GSK-3 over the phylogenetically related cyclin-dependent kinases, CDK1 and CDK5. From the co-crystal data this can be rationalized by noting that bulky substituents at position 6 take advantage of the sterically more accommodating ‘‘gatekeeper’’ residue of GSK-3 (Leu132) compared to the more demanding related residue (Phe80) for the cyclin-dependent kinases (CDKs). Furthermore, from this structure it is apparent that the 3u-oxime projects out from a solvent-accessible cavity and would appear to offer a vector from which to extend solubilizing functionality. This supposition was supported in a series of analogs that incorporated a basic moiety appended with a hydrocarbon linker bound to the oxygen atom of the oxime [84]. A diverse range of groups were examined and the molecules were evaluated for potency against GSK-3, CDK1/cyclinB, and CDK5/p25 and for cytotoxicity
12
Robert G. Gentles et al.
in an SH-SY5Y cell line. Compound 1 (GSK-3, IC50 5 nM; CDK1/cyclinB, IC50 600 nM; and CDK5/p25, IC50 500 nM), compound 2 (GSK-3, IC50 11 nM; CDK1/cyclinB, IC50 2,800 nM, and CDK5/p25, IC50 300 nM), and compound 3 (GSK-3, IC50 14 nM; CDK1/cyclinB, IC50 900 nM; and CDK5/ p25, IC50 310 nM), all displayed similar or improved potency and selectivity profiles relative to 6BIO (GSK-3, IC50 5 nM; CDK1/cyclinB, IC50 320 nM; and CDK5/p25, IC50 83 nM), and all were significantly less cytotoxic against an SH-SY5Y cell line. N Br
HO
N
Br
O
N
N HO NH
N H
N H
O 6BIO
O
(1)
N
N N
NH
Br
O
N
Br
O N
N O
O N H (2)
NH O
OH
N H
NH O
(3)
The cellular activity of this compound class was confirmed in a b-catenin reporter assay where 1 (IC50 700 nM) was demonstrated to be approximately equipotent to 6BIO (IC50 300 nM). Additionally, selected compounds also displayed activity in a cell culture luminescence assay of GSK-3-mediated circadian rhythmicity. Importantly, all of the above analogs were dramatically more soluble (0.1–4.2 mg/mL) than the parent bromo-indirubin (o5 mg/mL), a feature that should significantly facilitate the biological assessment of this compound class. In an unrelated study, a series of indirubins were prepared that were independently functionalized at positions 5- and 3u-, as depicted in the structures given below [85].
13
Recent Advances in the Discovery of GSK-3 Inhibitors
4′
O
HNAc
O2N
5
HO
6
4
O
N 7
5′
3′
6′ 7′
N H
NH 1
O
(4)
N H (5)
NH O
N H
NH O
(6)
Of the many reported analogs, only compounds 5 (GSK-3, IC50 2 nM; CDK1/cyclinB, IC50 19 nM; and CDK5/p25, IC50 6 nM) and 6 (GSK-3, IC50 7 nM; CDK1/cyclinB, IC50 50 nM; and CDK5/p25, IC50 18 nM) displayed single-digit nanomolar activity, and none of the analogs were particularly selective for GSK-3. Interestingly however, there appeared to be interdependent SARs at the positions explored, with the optimal group at one vector being dependent on the functionality incorporated at the other positions explored. This would argue that a matrix-based optimization of this chemotype could lead to further enhancements in potency and selectivity.
9.2 Maleimides The natural product staurosporine (7) [86] is a broadly promiscuous polycyclic kinase inhibitor. The related bis(indolyl)maleimide ruboxistaurin (8), although less conformationally constrained, is relatively specific in its inhibition of PKC-b, having a reported IC50 of 5 nM and no other significant activity in a broad kinase counter screen [87]. This selectivity has been attributed in part to the nonplanar disposition of the two indole moieties in 8, and recently reported work [73] has focused on the synthesis of analogs of 8 that exploit a cyclophane structure, as shown in compounds 9 through 14. These molecules also present a nonplanar arrangement of the bis-indolyl moiety, but in a more constrained ‘‘pyridinophane’’ cycle, and it was anticipated that this might favorably impact the potency and selectivity profiles previously observed with other macrocyclic bis(indolyl)maleimides.
14
Robert G. Gentles et al.
H N
H N
O
O
O R1
N
N
N
N
O R3
Ru
R2 O
MeO HN (7)
(15) R1 = R2 = R3 = H (16) R1 = OH, R2 = Br, R3 = CO2CH3
Expansion of the 14-membered macrocycle in ruboxistaurin to 16–22membered rings has previously been shown to not only retain excellent PKC-b inhibitory activity but also introduce significant activity against GSK-3. Contrastingly, the larger ring pyridinophanes 9 through 14 all display potent GSK-3 activity and are highly selective against PKC-b. For example, compound 13 inhibited GSK-3b and PKC-bII with IC50 values of 3 and 1,400 nM, respectively. This potency and selectivity profile had not previously been reported for any of the known bis(indolyl)maleimides. To further assess the broader kinase selectivity of this novel series of pyridinophanes, compounds 9, 10, and 12 were screened against a panel of 100 kinases. With the exception of the GSK-3a and GSK-b isozymes, the only other significant activities observed were against MSK1, PKC-y, and Rsk3. More specifically, compound 13 had IC50 values against these kinases of 510, 98, and 48 nM, respectively. A co-crystal structure of 13 with GSK-3b was obtained from which it was noted that the maleimide moiety makes key hydrogen bonds with the hinge residues, Asp133 and Val135, and an additional hydrogen bond through a bridging water molecule to Asp200. A number of hydrophobic interactions were observed, but interestingly, the 2-dimethylaminopyridine group is largely solvent exposed and does not interact directly with the enzyme, suggesting a site for further modification [73].
9.3 Organometallic GSK-3 inhibitors Organometallics have been used for a considerable time as pharmaceutical agents, especially in the oncology arena [88]. More recently, interest has grown in the use of transition metal complexes in chemical genetics, where it is believed that they may access unexplored chemical space, and thereby present opportunities for the design of small molecules with novel biological properties [89]. More specifically, given their unique
Recent Advances in the Discovery of GSK-3 Inhibitors
15
geometries, these compounds may be useful additions to the tools available to address some of the unanswered questions raised in the introduction of this review. In the area of kinase inhibitors, metal complexes are an expanding area of interest, and several highly potent and selective GSK-3 inhibitors have recently been disclosed. In all of the complexes discussed, the metals are thought to be biologically inert and function solely by preorganizing their ligands to present a complementary surface to cognate proteins. This can be appreciated by comparing the structurally complex staurosporine 7, with the simpler ruthenium complex 15, in which the indolocarbazole alkaloid scaffold has been replaced with a somewhat simpler bidentate pyridocarbazole ligand that retains the main features of the indolocarbazole aglycone [90]. The remaining metal ligands project into areas occupied by the glycoside element of staurosporine, and both structures have related overall topologies. Importantly, these molecular geometries are significantly easier to explore with transition metal complexes than they are with many organic macrocycles that are typically accessed by extended syntheses. Additionally, the complexes reviewed here have been shown to be stable in air and aqueous solution, and are tolerant of millimolar concentrations of thiols. H N
O
N O
Ru
O
N Cl NH
(17)
The racemate of the ruthenium complex 15 has IC50 values for GSK-3a and GSK-3b of 20 and 50 nM (100 mm ATP), respectively. In addition, it was demonstrated to inhibit Pim-1 kinase with an IC50 of 3 nM, as well as MSK1 (IC50 120 nM), nMRsk1 (IC50 300 nM), and TrkA (IC50 70 nM), but did not significantly inhibit other kinases in a panel of 50 isozymes explored, including the phylogenetically related CDKs [90]. To address these cross-reactivities, a limited SAR study resulted in the identification of compound 16 that was shown to be selective for GSK-3
16
Robert G. Gentles et al.
when screened in a panel of 57 kinases. This compound was resolved by chiral HPLC and the R isomer was highly potent against GSK-3a and GSK-3b (IC50 350 and 550 pM, respectively), and the previously noted activities against Pim-1, MSK1, nMRsk1, and TrkA were all significantly attenuated. Interestingly, the S isomer has the reverse selectivity for Pim1 over GSK-3 [90]. The complex 16 is configurationally stable in solution when stored in the freezer, but can be expected to slowly epimerize under physiological conditions. Of note is the fact that the uncomplexed pyridocarbazole ligand of 16 is a more potent Pim-1 inhibitor (IC50 10 nM) than GSK-3a (IC50 30 nM) or GSK-3b inhibitor (IC50 50 nM). Consequently, complexation of this ligand to the ruthenium half-sandwich fragment of 16 increases the potency for GSK-3 by more than an order of magnitude, and reverses the selectivity profile for GSK-3 over Pim-1 [89]. The cellular activity of (R)-16 was determined in a b-catenin-dependent luminescence reporter assay, in which the degree of luminescence relates to cellular b-catenin levels. Activity was observed at 30 nM and a luminescence increase factor of 700 was determined, indicative of significant b-catenin stabilization. This level of potency was significantly greater than that observed with the longer-studied GSK-3 inhibitor 6BIO, and confirmed the ability of these complexes to permeate cells and inhibit GSK-3, including the fraction of GSK-3 bound in the b-catenin destruction complex. Zebrafish embryos that were exposed to micromolar concentrations of (R)-16 demonstrated a number of developmental abnormalities, strongly suggesting that effective functional inhibition of GSK-3 had been achieved in vivo [89]. In an interesting extension to this work, a series of octahedral ruthenium complexes incorporating a bidentate pyridocarbazole in combination with a diversity of other ligands were explored for activity against GSK-3a, Pim-1, MSK1, and CDK2/cyclinA [91]. When bound to a target kinase, the pyridocarbazole makes key H-bond contacts with the target enzyme, and the metal and its remaining ligands occupy the approximately spherical ribose pocket of the enzyme’s active site. In the case of octahedral complexes, the choices of substituents on the four valences projecting into the sugar pocket are key determinants of selectivity and, as such, achieve this in a different fashion compared to many organic inhibitors. Of the octahedral complexes explored, compound 17 was identified as a potent GSK-3a inhibitor (IC50 8 nM) and was 10-fold selective over Pim-1.
Recent Advances in the Discovery of GSK-3 Inhibitors
H N
O
17
O
HO F O
N
N Ru
NH
O
O OH (18)
A space-filling model of 17 showed that the ruthenium atom is buried within the complex and is not able to directly interact with target proteins. As previously noted, the metal functions primarily to organize its coordinated ligands into specific and well-defined geometries. In addition, complexes such as 17 are relatively rigid and kinetically inert under physiological conditions. The most interesting feature of compound 17 is its observed selectivity for GSK-3a (IC50 8 nM) over GSK3b (IC50 50 nM). Selectivity between these isozymes is somewhat surprising given the high homology of their active sites (W97%) and has not been previously reported. Understanding the structural features contributing to this differential activity would be a valuable addition to the field. More recent studies directed at the further optimization of ruthenium-based GSK-3 inhibitors resulted in the identification of an extremely high-affinity GSK-3 inhibitor [92]. The complex (RRu)-NP549 (18) inhibits GSK-3b with a Ki of 5 pM and is one of the most potent kinase inhibitors yet reported. H N
O
O
H N
O
O
OH N
N Ru
N
N Os
O
(19)
OH
O
(20)
A co-crystal of (RRu)-NP549 and GSK-3b has been obtained and shows a remarkable complementarity between the surfaces of the
18
Robert G. Gentles et al.
ruthenium complex and the ATP-binding site of GSK-3. Nearly all of the polar functionality in 18 makes productive H-bonds with the enzyme. Interestingly, the CO ligand contacts the glycine-rich loop and is buried in a small pocket, contributing to the affinity and selectivity of this compound. In an unrelated study, the activities of a pair of ruthenium 19 and osmium 20 congeners of 18 were compared [93]. Both analogs were evaluated in a variety of biochemical and cell assays and had essentially indistinguishable properties. Both 19 and 20 were highly active at GSK-3b (IC50 1.4 and 0.6 nM, respectively), and both induced strong and essentially identical apoptotic effects in 1205 Lu melanoma cells. This effect is thought to be attributable to GSK-3 inhibition that produces p53-induced apoptosis. The equivalence of these ruthenium and osmium complexes in a cytotoxicity assay using 1205 Lu cells is noteworthy, as such exchange of one metal with its higher periodic table congener is not normally tolerated in many classes of cytotoxics. R2 N
S O
O
N R1
(21) R1 = Bn, R2 = Me: NP031112 (22) R1 = Ph, R2 = Et: NP01138 (23) R1 = Bn, R2 = Bn: NP00111
A co-crystal structure of the osmium analog 20 complexed to Pim-1 was obtained and displayed a binding mode similar to that for related ruthenium complexes. Not surprisingly, when 19 was modeled into this structure, the two analogs were essentially indistinguishable. This is consistent with their almost identical biological properties and with the hypothesis that the metals in these complexes function primarily as structural components and do not participate in direct interactions with target proteins.
9.4 Thiadiazolidinones: noncompetitive GSK-3 inhibitors Kinase inhibitors that are non-ATP-competitive are potentially attractive for several reasons. By not having to compete with endogenous ATP, they may show better cellular and in vivo potency in comparison with competitive inhibitors having comparable ADME properties. In addition, much better kinase selectivity may be expected from inhibitors that bind outside of the ATP pocket. This may be especially attractive for CNS
Recent Advances in the Discovery of GSK-3 Inhibitors
19
indications where target overlap is probably less desirable than it can be for anticancer therapies. A series of 1,2,4-thiadiazole-3,5-diones (TDZDs) have been described, examples of which appear to be noncompetitive with ATP [63]. The initial lead compound in this series, TDZD-8 (NP031112, 21), showed modest GSK-3b inhibition (IC50 2 mM), noncompetitive enzyme kinetics, and good selectivity against a limited set of other kinases (CDK1, CK2, PKA, and PKC). Putative binding sites, both inside and outside the ATP pocket, have been suggested through a combination of 3D-SAR and molecular docking analyses [94]. Dose-dependent reduction of tau phosphorylation in human SHSY5Y neuroblastoma cells has been reported in conference presentations (IC50 ¼ 51 mM). NP031112 was tested in GSK-3b conditional, and hAPPx tau transgenic mouse models (100–200 mg/kg/day, PO for 3 weeks and 3 months, respectively). Following these prolonged treatments, cognitive function was significantly improved and neuronal loss, amyloid deposition, tau phosphorylation, and neuroinflammation were reduced [95]. O H3CO H3CO N (24)
Further studies suggest that NP031112, as well as related compounds NP01138 (22) and NP00111 (23), may have more pronounced neuroprotective effects that may operate through alternate mechanisms, such as peroxisome proliferator-activated receptor g (PPARg) modulation under excitotoxic conditions [96]. Company reports state that NP031112 began phase I clinical trials for AD in April 2006.
9.5 Established drugs with GSK-3 inhibitory properties Donepezil (Aricepts, 24) is an acetylcholinesterase inhibitor that is widely used for the treatment of cognitive and behavioral symptoms of mild-to-moderate AD. Although its effect on disease progression has been a source of controversy, a clinical study has suggested that it may have benefit in severe AD patients [97]. A recent study has demonstrated GSK-3 inhibition in primary cortical neuron cultures challenged with Ab (20 mM) and treated with donepezil, resulting in neuroprotection (dosedependent, from 0.1 to 10 mM) and reduced tau phosphorylation (10 mM) [98]. The presence of a PI3 kinase inhibitor (LY294002) abolished activity,
20
Robert G. Gentles et al.
while a nicotinic acetylcholine blocker, mecamylamine, only partially reversed neuroprotection, suggesting that GSK-3 inhibition results from blockade of inhibitory phosphorylation. CN N
S
N NH N
NH
N
S
HN
N
N (25)
(26)
Olanzapine (25) is an atypical antipsychotic that is associated with weight gain and disturbances in glucose metabolism. A recent study demonstrated GSK-3 inhibition in brains of mice treated with atypical antipsychotics [99]. One group decided to look at direct inhibition of GSK-3 by 25, first by in silico molecular docking experiments utilizing the published co-crystallized structure of the known GSK-3 inhibitor AR-A014418, and then by enzyme assay [100]. Modeling suggested a good fit in the ATP pocket and, indeed, olanzapine was a fairly potent inhibitor of GSK-3b (IC50 91 nM). O F
OH
OH
N
HN
N
N
N
O Cl
N
NH2
(27)
O
(28)
N
Recent Advances in the Discovery of GSK-3 Inhibitors
21
O O HN S
NH2 N N
O
N
(29)
The same group carried out wider in silico docking studies on a structural database of established drugs and identified the following as potent inhibitors [101]: cimetidine (26) (IC50 13 nM), hydroxychloroquine (27) (IC50 33 nM), and gemifloxacin (28) (IC50 88 nM).
9.6 Miscellaneous chemotypes 9.6.1 Furopyrimdines A furopyrimidine scaffold that had previously yielded potent VEGFR2 and Tie-2 inhibitors was modified to provide a potent series of GSK-3 inhibitors [102]. This was done by rational design following analysis of the published binding modes (revealed by X-ray crystallography) of analogous aza- and diazaindazoles. An exemplary compound 29 demonstrated good binding affinity (IC50 30 nM), with good-to-excellent selectivity against a panel of nine other kinases including CDK2. Critical to GSK-3 selectivity and potency was the 3-pyridyl group whose nitrogen is expected to form a hydrogen bond with K85.
CN
F
H3CO
OCH3
S
O O
S
N
O
O
N
N N
N N (30)
(31)
9.6.2 1,3,4-Oxadiazoles A high-throughput screening effort resulted in the identification of a 2-aryl-1,3,4-oxadiazole hit, 30, with double-digit nanomolar potency against GSK-3b (IC50 65 nM) [71]. Subsequent optimization, guided by an
22
Robert G. Gentles et al.
X-ray structure of 30 in the GSK-3 ATP pocket, led to 31, a highly potent inhibitor (IC50 2.3 nM) with W1,000-fold selectivity against a panel of 23 other kinases, including CDK2. In a rat oral PK study, compound 31 showed low oral bioavailability (F : 1.7%), reportedly due to limited intestinal absorption.
F3C HN
N N
NH
HO OH (32)
9.6.3 2,5-Diaminopyrimidines One group’s recent screening efforts led to identification of a purinone scaffold that proved difficult to progress. However, investigation of synthetic intermediates led to a small series of adamantylaminopyrimidines that showed good GSK-3 inhibition. Compound 32 (GSK-3b IC50 41 nM) also showed good oral bioavailability in rats (F : 34%) [103]. N N
H N
Cl
N H
OH
N
N
(33)
9.6.4 Amino-1,3,5-triazines In a recent study, a series of biheteroaryl triazine CDK inhibitors were prepared and examined as potential antitumor agents [104]. The most potent compound in this class, 33 (CDK1, IC50 21 nM; CDK2, IC50 7 nM; and CDK5, IC50 3 nM), was similarly active against GSK-3b (IC50 20 nM), but fairly selective against a panel of 12 other kinases.
Recent Advances in the Discovery of GSK-3 Inhibitors
23
10. CONCLUSION In addition to the compounds discussed above, the patent literature is replete with examples of structures reported to be active at GSK-3, and it would appear reasonable to assume that compounds with sufficient potency, kinase-selectivity, and appropriate physicochemical properties can be identified to evaluate their use in the treatment of AD. However, the key outstanding issue to be addressed remains mechanism-based toxicity, and whether this can be avoided. This is unlikely to be known until a number of analogs (with a variety of inhibitory profiles) are comprehensively tested in vivo or significant clinical progress is reported [80].
REFERENCES [1] [2] [3] [4]
[5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23]
2009 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 2009, 5, 30. R. Gilstad John and E. Finucane Thomas, J. Am. Geriatr. Soc., 2008, 56, 1556. J. Hardy, J. Alzheimer’s Dis., 2006, 9(Suppl. 3), 151. J. Zaghi, B. Goldenson, M. Inayathullah, A. S. Lossinsky, A. Masoumi, H. Avagyan, M. Mahanian, M. Bernas, M. Weinand, M. J. Rosenthal, A. Espinosa-Jeffrey, J. Vellis, D. B. Teplow and M. Fiala, Acta Neuropathol., 2009, 117, 111. I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y. C. Tung, M. S. Zaidi and H. M. Wisniewski, J. Biol. Chem., 1986, 261, 6084. H. Stebbings, Cytoskeleton, 1996, 2, 113. M. L. Michaelis, S. Ansar, Y. Chen, E. R. Reiff, K. I. Seyb, R. H. Himes, K. L. Audus and G. I. Georg, J. Pharmacol. Exp. Ther., 2005, 312, 659. K. Vehmas Anne, H. Kawas Claudia, F. Stewart Walter and C. Troncoso Juan, Neurobiol. Aging, 2003, 24, 321. C. G. Dotti and B. De Strooper, Nat. Cell Biol., 2009, 11, 114. K. Jellinger, J. Neurol., 1977, 214, 195. J. A. Hardy and G. A. Higgins, Science, 1992, 256, 184. G. G. Glenner and C. W. Wong, Biochem. Biophys. Res. Commun., 1984, 120, 885. C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther, Proc. Natl. Acad. Sci. U.S.A., 1985, 82, 4245. J. W. Geddes, K. J. Anderson and C. W. Cotman, Exp. Neurol., 1986, 94, 767. M. Kawai, P. Cras and G. Perry, Brain Res., 1992, 592, 278. J. Rogers and J. H. Morrison, J. Neurosci., 1985, 5, 2801. J. B. Standridge and E. M. Welsh (eds), Trends in Alzheimer’s Disease Research, Nova Science Publishers, Hauppauge, NY, 2006, pp. 53–96. B. A. Yankner, Nat. Med., 1996, 2, 850. A. Lorenzo and B. A. Yankner, Ann. N.Y. Acad. Sci., 1996, 777, 89, Neurobiology of Alzheimers Disease. A. Ferreira, Q. Lu, L. Orecchio and K. S. Kosik, Mol. Cell. Neurosci., 1997, 9, 220. P. Delobel, S. Flament, M. Hamdane, A. Delacourte, J. P. Vilain and L. Buee, FEBS Lett., 2002, 516, 151. K. Leroy, Z. Yilmaz and J. P. Brion, Neuropathol. Appl. Neurobiol., 2007, 33, 43. K. Iqbal and I. Grundke-Iqbal, J. Alzheimer’s Dis., 2006, 9(Suppl. 3), 219.
24
Robert G. Gentles et al.
[24] C. M. Wischik, M. Novak, P. C. Edwards, A. Klug, W. Tichelaar and R. A. Crowther, Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 4884. [25] M. A. Glicksman, G. D. Cuny, M. Liu, B. Dobson, K. Auerbach, R. L. Stein and K. S. Kosik, Curr. Alzheimer Res., 2007, 4, 547. [26] C. Hooper, R. Killick and S. Lovestone, J. Neurochem., 2008, 104, 1433. [27] G. J. Biessels and L. J. Kappelle, Biochem. Soc. Trans., 2005, 33, 1041. [28] G. V. De Ferrari, A. Papassotiropoulos, T. Biechele, F. W. De-Vrieze, M. E. Avila, M. B. Major, A. Myers, K. Saez, J. P. Henriquez, A. Zhao, M. A. Wollmer, R. M. Nitsch, C. Hock, C. M. Morris, J. Hardy and R. T. Moon, Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 9434. [29] E. M. Reiman, J. A. Webster, A. J. Myers, J. Hardy, T. Dunckley, V. L. Zismann, K. D. Joshipura, J. V. Pearson, D. Hu-Lince, M. J. Huentelman, D. W. Craig, K. D. Coon, W. S. Liang, R. H. Herbert, T. Beach, K. C. Rohrer, A. S. Zhao, D. Leung, L. Bryden, L. Marlowe, M. Kaleem, D. Mastroeni, A. Grover, C. B. Heward, R. Ravid, J. Rogers, M. L. Hutton, S. Melquist, R. C. Petersen, G. E. Alexander, R. J. Caselli, W. Kukull, A. Papassotiropoulos and D. A. Stephan, Neuron, 2007, 54, 713. [30] C. J. Phiel, C. A. Wilson, V. M. Y. Lee and P. S. Klein, Nature (London), 2003, 423, 435. [31] X. Sun, S. Sato, O. Murayama, M. Murayama, J. M. Park, H. Yamaguchi and A. Takashima, Neurosci. Lett., 2002, 321, 61. [32] S. Hu, N. Begum Aynun, R. Jones Mychica, S. Oh Mike, K. Beech Walter, H. Beech Beverly, F. Yang, P. Chen, J. Ubeda Oliver, C. Kim Peter, P. Davies, Q. Ma, M. Cole Greg and A. Frautschy Sally, Neurobiol. Dis., 2009, 33, 193. [33] G. I. Welsh, C. M. Miller, A. J. Loughlin, N. T. Price and C. G. Proud, FEBS Lett., 1998, 421, 125. [34] G. I. Welsh and C. G. Proud, Biochem. J., 1993, 294(Pt 3), 625. [35] S. Kaku, S. Chaki and M. Muramatsu, Curr. Signal Transduct. Ther., 2008, 3, 195. [36] R. V. Bhat, J. Shanley, M. P. Correll, W. E. Fieles, R. A. Keith, C. W. Scott and C.-M. Lee, Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 11074. [37] S. Frame, P. Cohen and R. M. Biondi, Mol. Cell, 2001, 7, 1321. [38] J. J. Pei, T. Tanaka, Y. C. Tung, E. Braak, K. Iqbal and I. Grundke-Iqbal, J. Neuropathol. Exp. Neurol., 1997, 56, 70. [39] J.-J. Pei, E. Braak, H. Braak, I. Grundke-Iqbal, K. Iqbal, B. Winblad and R. F. Cowburn, J. Neuropathol. Exp. Neurol., 1999, 58, 1010. [40] B. R. Sperber, S. Leight, M. Goedert and V. M. Y. Lee, Neurosci. Lett., 1995, 197, 149. [41] K. Spittaels, C. Van den Haute, J. Van Dorpe, H. Geerts, M. Mercken, K. Bruynseels, R. Lasrado, K. Vandezande, I. Laenen, T. Boon, J. Van Lint, J. Vandenheede, D. Moechars, R. Loos and F. Van Leuven, J. Biol. Chem., 2000, 275, 41340. [42] T. Engel, P. Goni-Oliver, J. J. Lucas, J. Avila and F. Hernandez, J. Neurochem., 2006, 99, 1445. [43] N. Embi, D. B. Rylatt and P. Cohen, Eur. J. Biochem., 1980, 107, 519. [44] D. R. Alessi, Biochem. Soc. Trans., 2001, 29, 1. [45] D. A. E. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich and B. A. Hemmings, Nature (London), 1995, 378, 785. [46] R. Dajani, E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale and L. H. Pearl, Cell, 2001, 105, 721. [47] A. R. Saltiel and C. R. Kahn, Nature, 2001, 414, 799. [48] M. Ilyas, J. Pathol., 2005, 205, 130. [49] T. C. Dale, Biochem. J., 1998, 329(Pt 2), 209. [50] R. Dajani, E. Fraser, S. M. Roe, M. Yeo, V. M. Good, V. Thompson, T. C. Dale and L. H. Pearl, EMBO J., 2003, 22, 494. [51] V. H. Bustos, A. Ferrarese, A. Venerando, O. Marin, J. E. Allende and L. A. Pinna, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 19725.
Recent Advances in the Discovery of GSK-3 Inhibitors
[52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71]
[72]
[73] [74] [75] [76]
[77]
[78] [79]
25
H. Aberle, A. Bauer, J. Stappert, A. Kispert and R. Kemler, EMBO J., 1997, 16(13), 3797. J. Huelsken and J. Behrens, J. Cell Sci., 2002, 115, 3977. R. Nusse, Cell Res., 2005, 15, 28. G. M. Thomas, S. Frame, M. Goedert, I. Nathke, P. Polakis and P. Cohen, FEBS Lett., 1999, 458, 247. E.-K. Suh and B. M. Gumbiner, Exp. Cell Res., 2003, 290, 447. V. W. Ding, R.-H. Chen and F. McCormick, J. Biol. Chem., 2000, 275, 32475. T. D. King, B. Clodfelder-Miller, K. A. Barksdale and G. N. Bijur, Neurotox. Res., 2008, 14, 367. W. Yang, C. Leystra-Lantz and M. J. Strong, Brain Res., 2008, 1196, 131. N. Vanacore and F. Galeotti, Proc. Natl. Acad. Sci. U.S.A., 2008, 105, E35, author reply E36 Clinicaltrials.gov, Identifiers: NCT00790582 and NCT00818389. T. Yang, D. Arslanova, Y. Gu, C. Augelli-Szafran and W. Xia, Mol. Brain, 2008, 1, 15. A. Martinez, M. Alonso, A. Castro, C. Perez and F. J. Moreno, J. Med. Chem., 2002, 45, 1292. J. R. Woodgett, EMBO J., 1990, 9, 2431. J. R. Woodgett, Methods Enzymol., 1991, 200, 564. F. Mukai, K. Ishiguro, Y. Sano and S. C. Fujita, J. Neurochem., 2002, 81, 1073. B. Schaffer, M. Wiedau-Pazos and D. H. Geschwind, Gene, 2003, 302, 73. K. F. Lau, C. C. J. Miller, B. H. Anderton and P. C. Shaw, J. Pept. Res., 1999, 54, 85. B. W. Doble, S. Patel, G. A. Wood, L. K. Kockeritz and J. R. Woodgett, Dev. Cell, 2007, 12, 957. E. ter Haar, J. T. Coll, D. A. Austen, H.-M. Hsiao, L. Swenson and J. Jain, Nat. Struct. Biol., 2001, 8, 593. M. Saitoh, J. Kunitomo, E. Kimura, Y. Hayase, H. Kobayashi, N. Uchiyama, T. Kawamoto, T. Tanaka, C. D. Mol, D. R. Dougan, G. S. Textor, G. P. Snell and F. Itoh, Bioorg. Med. Chem., 2009, 17, 2017. D. A. Heerding, N. Rhodes, J. D. Leber, T. J. Clark, R. M. Keenan, L. V. Lafrance, M. Li, I. G. Safonov, D. T. Takata, J. W. Venslavsky, D. S. Yamashita, A. E. Choudhry, R. A. Copeland, Z. Lai, M. D. Schaber, P. J. Tummino, S. L. Strum, E. R. Wood, D. R. Duckett, D. Eberwein, V. B. Knick, T. J. Lansing, R. T. McConnell, S. Y. Zhang, E. A. Minthorn, N. O. Concha, G. L. Warren and R. Kumar, J. Med. Chem., 2008, 51, 5663. H.-C. Zhang, L. V. R. Bonaga, H. Ye, C. K. Derian, B. P. Damiano and B. E. Maryanoff, Bioorg. Med. Chem. Lett., 2007, 17, 2863. I. M. Withers, M. P. Mazanetz, H. Wang, P. M. Fischer and C. A. Laughton, J. Chem. Inf. Model., 2008, 48, 1448. H.-J. Kim, H. Choo, Y. S. Cho, K. T. No and A. N. Pae, Bioorg. Med. Chem., 2008, 16, 636. M. A. Fabian, W. H. Biggs, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, J. M. Ford, M. Galvin, J. L. Gerlach, R. M. Grotzfeld, S. Herrgard, D. E. Insko, M. A. Insko, A. G. Lai, J.-M. Lelias, S. A. Mehta, Z. V. Milanov, A. M. Velasco, L. M. Wodicka, H. K. Patel, P. P. Zarrinkar and D. J. Lockhart, Nat. Biotechnol., 2005, 23, 329. M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka and P. P. Zarrinkar, Nat. Biotechnol., 2008, 26, 127. M. Hong, D. C. R. Chen, P. S. Klein and V. M. Y. Lee, J. Biol. Chem., 1997, 272, 25326. N. Kirshenboim, B. Plotkin, B. Shlomo Shani, O. Kaidanovich-Beilin and H. EldarFinkelman, J. Mol. Neurosci., 2004, 24, 237.
26
Robert G. Gentles et al.
[80] M. Medina and A. Castro, Curr. Opin. Drug Discov. Dev., 2008, 11, 533. [81] L. Meijer,, N. Guyard,, L. A. Skaltsounis, and G. Eisenbrand (eds), Life in Progress, Station Biologique, Roscoff, France, 2006, p. 297. [82] P. Polychronopoulos, P. Magiatis, A.-L. Skaltsounis, V. Myrianthopoulos, E. Mikros, A. Tarricone, A. Musacchio, S. M. Roe, L. Pearl, M. Leost, P. Greengard and L. Meijer, J. Med. Chem., 2004, 47, 935. [83] L. Meijer, A.-L. Skaltsounis, P. Magiatis, P. Polychronopoulos, M. Knockaert, M. Leost, X. P. Ryan, C. A. Vonica, A. Brivanlou, R. Dajani, C. Crovace, C. Tarricone, A. Musacchio, S. M. Roe, L. Pearl and P. Greengard, Chem. Biol., 2003, 10, 1255. [84] K. Vougogiannopoulou, Y. Ferandin, K. Bettayeb, V. Myrianthopoulos, O. Lozach, Y. Fan, C. H. Johnson, P. Magiatis, A.-L. Skaltsounis, E. Mikros and L. Meijer, J. Med. Chem., 2008, 51, 6421. [85] M. J. Moon, S. K. Lee, J.-W. Lee, W. K. Song, S. W. Kim, J. I. Kim, C. Cho, S. J. Choi and Y.-C. Kim, Bioorg. Med. Chem., 2006, 14, 237. [86] T. Tamaoki and H. Nakano, Biotechnology, 1990, 8, 732. [87] M. R. Jirousek, J. R. Gillig, C. M. Gonzalez, W. F. Heath, J. H. McDonald, III, D. A. Neel, C. J. Rito, U. Singh, L. E. Stramm, et al., J. Med. Chem., 1996, 39, 2664. [88] J. Respondek and J. Engel, Drugs Future, 1996, 21, 391. [89] E. Meggers, G. E. Atilla-Gokcumen, H. Bregman, J. Maksimoska, S. P. Mulcahy, N. Pagano and D. S. Williams, Synlett, 2007, 1177. [90] G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, N. Pagano and E. Meggers, ChemBioChem., 2006, 7, 1443. [91] J. Maksimoska, L. Feng, K. Harms, C. Yi, J. Kissil, R. Marmorstein and E. Meggers, J. Am. Chem. Soc., 2008, 130, 5764. [92] G. E. Atilla-Gokcumen, N. Pagano, C. Streu, J. Maksimoska, P. Filippakopoulos, S. Knapp and E. Meggers, ChemBioChem., 2009, 10, 198. [93] J. Maksomiska, D. S. Williams, G. E. Atilla-Gokcumen, K. S. M. Smalley, P. J. Carroll, R. D. Webster, P. Filippakopoulos, S. Knapp, M. Herlyn and E. Meggers, Chem. Eur. J., 2008, 14, 4816. [94] A. Martinez, M. Alonso, A. Castro, I. Dorronsoro, J. L. Gelpi, F. J. Luque, C. Perez and F. J. Moreno, J. Med. Chem., 2005, 48, 7103. [95] E. Martin-Aparicio, A. Fuertes, M. J. Perez-Puerto, D. Perez-Navarro, M. Alonso, A. Martı´nez and M. Medina, Neurobiol. Aging, 2004, 25(Suppl. 2), Abst P4–428. [96] R. Luna-Medina, M. Cortes-Canteli, S. Sanchez-Galiano, J. A. Morales-Garcia, A. Martinez, A. Santos and A. Perez-Castillo, J. Neurosci., 2007, 27, 5766. [97] B. Winblad, L. Kilander, S. Eriksson, L. Minthon, S. Batsman, A. L. Wetterholm, C. Jansson-Blixt and A. Haglund, Lancet, 2006, 367, 1057. [98] M. Y. Noh, S. H. Koh, Y. Kim, H. Y. Kim, G. W. Cho and S. H. Kim, J. Neurochem., 2009, 108, 1116. [99] X. Li, K. M. Rosborough, A. B. Friedman, W. Zhu and K. A. Roth, Int. J. Neuropsychopharmacol., 2007, 10, 7. [100] M. K. Mohammad, I. M. Al-masri, M. O. Taha, M. A. S. Al-Ghussein, H. S. AlKhatib, S. Najjar and Y. Bustanji, Eur. J. Pharmacol., 2008, 584, 185. [101] M. O. Taha, Y. Bustanji, M. A. Al-Ghussein, M. Mohammad, H. Zalloum, I. M. Al-Masri and N. Atallah, J. Med. Chem., 2008, 51, 2062. [102] Y. Miyazaki, Y. Maeda, H. Sato, M. Nakano and G. W. Mellor, Bioorg. Med. Chem. Lett., 2008, 18, 1967. [103] C. Lum, J. Kahl, L. Kessler, J. Kucharski, J. Lundstrom, S. Miller, H. Nakanishi, Y. Pei, K. Pryor, E. Roberts, L. Sebo, R. Sullivan, J. Urban and Z. Wang, Bioorg. Med. Chem. Lett., 2008, 18, 3578.
CHAPT ER
2 Advancements in the Development of Nitric Oxide Synthase Inhibitors Shawn Maddaford, Subhash C. Annedi, Jailall Ramnauth and Suman Rakhit
Contents
1. Introduction 2. NOS — Structure and Function 2.1 Introduction 2.2 Isoform-selective inhibitors — structural basis 3. Selective NOS Inhibitors 3.1 Introduction 3.2 Selective nNOS inhibitors 3.3 Selective iNOS inhibitors 4. Clinical Findings with NOS Inhibitors 5. Future Directions — Dual Action NOS Inhibitors 5.1 Introduction 5.2 Dual action nNOS inhibitors 5.3 Dual action iNOS inhibitors 6. Conclusions References
27 28 28 29 32 33 33 38 41 43 43 44 45 46 47
1. INTRODUCTION Nitric oxide (NO) is perhaps one of the most intensively studied neurotransmitters since its discovery by Ignarro [1] and Furchgott [2] in the early 1980s as a mediator of vascular tone. This early work revealed NeurAxon Inc, 480 University Ave, Suite 900, Toronto, ON M5G 1V2, Canada Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04402-9
r 2009 Published by Elsevier Inc.
27
28
Shawn Maddaford et al.
that endothelium-derived relaxing factor (EDRF), the agent found in the endothelium that was responsible for dilation of blood vessels, was in fact NO. Since then, the unraveling of the diverse biological functions of NO has continued unabated as evidenced by more than 80,000 publications on nitric oxide synthase (NOS) and NO described in the literature. In addition to its role in regulating blood pressure, NO is important in platelet aggregation, bone remodeling, inflammation, and neurotransmission, wherein NO initiates changes in neuronal excitability and synaptic strength by acting at pre- and/or post-synaptic locations. The reduction in pathophysiological levels of NO through inhibition of NOS has the potential to be therapeutic in a multitude of indications including the treatment of septic shock, stroke, neurodegenerative disorders (e.g., Parkinson’s, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS)), and in the treatment of pain [e.g., migraine, chronic tension-type headache (CTTH), visceral, and neuropathic] [3]. However, the therapeutic control of NO synthesis has, until recently, been unattainable due to the difficulties in achieving isoform-selective inhibition. The selective inhibition of the neuronal NOS (nNOS) enzyme and/or the inducible (iNOS) over the endothelial NOS (eNOS) enzymes for the treatment of pain or migraine would be required to avoid the cardiovascular liabilities associated with eNOS inhibition [4]. Earlier reviews in this publication have focused on the enzymology and synthesis of NOS inhibitors [5,6]. This review focuses on recent advances in the design of selective inhibitors of NOS and some of the emerging preclinical and clinical developments of these newer inhibitors.
2. NOS — STRUCTURE AND FUNCTION 2.1 Introduction NO is synthesized by three isoforms of NOS, which catalyzes the fiveelectron oxidation of L-arginine to L-citrulline [7]. The neuronal or brain NOS (nNOS or NOS1) and endothelial form (eNOS or NOS3) are constitutively expressed, whereas the inducible form (iNOS or NOS2) is expressed under conditions of stress or upon the release of inflammatory mediators such as tumor necrosis factor-a, interleukin-1, or lipopolysaccharides (LPS). These homodimeric proteins consist of a C-terminal reductase domain that transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) through the flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) prosthetic groups to the Nterminal oxygenase domain that binds the arginine substrate, (1uR, 2uR, 6R)-5,6,7,8-tetrahydrobiopterin (BH4) and heme [8]. The two constitutive forms are activated by increasing Ca2+ concentration and the binding of a Ca2+/calmodulin complex while the activity of iNOS appears to be
29
Advancements in the Development of NOS Inhibitors
independent of Ca2+ concentration due to the tight binding of the complex at the dimer interface [9]. The active dimeric form of NOS is stabilized by a structural zinc binding at the oxygenase dimer interface [10], which forms the BH4-binding site. The closest related enzymes are the cytochrome (CYP) P450 enzymes, wherein both the function and amino acid sequence of the reductase domains and the function but not the sequence of the oxygenase domains are similar. Reduction of the BH4 and heme iron allows for the activation of O2 and subsequent CYP-like oxidation of L-arginine to No-hydroxy-L-arginine and finally to citrulline, ultimately releasing NO. In the absence of BH4, NOS reduces oxygen to form superoxide [11]. The inhibitor design reviewed herein has primarily focused on targeting the arginine or BH4-binding sites to prevent the overproduction of NO or the uncoupled reduction of O2 to superoxide, thus minimizing their deleterious effects.
2.2 Isoform-selective inhibitors — structural basis The three NOS isoforms possess approximately 50% overall sequence homology and identical structural architecture. With the exception of the human nNOS enzyme, the crystal structures for all three isoforms have been determined allowing for the application of structure-based inhibitor design [10,12–17]. However, analysis of the oxygenase domains reveals striking active site structural conservation across the three isoforms with ˚ of the substrate-binding site being identical 16 of 18 residues within 6 A [18]. Despite the high similarity of the binding pockets, inhibitors 1–4 derived from L-NG-nitroarginine (L-NNA) show selectivity for rat nNOS versus bovine eNOS (Table 1). These compounds make interactions with the L-amino acid-specific binding pocket demonstrating hydrogen (H) bonds to Gln249, Tyr359, Glu363, and Asn368 (rat nNOS) [19]. In all cases, the guanidine and aminopyridine groups exhibit similar bifurcated H-bonds with the conserved glutamate (e.g., Glu363 or 592) across the three isoforms. However, the nitro group of inhibitors 1–3 provides Table 1 Peptide, reduced amide, and aminopyridine-based substrate inhibitor selectivity for 1–4 Compound Rat nNOS
1 2 3 4
0.30 0.10 0.15 0.38
Note: Ki values are in mM.
Bovine eNOS
Murine iNOS
e/n
i/n
D597N nNOS
N368D eNOS
107 110 80 434
25 29 39 58
1538 1280 2617 1114
192 290 325 150
67 34 21 –
9.5 4.6 5.1 –
30
Shawn Maddaford et al.
additional hydrogen bonding and non-bonded contacts with the protein backbone, which results in enhanced binding affinity over L-arginine [20]. Inspection of the X-ray complexes suggests that the selectivity of 1–3 for nNOS over eNOS arises from a single amino acid substitution of a neutral Asn368 (eNOS) residue for a charged Asp597 (nNOS) residue (Figure 1). These inhibitors adopt a curled conformation in the nNOS active site placing the a-amino group between Glu592 and Asp597, ˚ ) and potentially a so that it makes a direct H-bond to Glu592 (2.8 A favorable electrostatic interaction with the charged Asp597 (nNOS). In contrast, the inhibitors bound to eNOS were in a fully extended conformation with the a-amino group in 1, reorienting to make a H-bond with Gln249 rather than Glu592. Mutagenesis studies confirmed that this single residue difference was responsible for the two orders of magnitude difference in potency between the two isoforms (Table 1). NO2 HN
H2N
NO2
NH
HN
NO2 NH
HN
N
NH
NH NH
NH
NH
O H N H2N
NH2 O
H N
O
H2N
H2N O
1
NH2
NH
HN
H N NH2
NH2
NH2
4
3
2
ASP597 GLN478 ASN368 ASN569
GLU592
GLN249
ASN340
GLU363
Figure 1 Active site poses of dipeptide amide 1 in the active site of nNOS (left) and eNOS (right). The a-amino group makes hydrogen bonding and electrostatic interaction with Glu592 in nNOS, whereas 1 displays an extended conformation in eNOS and makes an H-bond with Gln249 as opposed to Glu363. (See Color Plate 2.1 in Color Plate Section.)
31
Advancements in the Development of NOS Inhibitors
The D597N mutation in nNOS resulted in a drop in potency (1; w.t. ¼ 0.3 mM, D597 N ¼ 67 mM), whereas the corresponding eNOS mutant N368D resulted in an increase in potency (1; w.t. ¼ 107 mM, N368D ¼ 9.5 mM). Similar trends were observed for compounds 2 and 3. Finally, a crystal structure of the nNOS D597N mutant complexed with 1 revealed an extended conformation, whereas the eNOS mutant N368D complexed to 1 adopted a curled conformation [19]. Recently, it has been suggested that the selectivity for a series of quinazoline and aminopyridine inhibitors for the iNOS enzyme is due to an isozyme-specific residue plasticity, wherein residues distant from the active site modulate conformational changes of invariant residues in contact with the inhibitors [17]. In this ‘‘anchored plasticity approach,’’ an inhibitor core anchored in a conserved binding pocket and a rigid bulky substituent extend into remote specificity pockets upon conformational changes of ‘‘plastic residues.’’ This approach is conceptually different to the approach described earlier where the ligand changes its conformation to interact with variant residues within the immediate active site. Thus, non-selective ligands such as S-ethylisothiourea (SEITU), aminopyridine 5, or the selective aminopyridine 6 bound to human iNOS (Figure 2) are anchored through bidendate hydrogen bonds with Glu377. The bulky side chain of 6 induces an opening of invariant
Phe
Val Cα
Phe286
Val305 Cα
Leu288 Cα O
O Asn H2N
H2N
Asn
H2N
Asn
O Arg
HN
Ile269 Cα
NH
H HN N
Arg
Arg
NH2
NH2
H2N
H HN N
O
O O H2N hiNOS Gln-closed (A)
Gln
H2N hiNOS Gln-open
Gln
H2N
Gln
heNOS Gln-open
(B)
Figure 2 (A) X-ray crystal structures of human iNOS in the Gln-closed form (gray carbons-SEITU bound) and Gln-open form (green carbon atoms; compound 6). The bulky inhibitor 6 avoids steric clashes by creation of a new pocket as a result of rotation of first shell residue Gln263 about its w1 and w2 torsion angles. (B) Schematic representation of the movement of residues in iNOS. In eNOS, the Gln-open form is not possible due to the bulky third shell Leu and Ile residues. (See Color Plate 2.2 in Color Plate Section.)
32
Shawn Maddaford et al.
first-shell residues Gln263 and Arg373 inducing a cascading effect of second-shell residue Asn283 toward third-shell residues Phe286 and Val305. Small non-selective inhibitors do not induce this conformational change and thus bind to a first-shell Gln-closed state, whereas the bulky ligand 6 binds to the Gln-open state in a newly created binding pocket. Compound 6 binds weakly to eNOS in a Gln-closed state. In human eNOS, the invariant first (Gln246 and Arg249) and second shell residues (Asn266) are unable to undergo this conformational change required for binding since the final third shell residues are the much bulkier isoleucine (Ile269) and leucine residues (Leu288) compared with the smaller Phe and Val residues found in human iNOS.
O N N
NH2
N
N H
5: iNOS: 0.12 μM 6: iNOS: 0.37 μM eNOS: 0.32 μM eNOS: 100 μM nNOS: 0.16 μM nNOS: 23 μM
O
O
OEt
O
O N
N N
N H 7: iNOS: 0.52 μM eNOS: >100 μM nNOS: 15 μM
N
N H NH2 8: iNOS: 24 μM eNOS: >100 μM nNOS: 39 μM
Although the use of crystal structures can provide valuable insights into the understanding of drug–ligand interactions, caution must be used when interpreting structural data. In general, modelers and medicinal chemists make several assumptions about the protein crystal structure: 1) the protein structure and amino acid sequence is correct; 2) the structure of the ligand and its interactions with the protein are correct; and 3) the protein–ligand structure is relevant for drug discovery. Issues often arise when the resolution of the structure is insufficient to determine the identity or orientation of a ligand in the active site or the position of side chain residues. In addition, crystal structures do not provide information on the thermodynamics of ligand binding and desolvation contributions to the overall binding. A recent example illustrates these limitations of X-ray crystallography in the design of iNOS inhibitors related to structures 6 and 7 [21]. The co-crystal structure of mouse iNOS with 7 revealed a single amino acid difference in contact with the inhibitor (Asp376 in iNOS substituted for Asn in eNOS). Compound 8 was designed in attempts to exploit this difference through an interaction of the basic nitrogen with the Asp residue and displacement of a bound water molecule H-bonded to this residue. Both docking studies and a ˚ ) seemed to confirm this interaction. low resolution X-ray structure (3.3 A However, the in vitro NOS assay revealed a substantial reduction in potency for iNOS (24 mM). It is possible that the loss of hydrogen bonds between the displaced water molecule with the protein or an energy
Advancements in the Development of NOS Inhibitors
33
penalty associated with desolvation of the primary amine group accounts for this loss in potency. In another example, Silverman and co-workers [22] designed an N-hydroxy analog of 3 to displace a structural water molecule hydrogen-bonded between the heme propionate groups of the nNOS enzyme. A crystallographic analysis revealed that indeed the water molecule was successfully displaced, but this change failed to improve the in vitro potency. The successful use of NOS X-ray structures in drug design are discussed in Section 3.2.
3. SELECTIVE NOS INHIBITORS 3.1 Introduction Numerous attempts have been made toward the design of isozymeselective NOS inhibitors targeting both the L-arginine and BH4-binding sites. Early inhibitors were based on modifications of mono- and dipeptides, with subsequent inhibitor design and synthesis utilizing co-crystal structures of all NOS isozymes. Several review articles covering progress toward the development of selective nNOS inhibitor syntheses [23,24], selective iNOS inhibitor syntheses [25], and computational studies [26] have already appeared in the literature. The application of selective NOS inhibitors for various therapeutic indications such as the treatment of shock [27], asthma [28], migraine, tension-type and cluster headache [29], neurological diseases [30], and inflammatory joint diseases [31] were recently reviewed. Many early NOS inhibitors were modified substrate (L-arginine) or product (L-citrulline) analogs. First-generation arginine-based inhibitors such as NG-methyl-L-arginine (L-NMMA), NG-nitro-L-arginine (L-NNA) and its L-nitroarginine methyl ester (L-NAME), NG-amino-L-arginine (LNAA), NG-allyl-L-arginine (L-ALA), NG-cyclopropyl-L-arginine (L-NCPA), and NG-propyl-L-arginine (L-NPA) are reasonably potent but are poorly selective toward the NOS isoforms [23]. The most commonly used arginine-based NOS inhibitors for in vitro and in vivo assays are L-NMMA, L-NNA, and L-NAME, a consequence of commercial availability, chemical stability, water solubility, and low toxicity. Owing to the peptide nature and poor drug-like properties of these inhibitors, non-peptidic small molecule drug design and synthesis are warranted.
3.2 Selective nNOS inhibitors 3.2.1 Peptide-based inhibitors The amino group appears to be very important, whereas the carboxylic group seems unnecessary for enzyme inhibition. In an attempt to
34
Shawn Maddaford et al.
increase isozyme selectivity, the carboxylic acid can be functionalized with amino acids to form dipeptides. Most of the arginine-based dipeptides display excellent potency and selectivity (such as compounds 1 and 2) for rat nNOS over bovine eNOS and murine iNOS [24]. However, the activity of these compounds with human isoforms has not been reported. In an attempt to improve brain penetration, various aminopyridine analogs have been prepared using a de novo design strategy called ‘‘fragment hopping’’ and demonstrate a significant improvement in nNOS activity and selectivity over eNOS [32]. This strategy is based on pharmacophore requirements such as hydrophobic and steric interactions, as demonstrated with compound 4, which revealed lipophilic pockets near the 4-position of the aminopyridine ring and the terminal aminomethyl group. Compounds 9 and 10, derived from 4, are much more potent at nNOS (Ki ¼ 0.08 and 0.01 mM) and selective over eNOS (1000- and 2000-fold) than the corresponding unsubstituted parent compounds [18]. Both compounds prevented hypoxia-ischemia-induced death in a rabbit model for cerebral palsy, also reducing the number of newborn kits exhibiting symptoms of cerebral palsy without affecting blood pressure. Maternal administration of compounds 9 or 10 showed 83% and 69% normal kits, respectively, compared to 9% of saline-treated kits. H N
N H
R
H N
N n
H2N 9: n = 1, R = 4-Cl 10: n = 2, R = 3-F
3.2.2 Non-peptide-based inhibitors 7-Nitroindazole (7-NI, 11) and 1-(2-trifluoromethylphenyl)imidazole (TRIM) (12) [33] are two of the most extensively studied non-peptidic NOS inhibitors, due to a high in vivo selectivity for nNOS despite modest selectivity in vitro (7-NI; rat nNOS IC50 ¼ 0.47 mM and bovine eNOS IC50 ¼ 0.7 mM) [23]. The inhibitory mechanism and selectivity is the result of a reversible competitive interaction with both the L-arginine and the BH4-binding sites in nNOS [34], which is limited to the pterin cofactor site with iNOS and eNOS. In addition to NOS knockout studies, these early ‘‘brain selective’’ inhibitors provided much of the foundation for
35
Advancements in the Development of NOS Inhibitors
elucidating the pharmacological role of nNOS including nociception [35,36], antidepressant and anxiolytic properties [37], modification of opioid-induced side effects, and synergistic enhancement of serotonergic antidepressants [38].
CF3
H N
N N H
Cl N
NH
N
N H
NO2
11
12
S
13
Compound 13 (ARL17477) is a selective nNOS inhibitor with IC50 values of 0.035, 5.0, and 3.5 mM for human nNOS, iNOS, and eNOS, respectively [39]. Evaluation of ARL17477 in a global ischemia model produced a significant reduction (52% protection) in ischemia-induced hippocampal damage following global ischemia dosed immediately (50 mg/kg i.p.) post-occlusion [40]. In addition, ARL17477 was reported to provide greater neuroprotection (44%) than L-NAME (19%), 7-NI (22%), or TRIM (8%) in a gerbil model of global cerebral ischemia. In an endothelin-1 model of focal ischemia, a 1 mg/kg i.v. administration (0, 1, or 2 h post-endothelin-1) of ARL17477 significantly attenuated the infarct volume when compared to pre-treatment with the NMDA antagonist MK-801, post-treatment with the iGluR5 antagonist LY377770, or the immunophilin FK-506. In another study, a combination of ARL17477 with MK-801 or LY293558 provided 78% and 71% greater neuroprotection than the calculated additive effects of the individual treatments [41]. ARL17477 also inhibited electrically induced nitrergic relaxations in pig gastric fundus strips and gastric fundic compliance in conscious pigs in a dose-dependent manner [42]. On the basis of the knowledge that incorporation of a basic side chain could improve potency and selectivity in amidine compounds such as ARL17477, a series of related fused 2-aminodihydroquinoline compounds were designed [43]. Thus, incorporation of the amine side chain into 14a to give 15a improved the potency and selectivity (nNOS over eNOS) up to 224-fold. To improve brain penetration through a reduction in basicity, fluoro analogs 14b and 15b were synthesized. Incorporation of fluorine into the unsubstituted analog 14a decreased the pKa from 9.7 to 7.9 (14a and 14b, respectively) without affecting the potency or selectivity (nNOS ¼ 0.16 mM, 0.1 mM, eNOS ¼ 3.3 mM, 2.7 mM). However, fluorination of the corresponding amine side chain–containing compound 15a to give 15b led to a similar reduction in pKa (9.9 to 8.0) but
36
Shawn Maddaford et al.
was accompanied by a loss in potency relative to the parent compound 15a [44].
H
H X
Cl
X N H
NH
NHR N
NH 16a R = 1-(4-F-Benzylpiperidin-4-yl) 16b R = 2-(1H-Imidazol-5-yl)ethyl
15a: X = H, 15b: X = F
14a: X = H,14b: X = F
S
NH
HN N H
H N
S
A series of substituted 2-aminobenzothiazole inhibitors were shown to be selective toward nNOS over eNOS and iNOS [45]. By varying substitution at the 2-position, up to 40–50-fold selectivity was achieved for human nNOS over eNOS (16a; nNOS ¼ 0.2 mM, eNOS ¼ 8 mM, e/n ¼ 40). It is notable that substantial species differences were observed in some cases such as 16b (IC50 values for human nNOS ¼ 0.3 mM, eNOS ¼ 0.7 mM and iNOS ¼ 6 mM; rat nNOS ¼ 4.7 mM, bovine eNOS ¼ 362 mM). Compound 16b showed neuroprotection in a concentrationdependent manner, when preincubated for 60 min before NMDA challenge in rat cortical cultures. At 50 and 100 mM concentration, increases in cell survival rates of 80% and 90%, respectively, were observed, compared to 30% in NMDA-treated controls [46].
NH
N S H N
S NH
N
N H
NH
N
N
N H 17
H N
S
N 18
19
Various di-substituted indole compounds were investigated for their activity in all three human NOS isozymes and showed submicromolar potencies for nNOS and good selectivity for nNOS over both eNOS and iNOS [47,48]. In this study, the basic amine side chain was varied at both the 1- and the 3-positions on the indole and the amidine group between the 5- and the 6-positions. The most potent compound in the series was obtained with the basic amine group at the 1-position and with the amidine at the 5-position (IC50: human nNOS ¼ 0.02 mM; eNOS ¼ 1.92; iNOS ¼ 17 mM). Alternatively, the best selectivity was achieved with a quinuclidine-based system and the basic side chain at the 3-position
Advancements in the Development of NOS Inhibitors
37
(17; human IC50: nNOS ¼ 0.76 mM, eNOS ¼ 103 mM, iNOS ¼ 89; e/n ¼ 136, i/n ¼ 117). In further studies, compound 18 (human IC50: nNOS ¼ 1.2 mM, eNOS ¼ 15 mM, iNOS ¼ 60; e/n ¼ 12.5, i/n ¼ 50) was highly neuroprotective and demonstrated efficacy in multiple pain models. Pre-incubation of rat cortical cells at 25 mM concentration of 18 followed by an NMDA challenge resulted in 95% cell survival when compared to only 50% in NMDA-treated controls. In a separate experiment, 18 was able to reduce hippocampal cell death up to 95% in a concentration-dependent manner after oxygen–glucose deprivation. The antinociceptive effect of compound 18 was measured by formalininduced hyperalgesia and inflammation in an experimental model of sustained inflammatory nociception associated with long-term intracellular changes of nociceptive processing at the level of the spinal cord. Pre-administration of compound 18 (5 and 10 mg/kg i.p.) or 7-NI (2.5 and 5 mg/kg i.p.) reduced paw licking in a concentration-dependent manner for both compounds indicating efficacy for the treatment of inflammatory pain. In the Chung Spinal Nerve Ligation (SNL) neuropathic pain model, 18 demonstrated a complete reversal of both thermal and tactile hyperalgesia in rats after 3 and 20 mg/kg i.p. administration, respectively. A series of indoline, oxindole, tetrahydroquinoline, quinolone, and benzazepine derivatives were explored in an attempt to identify selective human nNOS inhibitors [49]. In this study, nanomolar potency for human nNOS (IC50 ¼ 0.01 mM) and more than 1,000-fold selectivity over eNOS (IC50 ¼ 14.2 mM) was achieved. Compound 19 (nNOS ¼ 0.34 mM, eNOS ¼ 48 mM, e/n ¼ 141) was able to completely reverse tactile allodynia in the sciatic nerve cuff model of neuropathic pain after i.p. administration at 30 mg/kg. At the same time, compound 19 was able to reduce the frequency of paw lifts up to 50% on a cold platform in the same model after multiple dose administration. The 2-aminopyridine group serves as an effective isosteric replacement of the guanidinium group and even simple derivatives such as 4-methyl-2-aminopyridine exhibit potent but non-selective inhibition of NOS. Analogs such as 20 are potent nNOS inhibitors with modest selectivity over eNOS (nNOS ¼ 140 nM, eNOS ¼ 887 nM, e/n ¼ 6) with minimal off-target activity at m2 and m4 receptors (Ki ¼ 0.32 mM and 0.59 mM, respectively) [50]. Pharmacokinetic studies with 20 after subcutaneous administration (24 mg/kg) gave a Cmax of 1.7 mg/mL in plasma, 0.45 mg/mL in cerebrospinal fluid (CSF), and 11 mg/g in whole brain, indicating sufficient brain levels to inhibit nNOS in vivo. Although the compound did not increase blood pressure in rats at doses of up to 100 mg/kg, the rat eNOS values were not reported. Further modifications of this scaffold by incorporating bulk onto the phenyl ring further increased the selectivity for nNOS (e.g., 21, e/n ¼ 50) [51]. Compound 21
38
Shawn Maddaford et al.
was active in the harmaline-induced cGMP model in rat cerebellum (ED50 ¼ 7 mg/kg s.c.). In contrast to 20, compound 21 inhibited phencyclidine (PCP)-induced hypermotility (2.8 mg/kg s.c.) in rats, a model used to assess antipsychotic agents.
N O
NH2
N
NH2
N
N
O
N Ph
20
21
A set of 41 pteridine nNOS-selective inhibitors employing four scaffolds was developed by a combination of ligand- and structure-based design [52]. The X-ray crystal structure for rat NOS-dimeric oxygenase domain with BH4 and L-arginine was used to develop a human isoform homology model. Substitution on the 4-, 5-, 6-, and 7-positions are necessary for both affinity and selectivity. Bulky and hydrophobic substituents at the 5- or 6-position increased the selectivity for nNOS over iNOS and eNOS. The tetrahydro antipterins were more active and selective for nNOS over eNOS; up to 58-fold selectivity was observed with compound 22. Ph Cl 5 H N
HN 4 3N
6
2 H2N
N H 8
N 1
7
22
3.3 Selective iNOS inhibitors Inducible NOS has been implicated in a number of inflammatory diseases such as septic shock, multiple sclerosis, rheumatoid and osteoarthritis, ulcerative colitis, and asthma. Not surprisingly, many research institutions have developed programs to design inhibitors of iNOS. In addition to
Advancements in the Development of NOS Inhibitors
39
potency, selectivity against the other two isoforms, especially eNOS, is required since they are important in normal physiology. Selective inhibitors of iNOS have been reviewed previously [25]. Early inhibitors of iNOS were simple analogs of the substrate L-arginine in which the guanidine group or the side-chain had been modified. Compound 23 (GW274150), a selective and modestly potent inhibitor of human iNOS (IC50 ¼ 1.4 mM) has completed a phase II clinical trial for the acute and prophylactic treatment of migraine headache and asthma [53]. HN
O S
HO NH2
O N
N H N H H
23
O
H
24
NH
N
N H
CN 25
In general, due to their physicochemical properties, amino acid arginine-like inhibitors will rely on active transport processes for their absorption and distribution. Consequently, a great deal of effort has been invested in discovering NOS inhibitors with more drug-like properties. Amidines and isothiourea derivatives have been developed to replace the guanidino group, a key anchor point in the active site. Generally, the isothioureas are more selective for nNOS while amidines tend to be selective for iNOS. Considerable effort has been expended in the design and synthesis of selective amidine iNOS inhibitors. Notably, the fused bicyclic amidine, 24, has been reported to inhibit human iNOS with an IC50 ¼ 22 nM and greater than 30-fold selectivity over eNOS, but only two-fold over nNOS [54]. The ability of compound 24 to inhibit iNOS activity in vivo was measured in a rat endotoxin assay. This model measures the plasma nitrate/nitrite (NOx) levels due to the induction of iNOS following LPS administration. An oral dose of 24 (10 mg/kg) given at 1 or 16 h before LPS challenge showed complete inhibition or 40% reduction of NOx respectively, at the 5-h time points. This demonstrates that efficacious levels of 24 can be maintained in circulation for more than 16 h. The 2-aminopyridine group used as an isosteric replacement for amidines is generally less basic and should therefore be more membrane permeable. The N-alkylated aminopyridine 25 is a potent (71 nM) and selective (W1,000- and 100-fold selective against eNOS and nNOS, respectively) inhibitor of iNOS [55]. Reported in a later publication, compound 25 was tested in a rat model of LPS-induced NO production and showed an oral dose-dependent inhibition of elevated plasma NOx levels (IC50 ¼ 1.8 mM) measured 4 h after LPS administration [17].
40
Shawn Maddaford et al.
Most competitive NOS inhibitors possess a minimum pharmacophore of a basic cis-amidine (a guanidine isostere) required for a bidentate interaction with the carboxyl group of Glu371. The imidazopyridine 26 and the spirocyclic quinazoline 27 represent novel classes of potent and selective iNOS inhibitors bearing a masked cis-amidine moiety. Compound 26, a potent iNOS arginine-competive inhibitor (86 nM) exhibiting more than 1,500-fold selectivity over eNOS and 80-fold selectivity over nNOS, was identified by screening a corporate compound library [56]. Inhibition of iNOS-derived NOx formation in various intact cells following LPS treatment was observed for compound 26: nitrite generation after induction of iNOS was inhibited with IC50 values of 3.1 mM in murine macrophage cell line RAW, 33 mM in rat mesangial cell line RMC, and 13 mM in a human HEK293/iNOS assay. The spirocyclic quinazoline 27 inhibits purified recombinant human iNOS (IC50 ¼ 37 nM) and NO synthesis in a whole cell assay (human DLD-1 cells, IC50 ¼ 0.9 mM) [57]. The compound was shown to be selective over nNOS (25-fold) and eNOS (W2,000-fold). When given orally to rats, 27 produced a dose-dependent inhibition of NO production induced by LPS (ID50 ¼ 3 mmol/kg, 4 h post-dose). In addition, 27 showed efficacy in the Freund’s complete adjuvant-induced polyarthritis model in rats. Administration of 27 (10–100 mmol/kg p.o., twice daily) commenced on the day of challenge delayed the onset of observable symptoms (inflammation, edema, pain, and joint destruction) and reduced their severity in a dose-dependent manner (ED50 at 20 d timepoint B10 mmol/kg). At a higher dose (100 mmol/kg), the compound completely abolished all indications of developing arthritis for the full 20 days of the experiment. O
O F N
N
N
F
N N
N
HN
26
NH2 N
H N
S
CN HN
O
O
NH2
27
28
The structure-based design of compound 28 was based on the ‘‘anchored plasticity’’ approach (vide ante) [17]. Compound 28, with a cyclic amidine, inhibits human iNOS with an IC50 ¼ 0.4 mM and greater than 100-fold selectivity over eNOS. However, the selectivity over nNOS was only 2-fold. Compound 29 is an L-arginine competitive human iNOS inhibitor (IC50 ¼ 90 nM) that was optimized from a high-throughput screening (HTS) hit [58]. The compound does not contain a guanidine mimic that
Advancements in the Development of NOS Inhibitors
41
distinguishes it from other compounds described in the literature. It appears to interact primarily through p-stacking and non-bonded interactions. Compound 29 inhibits rat nNOS (IC50 ¼ 0.56 mM) and bovine eNOS (IC50 ¼ 11.1 mM). A new series of aminopiperidines with potent human iNOS activity (IC50 ¼ 0.33 mM; e/iW25, n/i ¼ 16) represented by compound 30 was reported recently [59]. Again as in compound 29, the optimized HTS hit 30 does not contain a guanidine-like functionality, and docking studies reveal that 30 p-stacks with the heme.
CN O
NH2
Cl
O
H N
O
N O
N N
O
29
O
NH
Cl
N
N
30
N
31
A unique class of iNOS inhibitors was obtained by screening a combinatorial library using a whole-cell assay [60]. These compounds inhibit the dimerization of iNOS monomers, thus preventing the formation of the active dimeric form of the enzyme. Optimization led to the identification of compound 31 (IC50 ¼ 14 nM) with selectivity greater than 500 for eNOS and 300 for nNOS. This compound is orally available and was shown to significantly ameliorate adjuvant-induced arthritis in a rat model.
4. CLINICAL FINDINGS WITH NOS INHIBITORS Early clinical trials [61] shed light on the role of NO in the mechanism of migraine pain. In several double-blind studies [62–64], it was shown that after intravenous administration of nitroglycerine (GTN), non-migraineurs rapidly developed a headache that subsided after removal of GTN, whereas migraineurs developed an initial headache, followed by a delayed (B5–6 h) migraine attack [65], suggesting that NO may be partially or completely responsible for migraine pain. A similar observation was made by using sublingual isosorbide dinitrate, another NO donor [65]. The first clinical trial with a NOS inhibitor was conducted using the non-selective NOS inhibitor L-NMMA (32) for the treatment of migraine headache. In a randomized double-blind study, 15 migraine patients with
42
Shawn Maddaford et al.
single spontaneous attacks were infused with 6 mg/kg L-NMMA or placebo (5% dextrose) over a period of 15 min and monitored at 0, 30, 60, and 120 min post-dosing for headache severity, clinical disability (scored on a scale of 0–3), nausea, photophobia, and phonophobia. Heart rate, blood pressure, and ECG were also monitored continuously. A significant antimigraine effect was observed in patients relative to placebo, 67% vs. 25%, albeit with an increase in blood pressure by 17% and decrease in heart rate by 21%. The antimigraine effect was treatment related, most likely the result of specific inhibition of NOS [66–68] and not due to a direct vasoconstriction effect. Migraine relief associated with vasoconstriction was ruled out because of a lack of effect of L-NMMA observed on transcranial Doppler-determined velocity in the middle cerebral artery of the patients. A similar study in the reduction of CTTH by the infusion of L-NMMA was reported [69,70], although the effect was not as pronounced as in the case of migraine headache. NH N H
N H
CO2H NH2
32
In a recent study [71], the effect of infusion of 6 mg/kg L-NMMA on basal and acetazolamide induced changes in cerebral arteries and regional blood flow, indicating that the non-selective NOS inhibitor decreased regional cerebral blood flow only to a minor degree. The authors inferred that in migraine with aura where cerebral blood flow is reduced, treatment of migraine with aura with non-specific inhibitors of NOS might be problematic. Most recently, at the European Headache and Migraine Trust International Congress 2008, three companies presented the results of the effect of NOS inhibitors for the treatment of either acute migraine or migraine prophylaxis. In a study conducted with the selective iNOS inhibitor GW274150 (23) using up to 120 mg daily for 12 weeks for the prophylactic treatment of migraine, the drug was found to be no more effective than the placebo although it did not manifest any intolerable side effects [72]. In a related study utilizing an adaptive clinical trial of GW274150 in the treatment of acute migraine, no significant differences between any of the doses, ranging from 5 to 180 mg, and placebo were observed in the proportion of subjects who became pain free at 2 h after treatment [73]. In addition, no treatment-related benefit was observed for
Advancements in the Development of NOS Inhibitors
43
other migraine symptoms including nausea, photophobia, phonophobia, and allodynia. Since GW274150 is known to reduce exhaled NO levels in patients [74], these studies indicate that the antimigraine effect of L-NMMA is not related to inhibition at the iNOS isoform. In a placebocontrolled double-blind study, the non-selective NOS inhibitor S-alkyl isothiourea MTR-106 was found to be effective in female migraine patients without aura [75]. The study showed statistically significant pain reduction after 2 h with 23% of subjects remaining pain free after 24 h. Although there was no dose-dependent relationship (25, 50, 75, and 100 mg), the drug exhibited linear pharmacokinetics and more adverse effects with higher doses. Recent phase I clinical trials with NXN-188, a novel dual action nNOS inhibitor with 5-HT1B/D agonism, assessed the safety and tolerability of the drug after once daily or multiple twice daily oral doses [76]. The compound exhibited an initial rapid absorption, followed by a more prolonged absorption phase with a Tmax of 4–5 h. The drug displayed near linear pharmacokinetics over the dose range studied (0.027–16 mg/kg). Of the 168 patients that received active drug, no serious adverse events were reported up to the maximally administered dose of 800 mg. Importantly, it was noted that NXN-188 had no effect on blood pressure in the treated patients unlike the non-selective NOS inhibitor L-NMMA. NXN-188 was also studied for the treatment of acute migraine in a phase II study wherein the drug produced extended relief in patients [77]. Future studies will be required to fully elucidate the pharmacological effects of combined nNOS inhibition and 5HT1D/B agonism on the pharmacological profile relative to the existing triptans. Besides inhibition of NOS, another strategy to reduce the amount of NO in migraine patients is to use a NO scavenger. In an open trial, the NO scavenger hydroxocobalamin was assessed in migraine prophylaxis. Daily treatment with intranasal hydroxocobalamin (1 mg) for a period of 3 months demonstrated W50% reduction in the frequency of migraine attacks in 10 of 19 patients. Given the percentage of responders was 35–40%, it is unlikely that this was a placebo effect [78].
5. FUTURE DIRECTIONS — DUAL ACTION NOS INHIBITORS 5.1 Introduction Before the development of molecular biology, traditional drug discovery relied on the use of in vivo animal models of disease to seek out new medicines, often without knowledge of the molecular mechanisms of
44
Shawn Maddaford et al.
their action. Many of the older ‘‘dirty’’ drugs discovered by this means, albeit very efficacious, suffered from undesirable off-target-related side effects. This resulted in a paradigm shift in drug discovery toward optimization of compounds against a single molecular target. Although this approach has delivered many new drugs with potentially fewer side effects, many complex, multifactorial diseases such as cancer, diabetes, and pain are still inadequately treated with single-action drugs. It is likely that complex diseases arise from a complicated network of interdependent biological changes occurring in multiple organs over a period of time. Still, prediction of efficacy or off-target side effects for a single mechanism compound must be put in the context of interspecies differences in target potency and selectivity and the usefulness of acute animal models of disease for evaluating complex, chronic human diseases. To address this biological complexity, there is an increasing readiness to develop agents that modulate multiple targets simultaneously (polypharmacology) and to develop new animal models of chronic disease, with the aim of enhancing efficacy or improving safety relative to drugs that address only a single target.
5.2 Dual action nNOS inhibitors It has been shown that a combination of a nNOS inhibitor and an antioxidant in a model of focal ischemia was synergistic in reducing neuronal damage [79]. A novel strategy for the treatment of stroke consists of designing hybrid molecules such as compound 33, which possess a NOS inhibitor pharmacophore linked to an antioxidant fragment to scavenge reactive oxygen species (ROS). This compound displayed potent nNOS inhibition (Ki ¼ 0.12 mM) and inhibition of lipid peroxidation induced by ROS (IC50 ¼ 0.4 mM). Scavenging ROS and inhibiting NOS simultaneously has been shown to enhance neuronal survival after cerebral ischemia in animal models [80]. Given that NO reacts with O2 to form peroxynitrite, it is perhaps not surprising that the two mechanisms work synergistically. The inhibition of nNOS is known to enhance opioid analgesia and reduce the development of tolerance. It has been shown that the development of morphine-induced hyperalgesia after chronic administration in rats can be delayed or reversed by the addition of a selective nNOS inhibitor [46]. Thus, a dual nNOS inhibitor and m-opioid receptor agonist would be beneficial in the treatment of various pain states. Benzimidazole 34 inhibits nNOS (IC50 ¼ 0.44 mM) and binds to the m-opioid receptor with an IC50 ¼ 13 nM [81]. In a functional assay, the compound displayed much weaker m-opioid receptor agonist activity (EC50 ¼ 0.44 mM).
45
Advancements in the Development of NOS Inhibitors NEt2
N S
H N N H HO
NH
S
S
N
NH
H N
N
N H
NH
N H
OEt
33
34
35
NO derived from nNOS appears to modify the activity of many neurotransmitter systems including glutamate (NMDA), opioid, GABA, and serotonin, likely through spatiotemporal interactions of the nNOS protein with these systems. As an example, nNOS appears to co-localize with the serotonin transporter (SERT) in serotonergic neurons through PDZ-binding domains (PDZ is an acronym combining the first letters of three proteins — post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (DlgA), and zonula occludens-1 protein (zo-1)). This negatively regulates SERT activity, and SERT-mediated 5-HT uptake enhances nNOS activity. Conversely, administration of selective 5-HT reuptake inhibitors or tricyclic antidepressants into the hippocampus reduces nNOS activity. In an effort to reduce the cardiovascular side effect of the triptans, hybrid compounds with both selective nNOS inhibition and 5HT1D/1B agonism were designed. The triptan-like 35 inhibits nNOS (IC50 ¼ 0.89 mM, 40-fold selective over eNOS) and binds to both the 5HT1D and the 5HT1B receptors (5HT1D IC50 ¼ 130 nM and 5HT1B IC50 ¼ 310 nM) [48].
5.3 Dual action iNOS inhibitors In an inflammatory setting or in the presence of endotoxin and cytokines, the inducible NOS isoform is expressed in numerous cell types. Cyclooxygenase (COX), an enzyme which converts arachidonic acid to prostaglandins (PG), is another critical enzyme in many inflammatory diseases. Studies have shown that production of high levels of PG can be augmented in the presence of NO. Early amino acid–selective inhibitors of iNOS such as N-iminoethyl-L-lysine (L-NIL) have been shown to not only block NO formation but also attenuate the elevated release of prostaglandins [82]. The c-Src kinase was identified as a proto-oncogene, and in some abnormal cases, such as mutation or over-expression, these enzymes can become hyperactivated, resulting in uncontrolled cell proliferation. The role of iNOS during tumor development is highly complex and incompletely understood, but there is evidence to show that the malignant transformation, angiogenesis, and metastasis effects of tumors are all modulated by iNOS. A potential anticancer strategy involves the dual inhibition of c-Src and iNOS, two key enzymes in tumorigenesis.
46
Shawn Maddaford et al.
Modification of a protein tyrosine kinase inhibitor to incorporate an NOS pharmacophore led to compound 36. This compound potently inhibits c-Src kinase (IC50 ¼ 9.2 nM) and is a modest inhibitor for iNOS of mouse macrophage ANA-1 (IC50 ¼ 2.2 mM) [83]. Studies have shown that iNOS and peroxisome proliferator-activated receptor g (PPARg) play important roles in neuroinflammation. For instance, the PPARg agonists Rosiglitazone and Pioglitazone, which are approved for the treatment of diabetes, preserve cognitive function in early Alzheimer’s patients and attenuate learning and memory deficits in transgenic Alzheimer mouse models. In a rat spinal cord injury model, treatment of rats with thiazolidinedione PPARg agonists prevented neuronal damage, motor dysfunction, myelin loss, and the development of neuropathic pain [84]. Similarly, increased iNOS function is important in neuroinflammation and pain. A series of 2-phenyl-ethenesulfonic acid phenyl esters were synthesized and shown to suppress NO production in LPS/interferon g-stimulated RAW 264.7 cells and activate PPARg in a cell-based transactivation assay [85]. Compound 37 inhibits iNOS activity (IC50 ¼ 1.8 mM) in a whole cell assay and binds competitively to the PPARg receptor (IC50 ¼ 1.4 mM).
O
Cl
N
O
N
O S
N O
CN
O Cl
NH
S
Cl
N
36
37
6. CONCLUSIONS The preceding sections of this review exemplify the connection between NO and various central nervous system (CNS) disorders. Therefore, targeting isoforms of NOS may be a valid strategy to produce novel mechanism-based therapeutics. Despite the enormous efforts by multiple groups to obtain isoform-selective compounds, it is surprising that no candidates have progressed into the clinic until recently. One of the reasons may be that in most cases, the enzymes chosen for primary assay were of rat, mouse, or bovine origin and not of human origin. Although
Advancements in the Development of NOS Inhibitors
47
there is considerable homology between the enzymes from different species, differences in the inhibitory potencies exist between species (e.g., compound 16b). Therefore, a rat isoform-selective compound showing the desired pharmacological effect in rats (usual animal species for initial screening) may not translate into humans because of low potency or non-selectivity in human forms of the enzymes. Still, tremendous progress has been achieved in the design and synthesis of selective nNOS or iNOS inhibitors using various techniques including structure-based design and HTS. These recent compounds are more drug-like as demonstrated by preclinical animal studies and recent clinical trials. Novel chemical entities that combine several selective and additive mechanisms into one molecule (designed multiple ligands) [86] may also address the failure of current analgesics to control hyperalgesia and allodynia. It can be hoped that NOS inhibitors with appropriate potency and selectivity, and dual action selective nNOS or iNOS small molecule inhibitors incorporating additional mechanisms of action will ultimately improve the current standard of care for pain management [87] and the treatment of CNS disorders.
REFERENCES [1] L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns and G. Chaudhuri, Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 9265. [2] R. F. Furchgott, in Mechanisms of Vasodilation (ed. P. M. Vanhoutte), Raven, New York, 1988, pp. 401–404. [3] P. Vallance and J. Leiper, Nat. Rev. Drug. Disc., 2002, 1, 939. [4] A. J. Cayatte, J. J. Palacino, K. Horten and R. A. Cohen, Arterioscler. Thromb., 1994, 14, 753. [5] J. M. Fukuto and Y. Komori, Annu. Rep. Med. Chem., 1994, 29, 83. [6] J. E. MacDonald, Annu. Rep. Med. Chem., 1996, 31, 221. [7] D. J. Stuehr, Annu. Rev. Pharmacol. Toxicol., 1997, 37, 339. [8] D. S. Bredt, P. M. Hwang, C. E. Glatt, C. Lowenstein, R. R. Reed and S. H. Snyder, Nature, 1991, 351, 714. [9] H. J. Cho, Q. W. Xie, J. Calaycay, R. A. Mumford, K. M. Swiderek, T. D. Lee and C. Nathan, J. Exp. Med., 1992, 176, 599. [10] T. O. Fischmann, A. Hruza, X. D. Niu, J. D. Fossetta, C. A. Lunn, E. Dolphin, A. J. Prongay, P. Reichert, D. J. Lundell, S. K. Narula and P. C. Weber, Nat. Struct. Biol., 1999, 6, 233. [11] S. Pou, L. Keaton, W. Surichamorn and G. M. Rosen, J. Biol. Chem., 1999, 274, 9573. [12] B. R. Crane, A. S. Arvai, R. Gachhui, C. Wu, D. K. Ghosh, E. D. Getzoff, D. J. Stuehr and J. A. Tainer, Science, 1997, 278, 425. [13] B. R. Crane, A. S. Arvai, D. K. Ghosh, C. Wu, E. D. Getzoff, D. J. Stuehr and J. A. Tainer, Science, 1998, 279, 2121. [14] C. S. Raman, H. Li, P. Marta´sek, V. Kral, B. S. S. Masters and T. L. Poulos, Cell, 1998, 95, 939. [15] H. Li, C. S. Raman, C. B. Glaser, E. Blasko, T. A. Young, J. F. Parkinson, M. Whitlow and T. L. Poulos, J. Biol. Chem., 1999, 274, 21276.
48
Shawn Maddaford et al.
[16] H. Li, H. Shimizu, M. Flinspach, J. Jamal, W. Yang, M. Xian, T. Cai, E. Z. Wen, Q. Jia, P. G. Wang and T. L. Poulos, Biochemistry, 2002, 41, 13868. [17] E. D. Garcin, A. S. Arvai, R. J. Rosenfeld, M. D. Kroeger, B. R. Crane, G. Andersson, G. Andrews, P. J. Hamley, P. R. Mallinder, D. J. Nicholls, S. A. St-Gallay, A. C. Tinker, N. P. Gensmantel, A. Mete, D. R. Cheshire, S. Connolly, D. J. Stuehr, A. Aberg, A. V. Wallace, J. A. Tainer and E. D. Getzoff, Nat. Chem. Biol., 2008, 4, 700. [18] J. Haitao, L. Huiying, P. Marta´sek, L. J. Roman, T. L. Poulos and R. B. Silverman, J. Med. Chem., 2009, 52, 779. [19] M. L. Flinspach, H. Li, J. Jamal, W. Yang, H. Huang, J.-M. Hah, J. A. Go´mez-Vidal, E. A. Litzinger, R. B. Silverman and T. L. Poulos, Nat. Struct. Mol. Biol., 2004, 11, 54. [20] C. S. Raman, H. Li, P. Marta´sek, G. Southan, B. S. S. Masters and T. L. Poulos, Biochemistry, 2001, 40, 13448. [21] A. M. Davis, S. A. St-Gallay and G. J. Kleywegt, Drug. Disc. Today, 2008, 13, 831. [22] J. Seo, J. Igarashi, H. Li, P. Marta´sek, L. J. Roman, T. L. Poulos and R. B. Silverman, J. Med. Chem., 2007, 50, 2089. [23] E. P. Erdal, E. A. Litzinger, J. Seo, Y. Zhu, H. Ji and R. B. Silverman, Curr. Top. Med. Chem., 2005, 5, 603. [24] R. B. Silverman, Acc. Chem. Res., 2009, 42, 439. [25] A. C. Tinker and A. V. Wallace, Curr. Top. Med. Chem., 2006, 6, 77. [26] A. Tafi, L. Angeli, G. Venturini, M. Travagli, F. Corelli and M. Botta, Curr. Med. Chem., 2006, 13, 1929. [27] L. G. Howes and D. G. Brillante, Exp. Opin. Invest. Drugs, 2008, 17, 1573. [28] G. Folkerts and F. P. Nijkamp, Curr. Pharm. Des., 2006, 12, 3221. [29] J. Olesen, Pharmacol. Ther., 2008, 120, 157. [30] P.-E. Chabrier, C. Demerle-Pallardy and M. Auguet, Cell. Mol. Life Sci., 1999, 55, 1029. [31] D. O. Stichtenoth and J. C. Frolish, Br. J. Rheumatol., 1998, 37, 246. [32] H. Ji, B. Z. Stanton, J. Igarashi, H. Li, P. Marta´sek, L. J. Roman, T. L. Poulos and R. B. Silverman, J. Am. Chem. Soc., 2008, 130, 3900. [33] R. L. C. Handy, P. Wallace, Z. A. Gaffen, K. J. Whitehead and P. K. Moore, Br. J. Pharmacol., 1995, 116, 2349. [34] R. L. C. Handy and P. K. Moore, Life Sci., 1997, 60, 389. [35] M. Boulouard, P. Schumann-Bard, S. Butt-Gueulle, E. Lohou, S. Stiebing, V. Collot and S. Rault, Bioorg. Med. Chem. Lett., 2007, 17, 3177. [36] B. Cottyn, F. Acher, B. Ramassamy, L. Alvey, M. Lepoivre, Y. Frapart, D. Stuehr, D. Mansuy, J.-L. Boucher and D. Vichard, Bioorg. Med. Chem., 2008, 16, 5962. [37] V. Volke, G. Wegener, M. Bourin and E. Vasar, Behav. Brain Res., 2003, 140, 141. [38] G. Ulak, O. Mutlu, F. Y. Akar, F. I. Komsuog˘lu, P. Tanyeri and B. F. Erden, Pharmacol. Biochem. Behav., 2008, 90, 563. [39] L. Salerno, V. Sorrenti, C. Di Giacomo, G. Romeo and M. A. Siracusa, Curr. Pharm. Des., 2002, 8, 177. [40] M. J. O’Neill, T. K. Murray, D. R. McCarty, C. A. Hicks, C. P. Dell, K. E. Patrick, M. A. Ward, D. J. Osborne, T. R. Wiernicki, C. R. Roman, D. Lodge, J. H. Fleisch and J. Singh, Brain Res., 2000, 871, 234. [41] C. A. Hicks, M. A. Ward, J. B. Swettenham and M. J. O’Neill, Eur. J. Pharmacol., 1999, 381, 113. [42] R. A. Lefebvre, J. M. C. Dick, S. Guerin and C.-H. Malbert, Eur. J. Pharmacol., 2005, 525, 143. [43] S. Jaroch, P. Holscher, H. Rehwinkel, D. Sulzle, G. Burton, M. Hillmann and F. M. McDonald, Bioorg. Med. Chem. Lett., 2003, 13, 1981. [44] S. Jaroch, H. Rehwinkel, P. Holscher, D. Sulzle, G. Burton, M. Hillmann, F. M. McDonald and H. Miklautz, Bioorg. Med. Chem. Lett., 2004, 14, 743. [45] J. Patman, N. Bhardwaj, J. Ramnauth, S. C. Annedi, P. Renton, S. P. Maddaford, S. Rakhit and J. S. Andrews, Bioorg. Med. Chem. Lett., 2007, 17, 2540.
Advancements in the Development of NOS Inhibitors
49
[46] J. Ramnauth, N. Bhardwaj, S. Rakhit and S. Maddaford, US Patent 7141595 B2, 2006. [47] S. Maddaford, J. Ramnauth, S. Rakhit, J. Patman, P. Renton and S. C. Annedi, PCT Patent WO 2007118314 A1, 2007. [48] S. Maddaford, J. Ramnauth, S. Rakhit, J. Patman, P. Renton and S. C. Annedi, US Patent US2006258721 A1, 2006. [49] S. Maddaford, J. Ramnauth, S. Rakhit, J. Patman, S. C. Annedi, J. Andrews, P. Dove, S. Silverman and P. Renton, PCT Patent WO 2008116308 A1, 2008. [50] J. A. Lowe III, W. Qian, R. A. Volkmann, S. Heck, J. Nowakowski, R. Nelson, C. Nolan, D. Liston, K. Ward, S. Zorn, C. Johnson, M. Vanase, W. S. Faraci, K. A. Verdries, J. Baxter, S. Doran, M. Sanders, M. Ashton, P. Whittle and M. Stefaniak, Bioorg. Med. Chem. Lett., 1999, 9, 2569. [51] J. A. Lowe III, W. Qian, S. E. Drozda, R. A. Volkmann, D. Nason, R. B. Nelson, C. Nolan, D. Liston, K. Ward, S. Faraci, K. Verdries, P. Seymour, M. Majchrzak, A. Villalobos and W. F. White, J. Med. Chem., 2004, 47, 1575. [52] H. Matter, H. S. A. Kumar, R. Fedorov, A. Frey, P. Kotsonis, E. Hartmann, L. G. Froehlich, A. Reif, W. Pfleiderer, P. Scheurer, D. K. Ghosh, I. Schlichting and H. H. H. W. Schmidt, J. Med. Chem., 2005, 48, 4783. [53] R. J. Young, R. M. Beams, K. Carter, H. A. R. Clark, D. M. Coe, C. L. Chambers, P. I. Davies, J. Dawson, M. J. Drysdale, K. W. Franzman, C. French, S. T. Hodgson, H. F. Hodson, S. Kleanthous, P. Rider, D. Sanders, D. A. Sawyer, K. J. Scott, B. G. Shearer, R. Stocker, S. Smith, M. C. Takley and R. G. Knowles, Bioorg. Med. Chem. Lett., 2000, 10, 597. [54] R. N. Guthikonda, S. K. Shah, S. G. Pacholok, J. L. Humes, R. A. Mumford, S. K. Grant, R. M. Chabin, B. G. Green, N. Tsou, R. Ball, D. S. Fletcher, S. Luell, D. E. MacIntyre and M. MacCoss, Bioorg. Med. Chem. Lett., 2005, 15, 1997. [55] S. Connolly, A. Aberg, A. Arvai, H. G. Beaton, D. R. Cheshire, A. R. Cook, S. Cooper, D. Cox, P. Hamley, P. Mallinder, I. Millichip, D. J. Nicholls, R. J. Rosenfeld, S. A. St-Gallay, J. Tainer, A. C. Tinker and A. V. Wallace, J. Med. Chem., 2004, 47, 3320. [56] A. Strub, W.-R. Ulrich, C. Hesslinger, M. Eltze, T. Fuchss, J. Strassner, S. Strand, M. D. Lehner and R. Boer, Mol. Pharmacol., 2006, 69, 328. [57] A. C. Tinker, H. G. Beaton, N. Boughton-Smith, T. R. Cook, S. L. Cooper, L. Fraser-Rae, K. Hallam, P. Hamley, T. McInally, D. J. Nicholls, A. D. Pimm and A. V. Wallace, J. Med. Chem., 2003, 46, 913. [58] S. A. Jackson, S. Sahni, L. Lee, Y. Luo, T. R. Nieduzak, G. Liang, Y. Chiang, N. Collar, D. Fink, W. He, A. Laoui, J. Merrill, R. Boffey, P. Crackett, B. Rees, M. Wong, J.-P. Guilloteau, M. Mathieu and S. S. Rebello, Bioorg. Med. Chem., 2005, 13, 2723. [59] B. Le Bourdonnec, L. K. Leister, C. A. Ajello, J. A. Cassel, P. R. Seida, H. O’Hare, M. Gu, G.-H. Chu, P. A. Tuthill, R. N. DeHaven and R. E. Dolle, Bioorg. Med. Chem. Lett., 2008, 18, 336. [60] D. D. Davey, M. Alder, D. Arnaiz, K. Eagen, S. Erickson, W. Guilford, M. Kenrick, M. M. Morrissey, M. Ohlmeyer, G. Pan, V. M. Paradkar, J. Parkinson, M. Polokoff, K. Saionz, C. Santos, B. Subramanyam, R. Vergona, R. G. Wei, M. Whitlow, B. Ye, Z. Zhao, J. J. Devlin and G. Phillips, J. Med. Chem., 2007, 50, 1146. [61] J. Olesen, H. K. Iversen and L. L. Thomsen, NeuroReport, 1993, 4, 1027. [62] J. Olesen, L. L. Thomsen and H. Iversen, Trends in Pharmacol. Sci., 1994, 15, 149. [63] L. L. Thomsen, H. K. Iversen, T. A. Brinck and J. Olesen, Cephalalgia, 1993, 13, 395. [64] S. K. Afridi, H. Kaube and P. J. Goadsby, Pain, 2004, 110, 675. [65] P. Bellantonio, G. Micieli, M. G. Buzzi, S. Marcheselli, A. E. Castellano, F. Rossi and G. Nappi, Cephalalgia, 1997, 17, 183. [66] L. H. Lassen, M. Ashina, I. Christiansen, V. Ulrich and J. Olesen, Lancet, 1997, 349, 401. [67] L. H. Lassen, H. K. Iversen and J. Olesen, Eur. J. Clin. Pharmacol., 2003, 59, 499.
50
Shawn Maddaford et al.
[68] L. H. Lassen, M. Ashina, I. Christiansen, V. Ulrich, R. Grover, J. Donaldson and J. Olesen, Cephalalgia, 1998, 18, 27. [69] M. Ashina, L. H. Lassen, L. Bendtsen, R. Jensen and J. Olesen, Lancet, 1999, 353, 287. [70] M. Ashina, Exp. Opin. Pharmacother., 2002, 3, 395. [71] L. H. Lassen, B. Sperling, A. R. Andersen and J. Olesen, Cephalalgia, 2005, 25, 344. [72] K. Hoye, B. E. Laurijssens, L. O. Harnisch, C. K. Twomey, R. M. Dixon, A. Kirkham, P. M. Williams and A. L. Wentz, Cephalalgia, 2009, 29, 132. [73] J. E. Palmer, F. L. Guillard, B. E. Laurijssens, A. L. Wentz, R. M. Dixon and P. M. Williams, Cephalalgia, 2009, 29, 124. [74] D. Singh, D. Richards, R. G. Knowles, S. Schwartz, A. Woodcock, S. Langley and B. J. O’Connor, Am. J. Respir. Crit. Care Med., 2007, 176, 988. [75] A. Mosek, S. Groppa and R. Barkan, Cephalalgia, 2009, 29, 118. [76] D. Vaughan, J. Speed, R. Medve and J. S. Andrews, unpublished results. [77] R. A. Medve and J. S. Andrews, Cephalalgia, 2009, 29, 126. [78] P.-H. M. van der Kuy, F. W. H. M. Merkus, J. J. H. M. Lohman, J. W. M. ter Berg and P. M. Hooymans, Cephalalgia, 2002, 22, 513. [79] S. Auvin, M. Auguet, E. Navet, J. J. Harnett, I. Viossat, J. Schulz, D. Bigg and P.-E. Chabrier, Bioorg. Med. Chem. Lett., 2003, 13, 209. [80] P.-E. Chabrier, M. Auguet, B. Spinnewyn, S. Auvin, S. Cornet, C. Demerle-Pallardy, C. Guilmard-Favre, J.-G. Marin, B. Pignol, V. Gillard-Roubert, C. Roussillot-Charnet, J. Schulz, I. Viossat, D. Bigg and S. Moncada, Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 10824. [81] P. Renton, S. Maddaford, S. Rakhit and J. Andrews, PCT Int. Appl., WO2007017764 A2, 2007. [82] D. Salvemini, P. T. Manning, B. S. Sweifel, K. Seibert, J. Connor, M. G. Currie, P. Needleman and J. L. Masferrer, J. Clin. Invest., 1995, 96, 301. [83] X. Cao, Q.-D. You, Z.-Y. Li, Q.-L. Guo, J. Shang, M. Yan, J.-W. Chern and M.-L. Chen, Bioorg. Med. Chem., 2008, 16, 5890. [84] S.-W. Park, J.-H. Yi, G. Miranpuri, I. Satriotomo, K. Bowen, D. K. Resnick and R. Vemuganti, J. Pharm. Exp. Ther., 2007, 320, 1002. [85] Y.-Z. Lee, C.-W. Yang, I.-J. Kang, S.-H. Wu, Y.-S. Chao, J.-H. Chern and S.-J. Lee, Bioorg. Med. Chem. Lett., 2008, 18, 5676. [86] R. Morphy and Z. Rankovic, J. Med. Chem., 2005, 48, 1. [87] J. Woodcock, J. Witter and R. A. Dionne, Nat. Rev. Drug Discovery, 2007, 6, 703.
CHAPT ER
3 Small-Molecule Protein–Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions Simon N. Haydar*, Heedong Yun*, Roland G.W. Staal** and Warren D. Hirst**
Contents
1. Introduction 2. Ab Aggregation and Oligomers in Alzheimer’s Disease 2.1 Ab aggregation and neurotoxic oligomers 2.2 Small-molecule inhibitors of Ab aggregation 3. Tau Aggregation in Alzheimer’s Disease 3.1 Tau pathophysiology 3.2 Small-molecule inhibitors of tau aggregation 4. a-Synuclein Aggregation in Parkinson’s Disease 4.1 Biochemistry of a-synuclein aggregation 4.2 Small-molecule inhibitors of a-synuclein aggregation 5. Conclusion References
51 52 52 53 58 58 59 63 63 64 65 66
* Chemical Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543 ** Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543 Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04403-0
r 2009 Elsevier Inc. All rights reserved.
51
52
Simon N. Haydar et al.
1. INTRODUCTION Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common chronic, progressive neurodegenerative diseases affecting an estimated 10% and 1%, respectively, of the elderly population [1,2], with financial costs of hundreds of billions of dollars per year. AD is characterized by the presence of extracellular parenchymal and vascular amyloid deposits containing b-amyloid peptide (Ab) and intracellular neuronal tangles composed of hyperphosphorylated tau. a-Synuclein containing Lewy bodies, spherical inclusions found in the cytoplasm of surviving neurons, are the cardinal hallmark of PD. Despite their distinct pathologies, these neurodegenerative diseases are increasingly being realized to have common cellular and molecular mechanisms including protein aggregation and inclusion body formation. Compelling evidence strongly supports the hypothesis that accumulation of misfolded proteins leads to synaptic dysfunction, neuronal apoptosis, brain damage, and disease. However, the mechanisms by which protein misfolding and aggregation trigger neurodegeneration and the identity of the neurotoxic structures are still unclear. Current hypotheses propose that, in the aggregation process, there is an accumulation of small soluble oligomeric intermediates, which leads to the neuropathology, whereas the large insoluble deposits that make up the inclusion bodies might function as reservoirs of these toxic, soluble oligomers [3]. As we increase our knowledge of the role of oligomeric, fibrillar, and higher-order molecular entities of the misfolded proteins in neurodegenerative diseases, new approaches may offer themselves for therapeutic intervention. Over the past few years, there has been significant interest in developing therapeutics and chemical probes that inhibit these specific protein–protein interactions. This effort has been hampered by the size and the geometry of the protein interaction interface, which are devoid of defined ‘‘pockets’’ into which a small molecule can bind in an energetically favorable manner [4]. Despite the challenges of developing compounds that are capable of specifically inhibiting protein–protein interactions, there are a number of examples of small molecules that achieve this with reasonable potency [5]. This was made possible because of the discovery of ‘‘hot spots’’ on the protein interaction surfaces [6]. These ‘‘hot spots’’ are small regions on the protein interaction interface that are responsible for a disproportionate contribution to the binding energy of the two proteins. This review will highlight the recent progress in the development of small-molecule protein–protein interaction inhibitors that have applications in furthering the mechanistic understanding of neurodegenerative diseases and will potentially lead to the development of rational therapeutics.
Therapeutic Agents for Neurodegenerative Diseases
53
2. Ab AGGREGATION AND OLIGOMERS IN ALZHEIMER’S DISEASE 2.1 Ab aggregation and neurotoxic oligomers Substantial genetic and physiological evidence suggest that the Ab plays a central role in AD pathogenesis. Ab is a 39- to 42-amino acid peptide derived from the proteolytic processing of the amyloid precursor protein (APP) by secretases [7]. Gradual changes in the steady-state levels of Ab in the brain are thought to initiate the amyloid cascade [8,9]. Since the elucidation of the Ab sequences [10–12], investigators have used synthetic Ab to examine aggregation and its effects on physiology. Many in vitro studies have suggested that aggregation of Ab is essential for toxicity, but characterization of the Ab species that formed was limited. However, amyloid plaque number does not correlate well with severity of dementia [13–15], and instead, there is a stronger link between soluble Ab levels and the extent of synaptic loss and the severity of cognitive impairment [16–18]. Therefore, more recent studies have focused on various soluble forms of synthetic Ab1-40 and Ab1-42, ranging from monomeric to protofibrils [19]. A number of reports have described the biochemical characterization of the soluble Ab extracted from human AD brain. The presence of sodium dodecyl sulfate (SDS)-stable dimers and trimers in the soluble fraction of human brain and in extracts of amyloid plaques suggests that SDS-stable, low n oligomers of Ab are the fundamental building blocks of insoluble amyloid deposits and could be the earliest mediators of neuronal dysfunction [20]. Recent studies have described the physiological characterization of Ab dimers isolated from AD brains that inhibit long-term potentiation (LTP), a physiological correlate of memory, and reduce dendritic spine density in normal rodent hippocampus [21]. In addition, the dimers disrupt memory of a learned behavior when directly injected into the brains of normal rats. As outlined earlier, a number of Ab assemblies have been proposed to exert neurotoxic effects, but with evidence only recently emerging on which forms that are the pathological species in vivo, and the scarcity of structural data on the oligomers complicates a rational search for compounds that could inhibit Ab aggregation and toxicity. Despite these obstacles, a number of different compounds that interfere with Ab aggregation, in one way or another, have been described; these are reviewed in the following sections.
2.2 Small-molecule inhibitors of Ab aggregation 2.2.1 Scyllo-inositol Recent in vitro studies with scyllo-inositol (1) have shown that it can interact with Ab42 peptide promoting a conformational change from
54
Simon N. Haydar et al.
random coil to b-sheet structure and stabilized it in small, nonfibrillar complexes, blocking fibril formation [22]. These stabilized complexes were significantly less toxic to neuronal cell lines and primary neuronal cultures than untreated Ab42 or chiro-inositol-treated Ab42 [22]. Moreover, in in vivo studies in the TgCRND8 mouse model of AD, it was shown that compound 1 inhibited Ab aggregation, decreased Ab-induced impairments in spatial memory, reduced the cerebral Ab pathology, and attenuated the rate of mortality [23]. To explore the molecular details of the inositol–Ab42 interaction, a series of scylloinositols were prepared in which one or two hydroxyl groups were replaced with fluoro, chloro, methoxy, or hydrogen substituents [24]. After incubation with Ab42 for 7 days, the activity of the derivatives was measured by electron microscopy to monitor the formation of Ab42 fibers. Despite the synthesis of numerous analogs, only single hydroxyl substitutions such as 1-deoxy-1-fluoro-scyllo-inositol (2) and the disubstituted analog 1,4-dimethoxy-scyllo-inositol (3) were shown to have similar activity to the parent compound 1. Compound 3 was shown to exhibit the most pronounced effect on Ab42 aggregation, in that it produced a more homogenous population of small amorphous aggregates and no fibers were detected [24]. OH
HO HO HO
OH OH 1
OH
HO HO HO
OH F 2
OH
MeO HO HO
OH OMe 3
2.2.2 Tricyclic pyrones and pyridinones Hua et al. [25] used a neuronal cell line overexpressing a C-terminal fragment of APP (MC65 cells) to identify inhibitors of toxicity related to intracellular Ab and discovered a class of tricyclic pyrones (TP). In particular, a TP 4 that contains an adenine moiety (at N-3u) attached at the C7-alkyl side chain of the ring system showed significant protection in the MC65 cell assay with an EC50 value of 0.31 mM [25]. Further characterization of compound 4 using surface plasmon resonance (SPR) spectroscopy, atomic force microscopy (AFM), and protein quantification studies showed it binds to Ab42 oligomers, inhibits Ab aggregation, and disaggregates Ab42 oligomers and protofibrils [26]. Transgenic mice treated for 2 weeks with compound 4, administered i.c.v., resulted in 40% and 50% decreases in non-fibrillar and fibrillar Ab species, respectively. [26]. To further investigate the structure activity relationship, various heterocycles and nitrogen-containing TP were prepared [27]. It was concluded that attachment of N3u-adenine at C7 side chain in compound
Therapeutic Agents for Neurodegenerative Diseases
55
4 provides the strongest MC65 protective activity with an EC50 of 0.31 mM. However, tricyclic pyranoisoquinolinones lacking the adenine moeity as in compounds 5 and 6 still possess protective activity with EC50 values of 2.49 and 1.25 mM, respectively. The 6u-amino group in compound 4 enhances potency but is not required for activity. O
O 1
10
H
O N
7
NH2
N 14
12
N
3′
N 9′
4
OMe O
O
O H O
N
N 5
6
Among the various C7 side chain heterocycles prepared, none showed better protective activity than the adenine in compound 4. It is noteworthy that the most potent analog prepared in this class was a 2-aminopurine derivative 7 with EC50 of 0.86 mM. Replacement of the oxygen at position 2 with a nitrogen, as in compound 8, provides similar protective activity (EC50 ¼ 0.35 mM) as that of compound 4 [27]. O
O
OMe
1 10
H
O
O
H O
N 7
N
N
N 14
12
3′
N 7
N NH2
N
N N
NH2 8
56
Simon N. Haydar et al.
2.2.3 Indoles Highly ordered p-stacking interactions between aromatic ring systems are important in self-assembly of complex biological and chemical supramolecular structures [28]. Several studies showed that aromatic interactions may play a critical role in early-stage amyloid formation by providing stability, as well as order and directionality in the formation of amyloid fibrils, presumably facilitated by restricted geometry of interaction between planar aromatic systems [29]. In particular, in amyloid peptide fragments, a high frequency of aromatic residues was noted. When these aromatic residues were replaced with hydrophobic amino acids, a decrease in the amyloidogenic propensity was observed [30]. Gazit et al. screened various indole derivatives for their ability to prevent formation of amyloid fibrils using fluorescence spectroscopy, AFM, and electron microscopy. Three inhibitors were identified: indole-3-carninol (9), 3hydroxyindole (10), and 4-hydroxyindole (11) with IC50 values of 85, 100, and 200 mM, respectively. These simple indoles effectively inhibited Ab fibril formation and prevented cell death induced by 5 mM Ab40 in PC12 cells in culture. Curiously, analog 9 inhibited Ab fibrillization only at high concentration, and it did not show a dose dependency on inhibition of fibril formation. The inhibitory mechanism of these compounds remains unclear; however, the authors suggest that the hydroxyl group interacts with the backbone of the peptides preventing the ability of the Ab peptide to create a p-stacking interaction, which limit the fibrillogenesis process. OH
OH
HO
N H
N H 9
N H 10
11
Recent adsorption studies of Ab solutions on poly(tetrafluoroethylene) surfaces showed that the fluorinated surface strongly promoted a-helix re-formation [31]. A similar effect was observed with solution of Ab in CF3-containing solvents [32]. On the basis of these findings, Torok et al. [33] demonstrated the design and application of a new class of trifluoroethylindoles against amyloid fibrillogenesis. Analogs 12a–c showed significant inhibitory effect with IC50 values of 0.53, 0.23, and 0.36 molinhibitor/molAb. Further structure–activity relationship demonstrated that the CF3 and OH groups are necessary for binding to Ab peptide. It was suggested that the acidity of the hydroxyl group plays a key role in binding to one or both lysine residues of the Ab peptide. Interestingly, removing the ester group slightly diminished the inhibitory activity.
Therapeutic Agents for Neurodegenerative Diseases
57
HO CO Et 2 F3C X N H 12a, b, c a; X = Cl b; X = Br c; X = I
Tramiprosate (3-amino-1-propanesulfonic acid; 3APS; Alzhemedt) (13) was found to maintain Ab in a non-fibrillar form, decrease Ab42-induced cell death in neuronal cell cultures, and also inhibit amyloid deposition [34]. Treatment of TgCRND8 mice with Tramiprosate resulted in significant reduction (B30%) in the brain amyloid plaque load and a significant decrease in the cerebral levels of soluble and insoluble Ab40 and Ab42 (B20–30%) [34]. Although Tramiprosate ultimately failed in a phase III clinical trial, it provided a proof of concept that small-molecule inhibitors of Ab protofibril formation may be a viable approach to AD treatment [5].
H2N
O O S OH
13, Tramiprosate
Another recent development in Ab aggregation inhibitors was the development of Memoquin (14). This compound was shown to be a multifunctional therapy to AD, acting as an acetyl cholinesterase (AchE) inhibitor (Ki ¼ 2.6 nM), a free radical scavenger, and an inhibitor of Ab aggregation [35,36].
N O
O
H N
N H
O
N
O 14, Memoquin
Additional small molecules such as Congo red, curcumin, and galantamine have been described in the literature as inhibitors of Ab aggregation, recently reviewed by Hawkes et al. (2009) [37]. These molecules were also found to be inhibitors of a-synuclein, and we will report on their activity in Section 4.2.
58
Simon N. Haydar et al.
3. TAU AGGREGATION IN ALZHEIMER’S DISEASE 3.1 Tau pathophysiology Tau is predominantly expressed in neurons where its main function is thought to be stabilizing microtubules, particularly in axons. The tau gene consists of 16 exons and alternative splicing results in six isoforms of tau protein ranging in size from 352–441 amino acids [38]. Tau stabilizes microtubules by binding to them through an interaction with the three or four microtubule-binding domains at the C-terminus of the protein. Stabilization of microtubules by tau in neurons is important for maintenance of cellular morphology and transport of molecules and organelles over long distances [39]. Binding of tau to microtubules is also regulated post-translationally, primarily through phosphorylation, although other modifications such as glycosylation, ubiquitylation, and proteolysis have been reported for the tau protein [40]. Tau contains W80 serine and threonine residues, which are potential phosphorylation sites. The phosphorylation state, which is controlled by a balance of kinase and phosphatase activity, affects the microtubule-binding affinity. Hyperphosphorylation of tau at many sites, as seen in tauopathies, of which AD is the most common, leads to reduced affinity for microtubules, which causes disruption of cellular trafficking leading to degeneration of synaptic terminals. This loss of function may be exacerbated by a toxic gain of function, where higher than normal concentrations of tau increase the chances of pathogenic conformational changes, which in turn lead to the aggregation and fibrillization, which might block transport and cause cell death [40]. Phosphorylation of certain residues on tau, specifically S396 and S404, has been shown to increase the fibrillogenic nature of tau and contribute to its accumulation into paired helical filaments [41–43]. Similarly, the removal of the C-terminus of the protein increases tau aggregation [44,45]. It is thought that tau aggregation occurs in a multi-step process whereby tau is phosphorylated and dissociates from microtubules. The unbound hyperphosphorylated tau abnormally localizes to the somatodendritic compartment of the cell, undergoes conformational changes and further phosphorylation. Finally, the hyperphosphorylated tau forms fibrils that aggregate into neurofibrillary tangles (NFTs) [46]. Tau aggregates also form in axons and dendrites, called neuropil threads. Both NFTs and neuropil threads are postulated to have a toxic gain of function. In cell models, tau aggregation in the cell body causes cell death [47]. In axons, neuropil threads are thought to be toxic because they might physically impair transport, which would be toxic to synaptic terminals [48]. Similar to Ab, oligomeric forms of tau, which are promoted by phosphorylation [49] and are observed in aging and early AD [50], could
59
Therapeutic Agents for Neurodegenerative Diseases
also be the toxic species leading to neurodegeneration. In animal models of tauopathy, there is indirect evidence that soluble, not aggregated, forms of tau are toxic: flies expressing human tau can exhibit neurodegeneration without fibril formation [51], and in some mouse models of tauopathy, overexpression of tau causes neuronal loss in areas without extensive neurofibrillary pathology [52]. If oligomeric tau is toxic, formation of large aggregates could be viewed as protective because oligomers are sequestered into insoluble neurofibrillary pathology [3,49]. The two principal current strategies targeting tau in neurodegenerative disease are (i) reducing tau phosphorylation through inhibition of specific protein kinases [53] and (ii) anti-aggregation approaches [54]. The issue of whether phosphorylation of tau precedes or follows tau aggregation remains a subject of debate, but reducing tau phosphorylation is regarded by many as the preferred target, and some transgenic animal studies have shown this to be a valid strategy [53]. In the following sections, structurally diverse small-molecule inhibitors of tau aggregation are described.
3.2 Small-molecule inhibitors of tau aggregation 3.2.1 Phenylthiazolyl hydrazides In an effort to develop small-molecule inhibitors of tau aggregation, Mandelkow et al. [55,56] identified compounds related to structure 15 from a high throughput screen of a collection of 200,000 compounds. To establish the structure–activity relationship (SAR), a series of thiazolylhydrazides were prepared by synthetic derivatization of R1, R2, R3, and R4 [56]. Structure–activity relationship of phenylthiazolyl hydrazides demonstrated that two aromatic rings at R1 and R4, a hydrophobic region on the thiazole ring, and a hydrogen bonding acceptor on the carboxyl amide are essential for inhibitory effect of tau aggregation. Notably, compound 16 showed superior potency with IC50 value of 1.6 mM for inhibiting tau aggregation and reduced toxicity when tested in an N2A cell model of tau aggregation [57]. The potency of compound 16 is believed to be due to the hydrogen bonding capacity of the nitro group and to the p-stacking interactions with the indazole group as confirmed by saturation transfer difference (STD) NMR spectroscopy experiments. O
R2 R1
N H
H N
N
N
R4
S R3 15
N H
H N
N S
N H 16
NO2
60
Simon N. Haydar et al.
3.2.2 Rhodanine-based inhibitors Mandelkow’s group has also described the SAR of substituted rhodanines (2-thioxothiazolidin-4-ones) [58]. Extensive SAR studies resulted in the preparation of an interesting biphenyl rhodanine derivative 17, which displayed an IC50 of 170 nM for assembly inhibition and DC50 of 130 nM for disassembly induction. It is noteworthy that the presence of an aromatic side chain appeared necessary, supporting hydrophobic p-stacking interactions of this fragment [59]. Unfortunately, compound 17 and many other analogs showed a large discrepancy between in vitro and cell-based activity. Poor physiochemical properties were implicated as the likely cause of poor cellular results, reflecting a need for further optimization of this series. O
Ph
S
HO
N
S
O
O
17
3.2.3 Cationic thiacarbocyanine dye Thiacarbocyanine dye N744 (compound 18) has been shown to inhibit recombinant tau fibrillization in the presence of anionic surfactant aggregation inducers with an IC50 value of 0.3 mM [60]. In an effort to increase potency, a cyclic bis-thiacarbocyanine 19 was synthesized and characterized with respect to tau fibrillization inhibition by electron microscopy and ligand aggregation state by absorbance spectroscopy [61]. Data showed that the inhibitory activity of the bis-thiacarbocyanine 19 was similar to a monomeric cyanine dye, but was more potent with an IC50 of 80 nM. Data reported for these two compounds further suggest that the inhibitory activity of bis-thiacarbocyanine 19 results from multivalency. This finding might offer an new mode of interaction for design of tau aggregation inhibitors [61]. S
S Br
O
S
O
S
N
N
N
Br
N N
N
HO
OH 18
S
S 19
61
Therapeutic Agents for Neurodegenerative Diseases
3.2.4 N-Phenylamines and anthraquinones Additional small molecule tau aggregation inhibitors were reported in the literature derived from N-phenylamines (20) and anthraquinones such as daunorubicin (21) and adriamycin (22) [55,62].
NO2
O 2N
O
OH
A
B
C
D
O
O
OH O
H N N
O OH
OH
20
OH
A
B
C
O
O
OH O
NH2
21
D
O
O
O
O
HO OH
O OH
OH
NH2
22
Compared to the two compound classes discussed earlier (rhodamines and phenylthiazolylhydrazides), the N-phenylamines displayed far lower potencies in vitro and in cells, which precluded their use in in vivo models [54]. The b-hydroxyenone moiety in anthraquinone, also observed in other inhibitor classes, such as flavonoids and naphthoquinones, may play a significant role in the inhibitory potency of these chemotypes. Compounds 21 and 22 were able to inhibit the aggregation of the K19 tau construct and induced the disaggregation of preformed aggregates [55]. Substitution on the ring A in compound 21 does not appear to play a critical role of inhibitory activity. Ring D in compounds 21 and 22 bearing the sugar moiety is moderately sensitive to the substitutions on that ring, which indicates further opportunity for structural modifications to improve the inhibitory potency. Despite the observed activity of anthraquinones, it should be noted that they are known cytostatics and present a hazardous toxicological profile, which preclude them from being desired therapeutics for the chronic treatment of AD.
3.2.5 Polyphenols, phenothiazines, and porphyrins Taniguchi et al. [63] reported three classes of compounds (phenols, phenothiazines, and porphyrins) that were able to inhibit aggregation of human tau 46. Polyphenols such as compound 23 shared the SAR described in the previously section for anthraquinones with characteristic b-hydroxyenone moieties. Phenothiazines possess a tricyclic core that incorporates sulfur and nitrogen atoms on the central ring system. They possess positively charged atoms and hydrophobic
62
Simon N. Haydar et al.
aromatic groups similar to the benzothiazole inhibitors described previously. The charge-neutral phenothiazines are reported to have good blood–brain barrier permeability. The planarity and aromaticity of the central heterocyclic core appears to play a critical role of tau aggregation inhibitory activity. In particular, compound 24 (MTC, methylthioninium chloride) also known as methylene blue was reported as a potent in vivo tau aggregation inhibitor with sub-micromolar potency in cells [64,65]. Data from the phase II clinical trial with methylene blue reported a significantly lower rate of decline of cognitive functions compared with a placebo (81%, po0.0001). Although these data are preliminary and require further confirmation, it does present a promising approach for the management of AD and a potential proof of concept for the strategy of inhibiting tau aggregation.
OH HO
N O
HO
OH N
S
N
HO O
OH
23
24
Porphyrins such as compound 25 are the only organometallic compounds that bind differently than other reported tau aggregation inhibitors. The inhibitory activity depends on a central metal (iron or zinc) as phthalocyanine compound lacking the central metal has a weaker inhibitory potency [63]. It has been suggested that the coordination of the metal center with histidine on the protein–protein interface plays a significant role in tau aggregation inhibition [66]. HOOCC2H4
HOOCC2H4
N N Fe N
25
N
Therapeutic Agents for Neurodegenerative Diseases
63
4. a-SYNUCLEIN AGGREGATION IN PARKINSON’S DISEASE 4.1 Biochemistry of a-synuclein aggregation a-Synuclein is a small 140 amino acid, natively unfolded protein with little secondary or tertiary structure whose aberrant aggregation has been linked to the etiology of PD. a-Synuclein can assume either an a-helical conformation upon binding to lipids and membranes or a b-sheet conformation upon aggregation at high concentrations, elevated temperature, agitation, or in the presence of metals, simple alcohols, or detergents [67,68]. Increases in b-sheet content are associated with formation of small soluble oligomers, larger protofibrils, and the macromolecular fibrils. Dimers are the smallest oligomeric aggregates with limited b-sheet structure and have been proposed to act as seeds in the nucleation-dependent aggregation of a-synuclein [69,70]. Both oligomers and protofibrils have increased amounts of b-sheet structure compared with monomeric or lipid bound a-synuclein. The predominantly observed structure of the protofibrils is globular, although they are also able to form rod-like filaments as well as annular rings that can insert into lipid membranes enabling leakage of small molecules [67]. These annular protofibrils have been implicated in the pathogenesis of PD by the virtue that the A53T and A30P mutations either increase the propensity of a-synuclein to form annular protofibrils or stabilize them. The annular protofibrils can insert into lipid membranes and enable leakage of ions, neurotransmitters, and small dyes [67]. Although these properties make the oligomers and protofibrils attractive targets, their size and morphological continuum present a tremendous logistical hurdle for assay development and structure activity relationship analysis. Eventually, a-synuclein aggregates into insoluble fibrils that have a very high b-sheet content. It is the insoluble fibril that is deposited in Lewy bodies in the brains of patients suffering from PD, which are the defining pathological hallmark of the disease. A long-standing issue has been whether Lewy bodies are markers of a neurodegenerative process or a protective mechanism, serving as a means to sequester toxic oligomers and protofibrils [3]. Still, fibrils, as the end point of aggregation and the hallmark of pathological PD, have been targeted extensively in attempts to discover small-molecule inhibitors of a-synuclein aggregation as a treatment to slow down or halt the progression of PD. Many molecules have been shown to inhibit fibril formation (curcumin, Congo red, epigallocatechin gallate, peptide-mimetics, and non-steroidal anti-inflammatories) including the flavonoid, baicalein, and the neurotransmitter, dopamine [71–77]. More detailed studies with the latter two molecules reveal that while these compounds are inhibiting
64
Simon N. Haydar et al.
fibril formation, they are also stabilizing oligomers/protofibrils [77]. In the case of dopamine, the aggregates are much more stable than the oligomers/protofibrils produced under more ‘‘conventional’’ conditions, in that they are SDS stable. Caution should also be exercised when targeting disruption of fibril b-sheet as the tertiary structure of many proteins contains b-sheets. If inhibitors of fibril formation are to be developed as a therapeutic for PD, appropriate screens should be developed to assess their ability to stabilize soluble oligomers/protofibrils, to assess the toxicity of any stabilized species and the ability to disrupt the b-sheet structure in other proteins.
4.2 Small-molecule inhibitors of a-synuclein aggregation Conway et al. [77] have shown that catecholamines such as compound 26 can inhibit the formation of a-synuclein fibrils by stabilizing oligomeric intermediates. Li et al. [78] reported that the oxidation state of catecholamine affected the inhibitory activity. As such, dopaminochrome (27), one of the oxidation products of dopamine, was shown to be more potent at inhibiting a-synuclein fibril formation than the parent dopamine [78,79]. This also raises the possibility that the protein may be covalently modified by the dopaminochrome or dopamine under oxidative conditions. H
N O
HO
N H
O
HO 26
27
Various polyphenolic compounds such as flavonoids have also been shown to be effective inhibitors of a-synuclein aggregation [80]. One of these inhibitors is baicalein, 28, isolated from the Chinese skullcap plant (Scutellaraia baicalensis), has been shown to directly bind to a single site on a-synuclein with submicromolar affinity and, as such, inhibit formation of fibrils through the stabilization of oligomers [71,81]. It has been suggested that the quinone oxidation by-product (29) of baicalein is responsible for the observed inhibitory activity. HO
O
HO
O
O
O OH O
OH O
28
29
Therapeutic Agents for Neurodegenerative Diseases
65
Other small-molecule inhibitors of a-synuclein have been identified in the literature such as Congo red.[80]. Polyphenolic compounds such as rifampicin, curcumin, and tetracycline are capable of inhibiting both a-synuclein [79] and Ab aggregation [82] in a concentration-dependent manner with some potency (IC50o10 mM). Li et al. [83] point out that many of these polyphenolic anti-fibrillogenic compounds have antioxidant activities and readily oxidize in the presence of atmospheric oxygen to form quinones and thus may all act through oxidative modification of peptides. This modification, formation of quinone adducts or formation of Schiff-base, may act to inhibit fibril formation by constraining the peptides to a conformation not compatible with the tight orderly packing of b-sheets found in fibrils, but at the same time stabilizing soluble oligomers. Although some of these compounds have been demonstrated to protect cells against a-synuclein overexpression, in agreement with the biochemistry of a-synuclein aggregation [84], many reports either attribute the efficacy of the compounds to metal chelation and antioxidant activity or do not show the mechanism to be inhibition of protein aggregation. Furthermore, caution in pursuing these polyphenolic and catecholamine compounds as aggregation inhibitors is urged, however, as one long-standing hypothesis postulates that it is actually the soluble oligomers, not the insoluble fibrils that are neurotoxic in PD. Still, these polyphenolic/ anti-oxidant types of compounds appear to share a common mechanism: oxidation-dependent modification of a-synuclein, which inhibits fibril formation. If the issues, raised earlier, are resolved in the drug discovery process, then small-molecule inhibitors of a-synuclein aggregation could be key therapeutics for PD [82]. However, in general, it has been noted from the current literature that there are few reports and limited efforts to develop structural activity relationship around the compounds listed earlier, suggesting that drug discovery strategies to identify small-molecule inhibitors of a-synuclein are still evolving.
5. CONCLUSION In summary, the literature reviewed in this chapter imply two general assumptions regarding the inhibition mechanism of amyloid protein fibril formation by small molecules: (a) specific structural conformation is necessary for b-sheet interaction and stabilization of the inhibition– protein complex; (b) aromatic interaction between the inhibitor molecule and the aromatic residues in the amyloidogenic sequence, potential ‘‘hot spots,’’ may direct the inhibitor to the amyloidogenic core blocking
66
Simon N. Haydar et al.
the protein–protein interaction. These assumptions are highly relevant for future design of small-molecule inhibitors as therapeutic agents for the treatment of amyloid-associated diseases. In conclusion, drug development for AD and PD remains highly active, and there is a realistic expectation that new therapies will be evaluated in clinical trials in the near future.
REFERENCES [1] B. L. Plassman, K. M. Langa, G. G. Fisher, S. G. Heeringa, D. R. Weir, M. B. Ofstedal, J. R. Burke, M. D. Hurd, G. G. Potter, W. L. Rodgers, D. C. Steffens, R. J. Willis and R. B. Wallace, Neuroepidemiology, 2007, 29, 125. [2] L. M. Lau and M. M. Breteler, Lancet Neurology, 2006, 5, 525. [3] C. Haass and D. J. Selkoe, Nat. Rev. Mol. Cell. Biol., 2007, 8, 101. [4] M. R. Arkin and J. A. Wells, Nat. Rev. Drug Discov., 2004, 3, 301. [5] L. L. Blazer and R. R. Neubig, Neuropsychopharmacology, 2009, 34, 126. [6] A. A. Bogan and K. S. Thorn, J. Mol. Biol., 1998, 280, 1. [7] D. J. Selkoe, Physiol. Rev., 2001, 81, 741. [8] D. J. Selkoe, Neuron, 1991, 6, 487. [9] J. A. Hardy and G. A. Higgins, Science, 1992, 256, 184. [10] G. G. Glenner and C. W. Wong, Biochem. Biophys. Res. Commun., 1984, 120, 885. [11] C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther, Proc. Natl. Acad. Sci. U.S.A., 1985, 82, 4245. [12] D. J. Selkoe, C. R. Abraham, M. B. Podlisny and L. K. Duffy, J. Neurochem., 1986, 46, 1820. [13] R. Katzman, N. Engl. J. Med., 1986, 314, 964. [14] R. D. Terry, E. Masliah, D. P. Salmon, N. Butters, R. DeTeresa, R. Hill, L. A. Hansen and R. Katzman, Ann. Neurol., 1991, 30, 572. [15] D. W. Dickson, H. A. Crystal, C. Bevona, W. Honer, I. Vincent and P. Davies, Neurobiol. Aging, 1995, 16, 285. [16] L. F. Lue, Y. M. Kuo, A. E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J. H. Kurth, R. E. Rydel and J. Rogers, Am. J. Pathol., 1999, 155, 853. [17] C. A. McLean, R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, A. I. Bush and C. L. Masters, Ann. Neurol., 1999, 46, 860. [18] J. Wang, D. W. Dickson, J. Q. Trojanowski and V. M. Lee, Exp. Neurol., 1999, 158(2), 328. [19] M. A. Findeis, Pharmacol. Ther., 2007, 116, 266. [20] D. M. Walsh and D. J. Selkoe, J. Neurochem., 2007, 101, 1172. [21] G. M. Shankar, S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I. Smith, F. M. Brett, M. A. Farrell, M. J. Rowan, C. A. Lemere, C. M. Regan, D. M. Walsh, B. L. Sabatini and D. J. Selkoe, Nature Med., 2008, 14, 837. [22] J. McLaurin, R. Golomb, A. Jurewicz, J. P. Antel and P. E. Fraser, J. Biol. Chem., 2000, 275, 18495. [23] J. McLaurin, M. E. Kierstead, M. E. Brown, C. A. Hawkes, M. H. L. Lambermon, A. L. Phinney, A. A. Darabie, J. E. Cousins, J. E. French, M. F. Lan, F. Chen, S. S. N. Wong, H. T. J. Mount, P. E. Fraser, D. Westaway and P. George-Hyslop, Nat. Med., 2006, 12, 801.
Therapeutic Agents for Neurodegenerative Diseases
67
[24] Y. Sun, G. Zhang, C. A. Hawkes, J. E. Shaw, J. McLaurin and M. Nitz, Bioorg. Med. Chem., 2008, 16, 7177. [25] D. H. Hua, X. Huang, M. Tamura, Y. Chen, M. Woltkamp, L.-W. Jin, E. M. Perchellet, J.-P. Perchellet, P. K. Chiang, I. Namatame and H. Tomoda, Tetrahedron, 2003, 59, 4795. [26] H.-S. Hong, S. Rana, L. Barrigan, A. Shi, Y. Zhang, F. Zhou, L.-W. Jin and D. H. Hua, J. Neurochem., 2009, 108, 1097. [27] S. Rana, H.-S. Hong, L. Barrigan, L.-W. Jin and D. H. Hua, Bioorg. Med. Chem. Lett., 2009, 19, 670. [28] A. Aggeli, M. Bell, N. Boden, J. N. Keen, P. F. Knowles, T. C. McLeish, M. Pitkeathly and S. E. Radford, Nature, 1997, 386, 259. [29] E. Gazit, FASEB J., 2002, 16, 77. [30] T. Cohen, A. Frydman-Marom, M. Rechter and E. Gazit, Biochemistry, 2006, 45, 4727. [31] C. E. Giacomelli and W. Norde, Biomacromolecules, 2003, 4, 1719. [32] E. P. Vieira, H. Hermel and H. Mohwald, Biochim. Biophys. Acta, Proteins Proteomics, 2003, 1645, 6. [33] M. Torok, M. Abid, C. Mhadgut Shilpa and B. Torok, Biochemistry, 2006, 45, 5377. [34] F. Gervais, J. Paquette, C. Morissette, P. Krzywkowski, M. Yu, M. Azzi, D. Lacombe, X. Kong, A. Aman, J. Laurin, W. A. Szarek and P. Tremblay, Neurobiol. Aging, 2007, 28, 537. [35] A. Cavalli, M. L. Bolognesi, S. Capsoni, V. Andrisano, M. Bartolini, E. Margotti, A. Cattaneo, M. Recanatini and C. Melchiorre, Angew. Chem., Int. Ed., 2007, 46, 3689. [36] A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini and C. Melchiorre, J. Med. Chem., 2008, 51, 347. [37] C. A. Hawkes, V. Ng and J. McLaurin, Drug Dev. Res., 2009, 70, 111. [38] A. Andreadis, W. M. Brown and K. S. Kosik, Biochemistry, 1992, 31, 10626. [39] P. W. Baas and L. Qiang, Trends Cell Biol., 2005, 15, 183. [40] C. Ballatore, V. M. Lee and J. Q. Trojanowski, Nat. Rev. Neurosci., 2007, 8, 663. [41] J. Leger, M. Kempf, G. Lee and R. Brandt, J. Biol. Chem., 1997, 272, 8441. [42] J. Eidenmuller, T. Fath, T. Maas, M. Pool, E. Sontag and R. Brandt, Biochem. J., 2001, 357(Pt 3), 59. [43] T. Fath, J. Eidenmuller and R. Brandt, J. Neurosci., 2002, 22, 9733. [44] A. Abraha, N. Ghoshal, T. C. Gamblin, V. Cryns, R. W. Berry, J. Kuret and L. I. Binder, J. Cell Sci., 2000, 113(Pt 21), 3737. [45] R. W. Berry, A. Abraha, S. Lagalwar, N. LaPointe, T. C. Gamblin, V. L. Cryns and L. I. Binder, Biochemistry, 2003, 42, 8325. [46] J. Kuret, E. E. Congdon, G. Li, H. Yin, X. Yu and Q. Zhong, Microsc. Res. Tech., 2005, 67, 141. [47] I. Khlistunova, J. Biernat, Y. Wang, M. Pickhardt, M. Bergen, Z. Gazova, E. Mandelkow and E. M. Mandelkow, J. Biol. Chem., 2006, 281, 1205. [48] O. Katsuse, W. L. Lin, J. Lewis, M. L. Hutton and D. W. Dickson, Neurosci. Lett., 2006, 409, 95. [49] W. Chun and G. V. Johnson, J. Biol. Chem., 2007, 282, 23410. [50] S. Maeda, N. Sahara, Y. Saito, S. Murayama, A. Ikai and A. Takashima, Neurosci. Res., 2006, 54, 197. [51] C. W. Wittmann, M. F. Wszolek, J. M. Shulman, P. M. Salvaterra, J. Lewis, M. Hutton and M. B. Feany, Science, 2001, 293, 711.
68
Simon N. Haydar et al.
[52] T. L. Spires, J. D. Orne, K. SantaCruz, R. Pitstick, G. A. Carlson, K. H. Ashe and B. T. Hyman, Am. J. Pathol., 2006, 168, 1598. [53] M. P. Mazanetz and P. M. Fischer, Nat. Rev. Drug Disc., 2007, 6, 464. [54] B. Bulic, M. Pickhardt, B. Schmidt, E.-M. Mandelkow, H. Waldmann and E. Mandelkow, Angew. Chem., Int. Ed., 2009, 48, 1740. [55] M. Pickhardt, Z. Gazova, M. Von Bergen, I. Khlistunova, Y. Wang, A. Hascher, E.-M. Mandelkow, J. Biernat and E. Mandelkow, J. Biol. Chem., 2005, 280, 3628. [56] G. Larbig, M. Pickhardt, D. G. Lloyd, B. Schmidt and E. Mandelkow, Curr. Alzheimer Res., 2007, 4, 315. [57] M. Pickhardt, G. Larbig, I. Khlistunova, A. Coksezen, B. Meyer, E.-M. Mandelkow, B. Schmidt and E. Mandelkow, Biochemistry, 2007, 46, 10016. [58] B. Bulic, M. Pickhardt, I. Khlistunova, J. Biernat, E.-M. Mandelkow, E. Mandelkow and H. Waldmann, Angew. Chem. Int. Ed. Engl., 2007, 46, 9215. [59] M. L. Waters, Curr. Opin. Chem. Biol., 2002, 6, 736. [60] E. E. Congdon, M. Necula, R. D. Blackstone and J. Kuret, Arch. Biochem. Biophys., 2007, 465, 127. [61] N. S. Honson, J. R. Jensen, M. V. Darby and J. Kuret, Biochem. Biophys. Res. Commun., 2007, 363, 229. [62] M. Pickhardt, J. Biernat, I. Khlistunova, Y. P. Wang, Z. Gazova, E. M. Mandelkow and E. Mandelkow, Curr. Alzheimer Res., 2007, 4, 397. [63] S. Taniguchi, N. Suzuki, M. Masuda, S.-I. Hisanaga, T. Iwatsubo, M. Goedert and M. Hasegawa, J. Biol. Chem., 2005, 280, 7614. [64] C. M. Wischik, P. C. Edwards, R. Y. Lai, M. Roth and C. R. Harrington, Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 11213. [65] C. M. Wischik, J. E. Rickard, C. R. Harrington, D. Horsley, J. M. D. Storey, C. Marshall and J. P. Sinclair, Patent Application WO2007110630, 2007. [66] D. Howlett, P. Cutler, S. Heales and P. Camilleri, FEBS Lett., 1997, 417, 249. [67] M. J. Volles and P. T. Lansbury Jr., Biochemistry, 2003, 42, 7871. [68] V. N. Uversky, J. Neurochem., 2007, 103, 17. [69] S. Krishnan, E. Y. Chi, S. J. Wood, B. S. Kendrick, C. Li, W. Garzon-Rodriguez, J. Wypych, T. W. Randolph, L. O. Narhi, A. L. Biere, M. Citron and J. F. Carpenter, Biochemistry, 2003, 42, 829. [70] V. N. Uversky, J. Biomol. Struct. Dyn., 2003, 21, 211. [71] M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou and A. L. Fink, J. Biol. Chem., 2004, 279, 26846. [72] S. Mandel, G. Maor and M. B. Youdim, J. Mol. Neurosci., 2004, 24, 401. [73] M. Hirohata, K. Ono, A. Morinaga and M. Yamada, Neuropharmacol, 2008, 54, 620. [74] J. N. Rao, V. Dua and T. S. Ulmer, Biochemistry, 2008, 47, 4751. [75] A. M. Bodles, O. M. El-Agnaf, B. Greer, D. J. Guthrie and G. B. Irvine, Neurosci. Lett., 2004, 359, 89. [76] K. Ono and M. Yamada, J. Neurochem., 2006, 97, 105. [77] K. A. Conway, J. C. Rochet, R. M. Bieganski and P. T. Lansbury Jr., Science, 2001, 294, 1346. [78] J. Li, M. Zhu, A. B. Manning-Bog, D. A. Monte and A. L. Fink, FASEB J., 2004, 18, 962. [79] J. Li, M. Zhu, S. Rajamani, V. N. Uversky and A. L. Fink, Chem. Biol., 2004, 11, 1513. [80] Y. Porat, A. Abramowitz and E. Gazit, Chem. Biol. Drug Des., 2006, 67, 27. [81] D. P. Hong, A. L. Fink and V. N. Uversky, J. Mol. Biol., 2008, 383, 214.
Therapeutic Agents for Neurodegenerative Diseases
69
[82] T. Tomiyama, A. Shoji, K.-i. Kataoka, Y. Suwa, S. Asano, H. Kaneko and N. Endo, J. Biol. Chem., 1996, 271, 6839. [83] H. T. Li, D. H. Lin, X. Y. Luo, F. Zhang, L. N. Ji, H. N. Du, G. Q. Song, J. Hu, J. W. Zhou and H. Y. Hu, FEBS J., 2005, 272, 3661. [84] C. L. Kragh, L. B. Lund, F. Febbraro, H. D. Hansen, W. P. Gai, O. El-Agnaf, C. RichterLandsberg and P. H. Jensen, J. Biol. Chem., 2009, 284, 10211.
CHAPT ER
4 Case History: ChantixTM/ChampixTM (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid Jotham W. Coe, Hans Rollema and Brian T. O’Neill
Contents
1. Introduction 2. Partial Agonists at Nicotinic ACh Receptors 3. The Search for Partial Agonists: Cytisine as a Key Starting Point 4. Semi-Synthetic Analogs of Cytisine 5. Cytisine Synthesis and Early Template Expansion 6. Discovery of the Bicyclic Benzazepine Core 7. Fused Bicyclic Benzazepines 8. In vivo Efficacy of Partial Agonists 9. Properties of Varenicline 9.1 Pharmacology 9.2 Absorption, distribution, metabolism, excretion (ADME) 10. Clinical Studies 11. Conclusions References
71 74 77 80 84 87 91 93 95 95 97 98 98 99
Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04404-2
r 2009 Elsevier Inc. All rights reserved.
71
72
JOTHAM W. COE et al.
1. INTRODUCTION Serious attention to the public health impact of smoking emerged in the United Kingdom in the late 1950s after a prospective study, begun in 1951, focused on the frequency of lung cancer among doctors with known smoking habits [1]. Early data demonstrated a link between smoking tobacco and lung cancer, which was born-out over the 50-year span of the study and grew to include many other causes of death. The overall conclusions were that tobacco use will kill at least half of all smokers and that smokers lose on average 10 years of life compared with non-smokers. Smokers who were able to quit smoking when they were between 30 and 40 years of age decreased their risk of premature mortality to that of a non-smoker [2]. In the United States, the Surgeon General’s 1964 report concluded that ‘‘lung cancer and chronic bronchitis are causally related to cigarette smoking’’ [3]. The report also noted that there was suggestive evidence, if not definite proof, for a causative role of smoking in other illnesses. Surprisingly, it was not until the 11th Surgeon General’s report in 1979 that smoking was defined as a ‘‘nicotine addiction’’ [4]. In 2007, the U.S. Senate proposed removing the pejorative term ‘‘abuse’’ from the name of the National Institute of Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) replacing it with the words ‘‘diseases’’ and ‘‘addiction’’ [5]. Evidence that profound neurological changes result from smoking has led experts to characterize nicotine addiction as a disease, a clear shift in perception from the view that this behavior was a habit one simply stops. Awareness of smoking’s health toll has been beneficial in the United States; cigarette smoking rates in U.S. men have dropped steadily in the past 50 years, from more than 42% to the current rate of B21%. Despite this trend, cigarette smoking, still the leading cause of preventable illness and mortality in the United States, contributes to the death of 443,000 people each year. More than 5 million people die annually in the developed world from smoking-related illness, a statistic on course to double by 2030 [6]. As health care costs have risen, worldwide government awareness of the problem has intensified. The World Health Organization (WHO) effort to define targets for smoking rate reductions highlights this international shift [7]. Still, smoking remains a ritual ingrained in the societal fabric throughout the developed world. Recognition that nicotine addiction is initiated by a pharmacological substance that profoundly impacts the physiology of the patient was a large step forward. This tenet stimulated research toward therapies that could address nicotine addiction by acting directly at the receptors that mediate the addictive effects. In the late 1980s, the only available treatment was nicotine replacement therapy (NRT), introduced in the late 1970s, which
Case History: Chantixt/Champixt (Varenicline Tartrate)
73
increased quit rates in clinical trials [8]. Later, in 1997, after our entry into smoking cessation research, bupropion (Zybans), first marketed as the anti-depressant (Wellbutrins), was found to be efficacious for smoking cessation [9]. Behavioral therapy and counseling have been offered in various ‘‘quit smoking’’ settings, and although common, they have been generally underutilized, their success has been limited by commitment and finances of the smoker [10]. All of these treatments approximately doubled the chance of continuous abstinence compared with placebo controls, highlighting the need for more efficacious therapies. NH N N
varenicline (1)
Varenicline (1) is the first medicine targeting nicotinic acetylcholine receptors (nAChRs), other than nicotine (2) as replacement therapy (NRT), approved as an aid to smoking cessation by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) in 2006. The effort to discover and develop varenicline began at Pfizer in 1993, with the objective from the outset to find a partial agonist to treat nicotine dependence. A partial agonist was theorized to provide significant but reduced nicotinic reward that an abstinent smoker craves while simultaneously blocking the reward from relapse smoking. Prior pharmacological approaches to treat addiction were limited to opioid treatment for heroin addiction. Our nAChR partial agonist program was seeded in the growing appreciation of the effectiveness of buprenorphine as an aid to opioid addiction [11]. Buprenorphine, available today as Buprenexs (Suboxones, Subutexs), a semisynthetic analgesic, was shown in 1976 to be a m-opioid receptor partial agonist and was studied in the 1970s and 1980s as a treatment for heroin (and cocaine) addiction. Compared to methadone, a m-opioid receptor full agonist and naloxone, a m-opioid receptor competitive antagonist, buprenorphine is more effective, produces less physical dependence, has a reduced risk of respiratory suppression resulting from overdose, and fewer side effects. Rose and Levin [12] proposed the concept of a combined agonist and antagonist for smoking cessation in a series of publications in 1989–1992. They originally suggested that NRT (nicotine (2) as the nAChR agonist) when combined with mecamylamine (3) (nAChR antagonist) would theoretically improve quit rates. The effects of this combination were studied in clinical trials that demonstrated the dual agent approach provided higher quit rates than NRT alone. This was an attractive concept,
74
JOTHAM W. COE et al.
but suffered from the challenges of co-administration of two agents with different pharmacokinetic (PK) profiles, and the unfavorable side effect profile of mecamylamine (3). The dual agonist/antagonist approach could be better achieved with a single molecule, a partial agonist. In 1993, it was agreed at Pfizer to pursue a partial agonist as a novel smoking cessation agent, in part because one of the key challenges, how to measure partial agonist responses in vitro, was in principle achievable using cloned nAChRs for in vitro electrophysiological studies of ligand effects [13]. However, at that time, it was still much less evident how to identify or design partial agonist chemical structures. Herein we describe our efforts as they unfolded over time from the beginning of this project in 1993. Interestingly, the considerable synthetic and pharmacologic effort in the opioid field in the 1970s played a pivotal role in the discovery of varenicline.
2. PARTIAL AGONISTS AT NICOTINIC ACh RECEPTORS ‘‘Partial agonists are ligands that produce a smaller than maximal response compared with the natural ligand at full receptor occupation’’ [14]. Acetylcholine (4) is the natural full agonist at two known receptor subclasses important for neurotransmission: the muscarinic (mAChRs) and nicotinic (nAChRs) receptors, which are distributed throughout the central nervous system (CNS) and the periphery. The nicotinic receptor subtypes are ligand-gated ion channels that mediate fast synaptic transmission upon acetylcholine binding and also mediate the full agonist effect of nicotine. These ion channels are formed from pentameric assemblies of subunits creating a central aqueous pore. There are 12 neuronal nAChR subunits divided into a and b subtypes (a2a10, b2b4) differentiated by the presence or absence of a key ‘‘cys-cys loop’’ near the acetylcholine-binding site respectively. The known combinations of subunits form a broad range of nAChR subtypes with significantly different characteristics of ligand pharmacology (Figure 1) and cation permeability [15]. H N H N
N HN
N
N
O O
nicotine, 2
Figure 1
O
mecamylamine, 3
Nicotinic ligands.
acetylcholine, 4
cytisine, 5
Case History: Chantixt/Champixt (Varenicline Tartrate)
N
O O
N
acetylcholine, 4
A • O N
O O
5.9 Å
HN
75
• C • B
cation center (-)-cytisine, 5 H-bond acceptor
polarizing group
Figure 2 Nicotinic pharmacophore (Beers and Reich [17]).
Nicotine (2) binds tightly to the a4b2 heteromeric nAChR, which is the most abundant subtype in the CNS [16], and it acts as a full agonist at this nAChR subtype. The pharmacophore and binding requirements of the nAChR site were first explored and described by Beers and Reich in 1970 [17]. Their model is still useful today as it identifies a spatial relationship for key interactions within the nicotinic-binding site (Figure 2) and differentiates those interactions from the mAChrR-binding site (not shown). The defined distance between the cation/amine functionality and the hydrogen bond acceptor region has been verified with dozens of known receptor ligands, including nicotine (2), acetylcholine (4), and cytisine (5), but the connection between structural and functional activity has been less well understood. However, the level of polarization of the hydrogen bond and the electron density of the polarizable group make important but not well-defined contributions to functional activity. The complex functional characteristics of the receptor, as defined by Changeux [18], are a consequence of at least three distinguishable states: activated, desensitized, and inactivated during a response to drug binding (Figure 3) [19]. The functional outcome due to ligand binding over the dynamic course of all three receptor states is not well defined: it is likely that the scope of behavioral responses can be linked to the dynamic relationship among multiple nicotinic states whether activated or desensitized. Receptor binding is measured at the high affinity desensitized state, whereas functional activity is of limited duration at high concentrations during channel opening and ion flow in the activated state [20]. The 1980–1990s witnessed the development of in vitro functional assays of nicotinic receptors in Xenopus oocytes, which made it possible to assess the inherent agonist activity of compounds, as well as their antagonism of nicotine [13]. Despite this, we felt that in vivo models of behavior or specific biochemical endpoints could give us a more meaningful picture of the consequences of ligand binding.
76
JOTHAM W. COE et al.
Figure 3 Schematic representation of the transitions among the functional states of nAChRs, indicating the effects of agonists (open squares) and antagonists (black squares) on the equilibrium between the resting, active, and desensitized state of the nAChR (J. Med. Chem., 2005, 48, 4705, reprinted with permission).
At the outset of our program, stable human cell lines expressing nicotinic receptor subtypes were not readily available to screen our sample collection nor were high throughput functional screens (such as Fluorescent Imaging Plate Reader (FLIPR) platforms). The most informative biological tools available were animal models of the rewarding effects of nicotine [21]. These consisted of quantitative measurements of effects on dopamine (DA) release in brain or in brain slices, and nicotine selfadministration and drug discrimination in rats, mirroring subjective effects experienced by smokers. Nicotine discrimination was pioneered by Morrison and Stephenson [22] in an experiment that demonstrated that rats could detect and respond to nicotine’s presence. The exact receptor that mediated this effect was not known at the time; however, discrimination could be blocked by a central nicotinic antagonist such as mecamylamine but not by chlorisondamine, a peripheral antagonist. Later studies by Romano [23], Rosecrans and coworkers [24], and Stolerman and coworkers [25] identified central nAChR stimulation as the likely source of the nicotine cue rather than mAChRs. Self-administration of nicotine in rats had been achieved by Corrigall and Coen [26] mimicking many of the behavioral responses displayed by humans. As with the discrimination model, the response was dose-dependently reduced by pre-treatment with either nicotine or mecamylamine but not with hexamethonium (10), a peripheral nicotinic antagonist. The dependence-producing effects of nicotine are believed to be mediated through its action as a full agonist at a4b2 nAChRs [27,28]. Activation of a4b2 receptors in the ventral tegmental area by nicotine
Case History: Chantixt/Champixt (Varenicline Tartrate)
77
increases the release of DA in the nucleus accumbens and prefrontal cortex [29], an effect shared by most substances of abuse, although each through distinct neurochemical pathways. We measured the change in DA metabolites in response to activation by partial agonist ligands and after co-administration with nicotine. We sought compounds that would provide a reduced reward relative to that of nicotine while simultaneously blocking the full effect of nicotine itself. These models were assembled for our program and validated with known nicotinic receptor ligands.
3. THE SEARCH FOR PARTIAL AGONISTS: CYTISINE AS A KEY STARTING POINT Early in our drug discovery program, we sought information on the level of partial agonist efficacy that would be effective for smoking cessation and any available chemical tools to distinguish a partial agonist from the effects of the full agonist nicotine. We required a substance that would displace nicotine from its neuronal binding site and reduce the subjective experience of nicotine administration by simultaneously attenuating the dopaminergic response to nicotine. Evidence for partial agonism would include lower efficacy than nicotine and antagonism of nicotine’s effects in vitro and in vivo. The de novo design of a single agent nAChR partial agonist was and still is hampered by the lack of a clear understanding of structural requirements needed for the appropriate functionality and selectivity. Fortunately, nature’s portfolio in the nicotinic area is substantial, and we directed our focus there as a source of medicinal leads, rather than to an artificial compound sample collection [30]. Many of these natural structural classes are presumed to posses a favorable pharmacokinetic profile, but CNS penetration and potency remained the key issues to be resolved. We first profiled nicotinic agonists with lower functional efficacy than nicotine (o70%) such as anabaseine (6), GTS-21 (7) [31], anabasine (8) [32], lobeline (9), and cytisine (5) (Figure 4) in nicotinic assays. These included drug discrimination and self-administration behavioral models and ex vivo biochemical endpoints such as DA release. Early debate in the team focused on the perceived advantages of anabasine and derivatives, which had been shown to display partial agonist activity in rat neuronal a4b2 nAChRs expressed in Xenopus oocytes (EC50 ¼ 30 mM vs ACh EC50 ¼ 2 mM), but full agonist activity at muscle receptors [33]. Reports by Stolerman and coworkers [34] had indicated that the nicotinic agent cytisine (5) was 5-fold more potent than nicotine (2) in binding to CNS receptors but 10% less potent in producing the nicotine cue. The latter response was determined to be centrally mediated since mecamylamine (3, Figure 1) blocked the effect, but the non-CNS
78
JOTHAM W. COE et al.
H N
OMe
MeO
OH N
N
N
HN
N N
Anabaseine, 6 Anabasine, 8
O
O
GTS-21, 7
cytisine, 5
Lobeline, 9
N N Hexamethonium, 10
Figure 4
Early nAChR lead ligands and the peripheral antagonist hexamethonium.
penetrant antagonist hexamethonium (10) did not. Anabasine (8), which was 30- to 60-fold less potent than cytisine in discrimination assays, as well as cytisine, appeared to be reasonable partial agonist templates. They both produced a maximal B60% response to a nicotine cue at their highest tolerated dose without reducing the control response rate. An in vivo nicotine-like effect was considered crucial as the drug must be ‘‘experienced’’ as nicotine-like to the smoker, and so the weak agonist responses of anabasine and cytisine pointed to platforms from which a partial agonist therapeutic could be built. Lobeline (9), despite displacing [3H]-nicotine in cells and achieving high brain penetration, did not produce nicotinic-like behavioral effects, possibly due to PK issues such as free fraction concentrations below the IC50, and so we moved away from this lead. In vivo, anabasine and cytisine were reported initially to be full agonists in DA release in the striatum; however, our work and that reported later by Sibia confirmed partial agonist activity in the striatum and on DA turnover (DATO) in rat nucleus accumbens [35]. Although anabasine (8) was shown to have partial agonist activity, its weak effect in drug discrimination models required doses that were close to those that impaired control responding for food, suggesting a limited therapeutic index. We were also concerned by anabasine’s full agonist profile at the muscle receptor. Anabaseine (6) possessed less attractive structural features such as potentially unstable imine functionality and was not pursued further. (–)-Cytisine (5), a nicotinic agent isolated from natural sources more than 100 years ago [36], had garnered little attention from a medicinal chemistry standpoint despite its use as a natural smoking cessation aid in Eastern Europe [37]. Cytisine’s unusual properties as a high affinity, but low efficacy, ligand for the neuronal nAChR may have restricted interest in this compound as a therapeutic agent [38]. We hypothesized that cytisine’s rigid structure and polarizable pyridone ring could potentially
Case History: Chantixt/Champixt (Varenicline Tartrate)
79
contribute to its partial agonist profile at the receptor level, and we targeted derivatives of this compound as a starting point. At about the same time, Papke and Heinemann [39] demonstrated that cytisine behaves as a partial agonist relative to acetylcholine at a4b2 nAChRs in vitro with an EC50 of 9 mM. In the discussion that follows, we describe structure–activity relationships (SARs) based on cytisine and analogs that were aimed to maintain or improve its partial agonist activity in vitro and to substantially improve its in vivo pharmacokinetic profile, as part of our efforts to discover novel partial agonist platforms. Commercial supplies of (–)-cytisine were limited and expensive, but we made the most of small quantities while pursuing local sources of the natural product. Commercial material had been derived from extracts of natural plant sources and we engaged our suppliers to locate a source of bulk material to support analog studies. We were not able to readily obtain the natural product from Sopharma, the Bulgarian firm that sells cytisine under the trade name Tabex. Material was eventually secured by working through the Austin Chemical Co., USA, and the Specs-Biospecs Company in the Netherlands. They contracted with Chinese and Russian farms that could produce plant material from Thermopsis lupinoides (L Link), a legume species from which (–)-cytisine would be readily extractable. Precise timing was critical to intercept the bean pods at peak production of the natural product in mid-July before the pod fell from the plants. From these sources, we obtained 2 kg of W98% pure (–)-cytisine; an early batch was procured for $30,000/kg. This legume species was outside of the normal medicinal herb target population, but reasonable cost estimates put the eventual price of production quantities of (–)-cytisine at $150/kg. We were also able to estimate that quantities of 13–18 kg of purified cytisine could be produced per acre. While we were awaiting harvest, we initiated a parallel collaboration with Smith College Botanical Garden in Northampton Massachusetts. Cytisine was known to be a constituent of the Maackia amurensis (M. amurensis) species and material from tree pruning was made available by the college. Tree material, including bark, leaves, roots, and stems, was milled and extracted with methanol for up to 20 h followed by concentration and chromatographic separation from which we obtained 5.5 g of W95% pure (–)-cytisine from 64 kg of tree material. These small quantities allowed us to prepare several close analogs that we hoped would provide access to a library of molecules with good brain penetration and hopefully better potency. Cytisine was profiled [40] in neurochemical models, ex-vivo DATO in rat nucleus accumbens and [3H]-DA release in rat striatum. We found that cytisine functions as a partial agonist, producing lower than the maximal nicotine-induced increases in [3H]-DA release in striatal slices and in DATO. Cytisine also antagonized the effect of nicotine in these
80
JOTHAM W. COE et al.
assays, displaying the dual effects expected of a partial agonist. At 1 mg/ kg subcutaneous administration (s.c.), nicotine maximally increased DATO in nucleus accumbens to 170% of control (ED50 ¼ 0.156 mg/kg s.c.), whereas the maximal cytisine-induced increase was 130% of controls (ED50 ¼ 1 mg/kg). In addition, cytisine reversed the effect of 1 mg/kg s.c. nicotine on DATO in rat nucleus accumbens with an ID50 of 1.77 mg/kg. These results met our criteria for a partial agonist profile, except for the rather low in vivo potency, and validated our thoughts around a suitable structural framework for developing a partial agonist portfolio. The high cytisine dose required for inhibiting nicotineinduced DATO was eventually linked to low central exposure. Cytisine has low molecular weight and low polar surface area with moderate basicity, but it is hydrophilic, as shown by its partition coefficients in octanol/water (log P ¼ 0.01; log D7.4 ¼ 0.2), which may partially explain its limited brain penetration. The measured brain-to-plasma ratio of cytisine, which does not bind to plasma or brain proteins, was 0.1 and the cerebral spinal fluid (CSF)-to-free-plasma ratio was 0.27 resulting in low observed brain concentrations, ranging from 10 to 50 ng/g over the course of 6 h after a 1 mg/kg p.o. dose.
4. SEMI-SYNTHETIC ANALOGS OF CYTISINE Semi-synthetic analogs of cytisine were targeted once supplies of the natural product were secured [40]. Early on we established significant decreases in nAChR binding activity with N-group substitution (e.g., Me, Bn, Allyl, COR, SO2CF3), a result later confirmed in related templates. Medicinal chemistry enabling synthetic studies targeted aromatic ring modifications as well as total synthesis options, which would require the synthesis of novel templates. Although cytisine was the foundation for further nicotinic partial agonists, we were aware that improvements in cytisine’s profile might not succeed or be thwarted by issues of toxicity, CNS penetration, or other PK issues. Furthermore, novel rigid templates that offered receptor interactions complementary to cytisine would diversify the approach into novel matter. Cytisine binds with high affinity at the a4b2 nAChR with an in vitro agonist EC50 of 9 mM, but its poor brain penetration contributes to its reduced in vivo potency. Therefore, sufficient in vivo efficacy would either require a bold potency improvement within the cytisine structural class, or a physical property improvement that allowed CNS penetration from a novel template outside of the cytisine structural domain. Since we did not want to overplay the benefits of a particular series such that high doses would be required to achieve efficacy, it seemed a better strategy to look to novel series based on the cytisine framework for partial agonist activity to
Case History: Chantixt/Champixt (Varenicline Tartrate)
81
maintain and improve the profile we had from nature. We planned to move in parallel from cytisine to novel rigid templates that possessed similar receptor interactions, while monitoring partial agonist properties using electrophysiology, neurochemistry, drug discrimination, and selfadministration models. Early cytisine derivatives were intended primarily as intermediates for further analog synthesis. (–)-Cytisine (5), obtained from natural sources, was protected as the N-t-Boc derivative under standard conditions. Halogenation gave access to novel cytisine intermediates, with bromination of N-protected cytisine affording a mixture of monobromo and dibromo adducts. Although mono-halogenation of 11 using N-bromosuccinimide (NBS) or iodine monochloride (ICl) suffered from poor selectivity, reaction of 11 with N-chlorosuccinimde (NCS) gave a 1:9 mixture of regioisomeric compounds 15 and 18, respectively. The opposite regioisomer predominated when trifluoroacetamide 12 was iodinated with ICl in buffered methanol (Scheme 1, Table 1). Binding affinities of our analogs, including synthetic intermediates such as the halogenated cytisine derivatives, were routinely evaluated in nAChR-binding screens. We were gratified to see a large potency shift in moving from cytisine to 3-bromocytisine 14. This derivative was more potent than either the 5-bromo-derivative 17 or 3,5-dibromocytisine with a B100-fold shift in agonist efficacy (EC50 ¼ 95 nM compared to cytisine EC50 ¼ 9 mM). Thus, with a small change in molecular weight, the inherent potency of cytisine could be improved. Comparison of physical properties suggested that 3-bromocytisine’s enhanced potency could be partially ascribed to increased lipophilicity (3-bromocytisine: log P ¼ 0.99, log D ¼ 0.35 vs cytisine: log P ¼ 0.01, log D ¼ 0.2), without decreasing either ligand efficiency (the binding energy per atom) [41], which remained at nearly 0.90, or lipophilic lipid efficiency [42] (LLE ¼ pIC50log P) which is B12. These high values can be partially attributed to the small volume of the nAChR binding pocket. We also postulated that the electronic effect of halogens either improved the X O
O
O N
halogenate
N
N
+
deprotect N P 11. P = t-Boc 12. P = CF3CO−
Scheme 1
N H 13. X = I 14. X = Br 15. X = Cl
Halogenated cytisine derivatives.
N H 16. Y = I 17. Y = Br 18. Y = Cl
Y
82
JOTHAM W. COE et al.
Table 1
Halogenation of Cytisine Derivatives.
Condition
Protection
Product
Ratio
ICl CaCO3 ICl CaCO3 NBS CH2Cl2 NCS CH2Cl2
t-Boc TFA t-Boc t-Boc
13/16 13/16 14/17 15/18
1:1 9:1 3:2 1:9
H N
H N
H N 3-Br-cyt
(-)-cytisine
O 5
5
N C 3
Figure 5
13
C-NMR 163.6 ppm
H N
O 14
N C
3-Cl-cyt
13
C-NMR 160.1 ppm
Br
O 15
N C
N
13
C-NMR 159.0 ppm
Cl
O 19
X
Halide effects on N-C(O) polarization by 13C-NMR.
hydrogen bond acceptor properties of the pyridone carbonyl or favorably contributed to the aromatic polarizability by increasing the double-bond character of the pyridine C–N bond, as depicted in pyridinium oxide 19 in Figure 5. Pharmacokinetic measurements indicated that the increase in lipophilicity of 3-bromocytisine 14 improved CNS penetration (B/P ¼ 1.4) with a symmetric CSF/free plasma ratio of 1 and virtually no protein binding (Cytisine (5), B/P ¼ 0.1 and CSF/free plasma ratio 0.27). Parallel in vivo studies demonstrated that 3-bromocytisine 14 was a potent partial agonist in DATO with a B70-fold shift in agonist activity (ED50 ¼ 0.032 mg/kg) relative to cytisine and potent antagonist activity (ID50 ¼ 0.179 mg/kg). Compared to cytisine, 3-bromocytisine fully substituted for nicotine in a drug discrimination model showing a B70-fold leftward shift of the dose–response curve. Importantly, 3bromocytisine 14 also potently inhibited nicotine self-administration in rats with an ED50 of 0.05 mg/kg. Close in analogs of cytisine demonstrated additional examples of potency enhancement but none exceeded that of 3-bromocytisine 14. Synthetic chemistry efforts gave access to multiple derivatives beginning from 14 as shown in Scheme 2. The 3-chlorocytisine derivative 15 was also a potent partial agonist as were the 3-cyano and 3-methyl derivatives, 23 and 26, respectively. It has been theorized that electronic effects play a crucial and complementary role in binding and functional activity at the nicotinic receptor, leading to the proposal of a three-point nicotinic pharmacophore
83
Case History: Chantixt/Champixt (Varenicline Tartrate)
O Br N
N
O
O
N
N
HN
N
O HN
N
t-BOC
t-BOC
(-)-cytisine (5)
11
Boc-14
20 Acylation
plus regioisomer
Me
B(OH)2 N
N
O N
CN
N t-BOC N
21
N
O
O
26 Stille
25 Buchwald Hartwig CO2Me
23 Cyanation
X O N
HN
O
HN
22 Suzuki
Scheme 2
O
HN
HN
HN
N
O
24 Carbonylation
Cytisine analog semi-synthesis through Pd catalysis.
providing two contacts with the protein and one locus of polarizability [17]. We therefore explored isomeric changes that maintain the physical separation between the carbonyl and basic amine within a rigid framework directly related to cytisine. Nitrogen was repositioned across the ring to evaluate the effect of this structural change on biological activity (Figure 6) [43]. The isomeric cytisine analog, racemic N-methyl isocytisine (27), displayed a B100-fold drop in binding potency and was a functional antagonist. The alkyl substituent on nitrogen was critical for maintaining any nicotinic binding activity in this series. Although isosteric with H N
O
H N
N
O
27
N
H N
H N
N
N
O
O
28 isocytisine
(-)-3-methylcytisine, 26
Figure 6 Methyl-cytisine/isocytisine resonance forms.
84
JOTHAM W. COE et al.
3-methylcytisine (26), the subtle structural change and corresponding shift in efficacy point to a delicate balance between electronic structure and functional activity. Perhaps, building positive charge on nitrogen (the oxo-pyridinium tautomeric form, 28) in that region of the binding pocket is detrimental to the binding and functional activity, despite maintaining carbonyl H-bond acceptor capacity presumed to be similar to cytisine. The unsubstituted isocytisine pyridone (N-H) derivative was inactive, likely due to repulsion of the hydrogen bond donor in that binding pocket. The cytisine template served to initiate an essential SAR study for the nicotinic partial agonist program. Our early work demonstrated that CNS penetration could be improved compared with the natural product without sacrificing the desired pharmacodyamic parameters. We further showed that cytisine-derived partial agonists could be discriminated as nicotinic agents and would provide a reduced nicotinic-like reward while blocking the effect of nicotine. We uncovered a range of functional activities by modifying ring substitutions or by subtle changes in the electronic character of the polarizable heteroaromatic ring. Unfortunately, the overall profile of these ligands was marred by genetic toxicology findings within the substituted cytisine class. Our original plan to create novel scaffolds using the chemistry that follows opened up a broad and entirely novel range of partial agonist templates.
5. CYTISINE SYNTHESIS AND EARLY TEMPLATE EXPANSION With the advances provided by studies of cytisine and derivatives, access to compounds not available by direct analog generation became more important. The cost of cytisine as a raw material had originally been a concern (B$1.7 M/kg, Aldrich, B1995), but had been addressed through potential agricultural harvest. To support further derivatization and SAR development, synthetic approaches became essential, as they offered the ability to make not only cytisine but also novel cytisine-like derivatives inaccessible from cytisine itself. These synthetic efforts began in earnest within our group in 1995. Of the strategies we considered for cytisine’s construction, two novel synthetic designs were ultimately demonstrated and later published. The most concise strategy is exemplified by biaryl coupling chemistry of pyridine precursors 29 and 30 to access both the pyridone and the piperidine ring atoms of cytisine (5) (Scheme 3). This step-efficient approach requires a nucleophilic nitrogen component in 31 to reveal the cytisine pyridone in the bicycle formation step [44] and allows the introduction of a range of substituents on the final pyridone ring [45].
Case History: Chantixt/Champixt (Varenicline Tartrate)
H
N
Z
O
O
O
29
Scheme 3
N
N
N
X
N
X
Y
N
85
30
(+/-)-cytisine 5
31
Biaryl coupling approach to cytisine [44].
A second strategy employed a palladium-mediated Heck cyclization of a glutarimide derived enol triflate intermediate (33) to access the bicyclic ring core (34), ultimately providing racemic cytisine in six steps from cyclopent-3-enyl-methanol (32) (Scheme 4) [46]. In this approach, the N-C bond of the pyridone ring was established first, with the piperidine synthesis finalized after bicycle formation (34-5). The construction of alternative templates not containing a nitrogen ring fusion atom was possible utilizing the same strategic approach (32-37, Scheme 5). Soon after the successful syntheses of racemic cytisine were established, we targeted non-pyridone-containing derivatives and the efforts rapidly yielded active compounds [43,47]. An early anisole derivative (38) had high affinity (Ki ¼ 1.4 nM) and displayed weak partial agonist activity at the receptor in vitro in oocytes (30% relative to nicotine, Figure 7). In vivo this analog displayed weak activity in the DATO assay, in part due to rapid demethylation in vivo to the less active phenol (40, Ki ¼ 90 nM, partial agonist). These promising early results launched an 18-month effort of intensive chemical synthesis, producing B100 novel carbon analogs of cytisine. Despite the targeted chemical exploration, derivatives from this series generally displayed either reduced affinity or antagonist activity in oocytes (e.g., 39 and 41, o20% efficacy relative to nicotine). Compounds worthy of further pursuit as partial agonists did not emerge from the effort. The most potent non-pyridone cytisine
H N X N
N HO 32
Scheme 4
N
O
O 33
O 34
(+/-)-cytisine 5
Palladium mediated heck approach to cytisine [46].
86
JOTHAM W. COE et al.
H N X R2
R2
HO
32
Scheme 5
R2
R1
R1 35
R1 non-pyridone derivatives 37
36
Approach to non-pyridone cytisine derivatives.
derivatives generally were compounds with antagonist action at the receptor, such as the difluoroderivative 42 [48]. One aspect of the pharmacophore brought into question by SAR developed in this series was the role of the cytisine carbonyl group. Most published binding motifs suggested the existence of a hydrogen bond between the cytisine carbonyl and the receptor [17,49]. In contrast, we saw enhanced potency of compounds possessing electron withdrawing functionality, the most potent being the difluoro derivative 42, which possesses H-bond acceptor interactions that are arguably weak [50]. These data suggested that dipole or other electronic interactions are important for binding and functional efficacy at the a4b2 receptor. These results were consistent with the profound changes we observed between cytisine (5) and isocytisine (27) activity, wherein H-bonding alone is insufficient to explain the pharmacophore interactions. Furthermore, 42 was almost a full antagonist (3% agonist), clearly demonstrating
H N
H In vitro N Ki α 4β2 1.4 nM 30% ag. / 51% antag. vs. nicotine In vivo active short half-life H3CO
OCH3 38 H N
In vitro Ki α4β2 0.4 nM 3% ag. / 85% antag. vs. nicotine In vivo active antagonist
F
39
antagonists
In vitro Ki α4β2 2.9 nM
3
R O
2
H
Figure 7
40
41
1 C
H
HO OH
42
F
HN
H N In vitro Ki α4β2 90 nM partial agonist
H N
In vitro Ki α4β2 >500 nM
H
H
O H
H
binding site
Selected SAR and H-bond pharmacophore probes.
untolerated
43
87
Case History: Chantixt/Champixt (Varenicline Tartrate)
H N
HN
O 44
H N
H N
O
N
N O
H N
H N
O 45
O 46
N 27
N R 47
48
Figure 8 Additional templates.
non-parallel responses of ligand binding and functional receptor responses. With no rational explanation regarding control of functional efficacy, structural guidance from SAR was for the most part empirically derived. A brief exploration of heterocyclic derivatives (e.g., 48, Figure 8) [43], accessed by the same synthetic route design, provided compounds with either weak functional activity or minimal selectivity over the nicotinic muscle receptor, another undesirable property.
6. DISCOVERY OF THE BICYCLIC BENZAZEPINE CORE The weak in vitro and in vivo responses of non-pyridone cytisine derivatives (Figure 7) drove our expanded search for alternative structural scaffolds targeting improved potency and partial agonist activity (Figure 8). We synthesized various reasonable assemblies of the critical functional groups found in many natural nicotinic agents, probing alternative locations and orientations of necessary functionality. Many of these approaches proved disappointing, since they did not provide improvements in nAChR activity. The avenue that defined much of our future work came from the opioid literature, as we recognized that morphine and cytisine both possess embedded [3.3.1]-bicyclic core structures. Paul Mazzocchi’s work from the 1970s explored various simplified versions of morphine 49, the complex alkaloid from the opium poppy, Papaver somniferum. Bicyclic substructures of morphine were evaluated, including the [3.3.1]-bicyclic benzomorphan 50, and Mazzocchi and coworkers found that N-alkyl derivatives of 50 possessed morphine-like anti-nociceptive effects mediated through m-opioid receptors. Additional publications compared modified bicyclic frameworks of 50, including 51 and 52, all of which produced analgesia with particular nitrogen substituents (Figure 9) [51]. In 1979 Mazzocchi published the synthesis and anti-nociceptive activity of derivatives of an N-positional isomer of 52, namely [3.2.1]-bicyclic benzazepine 53 [51]. Analogs of 53 with N-alkyl substitution were found to have greatly reduced anti-nociceptive activity. Importantly, Mazzocchi
88
JOTHAM W. COE et al.
antinociceptive
OH
OH
N
HN O N
H
OH morphine
49
?
HN
H N
HN
O OH
50
51
52
53
Figure 9 Mazzocchi’s benzomorphane modifications [52]. (See Color Plate 4.9 in Color Plate Section.)
generalized and emphasized his key finding in the last sentence of the discussion: ‘‘Clearly, the change in nitrogen position in proceeding from ‘52 to 53’ manifests itself by an almost total loss of anti-nociceptive activity and a marked increase in toxicity.’’ The toxic nature of nicotinic agents derived from plants – for example nicotine (2), anatoxin a (54), cytisine (5), and epibatidine (55) – is to protect the host from microbial, insect, and animal predators. We wondered whether the non-pyridone cytisine scaffold 37 and the bicyclic benzazepine 53, both 3,5-disubstituted piperidines, possessed nicotinic pharmacology that could explain the increased toxicity of derivatives of 53 reported by Mazzocchi [52]. Truncated analogs 53 and 52 were prepared [53] (Figure 9), tested in opioid and nicotinic-binding assays and found to be highly selective, 53 for the a4b2 nAChR, and 52 for opioid receptors [51] (53 Ki m-opioid W2 mM; 52 Ki a4b2 W5 mM); no cross-reactivity was observed. Furthermore, benzazepine 53 was equipotent at the a4b2 nAChR to the unsubstituted parent non-pyridone cytisine derivative 37 R1 and R2 ¼ H (Ki ¼ 20 vs 34 nM, 53 and 37 respectively; Scheme 5). Both unsubstituted parent compounds were antagonists; however, the bridged benzazepine 53 provided an achiral symmetric template, greatly simplifying SAR development. Our studies expanded into this fertile area and yielded promising results. Electron-deficient and sp2-hybridized groups are common functionalities in nicotinic natural products, for example, acetylcholine (4), anatoxin a (54), cytisine (5), nicotine (2), and epibatidine (55), all contain acyl or pyridyl groups (Figure 10). We initially targeted similar structures to explore bridged benzazepine SAR. Our initial attempts to functionalize the bicyclic benzazepine by electrophilic substitution chemistry were unsuccessful, as the parent structure and typical N-protected versions proved inert to substitution. Usually nitration readily introduces functionality for subsequent SAR development, but early attempts at nitration reactions with both the N-carbamate-protected and the free
89
Case History: Chantixt/Champixt (Varenicline Tartrate)
HN
N
HN
O O acetylcholine, 4
anatoxin a, 54
N
N
N
O
H
Cl
HN
O
N epibatidine, 55
(-)-cytisine, 5
CH3
(-)-nicotine, 2
Figure 10 Naturally occurring nicotinic ligands.
benzazepine 53 did not progress, even under more forcing conditions. We were surprised to find that even nitronium triflate [54], a powerful nitrating agent, failed to derivatize the carbamate-protected benzazpine. We suspected that interactions of electrophilic reagents with the amine or protected amines would generate non-productive cationic piperidinium intermediates that served to insulate the aryl ring against electrophilic chemistry. To test this hypothesis, the trifluoroacetamide (TFA) group was chosen to mask the nitrogen functionality from competing for electrophilic attack. With the TFA group, aromatic substitution of 56 progressed smoothly (Scheme 6), with a breakthrough achieved while employing the combination of N-TFA protection and nitronium triflate in methylene chloride to afford the mononitrated derivative 57 in 78% yield. After deprotection, 58 was found to exhibit potent partial agonist activity in vitro and in vivo in DATO after both subcutaneous and oral administration in rats. This result established that nicotinic agents derived from 53 were excellent partial agonist targets. We then returned to the original non-pyridone cytisine [3.3.1]-bicyclic structure to introduce nitro functionality. Three isomers were generated (59, 60, and 61) under the nitration conditions, and each displayed weaker binding affinity than the nitrobenzazepine, but more importantly, all displayed weaker functional agonist activity than the nitro-benzazepine derivative 58, in line with findings of greater antagonist behavior observed with earlier non-pyridone-based cytisine analogs [47] (Scheme 5, 38). Although these templates differ by only a single core carbon atom, the consequent effect on potency and efficacy is remarkable (Figure 11) from 58. Given the relative ease of preparation of bicyclic
CF3 O
N
H N
CF3 2.6 equiv CF3SO3H 1.3 equiv HNO3
O
N
OH-
78% O
56
Scheme 6
NO2 N
O
SO3CF3
57
58 NO2
Nitro benzazepine: potent partial agonist revealed.
In vitro Ki α4β2 0.75 nM 64% ag. / 36% antag. vs. nicotine In vivo active 50% partial agonist in DATO s.c. and p.o.
90
JOTHAM W. COE et al.
H N
H N In vitro Ki α4β2 4.5 nM 20% ag. / 40% antag. vs. nicotine
59
NO2
Figure 11
H N
In vitro Ki α4β2 6.5 nM 2% ag. /50% antag. vs. nicotine NO2
60
In vitro NO2 Ki α4β2 14 nM 0% ag. /100% antag. vs. nicotine
61
Nitrated non-pyridone cytisines.
benzazepine analogs from a common intermediate, the partial agonist activity of suitably substituted compounds at a4b2 nAChRs, and the promising early in vivo efficacy signals, our active pursuit moved to this series. During the scale up of the nitration reaction with a slight excess of nitronium triflate (56-57), we discovered that a dinitrated by-product was formed. This reaction gave the desired mono-nitrated product 57 after crystallization in high yield (Scheme 6), but we re-examined the residues for a doubly nitrated by-product that had been observed in low yield by gas chromatography with mass spectrometry (GCMS) in the crude material, now enriched in the mother liquors. After isolation, a 9:1 mixture of two dinitro derivatives were identified, with the major isomer assigned the structure resulting from unexpected vicinal dinitration, compound 62, the minor was the expected meta isomer 63 (Scheme 7). Upon exposure to greater than two equivalents of nitronium triflate, the conversion to the dinitrated benzazepine 62 proceeded in 77% yield. This discovery fueled much of our future chemistry effort by facilitating rapid access to fused rings [55]. As SAR developed within this series (Figure 12), we found that monofunctionalized products (65, 66) were uniformly active at the a4b2 nAChR, with electron-deficient functional groups displaying subnanomolar affinity. Electron-donating groups (R1) conferred weaker binding affinity, and functional activity and peri-substitution further reduced activity (R2 position in 67), consistent with the SAR
O
O
CF3 N
CF3 N
> 2 eq NO2.OSO2CF3
9:1 NO2
O 2N
56
Dinitration of benzazepine 56.
CF3 N
-78 - 20 °C, 24 h
Scheme 7
O
NO2
62
O2N
63
Case History: Chantixt/Champixt (Varenicline Tartrate)
H N
H N
H N
H N
N O R Cytisine Derivatives 64
91
R2 R1
R1
Benzazapines less active enantiomer
Benzazapines more active enantiomer
Benzazapines less active regioisomer
65
66
67
Figure 12 Benzazepine SAR trends.
observed within the non-pyridone analog series. Electrophysiological measurements at a4b2 nAChRs expressed in oocytes showed that the partial agonist activity within mono-substituted benzazepines in racemic form ranged from 0 to 86%, with most electron withdrawing groups (R1) imparting partial agonist profiles worthy of further evaluation in optically pure form [56]. Most pharmacophore models for high-affinity nAChR ligands identify two critical ligand components: an ammonium ion and a Hbond acceptor [17,49]. The resolved enantiomers revealed an unexpected SAR trend. We expected that substituents on mono-functionalized compounds (R1) would align with cytisine’s carbonyl to establish Hbonding interactions with the receptor. We were surprised to find these isomers were less active i.e. 65 (Figure 12). The more potent enantiomers 66 positioned the electron withdrawing group away from the cytisine carbonyl orientation (typically the more potent isomers were B10-fold higher binding affinity with greater agonist functional efficacy, Figure 12). In addition, electron-withdrawing groups of widely varying H-bond acceptor ability were generally equipotent and efficacious, although each presents dissimilar H-bonding orientations into the receptor pocket (R1 ¼ NO2, Ac, CN, halo, CF3, etc.). These findings have led us to question the validity of assertions that H-bonding is a predominant feature within the a4b2 nAChR pharmacophore. Instead, these results suggest that a key feature governing affinity and possibly functional efficacy may be an interface between the ligand sp2-hybridized component and key receptor residues through productive p-electron interactions. This notion may extend our understanding of the welldocumented p-cation interaction of the ammonium head group common to all nicotinic agents [57] by including productive interactions of the ligand p-system and receptor aryl groups in addition to the ammonium p-cation interaction.
92
JOTHAM W. COE et al.
7. FUSED BICYCLIC BENZAZEPINES As mentioned earlier, the dinitration reaction of TFA-protected benzazepine (56-62) led to a number of important fused heterocycles. SAR development in the ‘‘6,6-fused’’ derivatives revealed the importance of the ‘‘quinoline nitrogen’’ (5-position) to affinity and functional activity (Figure 13). Quinoxaline derivatives (68), directly accessed from dinitro intermediates in two steps, displayed optimal partial agonist activity with hydrogen substitution (e.g., varenicline (1)). Small groups were welltolerated at C-6 and 7 (H, CH3, OH, OCH3, etc.) but reduced the functional potency of these derivatives. Aryl appendages generally decreased binding affinities and reduced partial agonist efficacy. Both quinoline (69) and quinazoline (70) derivatives with small groups displayed high affinity, but were uniformly full agonists, being more efficacious at 10 mM compared with the effect of 10 mM nicotine in oocytes. 3-Substitutied quinolines with groups larger than methyl (7-position of 69, Figure 13) displayed decreased agonist activity and affinity. Isoquinolines (71) were 10-fold less potent compared with similar quinoline (69) and quinazoline (70) derivatives. Electronic and steric changes at the ‘‘5-position,’’ which occupies a position similar to the ‘‘cytisine carbonyl’’ in molecular modeling overlays, considerably reduced activity and revealed the importance of this site. 6,5-Fused heterocyclic analogs also exhibited a broad range of functional activities in oocytes from full agonist to antagonist at 10 mM relative to 10 mM nicotine (Figure 14). With the exception of larger groups in the 6-position, most compounds based on this general construction (72–75) had Ki values o1 nM. The functional efficacy of analogs within this 6,5-fused heterocyclic series was sensitive to structural changes at the 6-position, as illustrated by benzimidazole (72) and benzisoxazole (73) derivatives. All C-6 hydrogen-substituted analogs are partial agonists with high affinity, whereas C-6 methyl substituted analogs were consistently found to be agonists with greater efficacy in oocytes than nicotine itself when measured at 10 mM. The 2-methyl benzothiazole (74) and benzisoxazole (75) derivatives were also particularly efficacious agonists, but increases in C-2 substituent size beyond methyl (in 72 and 73) appeared to inversely affect functional efficacy and binding affinity of
8 N
R′
R′
HN
1
3
68
N 5
N
HN
HN R
N
N
R
69
Figure 13 6,6-Fused heterocyclic benzazepines.
70
HN
N
R
71
93
Case History: Chantixt/Champixt (Varenicline Tartrate)
R′ N 7 HN N
3
1
72
S
O R
R
HN
73
HN
N
N
N
5
O R
74
75
Figure 14 6,5-Fused heterocyclic benzazepines.
analogs. Benzimidazoles (72) with R7-substituents were uniformly potent presumably by accessing a pocket not found to be productive within the 6,6-fused heterocycles of Figure 13. An available binding pocket for substitution appended to the aryl group is an SAR point observed with other known nicotinic agents, but the orientational distinctions between the effect of 6,6- and the effect of 6,5-fused heterocycle substitution on activity is striking [49].
8. IN VIVO EFFICACY OF PARTIAL AGONISTS The in vivo efficacy of analogs was determined by measuring effects on mesolimbic DATO, which reflects a change in postmortem tissue concentration ratios of DA and its metabolites in the rat nucleus accumbens. Compounds were evaluated subcutaneously (s.c.) and, if active, were re-examined after oral administration. In this assay, nicotine (2) produces a maximal DATO response at 1 mg/kg s.c. of B180% of control levels. The partial agonist activity of an agent alone was determined by comparison of the effect of maximum well-tolerated doses with that of 1 mg/kg s.c. nicotine. These partial agonist efficacies at the maximal well-tolerated dose of the compounds are represented as black bars in Figure 15, showing a wide range of efficacies relative to nicotine. Compounds with sufficient potency at well-tolerated doses were then examined for another hallmark of partial agonist activity, that is, the ability to inhibit nicotine-induced increases in DATO. This property was uncovered in the ‘‘antagonist mode’’ of DATO, in which attenuation of the maximal nicotine response was evaluated after co-administration of the compound and nicotine, and is represented by the shaded bars in Figure 15. Although many compounds act as partial agonists alone and produce sub-maximal DATO increases relative to nicotine, few compounds fully antagonized nicotine’s effect at their maximal welltolerated dose. Only compounds that effectively blocked nicotine’s effect with sufficient tolerability displayed the desired partial agonist dual action to warrant further pursuit. Figure 15 shows that many cytisine analogs have an optimal profile as efficacious partial agonists that can completely block nicotine-induced DATO increases. 3-Bromocytisine is particularly efficacious, displaying
94
JOTHAM W. COE et al.
110
agent alone
100
agent + 1 mg/kg s.c. nicotine
Dopamine turnover
% nicotine response + SEM
90 80 +
70
*
+
+
60
+
++
**
* *
50
*
*
*
40
*
*
**
*
**
+
++
30 20 10 0 -10 0
2
5.6
5
0.178
14
5.6
20
8.0
38
5.0
42
5.6
72
1.78
73
3.2
74
5.6
75
5.6 mg/kg sc
1
Figure 15 Effects of (–)-nicotine, (–)-cytisine, and selected agents on DATO in rat nucleus accumbens 1 h post-dose. All values are expressed as percentages of the effect of 1.0 mg/kg s.c. nicotine (100%)7SEM (N ¼ 510). Each compound was administered at the indicated dose (mg/kg s.c.) alone (black bars) and together with 1 mg/kg s.c. nicotine (shaded bars). *p o.05 agent alone vs vehicle; **p o.01 agent alone vs vehicle; +p o.05 and ++p o.01: agent with nicotine vs nicotine alone (oneway ANOVA with post hoc Dunnett’s test).
high partial agonist efficacy and fully antagonizing the effect of nicotine when co-administered at a very low dose of 0.178 mg/kg. This in vivo potency is consistent with 3-bromocytisine’s potent functional agonist activity in vitro in oocytes (EC50 ¼ 90 nM). However, this dose also represents the maximum tolerated dose in animals, which translates to a very narrow therapeutic index. The non-pyridone cytisine analogs failed to potently elevate DATO or to block nicotine’s effect, consistent with their weaker binding and presumably poor brain exposure. The bicyclic aryl piperidines (benzazepines) showed a wide range of agonist activities, with some analogs being highly active as antagonists of nicotine’s effect. Potent benzazepine analogs that were particularly efficacious were also well-tolerated at the high doses used in this assay. Comparing the in vivo effects of compounds on DATO greatly aided our triage for suitable clinical candidates and limited the selection to cytisine derivatives (e.g., 5, 14, 20), mono-substituted bicyclic benzazepine derivatives (e.g., 72, 73) and fused bicyclic benzazepine derivatives (e.g., 74, 75, varenicline (1)). Fused heterocyclic compounds were eliminated from further evaluation if they displayed functional efficacy
Case History: Chantixt/Champixt (Varenicline Tartrate)
95
either too low or too high and fell outside the in vitro window of acceptable partial agonism. We had targeted in vitro functional efficacy of 25–80% of nicotine (10 mM in oocytes), but many compounds that were progressed and evaluated in DATO lacked adequate partial agonist activity in vivo, which we attributed to insufficient free brain exposure necessary to exhibit robust agonist and antagonist efficacy. For example, benzimidazole derivatives of benzazepine (6-propyl and 6-butyl derivatives 74 and 75, respectively) are partial agonists when given alone, but failed to fully antagonize nicotine at tolerated doses, whereas the ‘‘nonpyridone’’ cytisine analogs (e.g., 38, 42) were less efficacious in vivo and poor antagonists of the nicotine response. Unlike cytisine derivatives, which were uniformly potent in vivo as agonists and as nicotine antagonists (e.g., 5, 14, 20), the other series displayed a broader range of in vivo efficacies and potencies.
9. PROPERTIES OF VARENICLINE Varenicline (1) was selected from the compounds described in this study as the primary development candidate. It is a low molecular weight (221.27 g/mol) achiral alkaloid with high CNS penetration in rat brain (B/P ¼ 3.5), a symmetric CSF/free plasma ratio of 1 and low protein binding in blood (B80% free) and brain (B67% free). Varenicline’s properties are highlighted by a ligand efficiency of 0.82 and LLE (pIC50log P) of 11.
9.1 Pharmacology Receptor binding studies [55,58] demonstrated that varenicline (1) has high affinity only for the a4b2 neuronal nicotinic receptor subtype in rat and human cortex (Ki B0.1–0.4 nM). Varenicline did not bind with significant affinity to various other neurotransmitter receptors and transporters, enzymes, modulatory binding sites, and ion channels, in membranes derived from relevant tissues and cell lines (Ki values W1,000 nM). In vitro functional patch clamp studies in Xenopus oocytes and HEK cells expressing human nAChRs showed that varenicline (1) is a partial agonist with 45% of nicotine’s maximal effect at the a4b2 nAChR that can fully antagonize the effect of simultaneously applied nicotine [55,58]. In neurochemical models, varenicline (1) displayed significantly lower efficacy (40–60%) than nicotine in stimulating [3H]-DA release from rat brain slices in vitro and in increasing DATO in rat nucleus accumbens, while it inhibited nicotine-induced DATO, as shown earlier [55,58]. In vivo microdialysis was used to examine the effects of varenicline (1) on the concentration of extracellular DA levels in the nucleus accumbens
96
JOTHAM W. COE et al.
225 nicotine Dopamine release in n. accumbens % of basal ± SEM
200
175 varenicline 150
125 nicotine + varenicline 100 Nicotine 0.32 mg/kg
Varenicline 1 mg/kg
75 -120
-60
0
60
120
180
240
300
360
Time (minutes)
Figure 16 Effects of 0.32 mg/kg s.c. nicotine alone (curve without symbols), 1 mg/kg p.o. varenicline alone (gray curve with triangles) and combined administration of 1 mg/kg p.o. varenicline with 0.32 mg/kg s.c. nicotine (black curve with open squares) on DA release in rat n. accumbens. Data are expressed as percentage of basal levels7SEM (N ¼ 35) (adapted from Coe et al., 2005) [55].
of conscious rats, to directly assess varenicline’s effects on the mesolimbic DA system. Dose–response curves indicated that varenicline maximally increased DA release to 153% of baseline with an ED50 of 0.032 mg/kg p.o. The maximal response of varenicline is about 63% of the full agonist nicotine (2), which produces a maximal increase in DA release at 0.32 mg/kg s.c. to 184% of basal levels. When administered together, varenicline reduced the peak effect of nicotine to the level of its own maximal effect on DA release, that is, about 60% of the maximal nicotine increase (Figure 16) [55,58]. In behavioral animal models, varenicline (1) reduces nicotine selfadministration in rats and supports lower self-administration break points than nicotine. In a progressive ratio self-administration paradigm, animals must work at increasingly harder levels (more bar presses) to receive their next drug infusion [58]. The lower breakpoint found for varenicline than for nicotine is consistent with the notion that a partial agonist is less reinforcing and less dependence producing than nicotine. Neurochemical support for the lack of abuse liability is provided by the
Case History: Chantixt/Champixt (Varenicline Tartrate)
97
time courses for the effects on DA release that demonstrate the slow onset and long-lasting effect of varenicline compared with nicotine’s rapid steep rise and fall in accumbens DA (Figure 16), thought to be characteristic of drugs of abuse. These animal studies, as well as data from a later abuse liability study in human subjects confirm that varenicline has no abuse potential [58]. Taken together, all data support the hypothesis that the partial agonist varenicline (1) will have utility as a smoking cessation aid. Through submaximal activation of the mesolimbic dopaminergic system, it can reproduce to some extent the subjective effects of smoking to reduce cravings and withdrawal symptoms without nicotine’s abuse liability. In addition, since varenicline effectively reduces the rapid and robust mesolimbic DA response to nicotine, the antagonist action will prevent the reinforcing and rewarding effects of nicotine to protect against smoking relapse. On the basis of these findings, varenicline (1) was advanced into clinical development.
9.2 Absorption, distribution, metabolism, excretion (ADME) As a small hydrophilic, weak base (log P ¼ 1.1; pKa ¼ 9.9; measured Elog D7.4 0.28, MW ¼ 211), varenicline (1) is well absorbed, as indicated by preclinical disposition studies that found 89% to be recovered in the urine of carbon-14-labeled material after oral administration (B1% in feces). Protein binding of varenicline is low (human blood free unbound B80%) and it has a moderate volume of distribution (1.9 L/kg). Varenicline is virtually not metabolized, comprising 90% of circulating drug-related material and is excreted mostly unchanged in the urine [59]. Four minor metabolites of varenicline were observed, with two minor urinary metabolites comprising less than 5% of the dose. Metabolites observed in excreta arose through N-carbamoyl glucuronidation and oxidation. These metabolites were also observed in the circulation, in addition to metabolites that arose through N-formylation and formation of a novel hexose conjugate. Unbound renal clearance is in slight excess of glomerular filtration rate. Varenicline is neither a substrate nor an inhibitor of cytochrome P450 enzymes. It is expected to be neither the cause of nor subject to drug interactions through alterations of P450 activities [59]. As such, drug–drug interactions are generally limited to those induced by decreased nicotine intake upon quitting smoking, as nicotine is a cytochrome P450 2A6 substrate [60]. In phase 1 clinical trials, varenicline (1) was found to have an excellent PK profile, with a half-life of 24 h, steady-state levels achieved in 4 days, no food effects, and with the drug essentially completely absorbed and not metabolized (W89% of C-14-labeled material accounted for in urine) [61,62]. The long half-life is a particularly
98
JOTHAM W. COE et al.
beneficial property for protecting smokers from smoking relapse, as nicotine is rapidly absorbed and displays a short 1–2 h half-life in human subjects. Toleration at higher doses was limited by nausea and vomiting. The maximum well-tolerated dose of 1 mg BID p.o. (twice daily, orally) was chosen to minimize the nausea signal and to maximize efficacy in smoking cessation.
10. CLINICAL STUDIES Results of phase 2 and phase 3 studies have been described in detail and have been reviewed elsewhere [63]. Efficacy was established in phase 2 studies for three different doses [1 mg QD (once daily), 0.5 mg BID and 1 mg BID] given for 6 or 12 weeks [64] One milligram BID for 12 weeks was chosen as the most efficacious treatment and used for all further clinical trials. In two identically designed phase 3 clinical trials, varenicline (1) was compared to placebo and the active comparator, bupropion SR (Zybans sustained release). In these studies smokers were treated for 12 weeks pharmacotherapy with 40 weeks post-treatment follow-up of smoking status. At the end of the 12 week treatment period, the CO-confirmed 4-week abstinence rates were 44.0% for smokers who received varenicline (N ¼ 696) compared with 29.7% in the bupropion SR group (N ¼ 671) and 17.7% in the placebo group (N ¼ 685). At the end of 1 year, 22.4% in the varenicline group, 15.4% in the bupropion group, and 9.3% in the placebo group remained completely abstinent from smoking. In pooled analyses, varenicline was statistically superior to both bupropion SR and placebo at the end of the treatment period and at the 1-year follow-up [65–68]
11. CONCLUSIONS When smokers quit tobacco, they typically experience considerable side effects [69] and are highly susceptible to relapse from re-exposure to inhaled tobacco smoke, especially during quit attempts. Properties of nicotine make this particularly true, as it is completely absorbed in the lungs and delivered to the brain within 7–10 s, making nicotine addiction one of the most challenging addictions to overcome. We sought a medicine that not only decreased nicotine craving and withdrawal symptoms but effectively and safely reduced the neurochemical reinforcement produced by smoking. Partial agonists theoretically address both of these primary physiologic aspects of nicotine dependence, but required the identification of compounds with in vivo features that effectively competed with inhaled nicotine. These objectives helped
Case History: Chantixt/Champixt (Varenicline Tartrate)
99
define the testing parameters necessary to identify an effective partial agonist as a smoking cessation aid, with long duration to reduce craving and withdrawal symptoms while effectively shielding smokers in the event they smoke during quit attempts. Varenicline met these stringent criteria, not only in preclinical models, but later in clinical trials. Many important medicinal agents originated from work on smallmolecule natural product progenitors. Cytisine helped us establish preclinical parameters for a discovery program and to elucidate a starting point for a chemical and medicinal journey. Natural products not only provided a starting point, they inspired total synthesis strategies that helped access unnatural analogs in the search for novel templates with the desired activity. This ultimately led us to studies of structurally related opioid natural products. In retrospect, it is fitting that a partial agonist approach for opioid addiction sparked the conceptual foundation of this approach and that opioid research should later provide new inspiration leading to varenicline. Disclosure: Jotham W. Coe, Hans Rollema, and Brian T. O’Neill are employees of Pfizer Inc.
REFERENCES [1] R. Doll and A. B. Hill, Br. Med. J., 1954, 1451. [2] R. Doll, R. Peto, J. Boreham and I. Sutherland, Br. Med. J., 2004, 328, 1519. [3] ‘‘Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service,’’ 1964. [4] Smoking and Health: A Report of the Surgeon General, 1979. [5] The ‘‘Recognizing Addiction as a Disease Act of 2007,’’ SB-1011. [6] B. Adhikari, J. Kahende, A. Malarcher, T. Pechacek and V. Tong, Morb. Mortal. Wkly. Rep., 2008, 57, 1226. [7] WHO Report on the Global Tobacco Epidemic, 2008 – The MPOWER package. http:// www.who.int/tobacco/mpower/en/index.html [8] K.-O. Fagerstro¨m, J. Behav. Med., 1982, 5, 343. [9] J. R. Hughes et al., Antidepressants for smoking cessation. Cochrane Database of Systemic Reviews 1, CD000031. DOI: 10.1002/14651858.CD000031.pub3, 2007. [10] (a) C. A. Hughes, Jr., Cancer J. Clin., 2000, 50, 143; (b) M. C. Fiore, et al., J. Am. Med. Assoc., 2000, 283, 3244.(c) M. C. Fiore et. al., U.S. Public Health Service, U.S. DHHS, Rockville, MD, May 2008. [11] S. Wakhlu, J. Opioid Manag., 2009, 5, 59. [12] (a) J. E. Rose and E. D. Levin, Pharmacol. Biochem. Behav., 1991, 41, 219; (b) J. E. Rose, F. M. Behm, E. C. Westerman, E. D. Levin, R. M. Stein and G. V. Ripka, Clin. Pharmacol. Ther., 1994, 56, 86. [13] J. Boulter, J. Connolly, E. Deneris, D. Goldman, S. Heinemann and J. Patrick, Proc. Nat. Acad. Sci. U.S.A., 1987, 84, 7763. [14] R. Lape, D. Colquhoun and L. G. Sivilotti, Nature, 2008, 454, 722. [15] A. A. Jensen, B. Frolund, T. Liljefors and P. Krogsgaard-Larsen, J. Med. Chem., 2005, 48, 4705. [16] D. Paterson and A. Nordberg, Neurobiology, 2000, 61, 75.
100
JOTHAM W. COE et al.
[17] (a) W. H. Beers and E. Reich, Nature, 1970, 228, 917; (b) R. P. Sheridan, J. Med. Chem., 1986, 29, 899. [18] J. P. Changeux, A. Devillers-Thiery and P. Chemouilli, Science, 1984, 225, 1335. [19] M. R. Picciotto, N. A. Addy, Y. S. Mineur and D. H. Brunzell, Prog. Neurobiol., 2008, 84, 329. [20] R. C. Hogg and D. Bertrand, Curr. Drug. Targets. CNS Neurol. Disord., 2004, 3, 123. [21] M. E. M. Benwell and D. J. K. Balfour, Br. J. Pharamacol., 1992, 105, 849. [22] C. F. Morrison and J. A. Stephenson, Psychopharmacologia (Berl.), 1969, 15, 351. [23] C. Romano, A. Goldstein and N. P. Jewell, Psychopharmacology, 1981, 74, 310. [24] W. T. Chance, M. D. Kallman, J. A. Rosecrans and R. M. Spencer, Br. J. Pharmac., 1978, 63, 609. [25] J. A. Pratt, I. P. Stolerman, H. S. Garcha, V. Giardini and C. Feyerabend, Psychopharmacology, 1983, 81, 54. [26] W. A. Corrigall and K. M. Coen, Psychopharmacology, 1989, 99, 473. [27] (a) M. R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L. M. Marubio, E. M. Pich, K. Fuxe and J. P. Changeux, Nature, 1998, 391, 173; (b) S. S. Watkins, M. P. Epping-Jordan, G. F. Koob and A. Markou, Pharmacol. Biochem. Behav., 1999, 62, 743. [28] A. R. Tapper, S. L. McKinney, R. Nashmi, J. Schwarz, P. Deshpande, C. Labarca, P. Whiteaker, M. J. Marks, A. C. Collins and H. A. Lester, Science, 2004, 5, 1029. [29] (a) G. Di Chiara, Eur. J. Pharmacol., 2000, 393, 295; (b) J. A. Dani and M. De Biasi, Pharmacol. Biochem. Behav., 2001, 70, 439. [30] R. M. Wilson and S. J. Danishefsky, J. Org. Chem., 2006, 71, 8329. [31] F. van Haaran, K. G. Anderson, S. C. Haworth and W. R. Kem, Pharmacol. Biochem. Behav., 1999, 64, 439. [32] W. R. Kem, V. M. Mahnir, R. L. Papke and J. L. Lingel, J. Pharmacol. Exp. Ther., 1997, 283, 979. [33] W. R Kem and R. L. Papke, Soc. Neurosci., 1992, 18, 1358. [34] C. Reavill, B. Walther, I. P. Stolerman and B. Testa, Neuropharmacology, 1990, 29, 619. [35] A. I. Sacaan, J. L. Dunlop and G. K. Lloyd, J. Pharmacol. Exp. Ther., 1995, 274, 224. [36] A. Partheil, Arch. Pharm., 1894, 232, 161. [37] G. Scharfenberg, S. Benndorf and G. Kempe, Dtsch Gesundheitsw., 1971, 26, 463. [38] C. W. Luetje and J. Patrick, J. Neurosci., 1991, 11, 837. [39] R. L. Papke and S. F. Heinemann, Mol. Pharmacol., 1994, 45, 142. [40] (a) R. Mansbach, F. D. Tingley, C. Rovetti, T. Davis, L. Chambers, C. Fox, S. Sands, E. Arnold, A. Elder, J. Huang, D. Schulz and B. T. O’Neill, Soc. Neurosci., 1998, 294, 10. (b) B. T. O’Neill, PCT Int. Appl. WO 98 18,798, Abstr. 1998, 119, 4774k, 1998. [41] A. L. Hopkins, C. R. Groom and A. Alex, Drug Discov. Today, 2004, 9, 430. [42] P. D. Leeson and B. Springthorpe, Nat. Rev. Drug Discov., 2007, 6, 881. [43] S. Demers, H. Stephenson, J. Candler, C. G. Bashore, E. P. Arnold, B. T. O’Neill and J. W. Coe, Tetrahedron Lett., 2008, 49, 3368. [44] (a) B. T. O’Neill, D. Yohannes, M. W. Bundesmann and E. P. Arnold, Org. Lett., 2000, 2, 4201; (b) E. Marriere, J. Rouden, V. Tadino and M.-C. Lasne, Org. Lett., 2000, 2, 1121; (c) O. Nicolotti, C. Canu Boido, F. Sparatore and A. Carotti, Farmaco, 2002, 57, 469; (d) C. Canu Boido, A. Carotti and F. Sparatore, Farmaco, 2003, 58, 265. [45] (a) A. P. Kozikowski, S. K. Chellappan, Y. Xiao, K. M. Bajjuri, H. Yuan, K. J. Kellar and P. l. A. Petukhov, Chem. Med. Chem., 2007, 2, 1157; (b) S. K. Chellappan, Y. Xiao, W. Tueckmantel, K. J. Kellar and A. P. Kozikowski, J. Med. Chem., 2006, 49, 2673. [46] J. W. Coe, Org. Lett., 2000, 2, 4205. [47] J. W. Coe, M. G. Vetelino, C. G. Bashore, M. C. Wirtz, P. R. Brooks, E. P. Arnold, L. A. Lebel, C. B. Fox, S. B. Sands, T. I. Davis, D. W. Schulz, H. Rollema, F. D. Tingley, III and B. T. O’Neill, Bioorg. Med. Chem. Lett., 2005, 15, 2974.
Case History: Chantixt/Champixt (Varenicline Tartrate)
101
[48] C. G. Bashore, M. G. Vetelino, M. C. Wirtz, P. R. Brooks, H. N. Frost, R. E. McDermott, D. C. Whritenour, J. A. Ragan, J. L. Rutherford, T. W. Makowski, S. J. Brenek and J. W. Coe, Org. Lett., 2006, 8, 5947. [49] R. A. Glennon and M. Ducat, Pharm. Acta. Helv., 2000, 74, 103. [50] E. Carosati, S. Sciabola and G. Cruciani, J. Med. Chem., 2004, 47, 5114. [51] (a) P. H. Mazzocchi and B. C. Stahly, J. Med. Chem., 1979, 22, 455; (b) M. Mokotoff and A. E. Jacobson, J. Het. Chem., 1970, 7, 773; (c) P. H. Mazzocchi and A. M. Harrison, J. Med. Chem., 1978, 21, 238. [52] T. Eisner and J. Meinwald (eds), Chemical Ecology: The Chemistry of Biotic Interaction, National Academy of Sciences, Washington, DC, 1995. [53] (a) P. R. Brooks, S. Caron, J. W. Coe, K. K. Ng, R. A. Singer, E. Vazquez, M. G. Vetelino, H. H. Watson, Jr., D. C. Whritenour and M. C. Wirtz, Synthesis, 2004, 11, 1755; (b) R. A. Singer, J. D. McKinley, G. Barbe and R. A. Farlow, Org. Lett., 2004, 6, 2357; (c) C. J. O’Donnell, R. A. Singer, J. D. Brubaker and J. D. McKinley, J. Org. Chem., 2004, 69, 5756. [54] C. L. Coon, W. G. Blucher and M. E. Hill, J. Org. Chem., 1973, 38, 4243. [55] J. W. Coe, P. R. Brooks, M. G. Vetelino, M. C. Wirtz, E. P. Arnold, J. Huang, S. B. Sands, T. I. Davis, L. A. Lebel, C. B. Fox, A. Shrikhande, J. H. Heym, E. Schaeffer, H. Rollema, Y. Lu, R. S. Mansbach, L. K. Chambers, C. C. Rovetti, D. W. Schulz, F. D. Tingley, III and B. T. O’Neill, J. Med. Chem., 2005, 48, 3474. [56] J. W. Coe, P. R. Brooks, M. C. Wirtz, C. G. Bashore, K. E. Bianco, M. G. Vetelino, E. P. Arnold, L. A. Lebel, C. B. Fox, F. D. Tingley, III., D. W. Schulz, T. I. Davis, S. B. Sands, R. S. Mansbach, H. Rollema and B. T. O’Neill, Bioorg. Med. Chem. Lett., 2005, 15, 4889. [57] J. P. Gallivan and D. A. Dougherty, Proc. Nat. Acad. Sci. U.S.A., 1999, 96, 9459. [58] H. Rollema, L. K. Chambers, J. W. Coe, J. Glowa, l. R. S. Hurst, L. A. Lebel, Y. Lu, R. S. Mansbach, R. J. Mather, C. C. Rovetti, S. B. Sands, E. Schaeffer, D. W. Schulz, F. D. Tingley, III and K. E. Williams, Neuropharmacol, 2007, 52, 985. [59] R. S. Obach, A. E. Reed-Hagen, S. S. Krueger, B. J. Obach, T. N. O’Connell, K. S. Zandi, S. A. Miller and J. W. Coe, Drug Metab. Dispos., 2006, 34, 121. [60] J. Hukkanen, P. Jacob, III and N. L. Benowitz, Pharmacol. Rev., 2005, 57, 79. [61] H. M. Faessel, B. J. Smith, M. A. Gibbs, J. S. Gobey, D. J. Clark and A. H. Burstein, J. Clin. Pharmacol., 2006, 46, 991. [62] H. M. Faessel, M. A. Gibbs, D. J. Clark, K. Rohrbacher, M. Stolar and A. H. Burstein, J. Clin. Pharmacol., 2006, 46, 1439. [63] K. I. Cahill, L. F. Stead, T. Lancaster, Cochrane Database of Systematic Reviews 1, 2007, Art. No.: CD006103, in The Cochrane Library, Issue 1, Wiley, Chichester, UK. doi:101002/ 14651858.CDC006103.pub2, 2007. [64] M. Nides, C. Oncken, D. Gonzales, S. Rennard, E. J. Watsky, R. Anziano and K. R. Reeves, Arch. Intern. Med., 2006, 166, 1547. [65] D. Gonzales, S. I. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, E. J. Watsky, J. Gong, K. E. Williams and K. R. Reeves, J. Am. Med. Assoc., 2006, 296, 47. [66] D. E. Jorenby, J. T. Hays, N. A. Rigotti, S. Azoulay, E. J. Watsky and K. E. Williams, J. Am. Med. Assoc., 2006, 296, 56. [67] S. Tonstad, P. Tonnesen, P. Hajek, K. E. Williams, C. B. Billing and K. R. Reeves, J. Am. Med. Assoc., 2006, 296, 64. [68] M. Nides, E. D. Glover, V. I. Reus, A. G. Christen, B. J. Make, C. B. Billing and K. E. Williams, Am. J. Health. Behav., 2008, 32, 664. [69] M. J. Jarvis, Bri. Med. J., 2004, 32, 277.
CHAPT ER
5 Case History on Tekturnas/ Rasilezs (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension Ju¨rgen Maibaum* and David L. Feldman**
Contents
1. 2. 3. 4.
Introduction Rationale for the Use of Direct Renin Inhibitors Pre-Clinical Models to Study Direct Renin Inhibitors Medicinal Chemistry Evolution — The Early Renin Inhibitor Program at Ciba-Geigy 4.1 The emerging novel topology design concept 4.2 Macrocyclic renin inhibitors 4.3 (P3-P1)-Tethered hydroxyethylene transition-state mimetics 4.4 SAR in the THQ series — early pre-clinical leads 4.5 Modification of the transition-state mimetic portion 4.6 SAR in the ‘Phenoxy’ series 4.7 Challenges of a multiple chemotype approach 5. First Convergent and Scalable Synthesis Development 6. Pre-Clinical Properties of Aliskiren 7. Effects of Aliskiren in Disease Models 8. Clinical Studies with Aliskiren 9. Conclusions References
105 106 107 108 110 111 112 113 115 116 119 120 122 122 123 124 124
Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland Novartis Institutes for BioMedical Research, East Hanover, NJ, USA
Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04405-4
r 2009 Elsevier Inc. All rights reserved.
105
106
Ju¨rgen Maibaum and David L. Feldman
1. INTRODUCTION Hypertension is a major risk factor for cardiovascular diseases, affecting more than 25% of adults worldwide [1]. The high percentage of patients with insufficiently controlled blood pressure (BP) levels suggests a continued need for improved antihypertensive drug therapies. Direct renin inhibition is a promising new type of treatment for high BP. The renin-angiotensin-aldosterone system (RAAS) is a key physiological regulator of BP and fluid homeostasis. The first and rate-limiting step (i.e., point of activation) of this cascade is catalyzed by the highly specific aspartic protease renin [2]. Direct blockade of this step has long been recognized as most attractive for therapeutic intervention. This triggered extensive research activities initiated in the late 1970s in the quest for identifying clinically efficacious orally active direct renin inhibitors. However, various challenges persisted in this area for more than two decades despite all the efforts made in the pharmaceutical industry. Recently, an unprecedented topological structure-based drug design strategy at Ciba-Geigy (now Novartis) enabled the discovery of novel, highly potent and selective non-peptide transition-state mimetic (TSM) renin inhibitors. These efforts culminated in the discovery of TEKTURNAs/RASILEZs (aliskiren, 1, Figure 1) recently approved as a new therapy for the treatment of hypertension. As a first-in-class direct renin inhibitor, aliskiren has demonstrated orally active anti-hypertensive efficacy and end-organ protection. Thus, more than 10 years after the introduction of the angiotensin (Ang) AT1 receptor blockers (ARBs), a therapy directed at renin is available to patients.
2. RATIONALE FOR THE USE OF DIRECT RENIN INHIBITORS Blockade of the RAAS is a primary treatment in many cardiovascularrenal diseases including hypertension, congestive heart failure and renal disease [3]. The ultimate goal of such therapy is to block the formation or action of Ang II, the principal effector of this pathway. Until the approval of aliskiren, the RAAS could be inhibited either at the step of conversion of Ang I to Ang II with Ang I converting enzyme inhibitors (ACEi) or at CH3O
OH
H N
H2N O CH3O
Figure 1
TEKTURNAs/RASILEZs (aliskiren).
O 1
CONH2
Case History on Tekturnas/Rasilezs (Aliskiren)
107
the Ang II receptor level with ARBs. Such interventions have yet to halt the progression of cardiovascular diseases. That is, tissue damage may continue in the heart, blood vessels and kidney, possibly because the RAAS is not comprehensively blocked with ACEi or ARB. In contrast, inhibiting the RAAS at the point of its activation (i.e., renin) may lead to superior downstream RAAS inhibition as compared to existing therapies. Moreover, formation of Ang II by alternative pathways (e.g., chymase) is limited with renin inhibition because Ang I formation is blocked. A unique feature of renin inhibition is the ability to block the increase in plasma renin activity (PRA) that accompanies the rise in the plasma levels of renin during RAAS blockade. Thus, although ACEi and ARB actually raise PRA, renin inhibitors reduce PRA despite the high levels of circulating renin. This action leads to effective inhibition of Ang II formation and potentially greater organ protection.
3. PRE-CLINICAL MODELS TO STUDY DIRECT RENIN INHIBITORS The road towards developing human renin inhibitors has been challenging with respect to establishing appropriate in vivo models in which to test the efficacy of these compounds. This difficulty relates, at least in part, to the prominent species specificity displayed by renin and the high primate specificity of potent human renin inhibitors. Thus, most inhibitors of human renin are only weakly effective in rats. Consequently, although rats are the most commonly used species in hypertension efficacy studies, such models have been of limited use to study human renin inhibitors [4]. Potent inhibitors of rat renin have allowed in vivo studies in this species; however, the design of dual human–rat renin inhibitors has been extremely challenging [5,6]. Normotensive nonhuman primates such as cynomolgus, squirrel, rhesus and marmosets [7–9], and dogs [10,11], in which the RAAS is stimulated by a low salt diet and/or a diuretic, have been used to demonstrate the efficacy of renin inhibition on BP, cardiac function and plasma RAAS components. We initially established a model of sodium-depletion in restrained conscious marmosets (Callithrix jacchus). In this model, BP and heart rate (HR) measurements were performed invasively and thereby allowed to determine only short-term hemodynamic effects [12]. Subsequently, the application of radio-telemetry for continuous measurement of BP, HR and changes in the electrocardiogram in freely moving animals permitted the assessment of the effects of drug treatment under less stressful conditions over a longer time range [13]. We also measured the 24 h timecourse of PRA ex vivo as a surrogate marker to indicate that BP-lowering effects were specifically related to renin inhibition.
108
Ju¨rgen Maibaum and David L. Feldman
The ability to manipulate the genome of rodents has permitted the development of several transgenic rat and mouse models, in which renin is expressed. This eliminated the issue of species specificity of renin inhibitors in vivo. Indeed, beneficial effects of renin inhibition, which are considered to be of important clinical relevance, have been demonstrated in these models [14]. Double transgenic rats (dTGR) express human genes for renin and angiotensinogen [15]. The high expression of this ‘human RAAS’ leads to high levels of Ang II and consequently to renal and cardiac damage [16]. These animals are highly responsive to inhibition of their RAAS with human renin inhibitors. Aliskiren, 1, has been intensively studied in dTGRs and other transgenic rodents for its effects on BP and organ protection.
4. MEDICINAL CHEMISTRY EVOLUTION — THE EARLY RENIN INHIBITOR PROGRAM AT CIBA-GEIGY Tremendous resources have been devoted to the design of orally efficacious renin inhibitors, starting in the late 1970s [17–20], and a vast number of potent and selective peptide-like TSM inhibitors have been reported. Several candidates progressed into the clinic but suffered from poor intestinal absorption or high liver first-pass elimination, high synthetic complexity and hence high cost of goods, and/or insufficient clinical efficacy. The renin drug discovery project at Ciba-Geigy started in 1980 and transitioned through the evolution over three generations of renin inhibitors, ranging from modified linear peptides initially, to more drug-like peptidomimetics and ultimately to completely novel chemical structures that still function as TSM inhibitors. Computer-aided molecular modeling along with X-ray crystallography of human renin with and without bound inhibitors enabled us to adopt a systematic direct targetstructure based strategy. This eventually culminated in the discovery of aliskiren, 1, representing a unique class of topological peptidomimetic renin inhibitors, as described in more detail by this review. The large peptide inhibitor CGP29287, 2 (Figure 2), derived from the N-terminal sequence of angiotensinogen by incorporation of the statine TSM at the renin cleavage site and with modification of both N- and Cterminal sites, was the first proteolytically stable, long-acting renin inhibitor shown to be active after intravenous and oral administration to monkeys [12]. Although not considered ‘drug-like’ due to its peptide characteristics, this first-generation inhibitor proved its importance as a pharmacological tool for studying the endocrine, hemodynamic, renal and cardiac responses to tissue and systemic renin inhibition in vivo in primates [21]. Subsequently, reduction of molecular size by truncation at both the N- and the C-terminus and incorporation of a hydroxyethylene
Case History on Tekturnas/Rasilezs (Aliskiren)
109 O
O
O
H N
N
H N O
NH
N
NH
HN
O
H N
NH2
HN
O
H N
N H
O
OH
O N H
O
O
H N
O
N H
O
O
N
O N H
NH HN
NH2
Figure 2 First generation peptide renin inhibitor — CGP29287 (2).
N
NH
O S O O
N H
H N
N OH
O
H N
O
S
H N
N H
O O
O
3 N
O N
S
O O
N H
NH
H N O
OH
O
OH
4
N
N
S
O N
OH
OH
S
O O
5
N H
H N O
OH OH
6
Figure 3 Second-generation peptide-based renin inhibitors.
(HE) isostere provided inhibitors spanning the S4-S2u enzyme recognition sites. Further structure refinement identified CGP38560, 3 (Figure 3) [22], a renin inhibitor of the second generation and the first selected at CibaGeigy for clinical investigations. This potent and selective inhibitor of human and marmoset plasma renin in vitro (IC50 ¼ 0.7 nM) reduced mean arterial pressure (MAP) and suppressed PRA in Na-depleted restrained marmosets (10 mg/kg oral dose) [23]. Owing to its short duration of action in hypertensive patients and low (o1%) oral bioavailability in humans, 3 was not considered to be a clinically viable drug [24,25]. Remikiren (RO-42-5892, 4), with a plasma human renin IC50 ¼ 0.8 nM, combined the N-terminal tert-butylsulfonyl of 3 with a shorter C-terminal diol TSM [8] and was investigated by Hoffmann–La Roche in phase II trials. RO-42-5892 caused significant BP lowering in hypertensive
110
Ju¨rgen Maibaum and David L. Feldman
patients, but antihypertensive responses were only short-lasting at the maximal tolerated dose [26]. Oral bioavailability of 4 was low in monkeys, rats, dogs and humans (B1%) due to rapid liver first-pass metabolism and biliary excretion of unchanged drug [27,28]. It is noteworthy that 4 was proposed to act primarily by inhibiting an extra-plasma renin pool [29]. RO-42-5892 is the first renin inhibitor for which extensive partitioning to, and retention by, the kidney has been reported [30]. More water soluble second generation inhibitors with superior pharmacokinetics in animal species were subsequently disclosed. SC56525, 5 (IC50 ¼ 1.2 nM), was reported by Searle to exert potent oral BP lowering effects in both Na-depleted and renal hypertensive dogs [11]. Oral bioavailability of 5 was 66% in dogs (30 mg/kg po); however, nonlinear pharmacokinetics and a short elimination half-life (1.3 h) were observed [31]. Zankiren (A-72517, 6, IC50 ¼ 1.1 nM) culminated from a structure–oral absorption optimization strategy at Abbott [7,32–34]. Oral bioavailability in cynomolgus monkey, dog and rat was 8, 53 and 24%, respectively, with the dog predicting best the human bioavailability [33]. Remarkably, distribution studies in animals showed selective uptake of 6 into the kidneys, which could explain its favorable effects on renal hemodynamics [34]. In patients, 6 showed rapid oral absorption and significant antihypertensive efficacy [35]. Zankiren has been considered a hallmark second-generation renin inhibitor, although the drug was not developed further [33].
4.1 The emerging novel topology design concept During the late 1980s, the need became apparent to identify a structurally novel concept that could lead to the development of orally active renin inhibitors with improved properties. Such improvements included reduced molecular weight, increased aqueous solubility and other factors considered to impact oral efficacy. In view of the experience with CGP38560, 3, it was deliberately decided to move away in a radical fashion from the classical peptidomimetic approach. Re-direction of the design strategy and medicinal chemistry resources towards ‘conceptually different inhibitors’, the title of the new project, gave birth to the topological (P3-P1-P0) working hypothesis during 1987–1988 (Figure 4). No validated hits resulted from a small ‘random screening’ campaign that was based on a collection of B20,000 compounds delivered by our newly established New Lead Discovery Unit. Our new design concept was entirely target structure-based and evolved through several major steps: i) using a human renin homology model, exploration of aryl and bulky alkyl P3 fragments linked to diverse cycloalkyl P1 templates bearing polar head groups as putative truncated TSMs ; ii) starting from P1u-P2u extended HE isostere TSMs and growing
Case History on Tekturnas/Rasilezs (Aliskiren)
P4
P3
P2 N
O S O O
N H
P1
P1′
P2′
NH H N
OH
P0 Truncated transition-state mimetic OH *H2N
H N
P1′
111 P2′
OH* *optional
O
O
3
P3
P1
Figure 4 The initial (P3-P1-P0) topology approach.
towards P3 from a rigid P1 residue, providing sub-micromolar leads; iii) introduction of H-bond acceptors/donors to optimized (P3-P1)pharmacophores, leading to a significant increase in potency and in vivo activity; iv) discovery of a distinct non-substrate pocket S3sp by X-ray crystallography as a canonical binding pocket for different sub-series and experimental confirmation of the topology design concept; v) structurebased lead optimization of key series and the search for novel (P3-P1)chemotypes. The conceptual innovation was based on the hypothesis that both the S3 and the S1 renin recognition sites constitute a contiguous ‘hydrophobic super-pocket’ — or ‘hydrophobic hot spot’ — similar to fungal aspartyl proteases with strong preference for lipophilic ligands positioned in spatial proximity. This notion provoked the search for hydrophobic scaffolds composed of directly linked P1 and P3 motifs. Initially, a diverse array of novel conformationally more or less constrained mono-, bi- and tricyclic core structures was intensively investigated, which were modeled on optimized SAR for P1 and P3 of peptide-derived renin inhibitors. These compounds were further characterized by one or more OH and NH2 groups of an acyclic or cyclic terminal scaffold envisaged to target the catalytic aspartates as simplified versions of a TSM truncated at its prime-site (P3-P1-P0 hypothesis, Figure 4). Despite the tremendous efforts and difficult chemical syntheses involved, none of these molecules was found to inhibit renin up to 100 mM in the enzymatic assay.
4.2 Macrocyclic renin inhibitors The lack of success in identifying even very low-affinity inhibitors initially was disappointing and raised major concerns about the validity of the design concept. Up to this point, our modeling depended on overlaps with the crystal structures of pepstatin or related peptides complexed with non-mammalian aspartyl proteases such as penicillopepsin and rhizopuspepsin [36]. In the course of our work, a more refined homology model of human renin derived from the endothiapepsin X-ray structure [37] was used to predict the active site conformation of 3 [38]. The first apo-crystal structure of human renin
112
Ju¨rgen Maibaum and David L. Feldman
N O O
N H O O
Figure 5
NH H N
OH
H N O
7
(P3-P1)-linked macrocyclic peptidomimetic renin inhibitor.
was reported only in 1989 [39]. In our group, the human renin/3 complex was resolved shortly thereafter, confirming the accuracy of the computational model [40]. At this point, interest arose in the design of P3-P1 macrocyclic inhibitors for probing the feasibility of covalently linking the P1 and P3 residues of an open-chain congener inhibitor. It was furthermore envisaged that freezing such constrained peptidomimetics in their enzyme-bound conformation would lead to a gain in entropy thereby possibly allowing elimination of peripheral elements (e.g., P4 and/or P2u residues), and hence diminishing molecular size. The in vitro activity of the non-optimized (P3-P1)-macrocycle 7 (Figure 5) against human renin (IC50 ¼ 2 mM), although moderate, supported the notion that the renin S1/S3 specificity sites are not separated from each other but form a large hydrophobic cavity. More potent macrocyclic inhibitors incorporating directly linked P1 and P3 side chains were reported after we had concluded our limited efforts [41]. The proximal topology of other recognition sites of renin inspired the design of various classes of potent macrocyclic inhibitors [9].
4.3 (P3-P1)-Tethered hydroxyethylene transition-state mimetics As the original approach targeting truncated transition-state surrogates had failed to deliver any starting points for further lead optimization, the emphasis of the exploratory design was redirected. Additional binding interactions to the P1u and/or P2u sites of renin were conceived to be likely more important than was initially acknowledged for such putative (P3P1)-pharmacophores lacking interactions to the P2-P4 sites. The cyclohexyl-substituted HE isostere 8 (IC50 ¼ 30 mM, Figure 6) was selected as a starting ‘fragment’ based on the well-established preference of human renin for bulky hydrophobic P1 residues, providing selectivity against other human aspartyl proteases [42]. Inhibitor 9 was one of the most active (IC50 ¼ 0.3 mM) of several tethered 1,3- or 1,4-cis and transdisubstituted cyclohexyl analogues [43]. The 100-fold potency increase for 9 vs. 8 strengthened the evidence for the feasibility of the tethered P3-P1 topological inhibitor design.
Case History on Tekturnas/Rasilezs (Aliskiren)
113
10: R = H H2N
OH CH3 H N
R
O
H2N
R
OH CH3 H N
11: R =
O
trans (rac)
12: R =
8: R = H Cyclohexyl- 9: R = ‘optimized’ P1
Gem-dimethyl ‘symmetrical’ P1
N O
13: R = CH2CO2H
Figure 6 Growing the TSM ‘fragment’ — growing the evidence.
The synthetic complexity of cycloalkyl-derived inhibitors such as 9 restricted further optimization. Symmetrization and hence avoiding any stereocenter at P1 by tethering the geminal-dimethyl position of the TSM 10 (IC50 W100 mM; Figure 6) afforded 11 (IC50 ¼ 0.7 mM). This and subsequently the incorporation of a functionalized spacer were major breakthrough steps towards more simplified early leads with impressively improved in vitro potencies. The tetrahydroquinoline (THQ) derivative 12 (IC50 ¼ 0.05 mM) was W2,000-fold more potent than 10, which further increased our confidence in the design concept. The advanced carboxylic acid 13, appropriately N,O-protected [44], enabled a systematic and rapid SAR exploration of the THQ moiety (vide infra). Variation of the P3-P1 motif was explored intensively with the aim to optimize the interactions to the spacious S1/S3 sites. Hydrophobic van der Waals contacts to this hydrophobic ‘hot-spot’ were considered as key contributing factors for strong ligand binding. We therefore envisaged to maximize the contacts of an optimally designed lipophilic and conformationally rigid P3-P1 pharmacophore to the large surface of the S3/S1 cavity, as exemplified by inhibitors 14 (IC50 ¼ 2.7 mM; Figure 7) and 15 (IC50 ¼ 2.6 mM). Less constrained analogues of 15 with improved in vitro potencies resulted from P1 mono-substitution, and hence reintroduction of a stereocenter with a preferred configuration [45]. Enlarging the size of P1 from methyl (16, IC50 ¼ 2 mM) to isopropyl afforded inhibitor 17 (IC50 ¼ 0.1 mM). Sterically demanding residues such as tert-butyl (18, IC50 ¼ 1.5 mM) and phenyl (19, IC50 ¼ 39 mM) resulted in decreased enzyme affinities. During this work, advances in synthetic chemistry facilitated the practical access to HE isosteres by starting from the corresponding enantiomeric amino acids [45–47]. Yet, early SAR optimization often remained cumbersome due to the non-convergent, lengthy and only partially stereo-controlled reaction sequences required for each single structural modification of the P3-P1 scaffolds. This was particularly evident for inhibitors 16–19, which raised some controversy about the chances to progress this series with reasonable efforts. Incorporation of functionalized spacers into the (P3-P1)-motif of 17, allowing more rapid
114
Ju¨rgen Maibaum and David L. Feldman
H2N
OH CH3 H N
H2N
OH CH3 H N
O
O
14
15 H 2N
OH CH3 H N O
R
16: R=CH3 17: R=CH(CH3)2 18: R=tert-Butyl 19: R=Phenyl
Figure 7
Morphing the (P3–P1)-pharmacophore as a hydrophobic ‘hot spot’.
SAR studies similar to those for 12, were evaluated later in the fully elaborated ‘phenoxy’ series; however, these efforts resulted only in inferior inhibitors.
4.4 SAR in the THQ series — early pre-clinical leads Despite all efforts to optimize the (P3-P1)-scaffold by the ‘hydrophobic approach’, a plateau for in vitro activity apparently had been reached, exemplified by the moderate activities of 12 and 17. Next, we focused our attention on additional design strategies to achieve a further substantial gain in potency. Close examination of SAR data for second-generation renin inhibitors, as well as X-ray crystal structures of peptide inhibitors bound to fungal aspartyl proteases, emphasized the importance of a canonical H-bond between the P3/P2 amide carbonyl and the backbone NH of Ser219 for strong binding affinity. Intriguingly, computational docking of 11 and related analogues into the renin homology model suggested the ‘upper’ portion of the P3 moiety to be positioned in proximity to Ser219 [48,49]. Introduction of H-bond acceptors/donors at the 3- or 4-position of the naphthalene in 11 was extensively probed; however, these early attempts did not result in any affinity increase [43]. In contrast, substitution of the THQ heterocycle of 12 with a carboxylic ester at C-3 afforded inhibitor 20 (IC50 ¼ 0.8 nM, Figure 8) with a dramatic boost in potency. The 3(R)-configured 20 was 50-fold more potent than its (S)-isomer and 12, which indicated a highly specific interaction to the enzyme requiring the proper spatial orientation of the ester group [48]. The sequential discovery of 12 and 20 occurred within a few weeks of each other and represented a hallmark event at about the same time when the renin project was under close scrutiny. The ester in 20 could be replaced with amides, hydroxylated alkyl and short-chained alkyl ethers without a significant drop in the IC50s. THQ modifications were investigated by substitution, incorporation of
Case History on Tekturnas/Rasilezs (Aliskiren)
O
O H2N N
HN
OH CH3 H N
OH
N
O O
20
O O
NH
OH
21 (2′ R or S)
H N
H2N N
H N
H 2N
S
O O
O
115
O O 22
Figure 8 SAR of the THQ series — early pre-clinical lead candidates.
heteroatoms and changing the ring size. The 1,4-benzthiazine 21 (Figure 8; absolute stereochemistry not assigned), bearing a P1u isopropyl at the TSM portion (vide infra), was found to be a potent inhibitor of human and marmoset plasma renin (IC50 ¼ 3 and 16 nM) with selectivity towards bovine cathepsin D and porcine pepsin (IC50s W50 mM). It is noteworthy that 21 and similarly analogue 22 showed excellent aqueous solubility (1.74 and 3.44 g/L, pH 7.4) and low lipophilicity (logPoct 1.71 and 1.70). In restrained Na-depleted marmosets, oral administration of 21 (10 mg/kg) lowered BP significantly by 30 mmHg at peak, while PRA was completely blocked over 6 h. This first early pre-clinical lead was not progressed further, as more attractive analogues emerged from both this and other sub-series. THQ analogue 20 was the first from a total of six novel renin inhibitors from different classes, for which X-ray structures in complex with human renin were resolved [50]. Importantly, this crystal structure confirmed both the S1 and the S3 sites to be fully occupied by the geminaldimethyl group and the aryl portion of the THQ, providing the first structure proof for the computational-based topographical design. An additional H-bond interaction of the spacer carbonyl of 20 to the flexible enzyme flap domain was observed. The ester carbonyl of 20 formed H-bonds with the Ser219 NH, as was predicted, and in addition with the side chain OH. Most surprisingly, the X-ray revealed the methoxy group pointing into the direction of a solvent-shielded non-substrate binding site. This Ssp 3 pocket extends towards the center of renin and is flanked partly by hydrophobic amino acids. Given these results, focused lead optimization then targeted substitutions that would penetrate more deeply into the Ssp 3 pocket [50]. Late-stage SAR advanced towards in vivo potent THQ analogues while pre-clinical development of inhibitor 30 from the ‘phenoxy’ class was well under way (vide infra). Inhibitor 22 showed a remarkable improvement in potency compared to 21 (plasma
116
Ju¨rgen Maibaum and David L. Feldman
renin IC50 ¼ 0.5 nM vs. 3 nM) and excellent dose-dependent oral efficacy over 24 h in telemetered Na-depleted marmosets (peak DMAP of 25 mmHg at 3 mg/kg), accompanied by suppression of PRA for up to 24 h. However, 22 did not demonstrate a superior profile as compared to 30 in exploratory in vivo cardiovascular studies.
4.5 Modification of the transition-state mimetic portion Replacements of the classical HE isostere by shortening the C-terminal portion and eliminating stereocenters have been investigated intensively as a strategy towards simpler peptide-derived inhibitors with improved oral activity and bioavailability [17]. We too explored a small set of such TSM analogues early in view of the synthetic challenges we encountered during initial SAR work. The norstatine ester (23, IC50 ¼ 2.2 mM), the Nethyl oxazolidinone (24, IC50 ¼ 0.64 mM) [51], and the ‘Roche’ erythro-1,2diol (25, IC50 ¼ 4.2 mM) were at least three orders of magnitude less potent than parent 20 (Figure 9). Remarkably, the truncated amino alcohol 26 was almost equipotent (IC50 ¼ 1.0 mM) compared to 23–25, which indicated only minor binding contributions by the S1u extended TSM portion relative to that of the (P3-P1)-scaffold. Similar findings were subsequently observed for related analogues of 30. SAR by substitution of the TSM primary amine revealed, in general, a significant affinity loss even for small N-alkyl or N-acyl residues in all sub-series. These efforts, however, were limited since retaining the peptide backbone was not part of our strategy, although this approach was being used by others [20]. These results clearly emphasized that for this class of topological renin inhibitors interactions to the extended prime site of human renin are required to induce strong binding affinities. As a consequence, we restricted all our subsequent SAR optimization to the classical HE isostere, as this was thought to provide the optimal trajectory into the S2u pocket. Retrospectively, the weak potency of 26 bearing an ‘optimized’ (P3-P1)-scaffold is noteworthy in view of the expectations for hit identification at the outset of our conceptual design program (Figure 4). At the time, sensitive biophysical methods such as protein NMR to detect very low-affinity ligands were not available [52].
OH H2N N
MeO2C
O O 26: R = Me, Q = H
H2N
O
Q 24: R = Et, Q =
O
Figure 9
O
23: R = Et, Q =
RO2C
N O
Modifying the transition-state mimetic (TSM).
N
OH OH
O 25 (2′ R/S)
Case History on Tekturnas/Rasilezs (Aliskiren)
117
4.6 SAR in the ‘Phenoxy’ series The concept of incorporating suitable H-bond acceptors/donors into the (P3-P1)-scaffold was successfully applied across different series. Starting from 17 (Figure 7) and tethering a terminal ethyl carboxylate to the ortho position relative to the tert-butyl group of the phenyl spacer resulted in a 20-fold potency increase (27, purified human renin IC50 ¼ 6 nM, Figure 10) [45]. Modelling had suggested the ester carbonyl to be in binding distance to Ser219 with the methoxy group pointing towards the P4 recognition site of renin. Carboxamide 28 (IC50 ¼ 20 nM) showed only a slight drop in affinity against purified renin. However, inhibitor 28 (plasma IC50 ¼ 460 nM) and most other tert-butyl analogues were very poor inhibitors in vitro in the human plasma renin assay with angiotensinogen as the substrate. The significantly reduced potency in plasma generally observed in this series was attributed to the high intrinsic local lipophilicity of the tert-butyl group, yet the actual underlying mechanism for the potency loss under the physiological assay conditions remained unclear [53]. An important milestone was the replacement of tert-butyl by the smaller and more polar methoxy group without compromising binding affinity. This afforded inhibitors such as 29 (purified renin IC50 ¼ 42 nM, plasma IC50 ¼ 95 nM) that were equipotent under the different assay conditions. This ‘rule breaking’ finding merits emphasis in the light of the perceived preference of human renin for hydrophobic aryl or bulky alkyl residues at P3, as was suggested by ample previous SAR data. Extensive SAR optimization of 29 then focussed on modifications of the phenoxy side chain, starting from a common advanced intermediate [53]. Shortening or lengthening of the flexible linear alkoxy substituent and placing one or two oxygen atoms at different positions afforded a
O O H2N
R
MeHN
OH CH3 H N
O
O 29: Q = CH3O MeO
O 27: OMe 28: NH2
30: Q =
O
MeO MeO
OH
H N
H2N O MeO
O 31
Figure 10 Milestone SAR of the ‘Phenoxy’ series.
H2N Q
OH CH3 H N O
118
Ju¨rgen Maibaum and David L. Feldman
library of potent inhibitors, the most prominent analogue of which was 30 (purified renin/plasma IC50 ¼ 1 nM, Figure 10). The X-ray structure of human renin-bound 30, resolved shortly after that of the THQ 12, confirmed the close hydrophobic interactions of the P1 isopropyl, the phenyl spacer and the P3 methoxy to the S3-S1 ‘superpocket’ [50]. Again unpredicted by modeling, and most striking, was the finding that the methoxypropoxy residue occupied the non-substrate Ssp 3 pocket by forming a H-bond to Tyr14 at the bottom of the cavity. It is quite remarkable that optimization of the phenoxy side chain in 30, permitting a perfect fit into Ssp 3 of renin, was completed before its true binding interactions to this site were uncovered by X-ray. In telemetered Nadepleted marmosets, 30 induced pronounced BP reductions (peak DMAP 20–25 mmHg), which were still significant after 24 h (at 30 mg/kg) [53]. No changes in HR were observed over the 1–30 mg/kg oral dose range. Bioavailability in non-depleted marmosets was moderate (16%) with a short terminal half-life (2 h). Pre-clinical cardiovascular safety pharmacology, however, revealed 30 to induce a dose-dependent transient reduction in HR and changes in cardiac conduction (intravenous dose range 0.3–10 mg/kg) to anesthetized sub-primates, which were unrelated to in vivo renin inhibition. Owing to the insufficient therapeutic margin, pre-clinical investigation of 30 was terminated. Ongoing lead optimization activities aimed to identify analogues that were more efficacious in vivo with longer duration of action. An increasing body of evidence emerged within this and other series that P1u isopropyl substitution of the HE isostere gave inhibitors with similar in vitro, but markedly superior in vivo potency as compared to their P1u methyl congeners. This increased potency may have been due to as yet unknown beneficial pharmacokinetic properties. For example, 31 (purified/plasma renin IC50 ¼ 1/4 nM) showed significantly stronger depressor effects (peak DMAP of 20 mmHg) as compared to 30 over 4–5 h (3 mg/kg) [54]. Considerable efforts targeting P2u modifications identified several N-terminal carboxamides, which demonstrated tight binding in vitro to plasma renin and markedly increased oral efficacy with prolonged duration of action in Na-depleted marmosets. From this sub-series, 1 (plasma renin IC50 ¼ 0.6 nM) emerged as one of the most potent inhibitors of human renin that we had identified at that time. In vitro potency was less against plasma renin from marmoset (IC50 ¼ 2 nM) and non-primates (mouse, rat, dog, rabbit and guinea pig IC50s ¼ 4, 80, 7, 11 and 63 nM, respectively). The promising drug candidate 1 was intensively studied in vivo, first in Na-depleted marmosets [54–56]. The dose-dependent and sustained decrease in BP following oral administration (0.3–30 mg/kg) was accompanied by a decrease in PRA and an increase in plasma renin levels. Maximal efficacy of 30 mmHg DMAP was achieved at 3 mg/kg, which corresponded to the maximal BP
Case History on Tekturnas/Rasilezs (Aliskiren)
119
depressor effect induced by ACEi and ARB in this model [56]. Inhibitor 1 was markedly more effective than equivalent oral doses of remikiren, 4, and zankiren, 6. Repeated once-daily oral dosing (10 mg/kg/day) over 8 days caused effective BP lowering over 24 h without altering HR and without rebound increase in BP after termination of treatment [55]. On the basis of its promising pharmacology and safety profile, 1, which came to be known later as SPP100 and then aliskiren, was taken forward to clinical development.
4.7 Challenges of a multiple chemotype approach In the course of our novel chemotype renin inhibitor program, at least four structurally diverse major lead series emerged from the initial topological design approach providing sub-micromolar inhibitors [49]. Principal conceptual considerations such as the introduction of suitable H-bond acceptors/donors to the distinct P3-P1 scaffolds could be successfully transferred between sub-series, leading to breakthroughs in in vitro potency in each case. Although key in vitro SAR were consistent between the various sub-series, lead optimization for in vivo efficacy and refining of other key inhibitor profiles proceeded in a less parallel fashion, hence involving different sets of lead SAR. An additional complication, particularly during the late stage of the project, was the need to develop separate efficient synthetic paradigms for candidate inhibitors from different sub-series. As an example, the potent indole inhibitor 32 (purified/plasma renin IC50 ¼ 1/4 nM, Figure 11) was derived from weakly active 11 by incorporation of a synthetically flexible spacer bridging a mono-alkyl P1 residue and a P3 aryl residue [48]. This lead demonstrated a more pronounced BP reduction (DMAP 20 mmHg) but was significantly shorter acting than 30 (10 mg/kg po) in Na-depleted marmosets. Unexpectedly, X-ray analysis of an analogue of 32 in complex with human OH O N
OH
H N
H2N
O
O
N H
N
H N
H2N
O
O
N H 33
32 MeO
MeO OH O
O
N H
Figure 11 Multiple
OH
H N
H2N O
NH2
O
O
N H
34
(P3-Psp 3 )-pharmacophore
H N
O H 2N
approach.
O 35
N O
120
Ju¨rgen Maibaum and David L. Feldman
renin showed that the indole moiety was posed in a flipped binding conformation with the N-benzyl substituent positioned within the same Ssp 3 pocket, that had been identified shortly before by X-ray of 20 and 30 [50]. As a consequence, the indole was in close hydrophobic contact with the S3 pocket instead of mimicking the peptide backbone as proposed by modeling. This suggested a promiscuous character of the rigid Ssp 3 pocket accommodating both hydrophobic aryl groups and more polar heteroaliphatic side chains. Psp 3 phenyl-substituted analogues in both the THQ [48] and the ‘phenoxy’ series [53] were found to be highly potent, although IC50s dropped markedly against plasma renin due to the local lipophilicity of the Psp 3 aryl. Vice versa, polar N-substitution in the ‘indole series’ resulted in the potent inhibitor 33 (purified/plasma renin IC50 ¼ 9/16 nM). Remarkably, the preferred configuration of the P1 isopropyl of 32 and 33 was opposite to that seen in two other lead series exemplified by 30 and 35, requiring elaboration of, at least in part, independent synthesis routes. In view of these hurdles and the lack of apparent benefits, further SAR in the indole series was discontinued. Work was not resumed even when the potential of P1u isopropyl substitution for improved in vivo potency [54] as well as simplified synthetic accessibility (vide infra) became fully recognized for more advanced candidate series. In the quest for more readily accessible inhibitors of less synthetic complexity, a promising series of O-alkylated salicylamides (34, 35; Figure 11) evolved from a computational fragment-based approach starting from the high-affinity compound 30 [57]. Independent docking of the components of 30 generated by disconnecting the spacer bond between P1 and the phenyl moiety suggested a three-atom carboxamide linker as being optimal to re-connect the P3 aryl fragment through its ortho position to P1 of the TSM. Initial SAR resulted in potent and selective inhibitors [20,57], thus supporting the binding mode predicted by modelling. Subsequently, this prediction was confirmed by X-ray [50]. Since the phenyl ring is positioned more deeply into S3, extension of the ortho-alkoxy side chain by one carbon was required for inducing an Hbond with Tyr14 of the Ssp 3 cavity. Strikingly, the in vivo SAR of P2u optimization did not parallel that of other sub-series. For example, 34 (plasma IC50 ¼ 0.5 nM) bearing the same P2u residue as 1 showed an inferior pharmacological profile despite comparable in vitro potencies. The most attractive salicylamide, 35, was highly potent towards primate plasma renin (IC50 ¼ 0.3, 2, 40 and 2,000 nM for human, marmoset, dog and rat) and selective against other human aspartyl proteases. Excellent oral potency was observed in Na-depleted marmosets with a pronounced dose-dependent (1–10 mg/kg) reduction in MAP similar to the effects seen with 1, and complete blockade of PRA over 24 h (3 mg/kg). No effects on the action potential measures in isolated Langendorff rabbit heart were seen at 30 mM, the highest concentration tested, suggesting an attractive
Case History on Tekturnas/Rasilezs (Aliskiren)
121
cardiac safety potential. The failure to identify a crystalline salt of 35 suitable for drug formulation terminated its pre-clinical development.
5. FIRST CONVERGENT AND SCALABLE SYNTHESIS DEVELOPMENT The continued interest in the clinical candidate 1 required a practical stereoselective synthesis for scale-up to support comprehensive evaluation in pharmacology and animal safety studies, as well as subsequent early clinical investigations. The initial linear research route was of high complexity (W25 steps, multiple chromatography purifications) and hence was not suitable to produce larger quantities [54]. Therefore, the drug discovery team in research took the initiative to elaborate a highly efficient, convergent and stereoselective synthesis of 1. Early and tight collaborative integration of the medicinal chemistry and the process chemistry groups was a key factor for effective knowledge transfer, further optimization and eventually successful transition into the first process synthesis. The structure of 1 is unique due to the four acyclic stereocenters, which rendered cost-effective synthesis extremely challenging. Retrosynthetic analysis (Figure 12) revealed the pseudo-symmetric features of the center portion of the all-carbon skeleton, comprising a geminal synamino alcohol as well as a 1,4-diisopropyl substitution motif of identical absolute configuration. We also took advantage of knowledge previously established for CGP38560, 3, enabling the stereoselective preparation of HE isosteres [58]. Intermediate 36 displayed all stereocenters of desired configuration and had the proper functionalities for further elaboration in place. On the basis of a highly stereo-controlled bromo-lactonization/ azide displacement sequence, 36 could be prepared in four steps with each step affording a crystalline intermediate [59]. Further key reactions involved Grignard-coupling of the 3,4-dialkoxy-aryl fragment to the aldehyde derived from 36 to afford 37, followed by direct lactoneopening with the P2u amine, and finally concomitant reduction of the activated benzylic alcohol and the azide through hydrogenation. This convergent route afforded 1 in nine linear steps overall and was MeO
MeO O
O OH
H N
O MeO
NH2
O
Pseudo-symmetric core structure (aliskiren, 1)
OH
O CONH2
O
O
HO2C N3
36
N3
MeO
37
Figure 12 Retrosynthetic concept towards aliskiren, 1, and key intermediates.
122
Ju¨rgen Maibaum and David L. Feldman
amenable to a multi-kilogram scale-up for phase I clinical development. An alternative and elegant process synthesis, again involving a bromolactonization protocol, at acceptable manufacturing cost-of-goods was subsequently developed [60,61].
6. PRE-CLINICAL PROPERTIES OF ALISKIREN Comprehensive reviews on aliskiren, 1, describing its pre-clinical pharmacology and safety profile, its pre-clinical in vitro/in vivo ADME properties, as well as clinical pharmacokinetics have appeared [54–56, 61–65]. Oral bioavailability of 1 was low to moderate in rats, dogs and marmosets (2.4%, 32% and 16–30%) [54,56]. Elimination of 1 in all species involves predominantly biliary/fecal excretion of unchanged parent drug [65]. In vitro studies showed poor substrate-affinity for 1 to CYP3A4 (Km ¼ 24.3 mM), no significant interactions with a large panel of human cytochrome P450 isozymes (e.g., IC50s W200 mM for CYPs 1A2, 2C8, 2C9, 2C19, 2D6, 2E1) [65,66] and low hepatic metabolic clearance in human liver microsomes. Aliskiren is a relatively high-affinity substrate for P-glycoprotein (MDR-1)-mediated transport, which may play a role in the hepatobiliary/intestinal excretion of the drug. The drug is not an inhibitor of MDR-1 and only weakly inhibited other transporters (BCRP, OATP2B1, hOCT1) at high concentrations. Further in vivo studies supported a low likelihood of drug–drug interactions through interference of 1 with CYP enzymes or efflux transporters [62,63]. Aliskiren showed an excellent cardiac safety profile in vitro, indicating a very low risk of impacting cardiac repolarization and conduction time and a low risk of torsade de pointes (TdP). The human hERG channel was very weakly inhibited in a cellular patch-clamp assay (IC25 ¼ 671 mM). No effects were observed on the action potential measures in the isolated rabbit heart up to 100 mM, suggesting a lack of interaction of 1 with cardiac ion channels in whole organ tissues at clinically relevant concentrations [64]. In normal rats, aliskiren distributed to the kidney, possibly to tissue structures that are involved in BP control [67]. Moreover, the compound showed a markedly prolonged renal residence time, being present in the kidneys of dTGR even after a 3-week wash-out period [68]. This finding suggested the potential for sustained inhibition of the intra-renal RAAS, as confirmed in preliminary studies in TG(mRen-2)27 rats [69]. Interestingly, 1 appears to incorporate into renin granules in cultured cells, which, when stimulated appropriately, secrete renin that is already inhibited [70]. Taken together, the earlier findings indicate that aliskiren may be able to access intra-renal renin, resulting in enzyme inhibition even before secretion to the extracellular compartment.
Case History on Tekturnas/Rasilezs (Aliskiren)
123
7. EFFECTS OF ALISKIREN IN DISEASE MODELS As indicated previously, dTGR, which express the human genes for renin and angiotensinogen [15], are very responsive to inhibition with a human renin inhibitor. Single oral dosing of 1 to chronically catheterized dTGR resulted in a dose-dependent, rapid and marked lowering of MAP with a long duration of action [71]. The first evidence that 1 exhibits potent cardio-renoprotective effects was determined in dTGR after chronic treatment [16]. Left ventricular hypertrophy associated with hypertension in dTGR was prevented by 1, and this was accompanied by reductions in various markers of inflammation in cardiac tissue. In a mouse model of myocardial infarction following coronary artery ligation, cardiac function was improved and remodeling was inhibited by a dose of 1 that did not lower BP [72]. These findings suggested a benefit in hypertensive diseases in humans. Hypertensive TG(mRen-2)27 rats expressing mouse renin, which efficiently cleaves rat angiotensinogen, develop type 1 diabetes and nephropathy when pre-treated with streptozotocin. In this model of hypertensive diabetic renal damage, 1 showed renoprotective effects as determined by attenuated albuminuria and renal structural changes [67,73]. The reduction of tubulo-interstitial damage to a greater extent in aliskiren vs. ACEi treated diabetic TG(mRen-2)27 rats is of potential importance, as it may indicate tissue protective effects beyond BP control [73]. The RAAS has been recognized as a major contributor to hypercholesterolaemia-induced atherosclerosis. In two models of atherosclerotic mice [74,75], and in Watanabe heritable hyperlipemic rabbits [76], aliskiren greatly attenuated the development of atherosclerosis without affecting plasma total cholesterol levels. Moreover, evidence for the ability of 1 to improve endothelial function was obtained in rabbits [76]. Finally, in a 2-week study in spontaneously hypertensive rats (SHR), co-administration of sub-maximal effective doses of 1 with either valsartan (ARB) or benazepril (ACEi) demonstrated a significant synergistic BP-lowering effect. This effect was attributed to RAAS inhibition at multiple sites [56].
8. CLINICAL STUDIES WITH ALISKIREN Results from an extensive clinical development plan for aliskiren continue to become available [61,77]. This renin inhibitor has a very long half-life (B40 h) and consequently provides 24 h BP control [78], despite its low absolute oral bioavailability of 2.6% in human [62]. Aliskiren consistently shows strong anti-hypertensive activity, at least as effective as ACEi or ARB, in patients with mild-moderate hypertension. The side effect profile is comparable to placebo. It is noteworthy that this
124
Ju¨rgen Maibaum and David L. Feldman
BP-lowering effect is long-lasting after stopping treatment [79], an effect that may have a basis in the renal retention of aliskiren observed in preclinical studies. Moreover, evidence that aliskiren attenuates albuminuria, independently of BP control, in patients with diabetic nephropathy [80], and lowers brain natriuretic peptide (BNP) in patients with congestive heart failure [81] indicates renal and cardio-protective effects of the drug. When combined with valsartan [82], the diuretic hydrochlorothiazide [83] or amlodipine [84], aliskiren showed additional BP lowering effects vs. either monotherapy. Long renal residence time may explain the prolonged anti-hypertensive action of aliskiren in patients.
9. CONCLUSIONS Novel non-peptide topological renin inhibitors have been designed and further optimized based on computational modeling and X-ray crystallography. The unprecedented binding interaction to a non-substrate binding pocket was crucial for the tight enzyme affinity of these TSMs. Elaboration of several major lead series culminated in aliskiren, a remarkably potent and highly selective renin inhibitor. Aliskiren is orally efficacious, safe and well-tolerated in pre-clinical and clinical trials. TEKTURNAs/RASILEZs (aliskiren) received marketing approval in 2007 by the FDA and in Europe as the first direct renin inhibitor for the treatment of hypertension. The extent to which this new mechanism of action will provide improved organ protection will be determined by ongoing clinical trials with this direct renin inhibitor.
REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9]
B. W. Van Tassell and M. Munger, Ann. Pharmacother., 2007, 41, 456. V. J. Dzau, D. W. Burt and R. E. Pratt, Am. J. Physiol., 1988, 255, F563. U. C. Brewster, J. F. Setaro and M. A. Perazella, Am. J. Med. Sci., 2003, 326, 15. D. T. Pals, J. A. Lawson and S. J. Couch, J. Pharmacol. Meth., 1990, 23, 239. J. M. Wood, S. C. Mah, H. P. Baum, M. De Gasparo, F. Cumin, H. Ru¨eger and J. Nussbaumer, J. Pharmacol. Exp. Ther., 1990, 253, 513. M. L. Mangiapane, J. T. MacAndrew, S. S. Ellery, A. H. Smith, I. M. Purcell, E. F. Kleinman, W. F. Holt and W. R. Murphy, Clin. Exper. Hypertens., 1994, 16, 507. H. D. Kleinert, S. H. Rosenberg, W. R. Baker, H. H. Stein, V. Klinghofer, J. Barlow, K. Spina, J. Polakowski, P. Kovar, J. Cohen and J. Denissen, Science, 1992, 257, 1940. J.-P. Clozel and W. Fischli, Arzneim.-Forsch./Drug Res., 1993, 43, 260. A. E. Weber, A. G. Steiner, P. A. Krieter, A. E. Colletti, J. R. Tata, T. A. Halgren, R. G. Ball, J. J. Doyle, T. W. Schorn, R. A. Stearns, R. R. Miller, P. K. S. Siegl, W. J. Greenlee and A. A. Patchett, J. Med. Chem., 1992, 35, 3755.
Case History on Tekturnas/Rasilezs (Aliskiren)
125
[10] J. L. Wessale, H. D. Kleinert, S. V. Calzadilla, P. J. Kovar and S. H. Rosenberg, Am. J. Hypertens., 1993, 6, 514. [11] E. G. McMahon, P.-C. Yang, M. A. Babler, S. E. Bittner, O. D. Suleymanov, K. J. CainJanicki, L. J. Bedell, G. J. Hanson and C. S. Cook, Hypertension, 1995, 26, 95. [12] J. M. Wood, N. Gulati, P. Forgiarini, W. Fuhrer and K. G. Hofbauer, Hypertension, 1985, 7, 797. [13] C. R. Schnell and J. M. Wood, Am. J. Physiol., 1993, 33, H1509. [14] D. N. Mu¨ller, W. Derer and R. Dechend, J. Mol. Med., 2008, 86, 659. [15] J. Bohlender, A. Fukamizu, A. Lippoldt, T. Nomura, R. Dietz, J. Me´nard, K. Murakami, F. C. Luft and D. Ganten, Hypertension, 1997, 29, 428. [16] B. Pilz, E. Shagdarsuren, M. Wellner, A. Fiebeler, R. Dechend, P. Gratze, S. Meiners, D. L. Feldman, R. L. Webb, I. M. Garrelds, A. H. J. Danser, F. C. Luft and D. N. Muller, Hypertension, 2005, 46, 569. [17] W. J. Greenlee, Med. Res. Rev., 1990, 10, 173. [18] S. H. Rosenberg and S. A. Boyd, in Antihypertensive Drugs (eds P. A. Van Zwieten and W. J. Greenlee), Harwood, Amsterdam, The Netherlands, 1997, pp. 77–111. [19] S. H. Rosenberg, Prog. Med. Chem., 1995, 32, 37. [20] C. M. Tice, Ann. Rep. Med. Chem., 2006, 41, 155. [21] J. M. Wood, F. Cumin and J. Maibaum, Pharmacol. Ther., 1994, 61, 325. [22] P. Bu¨hlmayer, A. Caselli, W. Fuhrer, R. Go¨schke, V. Rasetti, H. Ru¨eger, J. L. Stanton, L. Criscione and J. M. Wood, J. Med. Chem., 1988, 31, 1839. [23] J. M. Wood, L. Criscione, M. De Gasparo, P. Bu¨hlmayer, H. Ru¨eger, J. L. Stanton, R. A. Jupp and J. Kay, J. Cardiovasc. Pharmacol., 1989, 14, 221. [24] M. De Gasparo, F. Cumin, J. Nussberger, T. T. Guyenne, J. M. Wood and J. Me´nard, Br. J. Clin. Pharmac., 1989, 27, 587. [25] X. Jeunemaıˆtre, J. Me´nard, J. Nussberger, T. T. Guyene, H. R. Brunner and P. Corvol, Am. J. Hypertens., 1989, 2, 819. [26] A. H. van den Meiracker, P. J. J. Admiraal, F. H. M. Derkx, C. Kleinbloesem, A. J. Man in ‘t Veld, P. Van Brummelen, P. Mulder and M. A. D. H. Schalekamp, J. Hypertens., 1993, 11, 831. [27] P. Coassolo, W. Fischli, J.-P. Clozel and R. C. Chou, Xenobiotica, 1996, 26, 333. [28] C. Weber, H. Birnbo¨ck, J. Leube, I. Kobrin, C. H. Kleinbloesem and P. Van Brummelen, Br. J. Clin. Pharmac., 1993, 36, 547. [29] W. Fischli, J.-P. Clozel, K. E. Amrani, W. Wostl, W. Neidhart, H. Stadler and Q. Branca, Hypertension, 1991, 18, 22. [30] W. F. Richter, B. R. Whitby and R. C. Chou, Xenobiotica, 1996, 26, 243. [31] P.-C. Yang, M. Babler, S. Bittner, O. Suleymanov, M. Perez, K. Cain-Janicki, L. Bedell, G. Hanson, C. Cook, J. Ottinger, J. Baran and E. McMahon, FASEB J., 1994, 8, A882. [32] S. H. Rosenberg, K. P. Spina, S. L. Condon, J. Polakowski, Z. Yao, P. Kovar, H. H. Stein, J. Coehen, J. L. Batlow, V. Klinghofer, D. A. Egan, K. A. Tricarico, T. J. Perun, W. R. Baker and H. D. Kleinert, J. Med. Chem., 1993, 36, 460. [33] S. H. Rosenberg and H. D. Kleinert, Pharm. Biotech., 1998, 11, 7. [34] H. D. Kleinert, Cardiovasc. Drugs Ther., 1995, 9, 645. [35] R. S. Boger, H. N. Glassman, R. Thys, S. K. Gupta, R. L. Hippensteel and H. D. Kleinert, Am. J. Hypertens., 1993, 6, 103A. [36] K. Suguna, E. A. Padlan, A. Eduardo, C. W. Smith, W. D. Carlson and D. R. Davies, Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 7009. [37] B. L. Sibanda, T. Blundell, P. M. Hobart, M. Fogliano, J. S. Bindra, B. W. Dominy and J. M. Chirgwin, FEBS Lett., 1984, 174, 102. [38] N. C. Cohen, in Trends in Medicinal Chemistry’88 (eds H. van der Goot, G. Doma´ny, L. Pallos, and H. Timmerman), Elsevier, Amsterdam, The Netherlands, 1989, pp. 13–28.
126
Ju¨rgen Maibaum and David L. Feldman
[39] A. R. Sielecki, K. Hayakawa, M. Fujinaga, M. E. P. Murphy, M. Fraser, A. K. Muir, C. T. Carilli, J. A. Lewicki, J. D. Baxter and M. N. G. James, Science, 1889, 243, 1346. [40] J. Rahuel, J. P. Priestle and M. G. Gru¨tter, J. Struct. Biol., 1991, 107, 227. [41] C.E. Brotherton-Pleiss, S.R. Newman, L.D. Waterbury and M.S. Schwartzberg, Pept.: Chem. Biol., Proc. Am. Pept. Symp., 12th (1992), Meeting Date 1991, pp. 816–817. [42] M.G. Bock, R.M. DiPardo, B.E. Evans, R.M. Freidinger, W.L. Whitter, L.S. Payne, J. Boger, E.H. Ulm, E.H. Blaine, et al., Pept.: Struct. Funct., Proc. Am. Pept. Symp., 9th, 1985, p751. [43] V. Rasetti, N. C. Cohen, H. Ru¨eger, R. Go¨schke, J. Maibaum, F. Cumin, W. Fuhrer and J. M. Wood, Bioorg. Med. Chem. Lett., 1996, 6, 1589. [44] V. Rasetti, H. Ru¨eger, J. K. Maibaum, R. Mah, M. Gru¨tter and N. C. Cohen, Eur. Pat. EP 702004-A2, 1996, 2. [45] R. Go¨schke, N. C. Cohen, J. M. Wood and J. Maibaum, Bioorg. Med. Chem. Lett., 1997, 7, 2735. [46] M. W. Holladay, F. G. Salituro and D. H. Rich, J. Med. Chem., 1987, 30, 374. [47] D. J. Kempf, J. Org. Chem., 1986, 51, 3921. [48] J. Maibaum, V. Rasetti, H. Ru¨eger, N. C. Cohen, R. Go¨schke, R. Mah, J. Rahuel, M. Gru¨tter, F. Cumin and J. M. Wood, in Medicinal Chemistry: Today and Tomorrow, Proceedings of the AFMC International Medicinal Chemistry Symposium, Tokyo, September 3–8, 1995 (ed. M. Yamazaki), Blackwell Science, United Kingdom, 1997, pp. 155–162. [49] N. C. Cohen, Chem. Biol. Drug Des., 2007, 70, 557. [50] J. Rahuel, V. Rasetti, J. Maibaum, H. Ru¨eger, R. Go¨schke, N. C. Cohen, S. Stutz, F. Cumin, W. Fuhrer, J. M. Wood and M. G. Gru¨tter, Chem. Biol., 2000, 7, 493. [51] S. H. Rosenberg, J. F. Dellaria, D. J. Kempf, C. W. Hutchins, K. W. Woods, R. G. Maki, E. de Lara, K. P. Spina, H. H. Stein, J. Cohen, W. R. Baker, J. J. Plattner, H. D. Kleinert and T. J. Perun, J. Med. Chem., 1990, 33, 1582. [52] S. B. Shuker, P. J. Hajduk, R. B. Meadows and S. W. Fesik, Science, 1996, 274, 1531. [53] R. Go¨schke, S. Stutz, V. Rasetti, N. C. Cohen, J. Rahuel, P. Rigollier, H.-P. Baum, P. Forgiarini, C. R. Schnell, T. Wagner, M. G. Gru¨tter, W. Fuhrer, W. Schilling, F. Cumin, J. M. Wood and J. Maibaum, J. Med. Chem., 2007, 50, 4818. [54] J. Maibaum, S. Stutz, R. Go¨schke, P. Rigollier, Y. Yamaguchi, F. Cumin, J. Rahuel, H.-P. Baum, N. C. Cohen, C. R. Schnell, W. Fuhrer, M. G. Gru¨tter, W. Schilling and J. M. Wood, J. Med. Chem., 2007, 50, 4832. [55] J. M. Wood, J. Maibaum, J. Rahuel, M. G. Gru¨tter, N. C. Cohen, V. Rasetti, H. Ru¨eger, R. Go¨schke, S. Stutz, W. Fuhrer, W. Schilling, P. Rigollier, Y. Yamaguchi, F. Cumin, H.-P. Baum, C. R. Schnell, P. Herold, R. Mah, C. Jensen, E. O’Brien, A. Stanton and M. P. Bedigian, Biochem. Biophys. Res. Commun., 2003, 308, 698. [56] J. M. Wood, C. R. Schnell, F. Cumin, J. Menard and R. L. Webb, J. Hypertens., 2005, 23, 417. [57] J. Maibaum, N.C. Cohen, J. Rahuel, C. Schnell, H.-P. Baum, P. Rigollier, W. Schilling and J.M. Wood, XVth EFMC International Symposium on Medicinal Chemistry, Edinburgh, United Kingdom, 6–10 September 1998, Abstract Book, P229. [58] P. Herold, R. Duthaler, G. Rihs and C. Angst, J. Org. Chem., 1989, 54, 1178. [59] R. Go¨schke, J.K. Maibaum, W. Schilling, S. Stutz, P. Rigollier, Y. Yamaguchi, N.C. Cohen, P. Herold, Eur Patent EP 678503-A1, 1995. [60] J. Maibaum and D. L. Feldman, Expert. Opin. Ther. Patents, 2003, 13, 589. [61] C. Jensen, P. Herold and H. R. Brunner, Nat. Rev. Drug Discov., 2008, 7, 399. [62] S. Vaidyanathan, V. Jarugula, H. A. Dieterich, D. Howard and W. P. Dole, Clin. Pharmacokinet., 2008, 47, 515. [63] F. Waldmeier, U. Glaenzel, B. Wirz, L. Oberer, D. Schmid, M. Seiberling, J. Valencia, G. J. Riviere, P. End and S. Vaidyanathan, Drug Metab. Dispos., 2007, 35, 1414. [64] S. Ayalasomayajula, C.-M. Yeh, S. Vaidyanathan, B. Flannery, H. A. Dieterich, D. Howard, M. P. Bedigian and W. P. Dole, J. Clin. Pharmacol., 2008, 48, 799.
Case History on Tekturnas/Rasilezs (Aliskiren)
127
[65] S. Vaidyanathan, G. Camenisch, H. Schuetz, C. Reynolds, C.-M. Yeh, M.-N. Bizot, H. A. Dieterich, D. Howard and W. P. Dole, J. Clin. Pharmacol., 2008, 48, 1323. [66] S. Vaidyanathan, Y. Jin, H. Schiller and C. Jensen, Basic Res. Pharmacol. Toxicol., 2005, 97(Suppl 1), 230. [67] D. L. Feldman, L. Jin, H. Xuan, A. Contrepas, Y. Zhou, R. L. Webb, D. N. Mueller, S. Feldt, F. Cumin, W. Maniara, E. Persohn, H. Schuetz, A. H. J. Danser and G. Nguyen, Hypertension, 2008, 52, 130. [68] D. L. Feldman, E. Persohn, H. Schuetz, L. Jin, R. Miserindino-Moltini, H. Xuan, S. Zhuang and W. Zhou, J. Clin. Hypertens., 2006, 8, A80–A81, P-178. ˇ ervenka, L. Kopkan, Z. Vanˇourkova´ and Z. Huskova´, J. Hypertens., [69] I. Vaneˇcˇkova´, L. C 2008, 26, S521. [70] M. Krop, I. M. Garrelds, R. J. de Bruin, J. M. van Gool, N. D. Fisher, N. K. Hollenberg and A. H. J. Danser, Hypertension, 2008, 52, 1076. [71] D. F. Rigel, F. Fu, S. Li, W. Maniara, D. N. Mu¨ller and F. C. Luft, J. Am. Coll. Cardiol., 2004, 43(Suppl. A), 483A. [72] D. Westermann, A. Riad, O. Lettau, A. Roks, K. Savvatis, P. M. Becher, F. Escher, A. H. J. Danser, H. P. Schultheiss and C. Tschoepe, Hypertension, 2008, 52, 1068. [73] D. J. Kelly, Y. Zhang, G. Moe, G. Naik and R. E. Gilbert, Diabetologia, 2007, 50, 2398. [74] J. Nussberger, J. F. Aubert, K. Bouzourene, M. Pellegrin, D. Hayoz and L. Mazzolai, Hypertension, 2008, 51, 1306. [75] H. Lu, D. L. Rateri, D. L. Feldman, R. J. Jr., A. Fukamizu, J. Ishida, E. G. Oesterling, L. A. Cassis and A. Daugherty, J. Clin. Invest., 2008, 118, 984. [76] T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, H. Kitabata, T. Tanimoto, Y. Muragaki, S. Mochizuki, M. Goto, K. Yoshida and T. Akasaka, Hypertension, 2008, 52, 563. [77] H. Siragy, J. Huang and D. C. Lieb, Expert Opin. Emerg. Drugs., 2008, 13, 417. [78] A. H. Gradman and R. Kad, J. Am. Coll. Cardiol., 2008, 51, 519. [79] B. H. Oh, J. Mitchell, J. R. Herron, J. Chung, M. Khan and D. L. Keefe, J. Am. Coll. Cardiol., 2007, 49, 1157. [80] H. H. Parving, F. Persson, J. B. Lewis, E. J. Lewis and N. K. Hollenberg, N. Engl. J. Med., 2008, 358, 2433. [81] A. Seed, R. Gardner, J. McMurray, C. Hillier, D. Murdoch, R. MacFadyen, A. Bobillier, J. Mann and T. McDonagh, Eur. J. Heart Fail., 2007, 9, 1120. [82] S. Oparil, S. A. Yarows, S. Patel, H. Fang, J. Zhang and A. Satlin, Lancet, 2007, 370, 221. [83] A. Villamil, S. G. Chrysant, D. Calhoun, B. Schober, H. Hsu, L. Matrisciano-Dimichino and J. Zhang, J. Hypertens., 2007, 25, 217. [84] M. A. Munger, W. Drummond, M. R. Essop, M. Maboudian, M. Khan and D. L. Keefe, Eur. Heart J., 2006, 27(Suppl), 117P–784.
CHAPT ER
6 Advances in Vasopressin Receptor Agonists and Antagonists Thomas Ryckmans
Contents
1. Introduction 1.1 Emerging roles of V1a and V1b receptors in anxiety, depression and sociality 1.2 Challenges in the development of small-molecule peptidergic GPCR modulators. 2. V1a Receptor Antagonists 2.1 Azepines 2.2 Lactams 2.3 Spirocyclic piperidines 3. V1b Receptor Antagonists 3.1 Indolones and benzimidazolones 3.2 Lactams 3.3 Quinazolinones and isoquinolinones 3.4 V1b receptors and pain 4. V2 Receptor Agonists 4.1 Azepines and diazepines 4.2 Emerging chemotypes 5. V2 Receptor Antagonists 6. Dual V1a-V2 Receptor Antagonists 6.1 Azepines 6.2 Triazolones 7. Summary References
129 130 131 131 132 132 133 134 134 136 137 138 139 139 140 140 141 142 143 143 144
Pfizer PGRD, Sandwich, Kent, UK Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04406-6
r 2009 Elsevier Inc. All rights reserved.
129
130
Thomas Ryckmans
1. INTRODUCTION Arginine vasopressin (AVP) is a 9–amino-acid cyclic peptide that exerts its effect through the V1a, V1b, V2 and oxytocin (OT) family of G-proteincoupled receptors (GPCRs). V1a receptors are expressed mainly in the liver (glycogenolysis regulation), the vascular smooth muscle cells (vasoconstriction and contractility regulation) and the brain (regulation of memory formation, stress adaptation, temperature and circadian rhythm). These receptors are also involved in platelet aggregation [1]. Accordingly, V1a receptor antagonists have been progressed to the clinic for a range of indications, including Raynaud’s syndrome (vasoconstriction) and dysmenorrhea (uterine blood flow and contraction). V1b receptors (also known as V3 receptors) are expressed in the limbic system and the pituitary gland, where they regulate the hypothalamus-pituitaryadrenal (HPA) axis, which is responsible for response to stress. The V1b receptor antagonist SSR149415 has been progressed to phase II clinical trials for depressive disorders. V2 receptors are mainly expressed in the kidney and are involved in the regulation of water and sodium excretion [2–5], and several V2 receptor antagonists and mixed V1a-V2 receptor antagonists have been progressed to the clinic. It has been suggested that there is a distinct advantage in blocking both V1a and V2 receptors for indications such as congestive heart failure [6]. This review covers recent advances in the development of non-peptidic vasopressin receptor ligands, focusing on new series, structure–activity relationship (SAR) and preclinical data.
1.1 Emerging roles of V1a and V1b receptors in anxiety, depression and sociality There is growing evidence that AVP, through its action at V1a and V1b receptors, is involved in the modulation of several higher brain functions such as response to stress, mood, memory formation, aggressivity and sociality. AVP and corticotropin-releasing factor (CRF) synergistically modulate the release of adrenocorticotropic hormone (ACTH) by the pituitary gland, a key step in the HPA axis cascade, which controls response to stress. Although a detailed description of the HPA axis is beyond the scope of this review, the reader is referred to recent publications on the subject [3,7,8]. HPA axis dysfunction has been linked to anxiety, posttraumatic stress disorder (PTSD) and depression [7,9,10], and both preclinical and clinical evidence point at a key role of AVP in these conditions [10]. For example, rats bred for high anxiety-related behaviour have higher levels of AVP mRNA than rats bred for low anxiety-related behaviour. The Brattleboro rat strain, in which AVP secretion is impaired,
Advances in Vasopressin Receptor Agonists and Antagonists
131
displays reduced stress response at both the behavioural and the endocrine levels [3]. Clinical evidence has shown that both depressed and PTSD patients have higher levels of systemic AVP and that single-nucleotide polymorphism of the V1b receptor is correlated with a lower probability of developing major depression [11]. Both V1a and V1b receptors have been implicated in the modulation of aggression in rodents [12–14]. AVP has emerged as a key regulator of complex social behaviours [13,15–17]. Pair bonding in voles is modulated by the action of AVP on the V1a receptor [18–20], and a recent study demonstrated the association of genetic variation of the V1a receptor with pair bonding in humans [21]. OT has also been implicated in such processes, but this is beyond the scope of this review [22–25]. The possible implication of AVP dysfunction in conditions where sociality is impaired, such as autism and schizophrenia, has been put forward, but more evidence is clearly needed [2,26,27]. A recent review of the patent literature covering the anxiolytic and antidepressant potential of AVP antagonists is available [28], and we have therefore focused on the more recent data in the field.
1.2 Challenges in the development of small-molecule peptidergic GPCR modulators. The development of small-molecule ligands of peptidergic receptors (with the exception of opioid receptor ligands) is still considered a challenge by medicinal chemists. The average molecular weight, total polar surface area (TPSA) and cLogP of peptidergic ligands are significantly higher than those of ligands of other targets such aminergic GPCRs, ion channels and transporters [29]. Since high molecular weight, high TPSA and high cLogP are associated with poor drug-like properties [30], increased risk of offtarget toxicity [31] and poor CNS penetration, small-molecule peptidergic GPCR ligands have suffered from high attrition between the bench and the clinic. It is therefore not surprising that despite significant efforts from the pharmaceutical industry, a relatively small number of AVP antagonists have been approved for marketing.
2. V1A RECEPTOR ANTAGONISTS Relcovaptan (SR49059, 1) has shown clinical efficacy for indications modulated by the peripheral V1a receptor including Raynaud’s syndrome, dysmenorrhea and preterm labour [5], but its development has been interrupted as a result of possible interference with cytochrome P450 [32]. The development of OPC-21268 (2), another V1a receptor antagonist, has been discontinued in Europe and in the United States
132
Thomas Ryckmans
[33]. Nevertheless, the positive proof-of-concept studies with relcovaptan have triggered the interest of the pharmaceutical industry, resulting in the discovery of several classes of V1a receptor antagonists. Critically, a biomarker for V1a receptor antagonism in healthy volunteers has been recently developed [34], which could facilitate clinical development.
Cl
O OH O
O
N
O
O NH2
N
S
N N
O
O
O
O N H O
2
1
O
2.1 Azepines The activity of JNJ-17308616 (3) at V1a, V1b, V2 and OT human, rat and mouse receptors has been reported. Although JNJ-17308616 is a potent and selective antagonist of human V1a receptors (hV1a Ki ¼ 5 nM, hV1b KiW10 mM, hV2 Ki ¼ 421 nM, hOT Ki ¼ 6.5 mM), its affinity and selectivity for rat V1a receptors is lower (rV1a Ki ¼ 216 nM, rV1b KiW10 mM, rV2 Ki ¼ 276 nM, rOT Ki ¼ 1.8 mM). The compound was found to be active in several rat models of anxiety [35]. Since the kidney-localized rat V2 receptors are not believed to be associated with anxiety, the anxiolytic effect of JNJ-17308616 appears to be mediated by the V1a receptor. O
H N
O
O
O
N
O N
N O O
N
N N
O
N
N
O
F
N O
F
O
N H
F
O F
N
N
N H
O
3
4
5
133
Advances in Vasopressin Receptor Agonists and Antagonists
2.2 Lactams SRX251 (4) is a potent and selective V1a receptor antagonist (hV1a Ki ¼ 0.7 nM, hV1b KiW1 mM). The compound is orally bioavailable in rats (t1/2 ¼ 4 h), is claimed to be CNS penetrant and inhibited aggression in a hamster model when administered orally at a dose of 20 mg/kg [28,36,37]. Interestingly, non-aggressive behaviours such as locomotor activity, olfactory communication and sexual motivation were not affected. The ability of SRX251 to selectively block aggression in rats was confirmed by functional magnetic resonance imaging [12]. SRX251 has completed phase I trials and is scheduled for a phase II study targeting dysmenorrhea [38]. SRX246 (5) has a profile similar to that of SRX251 (hV1a Ki ¼ 0.3 nM, hV1b KiW10 mM, rat t1/2 ¼ 2 h) and an Investigational New Drug filing for stress-related disorders is pending [38].
2.3 Spirocyclic piperidines A range of small, low lipophilicity, selective and potent triazoles were disclosed as V1a receptor antagonists, exemplified by 6 (hV1a Ki ¼ 7 nM) [39,40]. In a related chemotype in which the triazole is replaced by an amide (as in OPC-21268), piperidines such as 7 and 8 were shown to be moderately potent V1a antagonists (hV1a Ki ¼ 25 and 31 nM respectively), but no selectivity data was disclosed.
N N
O
O
N
H N
N
N
N O
O
S
N
O
Cl Cl
6
7
8
Several patents describe related amides, with variations of the spirocyclic and heteroaryl moieties, and combinations thereof [41–47]. Spirocyclic groups and aryl substituents are preferred at the piperidine 4-position, whereas glycine amides and 2- or 3-indolecarboxamides are preferred derivatives of the piperidine nitrogen. Compounds 9–13 (hV1a Kio10 nM) are examples of such combinations.
134
Thomas Ryckmans O
O
H N
N
Ph
O
N
O
O
N HN
HN
Cl
Cl
O N
Cl
N
N
HN
O
O
O
O
O
O
O
11
10
9
Cl
N
N
O N
Cl
N
O
HN
O N 12
13
F O
3. V1B RECEPTOR ANTAGONISTS 3.1 Indolones and benzimidazolones SSR149415 (14), a potent, selective V1b receptor antagonist was progressed to phase II trials for major depression [48,49] but appears to have been discontinued [50]. The compound was extensively studied in a range of anxiety and depression models [3]. For example, SSR149415 was recently demonstrated to have efficacy similar to that of imipramine in the rat olfactory bulbectomy-induced (OBX) hyperactivity depression model [35]. The compound (at 10 and 30 mg/kg i.p.) completely inhibited OBXinduced hyperactivity upon chronic and subchronic but not acute dosing. Although the mechanism of these effects of SSR149415 is unclear, it does increase norepinephrine (but not serotonin or dopamine) levels in the prefrontal cortex and appears to act as an antidepressant rather than an anxiolytic [51]. The V1b vs. OT receptor selectivity of SSR149415 has been discussed [52], but a recent report on the ex vivo binding of radiolabelled SSR149415 appears to confirm the selectivity of this compound for V1b receptors [53]. Pituitary V1b receptors have been
135
Advances in Vasopressin Receptor Agonists and Antagonists
suggested to play a role in the anxiolytic effect of SSR149415, while the antidepressant effects appear to be mediated through central V1b receptors [7]. OH
R3
O R1
N
Cl
R3
N
N O
N O
S
R1 O
O N
R4
R4
N
S R2
O
S
O
O
R2
O
O
O
15
14
O
16
R1 = F, Cl, CN R2 = 4-CN or 4-OMe or 2-OMe, 4-OMe-phenyl or 8-quinolyl R3 = aromatic or heteroaromatic R4 = most variable group
O
Since the disclosure of SSR149415, a limited number of V1b receptor antagonists that can be distributed into three classes have appeared in the patent literature. Although indolones 15 and benzimidazolones 16 are both related to SSR149415 with clear structural overlap, new classes of compounds with beta-lactam and quinazolinone cores have also been reported. In a series of indolones related to SSR149415, 17–19 exemplify the substitution pattern with variations of R3, R2 and R4. Although urea 17 is reported to be a potent and selective V1b receptor antagonist (hV1b Kio10 nM, W50- and W100-fold selectivity over V1a and OT receptors, respectively), no selectivity data has been published for urea 18 (hV1b Kio10 nM) and carbamate 19 (hV1b Kio50 nM) [54–57].
N
O
O O
H N
N
N O
N
N N
O O
O N O O N
N
O N
17
18
N N
S
O O
N
O
N N
S
O
O N
O N
S
O O
H N
19
N
136
Thomas Ryckmans
Related high-affinity analogues (hV1b Kio1 nM) in which the R4 group is a cyclic amine have also been disclosed, such as 20 and 21 [56,58,59].
N
O
N O
O
( )n N
N
R1
O
N
O N S O O
O N S O O O
O
N
N
O
O
N
N
20
Cl
N
N
O
N
N S
21
O
(R1=F, Cl, n=1-2)
O
22
O
Compound 22, illustrating the benzimidazolone chemotype, has been reported as a V1b receptor antagonist (hV1b Kio100 nM), but no selectivity data was reported [60].
3.2 Lactams Beta-lactams 23–24 represent a new class of V1b receptor antagonists (23: rV1b Ki ¼ 70 rM, 24: rV1b Ki ¼ 30 nM; no selectivity data against the V1a receptor reported). Compound 24 was found to restore both biochemical (testosterone/cortisol levels) and behavioural (seed finding) markers in hamster at the dose of 1 mg/kg i.p. with activity comparable to that of fluoxetine, buspirone and chlordiazepoxide [61]. Interestingly, this chemotype is related to a previously discussed class of selective V1a receptor antagonists represented by 4 and 5.
O
O
O
O N
N
O
O
N
N O
O
O
N H
N H O N N
23
N N
24
137
Advances in Vasopressin Receptor Agonists and Antagonists
3.3 Quinazolinones and isoquinolinones Several V1b receptor antagonists from the chemotype 25 have been disclosed. Binding of selected compounds in CHO cells expressing hV1b receptors or in an ex vivo rat anterior pituitary cell assay was reported. Quinazolinones 26 and 27 are potent antagonists of the human receptor (hV1b Kio10 nM). Compound 28 (Y ¼ CH) is described as a rat V1b receptor antagonist (V1b Ki ¼ 10–100 nM) [62]. A very similar series of azaanalogues exemplified by 28 (Y ¼ N) has been reported (hV1b IC50 1 nM) [63]. R3
H N
H N
O
O
O
O R
2
O
N
N N X
R1
N N X=N, CH R2=OR, Het R3=iPr, tBu, nPr
25
H N
O
26
H N
O
O O
O
O
O N
N
N
N N
N
Cl
27
O
28
Y Y=CH Y=N
A potent and selective V1b receptor antagonist ORG 52186 (hV1b Ki ¼ 4 nM; hV1a, V2 and OTW10 mM) is reported to be active when administered at a dose of 5 mg/kg p.o. in a rat model of CRF-mediated release of ACTH [64]. The structure of this compound has not been disclosed, but it may belong to the quinazolinone class [8,33,62]. Compounds related to 25 (X ¼ N) with an R2 nitrogen substituent have been disclosed, exemplified by 29 (hV1b Kio10 nM) and 30 (hV1b Ki ¼ 10–100 nM), which demonstrates that an aromatic group at the 6-position is not required to achieve potency. Quinazolinone 31 (rV1b Ki ¼ 10–100 nM, ex vivo anterior pituitary cells) is disclosed as a rat V1b receptor antagonist [65]. Isoquinolinone analogues 25 (X ¼ CH) have been disclosed with a similar substitution pattern; 32 is reported to be an antagonist of human V1b receptors with a Kio10 nM.
138
Thomas Ryckmans
H N
H N
O O
O O
NH N
N
N
N
29
Cl
H N
NH N
N
30
H N
O
O O
O
N
O
N
N
N
N N
31
O
32
3.4 V1b receptors and pain Compounds 33 and 34 were shown to be active in the Chung model of neuropathic pain in rats at a dose of 10 mg/kg p.o. In the same model, SSR149415 was active at a comparable dose (6 mg/kg). Compound 34 was also active in a model of chronic inflammatory pain in rats (CFA) at 10 mg/kg p.o. [66]. Neither 33 nor 34 was active in the mouse tail-flick model of acute thermal pain. Interestingly, V1b receptor knockout mice (but not V1a receptor knockout mice) showed a hyponociceptive response in the hot plate model [67]. SSR149415 (14) was found to be efficacious in a rat model of chronic stress-induced visceral hyperalgesia, but not in an acute model. Taken together, these results indicate the potential of V1b receptor antagonists for the treatment of pain and the effect of stress on pain response.
H N
H N
O
O O
O
O N
N
N
N
N
N F
33 O
Cl
34
Advances in Vasopressin Receptor Agonists and Antagonists
139
4. V2 RECEPTOR AGONISTS The V2 receptor is mainly localized in the kidney and is responsible for fluid homeostasis. V2 receptor agonists increase the expression of aquaporin-2 water channels, which increase water reabsorption by the kidney, thus concentrating the urine (increased osmolality) and decreasing its volume. Inactivating mutations of the V2 receptor are linked to nephrogenic diabetes insipidus, in which polyuria and excessive thirst is observed. Desmopressin, a V2 receptor agonist, is indicated for the treatment of polyuria, but since the compound is also a V1b receptor agonist, and has low bioavailability, more selective agents with improved oral bioavailability have been actively sought [68].
4.1 Azepines and diazepines OPC-51803 (35), a partial V2 receptor agonist, and VNA-932 (WAY151932, 36) are both in phase II clinical trials for enuresia [33]. O N H N
N
N O
O
Cl
Cl N 35
N
N
36
Diazepine 37 was active (10 mg/kg p.o.) in a rat model of polyuria, decreasing urine volume by nearly 90%. The compound was selective for V2 receptors (rV2 binding 490 nM, rV2 EC50 1.7 nM) over V1a receptors (rV1a binding 6 mM, ex vivo blockade of AVP-induced contractions of rat tail artery IC50W30 mM) and was found to be a weak antagonist of rOT receptors (ex vivo blockade of OT-induced contractions of rat uterine strips IC50W1260 nM) [69]. The structurally related azepine 38 (hV2 Ki ¼ 5 nM, rV2 Ki ¼ 19 nM, rEC50 2 nM) was also active in a similar rat model when administered at the dose of 0.26 mg/kg p.o. [70]. Diazepine 39 (hV2 EC50 4 nM, intrinsic efficacy relative to AVP 0.85) and its analogues are also potent V2 receptor agonists [71]. Compound 40 was
140
Thomas Ryckmans
recently reported to be a potent full V2 receptor agonist (hV2 EC50 24 nM, intrinsic efficacy relative to AVP 1.0; V1a, V1b EC50W10 mM; OT KiW10 mM) and to show robust efficacy in the Brattleboro rat model (3 mg/kg p.o.), with almost full inhibition of urinary output for 2 h [72]. N HN H N
O
N
N
F F
O N
O N
N
O
N O
O
H N
O
F
N
Cl
F
O
Cl
N
F
O
N
N
37
38
O
N
39
N
40
4.2 Emerging chemotypes Phthalamide 41 (pEC50 9.4 intrinsic efficacy relative to AVP 0.27) and tetrazole 42 (pEC50 5.1 intrinsic efficacy relative to AVP 0.68) were identified as selective, partial agonists of the human V2 receptor. Compound 41 (10 mg/kg, p.o.) showed efficacy in the Brattleboro rat model, reducing urine output by 60% [68].
F HO
F F
O
N
O
N N N
N N
41
42
5. V2 RECEPTOR ANTAGONISTS Several V2 receptor antagonists, including tolvaptan 43, lixivaptan 44 and satavaptan 45, have entered clinical trials for the treatment of hyponatremia, liver cirrhosis, chronic heart failure and polycystic kidney disease and have been extensively reviewed elsewhere [5,33].
141
Advances in Vasopressin Receptor Agonists and Antagonists
Mozavaptan 46 was approved in Japan in 2006 for hyponatremia and tolvaptan was recommended for approval by an FDA advisory board for hyponatremia in June 2008 [5]. In a clinical trial aimed at evaluating the efficacy of tolvaptan in preventing heart failure, tolvaptan modestly relieved the congestive symptoms of heart failure, but failed to reduce morbidity or mortality when added to standard therapy [73]. O HO
O
N
N
N O N
O
N O
O S O
O N H
N H
O
F
Cl
O
N
N
O
O
NH
O O
HN
43
44
45
46
Compounds 47 and 48 related to satavaptan have been reported recently (47 hV2 Ki ¼ 1 nM, 48 hV2 Ki ¼ 2 nM; selectivity over OT, V1a and V1b W100 for both) but no in vivo data was disclosed [74]. In yet another variation of the beta-lactam chemotype, compounds such as 49 were reported as potent V2 receptor antagonists (hV2 Ki ¼ 0.4 nM). Activity of such compounds at the OT and neurokinin receptors was also claimed in this disclosure [75]. O Cl
N H
Cl
O
O NH
O
Cl
N
O
O
O N
O N
O
S
O O O
HN
HN O
47
N H
O
S
O
N O
N N
O
48
F
F F
49
6. DUAL V1A-V2 RECEPTOR ANTAGONISTS Conivaptan (YM-087, 50) is currently the only approved V1a-V2 receptor antagonist, and is used to treat hyponatremia. Chronic blockade of both the V1a and the V2 receptors may be advantageous in the treatment of
142
Thomas Ryckmans
congestive heart failure [6] and has prompted vigorous research in this area.
6.1 Azepines
O HN
H N
O
OH
N
N
N
N
N
O
F
O
O
Cl N H
N H
O
50
O
N H
O
51
O
52
Spirobenzazepine RWJ-339489 (51) was identified as a potent, balanced functional V1a-V2 receptor antagonist (hV1a IC50 45 nM, hV2 IC50 36 nM) with adequate rat PK (F ¼ 22%, t1/2 ¼ 6.5 h) and produced robust aquaresis when administered at the dose of 10 mg/kg p.o. [76]. Because of unexpected toxicology findings with 51, RWJ-676070 (52) was identified as a back-up candidate. Compound 52 has a functional antagonist profile at V1a and V2 receptors similar to that of 51 (hV1a IC50 14 nM, hV2 IC50 13 nM), has a favourable rat pharmacokinetic profile (F ¼ 68%, t1/2 ¼ 8.7 h) and did not display the toxicity of 51 [1,77]. The compound entered phase I clinical trials and was well-tolerated in healthy volunteers [34]. O H N
N O
HN
N
N
O
N
O
O F
N H
53
N H
O
54
N H
O
55
O
Advances in Vasopressin Receptor Agonists and Antagonists
143
Another spirobenzazepine (53) was reported to be a potent dual functional antagonist of V1a and V2 receptors (hV1a IC50 29 nM, hV2 IC50 64 nM) [78]. The subtle SAR of the balance between V1a and V2 receptor antagonism is illustrated by lactams 54 (hV1a IC50 50 nM, hV2 IC50 60 nM) and 55 (hV1a IC50 50 nM, hV2 IC50 W 3 mM) [79].
6.2 Triazolones A new series of triazolones exemplified by 56, 57 and 58 has been reported. These analogues range from selective V1a or V2 receptor antagonists or are mixed V1a-V2 receptor antagonists. For example, although 56 (hV1a IC50 42 nM, hV2 IC50 12 nM) is a balanced dual antagonist, the fluoro analogue 57 (hV1a IC50 960 nM, hV2 IC50 6 nM) is a V2 receptor antagonist with 160-fold selectivity over V1a receptors. Compound 58 (hV1a IC50 40 nM, hV2 IC50 W10 mM) is a selective V1a receptor antagonist [80]. O
R
O
O
O N
N
N
HN
N
N
HN
F F F
N
F F S
F
56 R=OMe 57 R=F
58
Cl
Cl
7. SUMMARY The historical development and the complexity of AVP pharmacology is clearly captured by the title of a recent review ‘‘The vasopressin system – from antidiuresis to psychopathology’’ [2]. V2 receptor antagonists and agonists are being evaluated in the clinic for the modulation of renal function and cardiovascular conditions. V1a receptor antagonists are being actively investigated for indications such as dysmenorrhea, given the unmet medical need and the large patient population. On the contrary, the involvement of the V1a and V1b receptors in depression, anxiety and stress disorders has been clearly demonstrated in preclinical models; however, the discovery of an orally bioavailable, well-tolerated
144
Thomas Ryckmans
and CNS-penetrant antagonist of these receptors is still a formidable challenge. To date, no V1a or V1b receptor antagonists have been approved, but the growing evidence of the key role of AVP in mood disorders is leading to renewed interest in this venue of research. The fascinating role of AVP in higher brain function and behaviour, such as sociality and bonding, has emerged in recent years, suggesting potential new indications for V1a and V1b receptor antagonists.
REFERENCES [1] J. W. Gunnet, P. Wines, M. Xiang, P. Rybczynski, P. Andrade-Gordon, L. de Garavilla, T. J. Parry, W.-M. Cheung, L. Minor, K. T. Demarest, B. E. Maryanoff and B. P. Damiano, Eur. J. Pharmacol., 2008, 590, 333. [2] E. Frank and R. Landgraf, Eur. J. Pharmacol., 2008, 583, 226. [3] A. Surget and C. Belzung, Eur. J. Pharmacol., 2008, 583, 340. [4] F. Ali, M. Guglin, P. Vaitkevicius and J. K. Ghali, Drugs, 2007, 67, 847. [5] G. Decaux, A. Soupart and G. Vassart, Lancet, 2008, 371, 1624. [6] S. R. Goldsmith, Am. J. Med., 2006, 119, S93. [7] F. Thomson and M. Craighead, Neurochem. Res., 2008, 33, 691. [8] J. Roper, A.-M. O’Carroll1, E. J. Grant and S. J. Lolait, Proc. Physiol. Soc., 2007, 5, C3. [9] B. E. Leonard, Drugs Today, 2007, 43, 705. [10] L. Q. Stewart, J. A. Roper, W. Scott Young, A.-M. O’Carroll and S. J. Lolait, Psychoneuroendocrinology, 2008, 33, 405. [11] D. van West, J. Del-Favero, Y. Aulchenko, P. Oswald, D. Souery, T. Forsgren, S. Sluijs, S. Bel-Kacem, R. Adolfsson, J. Mendlewicz, C. Van Duijn, D. Deboutte, C. Van Broeckhoven and S. Claes, Mol. Psychiatry, 2004, 9, 287. [12] C. F. Ferris, T. Stolberg, P. Kulkarni, M. Murugavel, R. Blanchard, D. C. Blanchard, M. Febo, M. Brevard and N. G. Simon, BMC Neurosci., 2008, 9, 111. [13] S. R. Wersinger, H. K. Caldwell, M. Christiansen and W. S. Young, Jr., Genes Brain Behav., 2007, 6, 653. [14] S. R. Wersinger, J. L. Temple, H. K. Caldwell and W. S. Young, Jr., Endocrinology, 2008, 149, 116. [15] A. H. Veenema and I. D. Neumann, Prog. Brain Res., 2008, 170, 261. [16] O. J. Bosch and I. D. Neumann, Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 17139. [17] B. C. Nephew and R. S. Bridges, Pharmacol. Biochem. Behav., 2008, 91, 77. [18] J. T. Winslow, N. Hastings, C. S. Carter, C. R. Harbaugh and T. R. Insel, Nature, 1993, 365, 545. [19] M. M. Lim, Z. Wang, D. E. Olazabal, X. Ren, E. F. Terwilliger and L. J. Young, Nature, 2004, 429, 754. [20] M. M. Lim, E. A. D. Hammock and L. J. Young, J. Neuroendocrinol., 2004, 16, 325. [21] H. Walum, L. Westberg, S. Henningsson, J. M. Neiderhiser, D. Reiss, W. Igl, J. M. Ganiban, E. L. Spotts, N. L. Pedersen, E. Eriksson and P. Lichtenstein, Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 14153. [22] T. Baumgartner, M. Heinrichs, A. Vonlanthen, U. Fischbacher and E. Fehr, Neuron, 2008, 58, 639. [23] M. R. Delgado, Neuron, 2008, 58, 470. [24] A. J. Guastella, P. B. Mitchell and M. R. Dadds, Biol. Psychiatry, 2008, 63, 3. [25] P. Kirsch, C. Esslinger, Q. Chen, D. Mier, S. Lis, S. Siddhanti, H. Gruppe, V. S. Mattay, B. Gallhofer and A. Meyer-Lindenberg, J. Neurosci., 2005, 25, 11489.
Advances in Vasopressin Receptor Agonists and Antagonists
145
[26] H. K. Caldwell, H.-J. Lee, A. H. Macbeth and W. S. Young, Prog. Neurobiol., 2008, 84, 1. [27] E. A. D. Hammock and L. J. Young, Philos. Trans. R. Soc., B, 2006, 361, 2187. [28] N. G. Simon, C. Guillon, K. Fabio, N. D. Heindel, S.-f. Lu, M. Miller, C. F. Ferris, M. J. Brownstein, C. Garripa and G. A. Koppel, Recent Pat. CNS Drug Discov., 2008, 3, 77. [29] R. Morphy, J. Med. Chem., 2006, 49, 2969. [30] P. D. Leeson and B. Springthorpe, Nat. Rev. Drug Discov., 2007, 6, 881. [31] J. D. Hughes, J. Blagg, D. A. Price, S. Bailey, G. A. DeCrescenzo, R. V. Devraj, E. Ellsworth, Y. M. Fobian, M. E. Gibbs, R. W. Gilles, N. Greene, E. Huang, T. Krieger-Burke, J. Loesel, T. Wager, L. Whiteley and Y. Zhang, Bioorg. Med. Chem. Lett., 2008, 18, 4872. [32] V. Bernier, J.-P. Morello, A. Zarruk, N. Debrand, A. Salahpour, M. Lonergan, M.-F. Arthus, A. Laperrier, R. Brouard, M. Bouvier and D. G. Bichet, J. Am. Soc. Nephrol., 2005, 17, 232. [33] M. Manning, S. Stoev, B. Chini, T. Durroux, B. Mouillac and G. Guillon, Prog. Brain Res., 2008, 170, 473. [34] L. Coltamai, M. Bucher, M. P. Maillard, U. Shukla, N. Bohidar, L. Haskell, K. Bertelsen, M. Fedgchin, B. Vogt and M. Burnier, Clin. Pharmacol. Ther., 2009, 85, 145. [35] C. J. Bleickardt, D. E. Mullins, C. P. MacSweeney, B. J. Werner, A. J. Pond, M. F. Guzzi, F. D. C. Martin, G. B. Varty and R. A. Hodgson, Psychopharmacology, 2009, 202, 711. [36] C. F. Ferris, S.-F. Lu, T. Messenger, C. D. Guillon, N. Heindel, M. Miller, G. Koppel, F. R. Bruns and N. G. Simon, Pharmacol. Biochem. Behav., 2006, 83, 169. [37] C. D. Guillon, G. A. Koppel, M. J. Brownstein, M. O. Chaney, C. F. Ferris, S.-F. Lu, K. M. Fabio, M. J. Miller, N. D. Heindel, D. C. Hunden, R. D. G. Cooper, S. W. Kaldor, J. J. Skelton, B. A. Dressman, M. P. Clay, M. I. Steinberg, R. F. Bruns and N. G. Simon, Bioorg. Med. Chem., 2007, 15, 2054. [38] http://www.azevan.com/pipeline/default.asp, 2009. [39] J. S. Bryans, M. E. Bunnage, P. S. Johnson, H. J. Mason, L. R. Roberts, T. Ryckmans, A. Stobie and T. J. Underwood, WO Patent Application 2006114706, 2006. [40] J. S. Bryans, P. S. Johnson, L. R. Roberts and T. Ryckmans, WO Patent Application 2006123242, 2006. [41] C. Bissantz, E. Goetschi, C. Grundschober, R. Masciadri, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2008084005, 2008. [42] C. Bissantz, C. Grundschober, R. Masciadri, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2008068185, 2008. [43] C. Bissantz, C. Grundschober, R. Masciadri, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2008068183, 2008. [44] C. Bissantz, C. Grundschober, R. Masciadri, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2008068184, 2008. [45] C. Bissantz, C. Grundschober, R. Masciadri, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2008068159, 2008. [46] C. Bissantz, C. Grundschober, H. Ratni, M. Rogers-Evans and P. Schnider, US Patent Application 2007155761, 2007. [47] C. Bissantz, C. Grundschober, H. Ratni, M. Rogers-Evans and P. Schnider, WO Patent Application 2007006688, 2007. [48] http://clinicaltrials.gov/ct2/show/NCT00361491, 2006. [49] http://clinicaltrials.gov/ct2/show/NCT00358631, 2006. [50] Sanofi-Aventis, half-year financial report, 2008. [51] C. Louis, C. Cohen, R. Depoortere and G. Griebel, Neuropsychopharmacology, 2006, 31, 2180. [52] C. Griffante, A. Green, O. Curcuruto, C. P. Haslam, B. A. Dickinson and R. Arban, Br. J. Pharmacol., 2005, 146, 744.
146
Thomas Ryckmans
[53] C. Serradeil-Le Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon and M. A. Ventura, Am. J. Physiol., 2007, 293, R938. [54] W. Lubisch, T. Oost, W. Wernet, W. Hornberger, L. Unger and H. Geneste, WO Patent Application 2006100081, 2006. [55] W. Lubisch, T. Oost, W. Wernet, W. Hornberger, L. Unger and H. Geneste, WO Patent Application 2006100080, 2006. [56] T. Oost, W. Lubisch, W. Wernet, W. Hornberger and L. Unger, WO Patent Application 2006100082, 2006. [57] T. Oost, W. Lubisch, W. Wernet, W. Hornberger, L. Unger, H. Geneste and A. Netz, WO Patent Application 2007063123, 2007. [58] H. Geneste, T. Oost, C. W. Hutchins, W. Wernet, L. Unger, W. Hornberger, W. Lubisch and A. Netz, WO Patent Application 2008107399, 2008. [59] T. Kuwata, H. Nozawa and S. Hayashi, JP Patent Application 2008050354, 2008. [60] T. Arndt, T. Oost, W. Lubisch, W. Wernet, W. Hornberger, L. Unger and J. Ruiz Caro, WO Patent Application 2008025736, 2008. [61] G. A. Koppel, WO Patent Application 2006102308, 2006. [62] J. Letourneau, C. Riviello, K.-K. Ho, J.-H. Chan, M. Ohlmeyer, P. Jokiel, I. Neagu, J. R. Morphy and S. E. Napier, WO Patent Application 2006095014, 2006. [63] T. Kuwada, D. Nozawa, T. Ishizaka, M. Yoshinaga and K. Yoshikawa, WO Patent Application 2009017236, 2009. [64] M. Craighead, R. Milne, L. Campbell-Wan, L. Watson, J. Presland, F. J. Thomson, H. M. Marston and C. P. MacSweeney, Prog. Brain Res., 2008, 170, 527. [65] J. Letourneau, P. Jokiel, E. Napier, K.-K. Ho, M. Ohlmeyer, D. R. McArthur, J. Fiona, P. D. Ratcliffe and S. Jurgen, WO Patent Application 2008033764, 2008. [66] I. Neumann, WO Patent Application 2008071779, 2008. [67] K. Honda and Y. Takano, J. Pharmacol. Sci. (Tokyo, Jpn.), 2009, 109, 38. [68] A. L. Del Tredici, K. E. Vanover, A. E. Knapp, S. M. Bertozzi, N. R. Nash, E. S. Burstein, J. Lameh, E. A. Currier, R. E. Davis, M. R. Brann, N. Mohell, R. Olsson and F. Piu, Biochem. Pharmacol., 2008, 76, 1134. [69] A. A. Failli, J. S. Shumsky, R. J. Steffan, T. J. Caggiano, D. K. Williams, E. J. Trybulski, X. Ning, Y. Lock, T. Tanikella, D. Hartmann, P. S. Chan and C. H. Park, Bioorg. Med. Chem. Lett., 2006, 16, 954. [70] I. Tsukamoto, H. Koshio, S. Akamatsu, T. Kuramochi, C. Saitoh, T. Yatsu, H. YanaiInamura, C. Kitada, E. Yamamoto, S. Sakamoto and S.-i. Tsukamoto, Bioorg. Med. Chem., 2008, 16, 9524. [71] M. Kanbara, T. Suzuki, T. Kondo, K. Yokoyama and H. Kobayashi, JP Patent 2007308391, 2007. [72] C. M. Yea, C. E. Allan, D. M. Ashworth, J. Barnett, A. J. Baxter, J. D. Broadbridge, R. J. Franklin, S. L. Hampton, P. Hudson, J. A. Horton, P. D. Jenkins, A. M. Penson, G. R. W. Pitt, P. Riviere, P. A. Robson, D. P. Rooker, G. Semple, A. Sheppard, R. M. Haigh and M. B. Roe, J. Med. Chem., 2008, 51, 8124. [73] J. L. Cavalcante, S. Khan and M. Gheorghiade, Expert Rev. Cardiovasc. Ther., 2008, 6, 1331. [74] L. Foulon, P. Rochard, C. Serradeil Le Gal and G. Valette, FR Patent Application 2909668, 2008. [75] G. A. Koppel and N. D. Heindel, WO Patent Application 2007109615, 2007. [76] M. A. Xiang, R. H. Chen, K. T. Demarest, J. Gunnet, R. Look, W. Hageman, W. V. Murray, D. W. Combs, P. J. Rybczynski and M. Patel, Bioorg. Med. Chem. Lett., 2004, 14, 3143. [77] M. A. Xiang, P. J. Rybczynski, M. Patel, R. H. Chen, D. F. McComsey, H.-C. Zhang, J. W. Gunnet, R. Look, Y. Wang, L. K. Minor, H. M. Zhong, F. J. Villani, K. T. Demarest, B. P. Damiano and B. E. Maryanoff, Bioorg. Med. Chem. Lett., 2007, 17, 6623.
Advances in Vasopressin Receptor Agonists and Antagonists
147
[78] M. A. Xiang, M. Patel, P. Rybczynski, J. Gunnet, K. T. Demarest, R. Look, B. Maryanoff, M. J. Costanzo and S. C. Yabut, WO Patent Application 2008036755, 2008. [79] M. A. Xiang, M. Patel, P. Rybczynski, J. Gunnet, K. T. Demarest, R. Look, B. Maryanoff, M. J. Costanzo and S. C. Yabut, WO Patent Application 2008036759, 2008. [80] H. Meier, E. Bender, U. Brueggemeier, I. Flamme, D. Karthaus, P. Kolkhof, D. Meibom, D. Schneider, V. Voehringer, C. Fuerstner, J. Keldenich, D. Lang, E. Pook and C. Schmeck, WO Patent Application 2007134862, 2007.
CHAPT ER
7 The Emergence of GPR119 Agonists as Anti-Diabetic Agents Robert M. Jones and James N. Leonard
Contents
1. Introduction 2. Discovery and Characteristics of GPR119 3. The Biology of GPR119 3.1 Proposed endogenous regulators of GPR119 3.2 GPR119 regulation of insulin release 3.3 GPR119 regulation of GLP-1 and GIP release 4. GPR119 Agonists: Medicinal Chemistry 4.1 Six-membered heterocyclic ring–based agonists 4.2 Five-membered heterocyclic ring–based agonists 4.3 Bicyclic core–based agonists 4.4 Linear core–based agonists 5. Clinical Trial Status and Future Prospects References
149 150 150 150 152 153 154 154 159 161 164 166 167
1. INTRODUCTION Type 2 diabetes mellitus (T2DM) is emerging as a disease of staggering proportions in the twenty-first century, with an estimated 300 million cases worldwide projected by 2020 [1]. The physiological hallmarks of T2DM are severe insulin resistance, inappropriate hepatic glucose production in the hyperglycemic state, and insufficient insulin production Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, CA 92121, USA Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04407-8
r 2009 Elsevier Inc. All rights reserved.
149
150
Robert M. Jones and James N. Leonard
from pancreatic b cells. Historically, treatment regimens for T2DM have shown significant effectiveness for improving glucose homeostasis; however, after about 2 years of therapy, increasing failure to maintain glycemic control is observed [2]. Recent approaches based on the biology of glucagon-like peptide-1 (GLP-1) have offered new hope for T2DM patients, due to the ability of this gut hormone to (1) elicit insulin release in a glucose-dependent fashion, (2) maintain and perhaps even enhance b-cell mass, and (3) promote satiety and thus weight loss [3]. These features suggest that GLP-1 could promote improved glycemic control acutely and, furthermore, might have a chronic, disease-modifying effect by virtue of prevention or reversal of b-cell failure. GLP-1-based therapies have so far consisted of stabilized peptide agonists of the GLP-1 receptor and small molecule inhibitors of dipeptidyl peptidase-IV (DPP-IV), the enzyme primarily responsible for inactivation of endogenously produced GLP-1 [4]. DPP-IV inhibitors also prevent degradation of glucose-dependent insulinotropic peptide (GIP), the other major gutderived insulinotropic hormone, or ‘‘incretin.’’ Agonists of GPR119 have emerged from pharmaceutical discovery efforts to identify an improved GLP-1 therapeutic by combining the convenience offered by oral dosage of DPP-IV inhibitors and the pharmacological robustness of GLP-1 receptor agonists. Mounting data support this hypothesis and moreover indicate that GPR119 agonists may also spearhead a new class of anti-diabetic therapies through modulation of intestinal endocrine cells that sequester key regulators of energy homeostasis.
2. DISCOVERY AND CHARACTERISTICS OF GPR119 After the discovery of GPR119 in 1999 using data afforded by the Human Genome Project, it was subsequently described in the peer-reviewed literature as a Class A receptor with no close relatives [5]. The receptor possesses distant similarity to biogenic amine and cannabinoid receptors (B40% identity in the transmembrane regions). The complete understanding of GPR119 expression is rather recent due to the complexity of its distribution in rare endocrine cell types. Several laboratories eventually showed that GPR119 is highly expressed in pancreatic islets and in some regions of the gut, particularly, the colon [6–8]. There is some discrepancy regarding the GPR119-expressing cell types within the islet [9], but the most convincing data firmly demonstrate that GPR119 is present in the great majority of pancreatic b cells [7]. Heterologous expression of GPR119 causes substantial increases in 3’,5’-cyclic adenosine monophosphate (cAMP) levels, which are further elevated
151
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
by agonists of the receptor [6,7,10]. Therefore, like the GLP-1 receptor, GPR119 is both b-cell-expressed and Gas-coupled.
3. THE BIOLOGY OF GPR119 3.1 Proposed endogenous regulators of GPR119 Lysophosphatidylcholine (LPC, 1) was the first proposed endogenous ligand for GPR119, based on its ability to stimulate glucose-dependent insulin release and increase cAMP in GPR119-transfected cells [6]. However, subsequent studies showed that the efficacy of 1 is poor, relative to other GPR119 modulators [10–11]. 1 also mediates insulin release in insulinoma cell lines that lack GPR119, shedding further doubt on the likelihood that this lipid is a true endogenous regulator of GPR119 [11].
Me3N HO O
O P H3C
O
HO
O
O O
1
OH
2
NH
NH
O
O
3
In contrast, the satiety factor oleoyl ethanolamide (OEA, 2) is a significantly more efficacious agonist of GPR119 [10]. The in vitro efficacy of 2 is similar to that of synthetic GPR119 agonists [11]. 2 is also capable of eliciting biological responses in GLUTag cells that endogenously express GPR119, but this response is greatly attenuated when receptor levels are reduced by siRNA treatment [12]. Furthermore, levels of 2 in the gut are nutrient-regulated, consistent with the proposed role of GPR119 as a mediator of energy homeostasis [13]. On the contrary, some data cast doubt on the likelihood that 2 is a true endogenous regulator of GPR119. Nutrient regulation of 2 levels is seen primarily in the jejunem, which is not a site of significant GPR119 expression [13]. Additionally, 2 is known to modulate other molecular targets governing energy homeostasis, including the nuclear receptor PPARa [14]. It is therefore challenging to assess the relative contribution of GPR119 activation to the
152
Robert M. Jones and James N. Leonard
known functions of 2. Data from GPR119 knockout (KO) mice shed at least some light on this issue. Weight loss mediated by 2 is not seen in mice lacking PPARa, but remains fully intact in mice lacking GPR119 [14,15]. Moreover, the ability of 2 to trigger insulin release is at least partly GPR119-independent [16]. Therefore, at least some aspects of the function of 2 in vivo are not mediated through GPR119.
OH
HO
O NH
HN OH
O
4
O
5
Regardless of its putative role as an endogenous ligand, the identification of 2 as a GPR119 agonist suggests that fatty acyl amides warrant further exploration as possible ligands for the receptor. Neither endocannabinoids nor shorter chain fatty acyl amides (e.g., capsaicin) are active in this regard. However, the endovallinoids N-oleoyl dopamine (OLDA, 3) and olvanil 4 have emerged as a third class of lipidic signaling molecules proposed to be endogenous modulators of GPR119 [11]. Interestingly, close relatives of these endovallinoids, such as (R)-Noleoyltyrosinol 5, are the most potent fatty acyl amide agonists of GPR119 identified to date [11]. 3 is essentially indistinguishable from 2 in terms of its ability to stimulate cAMP in GPR119-transfected cells. 3 also stimulates insulin release in vitro, elevates the incretin hormone GIP in vivo, and improves glucose tolerance, all in a largely GPR119-dependent manner and to an extent similar to that of synthetic GPR119 agonists [11]. Synthesis of 3 in the gut and pancreas has not been assessed in the literature. However, it is noteworthy that fatty acyldopamines may be produced by direct conjugation of fatty acids and dopamine [17], both of which are highly regulated by nutrient challenge in the gut [18–19].
3.2 GPR119 regulation of insulin release Potent, selective GPR119 agonists have been used to demonstrate that the receptor mediates robust glucose-dependent insulin release in rodent islets, insulinoma cell lines, and in vivo [7]. By using the agonist AR231453
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
153
6, these effects were shown to be completely GPR119-dependent in GPR119-deficient mice and in a mouse model using siRNA to depress GPR119 levels. The hamster insulinoma cell line HIT-T15 expresses GPR119 at levels similar to those seen in pancreatic islets, which likely accounts for its particularly robust response to GPR119 agonists [7]. It is therefore a convenient in vitro model of GPR119 function. When measuring both cAMP and insulin release, the efficacy of 6 is similar to that achieved with forskolin. These data suggest that the insulinotropic effects of GPR119 agonists are highly significant. The GPR119 agonist tools, PSN375963 7, PSN632408 8, and 2, have been assessed in MIN6c4 cells, where a comparatively poor cAMP response was observed [16]. This is most likely due to relatively low levels of GPR119 in MIN6 cells when compared with HIT-T15 cells, although recent reports cast doubt on the GPR119 specificity of 7 and 8 (see Section 4.2).
N
O
N O
N
O NO2
N N
O
N
O N
NH
N
O N
N
F N
N
SO2Me AR231453 6
PSN375963 7
PSN632408 8
In rat and mouse islets, 6 stimulates insulin release at glucose concentrations of 8 mM or higher [7]. Thus, the actions of GPR119 are glucose-dependent, as would be expected from a Gas-coupled b-cell receptor. The agonist effects are robust, achieving efficacy similar to that of GLP-1. They are also GPR119-dependent, since 6 is inactive when incubated with islets from GPR119-deficient mice. These data suggest that oral GPR119 agonists should improve insulin release and glucose tolerance in vivo, and indeed, this has been shown to be the case in normoglycemic and diabetic rodent models [7]. Collectively, these data demonstrate the feasibility of developing orally active GPR119 modulators with a GLP-1-like ability to improve b-cell function.
154
Robert M. Jones and James N. Leonard
3.3 GPR119 regulation of GLP-1 and GIP release Aside from pancreatic islets, sub-regions of the gut are the only other sites of robust GPR119 expression identified to date. Cellular expression studies have extended these observations by showing that most GLP-1producing L cells in the ileum and colon also contain GPR119 [8]. This is consistent with data showing high GPR119 expression in most in vitro L-cell models [8,12]. GIP, the other major insulinotropic hormone of the gut, is produced primarily in the duodenal K cells. Here, the cellular expression of GPR119 is less clear. In one study, detectable levels of GPR119 were not seen in GIP-positive cells [8], but others have reported that primary K-cell cultures contain significant amounts of GPR119 [20]. Nevertheless, it is clear that GPR119 agonists such as 6 increase plasma levels of both GLP-1 and GIP in vivo [8]. In concordance with these data, GPR119 agonists stimulate GLP-1 release from primary colonic crypt cultures [21], fetal rat intestinal cultures [12], and GLUTag cells [8], an immortalized mouse L-cell line. GPR119 therefore enhances incretin release, whereas DPP-IV inhibitors mitigate incretin inactivation. Such joint therapeutic approaches will function synergistically with regard to GLP-1 secretion and glycemic control. In support of this hypothesis, combined administration of 6 and a DPP-IV inhibitor acutely increases plasma GLP-1 levels and improves glucose tolerance to a significantly greater degree than either agent alone [8]. Combination treatment also elevates GLP-1 release in a nutrientindependent fashion and thus may offer a more effective means to maintain elevated GLP-1 levels between meals in diabetic patients.
4. GPR119 AGONISTS: MEDICINAL CHEMISTRY 4.1 Six-membered heterocyclic ring–based agonists Following a cyclase-based high throughput screening (HTS) campaign, pyrimidine 9 was identified as an inverse agonist of hGPR119 (IC50 ¼ 84 nM) [22]. In structure activity relationship (SAR) studies related to 9, the trifluoromethyl pyrazole motif was replaced with a series of aryl ethers leading to the identification of agonists 10 (EC50 ¼ 1 mM) and 11 (EC50 ¼ 1.7 mM). Further extensive parallel SAR work led to the identification of multiple additional agonist trigger moieties, including sulfones, sulfonamides, and various five-membered heterocyclic substituents. The best activity was seen when such a group was attached to the 4-position of the phenyl ring. In addition, with the appropriate trigger in place, agonist activity was maintained with either an ether or aniline linker to the pyrimidinyl core.
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
155
Me
Me O
O
O
O
N
N
N NO2
N N
O
N NO2
N N
N O
O
NO2
N N
NH
N N F F F
X R
9
SO2Me
O
10. X = CO, R = OMe 11. X = CH2, R = Me
12
In further SAR work, the aniline sulfone group was fixed, and conservative ester replacements afforded potent GPR119 agonists. The SAR of the alkyl substituent on the oxadiazole ring was particularly remarkable. Increasing the size of this substituent from methyl to ethyl provided a more than 25-fold improvement in agonist potency. The inclusion of a-branching in this group again gave a significant improvement in potency, as exemplified by 12 (hGPR119 EC50 ¼ 5.8 nM, melanophore dispersion assay). Fluoro substituents on the aryl ring further improved potency, with 6 being the first agonist with subnanomolar potency (EC50 ¼ 0.68 nM) observed. Standard profiling of 6 (CEREP) and exhaustive counter screens against other receptors indicated that 6 is a highly selective GPR119 agonist [22–24]. In addition, 6 had no activity against DPP-IV in a fluorescent-based assay using diprotin. Importantly for a pharmacological tool, 6 had GPR119 agonist activity across species, albeit with somewhat lower potency for rodent GPR119 (cynomolgus monkey GPR119 EC50 ¼ 0.4 nM; mouse GPR119 EC50 ¼ 12 nM; rat GPR119 EC50 ¼ 14 nM; dog GPR119 EC50 ¼ 1.6 nM: melanophore dispersion assay). Notably, across all species, 6 displayed a significantly greater level of efficacy in these assays than the putative endogenous ligand 2. Importantly, 6 stimulated cAMP production through endogenously expressed GPR119 in the b-cell-like hamster insulinoma cell line HIT-T15, with an EC50 of 4.7 nM, a value comparable to the EC50 observed in cell lines over-expressing the cloned rodent receptors [24]. Notably, the EC50 for insulin release from this cell line was 3.5 nM.
156
Robert M. Jones and James N. Leonard
Oxadiazole 6 did not significantly inhibit any of the major cytochrome P450 enzymes and had no activity up to 10 mM at the human Ether-ago-go Related Gene (hERG) channel in a patch clamp assay. Furthermore, excellent exposure was observed after oral administration to C57/bl6J mice (10 mg/kg po: tmax ¼ 0.5 h, Cmax ¼ 9.84 mM). The in vivo effect of 6 with respect to % inhibition of glucose area under the curve (AUC) in an oral glucose tolerance test (oGTT) was similar in C57/bl6J mice and Sprague–Dawley (SD) rats at a dose of 3 mg/kg ip despite a clear species difference in the magnitude of the glucose excursion. This similarity may be expected in light of the similar potency and efficacy of 6 at both mouse and rat GPR119. In addition, 6 improved oral glucose tolerance in wildtype C57/bl6J mice after oral administration. Importantly, 6 also enhanced glucose-dependent insulin release and improved oral glucose tolerance in wild-type C57/bl6J mice but not in GPR119-deficient mice at a dose of 20 mg/kg po, clearly demonstrating the receptor dependence of the observed effects [23,24]. However, a statistically significant effect on glucose excursion in an oGTT following oral administration of 6 was not observed in rats, although a trend toward efficacy was seen at a dose of 30 mg/kg. The lack of a consistent effect was believed to result from the combination of a narrower window for measuring the decrease in glucose excursion in rats as well as the significantly poorer exposure of 6 in rats compared to mice following oral administration (rat, 10 mg/kg, po: tmax ¼ 1 h, Cmax ¼ 0.250 mM, F ¼ 12%). A key aspect of b-cell Gas-coupled receptors is their ability to enhance insulin release in a glucose-dependent fashion, and 6 has been used to show this is characteristic of GPR119. In both rat and mouse islets, 6 had no effect on insulin release at basal (5 mM) glucose concentrations but had GLP-1-like efficacy when the glucose concentration was W8 mM. Also, unlike the sulfonyl urea glyburide, 6 did not stimulate insulin release or cause hypoglycemia during a drug challenge to fasted mice. As noted earlier, 6 (10 mg/kg po) also stimulates both GLP-1 and GIP release during OGTTs in C57BL/6J mice [8,12,21]. No effect was seen on GIP release in GPR119 KO mice. Moreover, co-administration of 6 with a DPP-IV inhibitor leads to synergistic increases in GLP-1 levels, which results in inhibition of the glucose excursion during an OGTT by the 6/DPP-IV inhibitor combination that is greater than that achieved by either agent alone [8]. The potential of GPR119 agonists to exert b-cell protective effects through increased cAMP levels has also been demonstrated. In MIN6 pancreatic b cells expressing GPR119, 6 induced Akt phosphorylation and IRS-2 expression, key measures of islet mass protection [24,25].
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
157
O
O O
O
N
N
O
O N
N
R′
Me N
N
NH
O
Me
Me N
N R
13
14. R′ = Me, R = SO2Me 15. R′ = MeO, R = 1,2,4-triazolo
Several patent applications published during the past 24 months disclosed additional GPR119 agonists bearing six-membered ring heterocyclic core motifs. Picoline 13 was described as a selective agonist of human, dog, cynomolgus monkey, mouse, and rat GPR119 expressed in melanophores with EC50s of 2, 1, 35, 41, and 44 nM respectively [26]. Furthermore, 13 possessed significant aqueous solubility at pH 7, with no appreciable inhibition of five cytochrome P450 enzymes. Picoline 13 also elicited a dose-responsive mean inhibition of glucose excursion of 22, 24, and 70% when orally administered to normoglycemic male SD rats at doses of 0.3, 3, and 30 mg/kg respectively. Related pyrimidines including sulfone 14 and 1,2,4-triazole 15 have also been described [27,28]. Sulfone 14 displayed agonist activity at GPR119 from different species in melanophores (EC50 ¼ 2, 8, 43, and 42 nM; human, dog, cynomolgus monkey, mouse, and rat respectively). Upon dose escalation in rats, 14 afforded linearly increasing plasma exposure (AUC ¼ 4.73, 55.9, and 515.32 mg h/mL at per oral doses of 3, 30, and 300 mg/kg respectively). The ability of 14 to affect glucose homeostasis in male SD rats was assessed using an oGTT. 14 exhibited a 38% mean inhibition of glucose excursion following an oral 10 mg/kg dose. Similarly, triazole 15 showed agonist activity in GPR119-transfected melanophores (EC50 ¼ 2, 4, 57, and 81 nM at human, dog, cynomolgus monkey, mouse, and rat GPR119 respectively). It also exhibited linear plasma exposure upon dose escalation in rats (AUC ¼ 3.59, 79.82, and 285.99 mg.h/mL at 3, 30, and 300 mg/kg po), in addition to displaying oral efficacy in an oGTT.
158
Robert M. Jones and James N. Leonard
O
O
N
N
N O
O
N
O
O N
O
N
O N N
N F
F
SO2Me
SO2Me
SO2Me
16
17
18
A series of 3,6-substituted pyridines exemplified by 16 and 17 have been described as GPR119 agonists in a patent application [29]. The compounds, their salts, and their use for the treatment of a condition mediated through GPR119 such as metabolic disorders, diabetes, and obesity are claimed. Test compounds from this patent application were assayed for their effects on GLP-1 levels in vivo. Treatment of male C57/ B16 mice with 16 (30 mg/kg po) caused an increase in the total GLP-1 level to 7.572.0 pg/mL, compared to 2.371.2 pg/mL for vehicle-treated mice. A related pyridazine series has been independently disclosed exemplified by 18 [30]. Pyridazine 18 was reported to have a hGPR119 EC50 value of 0.046 mM. Assays to determine the effect of the compounds on weight gain and glucose-stimulated insulin release in mice are described, but no specific data are given. Additional GPR119 agonists bearing six-membered ring cores exemplified by pyridine 19 and bispiperidine 20 have recently been disclosed [31,32]. F O O
N
N
N N
O
N
O
N N
MeO2S SO2Me 19
20
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
159
4.2 Five-membered heterocyclic ring–based agonists In a seminal paper that described deorphanization of GPR119, the pharmacological profile of the 1,2,4-oxadiazole carbamate 8, identified by optimization of the HTS hit 7, was also disclosed as a GPR119 agonist [10]. Like the putative endogenous ligand 2, oxadiazole 8 produced a concentration-dependent increase in intracellular cAMP levels in a human embryonic kidney (HEK) cell line expressing GPR119 with an EC50 of 1.9 mM. Oral administration of 8 to rats at a dose of 100 mg/kg po reduced 24 h cumulative food intake. The reduction in food intake was not associated with drug-induced malaise, as no effects were seen on locomotor activity or in conditioned taste aversion and kaolin consumption tests. The acute anorectic effect translated into chronic effects on body weight. In dietinduced obese mice and in growing, high-fat diet-fed SD rats, attenuation of body weight gain produced by 8 (100 mg/kg/day po) was comparable to that of the prescribed anorectic drug sibutramine hydrochloride hydrate (5 mg/kg/day po) [33]. More recently, it was reported that 8 possessed similar potency and efficacy at hGPR119 (EC50 ¼ 5.6 mM, Emax ¼ 110%) relative to the putative endogenous ligand 2 (EC50 ¼ 3.2 mM, Emax ¼ 100%) in a yeast/b-galactosidase fluorescence reporter assay [34]. However, in MIN6c4 cells expressing endogenous GPR119, the synthetic agonists 7 and 8 differ from 2 in their effects on intracellular cAMP and calcium levels and insulin secretion [16]. While the endogenous GPR119 ligand 2 signals through GPR119 in a manner similar to GLP-1 and its receptor to elicit increased insulin secretion and increased intracellular Ca2+ and cAMP levels, oxadiazoles 7 and 8 produced divergent effects on these parameters. These studies suggest that 7 and 8, although they do weakly activate GPR119, may also modulate GPR119-independent pathways and thus may be unsuitable as GPR119-specific pharmacological tools [16]. These observations are somewhat corroborated by a recent report in which 8 was shown to possess an EC50 W20 mM in a CHO6CRE luciferase reporter assay [35].
O
O
O
O
O
R
O N
N
SO2Me 21
F
O O N
N
SO2Me 22 (PSN119-2)
O N
N
N
N
O N
N
O
F
N
SO2Me 23
160
Robert M. Jones and James N. Leonard
Exchange of the 4-pyridyl motif present in 7 and 8 with a 3-fluoro-4(methanesulfonyl)phenyl moiety led to agonist 21 (R ¼ F) possessing EC50 and Emax values of 0.9 mM and 375% respectively in a yeast reporter assay expressing recombinant human GPR119. Focused SAR modifications of the aromatic moiety in which the R-substituent was either replaced by other substituents (21, R ¼ –H, –Cl, –Me, –OMe) or moved to the adjacent 2-position led to reduced potency or to inactivity. Subsequently, installation of an (R)-methyl group to the methyleneoxy linker of 21 afforded PSN119-2 22 (EC50 ¼ 0.4 mM, Emax ¼ 358%). The antipode of 22 was substantially less active (10-fold) and less efficacious (twofold), as were the enantiomeric ethyl homologues. 22 was shown to stimulate insulin secretion from the hamster-derived insulinoma HITT15 cell line (EC50 ¼ 18 nM) and GLP-1 release from the immortalized entero-endocrine murine GLUTag cell line (EC50 ¼ 8 nM). In male SD rats, 22 orally administered at doses of 10 and 30 mg/kg achieved a Cmax of B2 and B5.1 mM, respectively, and significantly attenuated the glucose excursion in an oGTT. At the same doses, 22 significantly reduced cumulative 24 h food intake levels in SD rats compared to vehicle-treated control rats, but these effects were not as robust as those observed for sibutramine (5 mg/kg, po). Analogs of 22, resulting from replacement of the terminal tert-butyl carbamate with an N-linked 5-isopropyl-1,2,4-oxadiazole, 23, are the subject of a recent patent application [36]. Bioisosteric replacement of a carbamate by an oxadiazole is a successful GPR119 agonist SAR theme previously disclosed in earlier patent applications [37–41]. Additional five-membered ring core agonists have been independently reported in several recent patent applications [42–44]. In one disclosure, compounds were evaluated in cAMP stimulation assays, and thiazole 24 (10 mM) demonstrated a 69% change in Forster resonance energy transfer (FRET) signals relative to control [43]. Derivative 24 was also shown to stimulate insulin secretion by 1.66-fold in a SD rat–derived islet perfusion assay following a 16 mM glucose treatment [43]. Thiazole 24 (30 mg/kg, po) also facilitated a 52% reduction in glucose AUC in 8- to 10-week-old C57/6J fasted mice following a 2 g/kg oral glucose bolus challenge. In a more recent disclosure, a closely related series of triazolyl piperidine–based GPR119 agonists was described [43]. In vitro GPR119 agonism was again determined by measurement of the decrease in FRET signaling in response to changes in intracellular cAMP levels. Many of these compounds were reported to cause a significant reduction in FRET signaling relative to positive control (e.g., 25, 87.61% reduction). Additionally, triazole 25 (30 mg/kg po) was shown to reduce mean glucose excursion in male C57/6J mice by 40.8%.
161
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
F3C N
O O
N
N
S N
O
O
N
N
F N N N
O
N O N
O F
N F
N N 24
N
N N N
SO2Me
25
26
The characterization of the potent, selective, and orally bioavailable GPR119 agonist, MBX-3152 (structure not disclosed), has been reported [45]. In CHO cells stably expressing hGPR119, MBX-3152 afforded an EC50 value of 1.8 nM, and in immortalized murine GLUTag cells, it increased GLP-1 secretion 1.5-fold at concentrations of 200 nM and above with an EC50 value of 82 nM. When administered chronically to high fat– fed female Zucker diabetic fatty (ZDF) rats, MBX-3152 (30 mg/kg, po, 35 days) was shown to concomitantly delay disease onset and reduce food intake, body weight gain, and plasma triglycerides, thereby mitigating the profound increase in insulin resistance that develops in this animal model. In wild-type mice, but not in GPR119 KO mice, the compound [30 mg/kg, po] also improved glucose tolerance and increased incretin release in the presence of the DPP-IV inhibitor sitagliptin (1 mg/kg, po]. In rats, MBX-3152 (30 mg/kg, po) increased insulin secretion and glucose infusion rate under hyperglycemic clamp conditions implying a direct action of the agonist at pancreatic b cells. Pyrrolidinyl 1,3,4-oxadiazole 26 is representative of another chemical series of GPR119 modulators [44]. These analogs are similarly potent at stimulating cAMP in Flp-In-CHO-hGPR119 cells and are claimed to be useful for the treatment or prevention of disorders associated with GPR119.
4.3 Bicyclic core–based agonists The structure of GSK252A 27a has recently been disclosed [21]. This GPR119 agonist possesses a novel pyrrolopyrimidine-based bicyclic core and bears a striking resemblance to GPR119 agonists in which a pyrazolo
162
Robert M. Jones and James N. Leonard
[3,4-d]pyrimidine was utilized as the core scaffold, exemplified by 28, disclosed in an earlier application by an independent group [41]. Compound 27a was reported to have good pharmacokinetic properties in SD rats. At a dose of 30 mg/kg po, 27a achieved a Cmax ¼ 14 mM, a half life of 3.1 h, and absolute oral bioavailability of 60%. In a CHO6CRE reporter assay, 27a afforded an EC50 ¼ 40 nM compared to an EC50 ¼ 200 nM for 28 [21,41]. R N O
O O
O
O
N
N
N
N O O
O
N
N
N N N
N
N
N
N
N
F
F
SO2Me 27a. R = H = GSK252A 27b. R = Me
F MeO2S 28
NC 29
The effects of 27a on incretin, Peptide YY (PYY), glucagon, and insulin secretion both in vitro and in vivo were disclosed. The compound stimulated GLP-1 release from both GLUTag (EC50 ¼ 22 nM) and primary mouse colonic crypt cell cultures in vitro. In addition, 27a augmented glucose-stimulated insulin secretion from rat islet cells in the presence of 12 mM glucose but did not affect insulin output in the presence of 3 mM glucose, consistent with similar glucose-dependent effects of 6. Oral administration of 27a (10 mg/kg, po) to mice fasted overnight resulted in a fourfold increase in GLP-1 levels and a twofold increase in GIP levels when compared to vehicle control, with no increase seen in GPR119 KO mice. In addition, there was also a threefold increase in PYY levels and a twofold increase in glucagon levels in wild-type, but not in GPR119 KO mice. Augmentation of insulin secretion by 27a (10 mg/kg, po) was assessed in rats using the hyperglycemic clamp model. In the hyperglycemic state targeting a glucose concentration of 200 mg/dL, both glucose infusion rate and C-peptide levels were significantly increased indicating a robust enhancement of insulin release. Consistent with these data, 27a decreased the glucose AUC by 43% and increased the peak insulin levels by 1.4-fold during the intravenous glucose tolerance test (IVGTT) and improved glucose tolerance during the oGTT by 38% with no significant effect on the
163
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
insulin response. This effect was not significantly different from that of the DPP-IV inhibitor LAF237. A hyperglycemic euglycemic clamp was also used to show that GPR119 activation may also impact glucose utilization independent of insulin secretion. The glucose infusion rate needed to maintain euglycemia was approximately threefold higher in rats treated with 27a compared to vehicle-treated rats, suggesting that 27a promoted significantly enhanced glucose utilization [21]. Tert butyl carbamate 27b and related bicyclic pyrrolo[2,3-d]pyrimidines, including 1,2,4-oxadiazole 29 together with indoline core congeners, are claimed in two recent patent applications [46,47]. To test the effect of 27b on insulin sensitization in male SD rats, a hyperinsulinemic euglycemic clamp was initiated 90 min after oral administration of 27b (10 mg/kg po) or vehicle. As observed for 27a, the glucose infusion rate required to maintain euglycemia in rats given 27b was three times that of vehicle-treated rats. Br O
O O O
O N
N
O N N O
N N
N N N
N N O
N
N
NH
NH
F
Cl MeO2S 30
31
MeO2S 32
More recent patent filings describe selective GPR119 modulators comprised of a fused pyrimidinone core 30, specifically, 6-substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-ones and 7-substituted 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-ones [48,49]. Both series of GPR119 modulators are described as being useful for treating or preventing obesity, diabetes, metabolic disease, cardiovascular disease, or a disorder related to the activity of GPR119 in a patient. Undisclosed compounds from these applications are purported to activate GPR119 and stimulate cAMP production in transfected HEK293 cells, exhibiting EC50 values ranging from about 50 nM to 14,000 nM. A mouse oGTT protocol is described for assessing the activity of these compounds in vivo, and various undisclosed fused pyrimidinone examples were reported to be effective in lowering blood glucose levels after glucose challenge.
164
Robert M. Jones and James N. Leonard
Furthermore, illustrative examples were found to produce a sustained decrease in blood glucose in a non-genetic mouse model of T2DM. Building on the existing knowledge base of the SAR of bicyclic-based GPR119 agonists, two series of azabicyclic agonists have been described, exemplified by 31 and 32 [50,51]. An in vitro luciferase assay using HEK 293 cells expressing hGPR119 was conducted to assess the efficacy of the compounds. Bicyclic triazole 31 exhibited a hGPR119 EC50 value of 19.49 nM, and the pyrimidine fused oxazine 32 exhibited an EC50 value of 2.78 nM.
4.4 Linear core–based agonists Removal of the oxadiazolo core unit of 8 has been the focus of recent SAR optimization work [52]. The linear ether derivative 33a was equipotent with 8 but was a partial agonist in a yeast reporter assay expressing recombinant human or mouse GPR119. Repositioning the ether linkage as in pyridyl ether, 33b produced a marginal improvement in potency (EC50 ¼ 0.5 mM) without increasing in vitro efficacy. Exchange of the pyridine ring with a 3-fluoro-4-(methanesulfonyl)phenyl moiety produced PSN119-1M 35, which afforded a dramatic increase in efficacy (EC50 ¼ 0.2 mM, Emax ¼ 392%), implicating the hydrogen bond acceptor feature as a critical driver of potency and efficacy at human GPR119.
O
O
O
O
O
N
N
O N
Y O
X
N
F
F SOMe
33a. Y = O, X = CH2 33b. Y = CH2, X = O
O
34
SO2Me 35
Extensive pharmacological characterization of racemic sulfoxide PSN119-1 34 (EC50 ¼ 0.5 mM; Emax ¼ 407% yeast reporter assay) has been reported [52–54]. Unlike the glucose-independent insulin secretagogue repaglinide (1 mg/kg, po), 34 (30 mg/kg, po) did not cause hypoglycemia when evaluated in an oGTT in high fat diet–fed (10 days) SD rats. The anti-hyperglycemic effects of 34 were confirmed in 13-week-old diabetic ZDF rats, where its effect on glucose tolerance was similar to that
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
165
of the DPP-IV inhibitor P32/98. In contrast, its glucose-lowering effect was drastically reduced during an IVGTT, pointing to a significant contribution from gastrointestinal tract (GI)-derived incretins. Like the prescribed anorectic agent sibutramine (5 mg/kg, po), 34 (50 mg/kg, po) facilitated a statistically significant reduction in cumulative food intake at both the 6 and 24 h time points post dose. Following oral administration to SD rats, sulfoxide 34 was reported to be extensively metabolized to sulfone 35 [52]. Further pharmacological characterization demonstrated that sulfoxide 34 elicited a dose-responsive effect on GLP-1 secretion in murine GLUTag cells (EC50 ¼ 153770 nM). This was confirmed in a meal tolerance test using P32/98 (50 mg/kg, po) in combination with 34 (100 mg/kg) in rats. In addition, 34 (30 mg/kg, po) inhibited gastric emptying in rats in a manner similar to the antiobesic agent HMR1426 (50 mg/kg, po). Subchronic daily dosing of 34 to high fat diet–fed rats for 21 days (100 mg/kg/qd po) significantly lowered plasma glucose and insulin levels during an oGTT test performed on day 21 and also decreased fat pad mass and plasma leptin levels [53,54]. In addition, subchronic once daily oral administration (100 mg/kg/day) slowed the progression of diabetes in a study in young db/db mice, as highlighted by the ability of 34 to maintain normal fed blood glucose levels and glucose tolerance following an oGTT on day 21 of the experiment. Further optimization of 34 afforded development candidate PSN821 [54,55]. Although the structure of PSN821 has not been disclosed, it may be encompassed by generic structure 36, which captures the essential features of a series of GPR119 agonists disclosed in five recent patent applications [56–60]. Little biological and pharmacological characterization of these analogs is provided. However, the methods associated with the biological assays used to characterize the examples are given; a yeast-based reporter assay expressing human and mouse GPR119, a cAMP AlphascreenTM, an in vivo feeding study, HIT-T15 cAMP and insulin secretion assays, and an oGTT performed in either SD rat, male C57Bl/6, or male ob/ob mice.
N
N O
N
Me O E R1
Q R2
36
36a. E = CH, Q = CH, R2 = F, R1 = SO2CH3 36b. E = CH, Q = CH, R2 = F, Me, R1 = CONHR 36c. E = CH, Q = CH, R2 = F, R1 = CH2SO2CH3 36d. E = CH, Q = N, R2 = Me, R1 = CONHR 36e. E = N, Q = CH, R2 = Me, R1 = NHCMeCH2OH
166
Robert M. Jones and James N. Leonard
Other linear core–based agonists include a recently disclosed series of [[1,2,3,4-tetrahydro-2-(methylsulfonyl)-6-isoquinolinyl]oxy]propyl derivatives exemplified by 37 [61]. The compounds of this genus were characterized using Flp-In-CHO-hGPR119 cells wherein compound 37 showed a concentration-dependent increase in cAMP levels with an EC50 o100 nM. In addition, it was reported that the simple linear thioester 38 attenuated fed blood glucose levels in diabetic db/db mice [62]. Separately, it was reported that 38, which raised intracellular cAMP levels with an EC50 of 3.2 mM in 293-EBNA cells, stimulated insulin secretion and improved glucose tolerance in an oGTT when administered at the dose of 100 mg/kg ip to SD rats [63]. GPR119 agonist 38 also demonstrated antihyperglycemic effects in diabetic Goto–Kakizaki rats following oral administration at a dose of 100 mg/kg. O N
O
O
N SO2Me 37
S
O
N 38
5. CLINICAL TRIAL STATUS AND FUTURE PROSPECTS To date, four GPR119 agonists have been reported to be in the early stages of clinical development. The structures of these compounds have not been revealed. The first compound advanced to the clinic, APD-668, was co-developed by Arena Pharmaceuticals and Ortho McNeil [64–67]. Following two initial phase I trials, it was reported in January 2008 that APD-668 may improve glucose control in diabetic patients [68]. Subsequently, further development of APD-668 was halted and APD597 was advanced into a phase I trial in December 2008 [69]. Metabolex initiated a phase I trial with MBX-2982 in March 2008 [70], and in November 2008, phase 1a data were presented [71]. The placebocontrolled trial evaluated 10–1,000 mg of MBX-2982 in healthy volunteers. The drug was rapidly absorbed, had good exposure, and
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
167
demonstrated a half-life consistent with once-daily dosing. MBX-2982 also caused dose-dependent reductions in glucose and increases in GLP1 in these individuals following a mixed meal. All doses were well tolerated with no drug-related adverse events reported; at that time, a multiple-dose, pharmacokinetics, and pharmacodynamics phase Ib trial was under way [72]. In September 2008, OSI Pharmaceuticals began a phase I trial of PSN-821 [55]. To date, no results have been reported for this compound. It is clear from these reports that there are presently insufficient data to confirm the promise of GPR119 agonists suggested by pre-clinical studies. Nevertheless, the early reports are encouraging. Based on the robust activity around this target in the patent literature, GPR119 agonists are very likely to undergo vigorous clinical testing over the next few years, and the therapeutic value of this approach should clarify significantly. Clearly, the paramount consideration will be to determine the robustness of this mechanism with regard to the lowering of fasting plasma glucose and HbA1c in diabetic patients. The effects of GPR119 agonists on incretin and insulin levels will also be extremely valuable information to clinicians, who ultimately need to determine where GPR119 agonists belong in the treatment paradigm for T2DM.
REFERENCES [1] [2] [3] [4] [5] [6]
[7]
[8]
[9] [10]
[11]
J. C. Seidell, Br. J. Nutr., 2000, 83(Suppl. 1), S5. UK Prospective Diabetes Study Group., Lancet, 1998, 352, 854. D. J. Drucker, Cell Metab, 2006, 3, 153. D. J. Drucker and M. A. Nauck, Lancet, 2006, 368, 1696. R. Fredriksson, P. J. Ho¨glund, D. E. I. Gloriam, M. C. Lagerstrom and H. B. Schio¨th, FEBS Lett, 2003, 554, 381. T. Soga, T. Ohishi, T. Matsui, T. Saito, M. Matsumoto, J. Takasaki, S. Matsumoto, M. Kamohara, H. Hiyama, S. Yoshida, K. Momose, Y. Ueda, H. Matsushime, M. Kobori and K. Furuichi, Biochem. Biophys. Res. Commun., 2005, 326, 744. Z.-L. Chu, R. M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, D. Unett, Y. Liang, K. Demarest, G. Semple, D. P. Behan and J. Leonard, Endocrinology, 2007, 148, 2601. Z.-L. Chu, C. Carroll, J. Alfonso, V. Gutierrez, H. He, A. Lucman, M. Pedraza, H. Mondala, H. Gao, D. Bagnol, R. Chen, R. M. Jones, D. P. Behan and J. Leonard, Endocrinology, 2008, 149, 2038. Y. Sakamoto, H. Inoue, S. Kawakami, K. Miyawaki, T. Miyamoto, K. Mizuta and M. Itakura, Biochem. Biophys. Res. Commun., 2006, 351, 474. H. A. Overton, A. J. Babbs, S. M. Doel, M. C. T. Fyfe, L. S. Gardner, G. Griffin, H. C. Jackson, M. J. Proctor, C. M. Rasamison, M. Tang-Christensen, P. S. Widdowson, G. M. Williams and C. Reynet, Cell Metab, 2006, 3, 167. Z. Chu, R. Jones, R. Chen, C. Carroll, V. Gutierrez, A. Lucman, D. P. Behan and J. Leonard, Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology, 2007, Abstract 230.
168
Robert M. Jones and James N. Leonard
[12] L. Lauffer, R. Iakoubov and P. L. Brubaker, Diabetes, 2009 Feb 17. [Epub ahead of print] PMID: 19208912. [13] J. Fu, G. Astarita, S. Gaetani, J. Kim, B. F. Cravatt, K. Mackie and D. Piomelli, J. Biol. Chem., 2007, 282, 1518. [14] J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrani, F. Rodriguez de Fonseca, A. Rosengarth, H. Luecke, B. Di Giacomo, G. Tarzia and D. Piomelli, Nature, 2003, 425, 90. [15] H. Lan, G. Vassileva, A. Corona, L. Liu, H. Baker, A. Golovko et al., Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology, 2007, Abstract 253. [16] Y. Ning, K. O’Neill, H. Lan, L. Pang, L. X. Shan, B. E. Hawes and J. A. Hedrick, Br. J. Pharmacol., 2008, 155, 1056. [17] S. M. Huang, T. Bisogno, M. Trevisani, A. Al-Hayani, L. De Petrocellis, F. Fezza, M. Tognetto, T. J. Petros, J. F. Krey, C. J. Chu, J. D. Miller, S. N. Davies, P. Geppetti, J. M. Walker and V. Di Marzo, Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 8400. [18] G. Eisenhofer, A. Aneman, P. Friberg, D. Hooper, L. Fa˚ndriks, H. Lonroth, B. Hunyady and E. Mezey, J. Clin. Endocrinol. Metab., 1997, 82, 3864. [19] E. Eldrup and E. A. Richter, Am. J. Physiol. Endocrinol. Metab., 2000, 279, E815. [20] H. E. Parker, A. M. Habib, G. J. Rogers, F. M. Gribble and F. Reimann, Diabetologia, 2009, 52, 289. [21] C. Ammala, S. Bullard, J. Kashatus, S. Katamreddy, J. Way and A. Carpenter, Keystone Symposium, Islet and b-Cell Biology, 2008, Abstract #102. [22] G. Semple, B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D. J. Unett, C. Xing, S. Bossie, C. Carroll, Z. L. Chu, A. J. Grottick, E. K. Hauser, J. N. Leonard and R. M. Jones, J. Med. Chem., 2008, 51(17), 5172. [23] G. Semple, Abstracts of Papers, 41st Western Regional Meeting of the American Chemical Society, San Diego, CA, United States, October 9–13 2007, GEN-033. [24] R. M. Jones, Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10–14, 2006, MEDI-275. [25] Z. Chu, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao et al., Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology, Keystone, Colorado, USA, 14–19 January 2007, Abstract 117. [26] R. M. Jones and J. Lehmann, WO Patent Application 2007035355 A2, 2007. [27] R. M. Jones and J. Lehmann, WO Patent Application 2008005576 A1, 2008. [28] R. M. Jones, J. Lehmann and A. Siu-Ting Wong, WO Patent Application 2008005569 A2, 2008. [29] J. Fang, J. Tang, A. J. Carpenter, G. Peckham, C. R. Conlee, S. K. Du and S. R. Katamreddy, WO Patent Application 2008070692, 2008. [30] P. Brandt, G. Johansson, L. Johansson, T. Koolmeister, B. M. Nilsson and T. Sandvall, WO Patent Application 2008025799, 2008. [31] D. A. Wacker, K. A. Rossi and Y. Wang, WO Patent Application 2009012277 A1, 2009. [32] H. B. Wood, A. D. Adams, S. Freeman, J. W. Szewczyk, C. Santini and Y. Huang, WO Patent Application 2008085316 A1, 2008. [33] M. C. T. Fyfe, H. Overton, J. White, R. Jones, R. V. Sorensen and C. Reynet, Diabetes, 2006, 55(Suppl. 1), 346-3OR. [34] M. C. T. Fyfe, A. J. Babbs, L. S. Bertram, S. E. Bradley, S. M. Doel, S. Gadher, W. T. Gattrell, R. P. Jeevaratnam, J. F. Keily, J. G. McCormack, H. A. Overton, C. M. Rasamison, C. Reynet, C. P. Sambrook Smith, V. K. Shah, D. F. Stonehouse, S. A. Swain, J. R. White, P. S. Widdowson, G. M. Williams and M. J. Procter, Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, August 17–21, MEDI-197, 2008.
The Emergence of GPR119 Agonists as Anti-Diabetic Agents
169
[35] A. Carpenter, C. Ammala, C. Briscoe, S. Bullard, J. Kashatus, S. Katamreddy, R. Mertz and S. Ross, Symposium, Islet and b-cell biology, 2008, Abstract #102. [36] L. S. Bertram, M. C. T. Fyfe, M. J. Procter and G. M. Williams, WO Patent Application 2007116229 A1, 2007. [37] R. M. Jones, G. Semple, Y. Xiong, Y-J Shin, A. S. Ren, I. Calderon, K. Choi, B. Fioravanti, J. Lehmann and M. A. Bruce, WO Patent Application 2005007647A1, 2005. [38] R. M. Jones, G. Semple, Y. Xiong, Y-J Shin, A. S. Ren, I. Calderon and K. Choi, WO Patent Application 2005121121A2, 2005. [39] R. M. Jones, J. Lehmann, A. Wong, D. Hirst and Y-J Shin, US Patent Application 2006155128 A1, 2006. [40] R. M. Jones, J. Lehmann, A. Wong, D. Hirst and Y-J Shin, US Patent Application 2007167473 A1, 2007. [41] R. M. Jones, G. Semple, Y. Xiong, Y-J Shin, A. S. Ren, I. Calderon, K. Choi, B. Fioravanti and C. R. Sage, WO Patent Application 2005007658 A2, 2005. [42] X. Chen, P. Cheng, E.L. Clemens, J.D. Johnson, J. Ma, A. Murphy, I. Nashashibi, C.J. Rabbat, J. Song, M.E. Wilson, Y. Zhu and Z. Zhao, WO Patent Application 2008083238 A2, 2008. [43] J. Ma, C. J. Rabbat, J. Song, X. Chen, I. Nashashibi, Z. Zhao, A. Novack, D.-F. Shi, P. Cheng, Y. Zhu and A. Murphy, WO Patent Application 2009014910 A2, 2009. [44] P. B. Alper, G. Lelais, R. Epple and D. Mutnick, WO Patent Application 2008109702 A1, 2008. [45] M. Wilson, F. Gregoire, B. Pandey, A. Chandalia, P. Zhang, O. Abdel-aleem, K. Marlen, E. Clemens, J. Johnson, X. Chen, J. Ma, I. Nashashibi, C. Rabbat, J. Song, A. Novack, D-F. Shi, S. Zhao and B. Lavan, Keystone Symposium, Type II Diabetes and Insulin Resistance, Banff, Canada, Abstract #369, January 2009. [46] S. R. Katamreddy, R. D. Caldwell, D. Heyer, V. Samano, J. B. Thompson, A. J. Carpenter, C. R. Conlee, E. E. Boros and B. D. Thompson, WO Patent Application 2008008887 A2, 2008. [47] C. Ammala and C. Briscoe, WO Patent Application 2008008895 A1, 2008. [48] C. D. Boyle and B. R. Neustadt, WO Patent Application 2008130615 A1, 2008. [49] C. D. Boyle, S. Chackalamannil, C. M. Lankin, U. Shah, B. R. Neustadt, H. Liu and A. W. Stamford, WO Patent Application 2008130584 A1, 2008. [50] J. M. Fevig and D. A. Wacker, WO Patent Application 2008137436 A1, 2008. [51] J. M. Fevig and D. A. Wacker, WO Patent Application 2008137435 A1, 2008. [52] M. C. T. Fyfe, A. Babbs, L. S. Bertram, S. E. Bradley, S. M. Doel, S. Gadher, W. T. Gattrel, J. G. Horswill, R. P. Jeevaratnam, J. F. Keily, J. G. McCormack, H. A. Overton, C. M. Rasamison, C. Reynet, P. J. Rushworth, C. P. Sambrook Smith, V. K. Shah, D. F. Stonehouse, S. A. Swain, J. R. White, P. S. Widdowson, G. M. Williams and M. J. Proctor, Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19–23, 2007, MEDI-062. [53] M. C. T. Fyfe, J. White, P. Widdowson, H. Overton and C. Reynet, Diabetes, 2007, 56(Suppl. 1), 532-P. [54] M. C. T. Fyfe, J. White, P. Widdowson, H. Overton and C. Reynet, 67th Sessions ADA Meeting, Chicago, Illinois, USA, 2007. [55] OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821, Company Press Release, September 3, 2008. [56] M. C. T. Fyfe, J. Keily and S. A. Swain, WO Patent Application 2008081204 A1, 2008. [57] L. S. Bertram, M. C. T. Fyfe, R. P. Jeevaratnam, J. Keily and S. A. Swain, WO Patent Application 2008081205 A1, 2008. [58] M. C. T. Fyfe, J. Keily, M. Proctor, D. F. Stonehouse and S. A. Swain, WO Patent Application 2008081206 A1, 2008.
170
Robert M. Jones and James N. Leonard
[59] M. C. T. Fyfe, R. P. Jeevaratnam, J. Keily and S. A. Swain, WO Patent Application 2008081207 A1, 2008. [60] M. C. T. Fyfe, R. P. Jeevaratnam, J. Keily and S. A. Swain, WO Patent Application 2008081208 A1, 2008. [61] P. Alper, M. Azimioara, C. Cow, R. Epple, S. Jiang, G. Leleais, P. Michellys, T. N. Nguyen, L. Westcott-Baker and B. Wu, WO Patent Application 2008097428 A2, 2008. [62] T. Ohishi, J. Takasaki, M. Matsumoto, T. Saito, M. Kamohara, T. Soga, S. Yoshida and Y. Ueda, WO Patent Application 2002044362 A1, 2002. [63] T. Ohishi, J. Takasaki, M. Matsumoto, T. Saito, M. Kamohara, T. Soga, S. Yoshida and Y. Ueda, EP Patent Application 1338651 A1. [64] Arena Pharmaceuticals Announces Global Diabetes Collaboration with Ortho-McNeil Pharmaceutical, December 21, 2004, http://invest.arenapharm.com/releasedetail.cfm? ReleaseID ¼ 320780 [65] Arena Pharmaceuticals Announces Selection of Two Arena-Discovered Compounds for Preclinical Development by Ortho-McNeil, December 23, 2004, http://invest. arenapharm.com/releasedetail.cfm?ReleaseID ¼ 320778 [66] Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil, February 7, 2006, http://invest.arenapharm.com/releasedetail.cfm?ReleaseID ¼ 320321 [67] Arena Pharmaceuticals Announces That Ortho-McNeil Extends Research Term Under Partnership to Develop Drugs to Treat Type 2 Diabetes, September 27, 2006, http:// invest.arenapharm.com/releasedetail.cfm?ReleaseID ¼ 320291. [68] Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes, January 7, 2008, http://invest.arenapharm.com/releasedetail. cfm?ReleaseID ¼ 320208 [69] Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals, December 15, 2008, http://invest.arenapharm.com/releasedetail.cfm?ReleaseID ¼ 354391 [70] Metabolex initiates Phase 1 Trial of MBX-2982, March 26, 2008, http://www.metabolex. com/news/mar262008.html [71] S. Zhao, F. Gregoire, E. Clemens, D. Karpf, X. Chen, B. Lavan, J. Johnson and M. Wilson, The World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). October 30–November 2, 2008, Barcelona, Spain. [72] Metabolex Announces Positive Results from Phase 1a Clinical Trial of MBX-2982, November 12, 2008, http://www.metabolex.com/news/nov122008.html
CHAPT ER
8 Non-Peptide Ligands for the Gonadotropin Receptors Nicole van Straten and Marco Timmers
Contents
1. Introduction 2. Non-Peptide Small Molecule Gonadotropin Receptor Ligands 2.1 LHR agonists 2.2 LHR antagonists 2.3 FSHR agonists 2.4 FSHR antagonists 3. Therapeutic Indications and Clinical Findings 3.1 Infertility 3.2 Contraception and disorders of the reproductive tract 4. Conclusions and Future Prospects References
171 173 173 175 175 179 182 182 183 184 185
1. INTRODUCTION The gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) play fundamental roles in the complex process of human reproduction. LH and FSH belong to a family of glycoprotein hormones, also including choriogonadotropin (CG) and thyroid-stimulating hormone (TSH). These glycoproteins are large, non-covalently linked heterodimers consisting of a common a-subunit and a hormone-specific Schering-Plough Research Institute, Department of Medicinal Chemistry, PO Box 20, 5340BH Oss, The Netherlands Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04408-X
r 2009 Elsevier Inc. All rights reserved.
171
172
Nicole van Straten and Marco Timmers
b-subunit. The a-subunit contains 92 amino acids, whereas the b-subunit incorporates 121 (LH) and 111 (FSH) amino acids [1]. LH induces ovulation in females and controls testosterone production in males. FSH is responsible for ovarian follicle growth in females and is involved in spermatogenesis in males. LH and FSH are secreted from the anterior pituitary gland and transported to the gonads to activate the G-proteincoupled LH receptor (LHR) and FSH receptor (FSHR) respectively. LHRs are present on theca cells (women) and Leydig cells (men), whereas FSHRs can be found on granulosa cells (women) and Sertoli cells (men). Binding of LH stimulates the theca and Leydig cells to produce testosterone. Subsequently, testosterone is converted into estradiol in the female granulosa cell by the cytochrome P450 enzyme aromatase, which is generated after activation of the FSHR. CG is produced during pregnancy and is involved in maintaining early pregnancy. Interestingly, CG and LH both bind and activate the LHR with similar potency. H2N
LH
Testosterone
HOOC LH receptor GnRH (Theca cells) H2N
FSH
Aromatase
Estradiol
Follicle growth and ovulation
HOOC FSH receptor (granulosa cells)
FSH and CG are applied clinically for the treatment of infertility during assisted reproductive therapy (ART). In in vitro fertilization (IVF) protocols, multiple oocytes are generated by controlled ovarian stimulation (COS) with FSH. After downregulation of the hypothalamicpituitary-gonadal axis with a gonadotropin-releasing hormone (GnRH) receptor agonist or antagonist, FSH is used during the first half of the cycle to induce follicle growth. CG is then administered to induce the final oocyte maturation, after which the oocytes can be retrieved for fertilization. In ovulation induction protocols, FSH is used to induce
Non-Peptide Ligands for the Gonadotropin Receptors
173
monofollicular growth and CG is applied to effect oocyte maturation and ovulation. The currently marketed hormones are obtained either from urinary sources or produced using recombinant biotechnology and are administered parenterally through multiple injections. The development of orally administered non-peptide LH and FSH mimics would be a more convenient approach to infertility treatment and may improve patient compliance. Moreover, synthetically prepared low-molecular-weight (LMW) gonadotropin mimics should exhibit improved stability, consistency and homogeneity compared to their glycoprotein counterparts. Since chemical synthesis does not involve the use of human- or animalderived materials (from urinary origin or serum required for recombinant protein expression), the danger of viral contamination or transmissible spongiform encephalopathy would be eliminated. The risk for ovarian hyperstimulation syndrome that is associated with the long half-life of CG may also be reduced. Conversely, antagonists of the LHR and/or FSHR may also prove to be valuable as additions to the currently available palette of contraceptive methods. The discovery and development of non-peptide, orally available LHR or FSHR antagonists would open the way to innovative non-steroidal and gonad-specific contraceptive methods. In a review by Guo in 2005 [2], an excellent assessment of non-peptide ligands for the gonadotropin receptors was presented. In 2008, Heitman and IJzerman [3] reviewed the literature on ligands for the hypothalamicpituitary-gonadal axis with selective coverage of the patent literature related to FSHR ligands. The current review will briefly summarize the patent literature on gonadotropin ligands up to 2005 and new literature on compound classes and biological data that has appeared during the past 3–4 years.
2. NON-PEPTIDE SMALL MOLECULE GONADOTROPIN RECEPTOR LIGANDS The discovery of LMW agonists for G-protein-coupled receptors (GPCRs) that are normally activated by large proteins has met with limited success. Attempts to mimic the action of FSH with small peptide-like molecules have turned out to be unsuccessful [4]. Non-peptide antagonists for peptide-binding GPCRs are more often documented in literature. Since the late 1990s, several breakthrough starting points for both non-peptide agonists and antagonists of the gonadotropin receptors have emerged as a result of high-throughput screening. However, optimization of these initial hits into suitable drug candidates has proven to be a challenging task. Several factors are responsible for this, the most
174
Nicole van Straten and Marco Timmers
important of which is the difficulty in reducing lipophilicity while retaining potency. The relatively high lipophilicity reflects the assumed binding mode of these non-peptide ligands. Whereas the endogenous ligand is known to bind to the large extracellular domain of the receptor, which is hydrophilic in nature, LMW compounds are believed to bind to the lipophilic transmembrane domain of the receptor [5,6].
2.1 LHR agonists To date, two distinct classes of LHR agonists have been reported in the literature. This low number can partly be explained by the difficulty in finding non-peptide agonists for protein-binding GPCRs. On the contrary, LHR ligands have applications in limited market segments that are currently explored only by a relatively small number of laboratories. 1 R = OMe (Org 41841) R 2R=
H N N
NH2
O
O
N S
S
N
H N
HN
3R=
N O
O
N
(Org 43553) O
OH
N
NH N NH2
O
N O
N
N H
O
NH2
OH
N
4
5
The first compound class is characterized by a bicyclic thieno-[2,3-d]pyrimidine scaffold in 2000 [7]. Org 41841 (1, human LHR: EC50 ¼ 20 nM)
Non-Peptide Ligands for the Gonadotropin Receptors
175
was reported as the first orally active LMW agonist of the LHR. A model where immature mice were primed with FSH and then treated with Org 41841 resulted in ovulation in 40% of the animals at a dose of 50 mg/kg [8]. It was established that replacement of the pyrimidine scaffold by a pyridine scaffold was tolerated, as was substitution of the five-membered thiophene ring by a six-membered ring (4) [9]. Moreover, the thiophene ring could be replaced by a furan or pyrrole moiety. Methylation of the t-butylamide functionality was reported to yield a combined LHR/TSH receptor (TSHR) agonist [10]. Using a model of the Org 41841/TSHR complex, Org 41841 was later used as a starting point to identify TSHR antagonists in a rational design approach [11]. Lead optimization of Org 41841 yielded Org 43553 (2, human LHR: EC50 ¼ 3.7 nM), in which the –NH2 substituent of the 4-phenyl group is derivatized as a morphilinoacetamide [12]. 3H-labelled Org 43553 was used to assess the relationship between LHR binding affinity (Ki) and functional activity (EC50) of a series of related analogues, which was found to be linear [13]. Org 43553 was active in an ex vivo proof-ofprinciple ovulation induction assay and showed promising pharmacokinetic properties (rat, p.o.: Cmax ¼ 3.8 mg/L, T1/2 ¼ 4.5 h, F ¼ 79%). It is the first compound reported to induce complete ovulation in cyclic rats after single-dose oral administration. Fertilization of the Org 43553induced oocytes resulted in normal implantation of healthy embryos [14]. Based on its in vivo activity and bioavailability, Org 43553 was selected as a development candidate and progressed into phase 1 clinical studies. Interestingly, Org 43553 was reported to have some FSHR agonistic activity (human FSHR: EC50 ¼ 110 nM) in addition to its LHR agonistic activity. This phenomenon was further exemplified in so-called open chain analogues such as 3 (human LHR: EC50 ¼ 2.7 nM, human FSHR: EC50 ¼ 5.7 nM) [15]. A series of 1-phenylpyrazoles was disclosed in 2001 [16]. Solid-phase synthesis of focused libraries around the original hit and subsequent lead optimization yielded compound 5 (human LHR: EC50 ¼ 20 nM). When administered intraperitoneally, 5 induced increased testosterone levels in male rats in a dose-dependent manner [17]. As with the thieno[2,3-d] pyrimidine series, the pyrazoles also showed activity at the FSHR (human FSHR: EC50 ¼ 62 nM).
2.2 LHR antagonists A set of previously disclosed compounds, some of which are also phosphodiesterase inhibitors, were claimed as LHR antagonists for the treatment of estrogen deficiencies. Contraceptive applications were also claimed, but no pharmacological data were presented to support this [18].
176
Nicole van Straten and Marco Timmers
2.3 FSHR agonists In the field of non-peptide FSHR agonists, significantly more literature on discrete compound classes has appeared when compared to the nonpeptide LHR agonists. Piperidinecarboxamide 6, which was claimed for infertility treatment, was the first FSH mimetic described (human FSHR: EC50 ¼ 3.9 nM). Compound 6 induced estradiol production in a primary rat granulosa cell assay (EC50 ¼ 1.2 mM). No pharmacokinetic or in vivo efficacy data were revealed [19]. A series of 5-alkylated thiazolidinones displayed FSHR agonistic activity [20]. The thiazolidinone derivatives were prepared using solid-phase combinatorial chemistry methods [21]. A major drawback of structure 7 (human FSHR: EC50 ¼ 14 nM) proved to be the lack of control over the relative stereochemistry at the 2- and 5-positions of the thiazolidinone ring during synthesis. Furthermore, this compound was prone to isomerization after chiral purification, possibly caused by the activated hydrogen at position 5. To overcome the chemical instability, a methyl group was introduced at position 5 [22], furnishing compound 8 (human FSHR: EC50 ¼ 51 nM). In a second stabilization approach, the thiazolidinone scaffold was replaced by a g-lactam unit [23], exemplified by compound 9 (human FSHR: EC50 ¼ 25 nM). These compounds were shown to interact within the seven-transmembrane region of the FSHR in studies using FSH/TSH receptor chimeras [24]. O H N
N O O
R H N
N
H2N
X O
O
O
O O
N
O
O
6
7 X = S, R = H 8 X = S, R = CH3 9 X = CH2, R = CH3
R1 R2
O
N R3
N N
H N
N O
O
S
N
OO
N
S
10 R1 = R2 = R3 = OMe
12 N
11 R1 = R2 = H, R3 = O
N H
N
177
Non-Peptide Ligands for the Gonadotropin Receptors
Optimization of a micromolar hit obtained from high-throughput screening of an encoded combinatorial library of diketopiperazines yielded biaryl derivatives 10 and 11 as leads [25,26]. Trimethoxy derivative 10 and aminomethylurea 11 were reported to activate the FSHR with EC50 values of 13 and 1.2 nM respectively. The compounds were claimed for use in controlling fertility, for contraception or for treatment of hormone-dependent disorders [27].
O N O CF3 H 2N H N
N O
O
N
13
O
14
O N
S N S
N N O
N N
NH
15
N-Alkylated sulfonylpiperazines such as compound 12 were claimed as FSHR agonists (human FSHR: EC50 ¼ 13 nM), useful for the treatment of infertility [28]. In 2003, tetrahydroquinoline 13 (human FSHR: EC50 ¼ 4.4 mM) was identified in a screening campaign [29,30]. It is noteworthy to mention that hit optimization resulted in an agonist-toantagonist switch. Derivatization of the 6-amino substituent with lipophilic groups resulted in FSHR antagonists with IC50 values as low
178
Nicole van Straten and Marco Timmers
as 5 nM [30]. Depending on the nature of the 6-amino substituent and on the substituent on the phenyl ring at position 4 (see, e.g., compound 14), analogues showed partial agonistic or partial antagonistic activity with EC50 or IC50 values of less than 100 nM [31,32]. Since the various representatives in this series appear to be able to activate and/or inactivate the receptor, they were claimed for use in fertility regulation, including both infertility treatment and contraception. A series of thiazolyl-isoxazoles such as 15 (human FSHR: EC50 ¼ 1.1 mM) were claimed in a patent application for the treatment of infertility and related disorders [33]. In 2005 and 2006, a series of richly decorated hexahydroquinolines was claimed for the treatment of infertility disorders including COS and in vitro fertilization procedures. Compounds of this series such as 16 were described to have FSHR IC50s of less than 1 nM [34]. A Hantzschtype cyclocondensation reaction was used for the preparation of analogues in this series resulting in a mixture of four diastereoisomers that could be separated using a chiral auxiliary [35]. For example, compound 17 (human FSHR: EC50o1 nM) was obtained in 99.2% diastereomeric excess.
F OMe
F O S N H
O MeO
O OMe
O
Br
O
O CN
CN
N H 16
O
N H 17
In an attempt to reduce the lipophilicity of compounds within this series, pyridyl- and sulfonamide-substituted hexahydroquinolines such as 18 (human FSHR: EC50o10 nM) were prepared [36]. Substitution of a phenyl ring with a less lipophilic aliphatic sulfonamide was also tolerated (19, human FSHR: EC50o10 nM) [37].
179
Non-Peptide Ligands for the Gonadotropin Receptors
O N
HN
O S NH
O
H N
Br
Br
S O
O
O
O
O CN
CN
N H
N H
18
19
2.4 FSHR antagonists In 1992, suramine was reported to inhibit binding of FSH to its receptor [38]. Since suramin is a large heavily sulfonated compound and a notoriously promiscuous binder to a plethora of (glyco)proteins, it is not suitable for use as a non-hormonal gonad-specific contraceptive method. Still, it was the starting point for a more selective FSHR antagonistic sulfonic acid series [39,40]. Although stilbene bis-sulfonic acid 20 was only active in the micromolar range in an in vitro cAMP (cyclic AMP, adenosine 3’, 5’-cyclic monophosphate) assay (human FSHR: IC50 ¼ 1.3 mM), it turned out to be equipotent in an in vitro proof-of-principle assay using human granulosa cells (IC50 ¼ 2.7 mM) [41]. In contrast to other non-peptide ligands of the gonadotropin receptors, stilbene 20 was able to inhibit binding of 125 I-labelled human FSH to the truncated extracellular domain of the human FSHR [42], indicating that this relatively hydrophilic compound may exert its biological action by binding to the extracellular part of the receptor. SMe HO3S
O
H N
O S O O
N
N
O O
S O
N H
SO3H
O
MeS 20
It is known that within a single structural class, both FSHR agonists and FSHR antagonists can be identified, depending on the nature of their
180
Nicole van Straten and Marco Timmers
pharmacophores. This phenomenon can be seen in the thiazolidinone series [43], where compound 21 (human FSHR: IC50 o11 mM) showed antagonistic properties, as opposed to the earlier mentioned analogues 7–9 that showed agonist activity. This can also be seen in the tetrahydroquinoline series (see FSHR agonist 13 and 14). Derivative 22 was reported to be a FSHR antagonist (human FSHR: IC50 ¼ 28 nM), active in an ex vivo mouse follicle culture model, in which it significantly inhibited follicle growth, resulting in 78% inhibition of ovulation [30]. O H N
N
H2N
S
H N
O
H N
O
O
S
N O
21
22
The biphenyl FSHR pharmacophore present in the tetrahydroquinolines (22), diketopiperazines (10) and thiazolyl-isoxazoles (15) is also an essential element of aminoalkylamide FSHR antagonists exemplified by compound 23 (human FSHR: IC50 ¼ 40 nM) [44]. This compound inhibited cAMP production in primary rat granolusa cells (IC50 ¼ 20 nM), and its in vivo effects on progesterone levels in female cyclic rats (p.o. dosing, 20 mg/kg BID) and on the number of sperm cells in the testes of male rats were measured (p.o. dosing, 20 mg/kg BID for 25 days). The series was claimed for contraceptive use and reproductive disorders such as endometriosis, uterine fibroids, polycystic ovary syndrome and breast and ovarian cancers. N H N
O NH2
O N
H N
O S
N Cl N
NH
O O
23
24
N H
OH
181
Non-Peptide Ligands for the Gonadotropin Receptors
Pyrrolobenzodiazepines have also been claimed as FSHR antagonists for contraception [45–48]. Here, again, the biphenyl unit is present as an important pharmacophore element. Compound 24 was found to inhibit cAMP production (human FSHR: IC50 ¼ 70 nM), but in vitro or in vivo efficacy data were not provided. It is of interest to note that the same structural core is present in a series of oxytocin receptor antagonists earlier claimed by the same research group [49]. Acyltryptophanols such as compound 25 were claimed as FSHR antagonists for control of fertility in both men and women or for the prevention and/or treatment of osteoporosis [50]. Inhibition of cAMP production by 25 was reported to be in the submicromolar range (25, human FSHR: IC50 ¼ 100 nM).
OMe OH
25 R1 = nBu-CN, R2 = H, X =
F
R1 N NH X O
26 R1 = Et, R2 = O-iPr, X = R2
OMe
It is tempting to classify the biphenyl substituent in the acyltryptophanol series as another example of this frequently observed substructure in FSHR antagonists. However, it was shown [51] that separation of the two phenyl units by an acetylene linkage provided nanomolar active compounds, demonstrated by 26 (human FSHR: IC50 ¼ 20 nM). In the acetylene series, non-aromatic substituents were also tolerated [52]. Furthermore, it was established that the hydroxymethyl group could be replaced by a cyanomethyl group [53] and that a-substitution of the tryptophanol entity was tolerated [54]. Given the lipophilicity of the compounds, it is likely that representatives from this series bind to the seven helical transmembrane domain of the receptor. The plasticity of the transmembrane part of the receptor is illustrated by structures 27–29. Incorporation of a tetrahydroisoquinoline substituent (27, human FSHR: IC50 ¼ 6 nM) [55], a chromene core (28, human FSHR: IC50 ¼ 14 nM) [56,57] or a tetrahydrocarbazole group (29, human FSHR: IC50 ¼ 70 nM) [58,59] are well tolerated. Interestingly, the indole moiety seems to be the optimal FSHR pharmacophore [60]. No in vivo efficacy data has been reported for these acyltryptophanols.
182
Nicole van Straten and Marco Timmers
H N
F
H N
NH
NH
HO
NH
HO
O
O
O
HO O
O
NH O
F
HN O
HN O
27
28
HN
Cl O 29
3. THERAPEUTIC INDICATIONS AND CLINICAL FINDINGS 3.1 Infertility Infertility is generally defined as ‘the inability to conceive after 12 months of having regular unprotected sexual intercourse’. Women reach their maximum ability to conceive around the age of 24, while the average age of women seeking medical help to conceive is 32. Today 1 out of 6 couples of reproductive age experiences fertility problems [61]. A substantial percentage (10–15%) of infertility is unexplained, but known causes in women are of hormonal (oligo- or amennorhoea) and tubal (blocked fallopian tubes) origin and are related to age. Female infertility is often the result of a disorder of the reproductive tract such as endometriosis, polycystic ovarian syndrome or uterine fibroids. Tubal and pelvic pathology is responsible for 30% of female infertility, and ovulatory dysfunction affects 20% of the patient population. Although male infertility accounts for the remaining 35% of all infertility cases, treatment is focused on the female. This may be explained by the development of novel fertilization techniques, such as intracytosolic sperm injection, allowing in vitro fertilization by male partners with low sperm count and/or mobility. Infertility treatment does not aim at solving the cause of infertility (if known) but rather focuses on ART to become pregnant. Several forms of ART are available
Non-Peptide Ligands for the Gonadotropin Receptors
183
to help couples. In the first instance, anti-estrogens, such as clomiphene citrate, may be used to accomplish ovulation induction. A second-line option is the use of gonadotropins for ovulation induction. This can be followed by intrauterine insemination to instigate a natural, monofollicular conception. To establish multifollicular fertilization in the laboratory, gonadotropins are used for COS and subsequent in vitro fertilization, after which one or more embryos are transferred. The fertility market is growing, and the recombinant and urinary gonadotropins account for the majority of sales. It is envisaged that replacement of these agents by orally active LMW mimics will improve patient convenience and even compliance, reduce the risk of side effects, improve the ‘time-to-pregnancy’ and ultimately may lead to higher ‘takehome-baby-rates’. The current success rates for IVF treatment are about 30%, which represents a major need for improvement. On the contrary, scientific developments in human reproductive biology and medicine have the potential to positively affect pregnancy outcomes [62]. Potential additional indications for LMW LHR and FSHR agonists include male indications such as male infertility, late onset hypogonadism in elderly men, and delayed puberty and mal-descendent testes in boys. Since the majority of the LMW non-peptide agonists for the gonadotropin receptors have only been identified in the past decade, almost no clinical data are available. Moreover, for those in development, clinical proof-of-concept has yet to be reported. For LHR agonist Org 43553 (2), phase I clinical data have been published [63]. Tolerability and pharmacokinetic effects of Org 43553 were assessed in sterilized women of reproductive age following single oral administration of seven escalating doses (5–2,700 mg). Mean elimination half-life varied between 30 h and 47 h, and exposure was dose proportional up to 1,800 mg. Pharmacodynamic evaluation included progesterone measurements and ultrasound to confirm ovulation. Ovulation was observed in 83 and 75% of the women in the 300 and 900 mg groups respectively. No serious adverse events occurred and those reported were mild in severity.
3.2 Contraception and disorders of the reproductive tract In principle, all women of reproductive age are potential users of contraceptive agents. In the western world, there is high penetration of contraceptives in the target population but a declining number of women of childbearing age. Special attention is needed for the developing countries, where thousands of maternal deaths are related to unintended pregnancies every year [64]. The significant population growth in the developing world further emphasizes the importance of broadly available and effective contraceptive methods.
184
Nicole van Straten and Marco Timmers
Female contraception includes core benefits related to pregnancy prevention (the need for which is well met), menstruation disorders and menstruation management. Current contraception methods rely on the prevention of follicle maturation, ovulation and implantation by the action of estrogenic and/or progestagenic steroids [65]. The active pharmaceutical ingredients can be delivered orally, as in the contraceptive pill, or through alternative routes. Most recent advances are developments of new delivery systems such as intrauterine devices [66], vaginal ring [67] or implantable polymeric rod [68,69] containing known steroidal compounds. Several non-steroidal progestins have been reported in the literature [70], and one non-steroidal progestin has thus far progressed into clinical development [71]. The only effective contraceptive in the marketplace still relies on the administration of steroidal drugs. The impact of genomics and proteomics for the discovery of new, validated non-steroidal targets for female contraception is still in the discovery stage [72]. A second drawback is the fact that currently available contraception methods are solely available for women. A safe, 100% effective male contraceptive is regarded as desirable [73]; yet, no male contraceptive pill is on the market. As more and more knowledge of the genes involved in male fertility is generated, new opportunities for male contraception may arise. The currently available palette of male fertility-associated genes may contain good target candidates for discovery of male contraceptives [74]. Thus far, the most obvious and well-validated target in this respect is the FSHR, since mutations may lead to subinfertility or complete infertility in men [75]. Vaccination against FSH-b chain leads to infertility in male primates [76], supporting the concept that the FSHR is a validated target for male contraception. In this light, the discovery of orally available non-peptide antagonists for the gonadotropin receptors may be a novel alternative to contraceptive steroids. Such a discovery would open the way for a new, non-steroidal, gonad-specific approach for contraception in both women and men. Furthermore, numerous disorders of the female reproductive tract are estrogen-related. Since the action of FSH at its receptor influences the levels of estrogens, it is suggested that FSHR antagonists may become valuable drugs to treat, for example, endometriosis, uterine fibroids, polycystic ovarian syndrome and even hormone-dependent breast cancer and ovarian cancer. These assumptions remain speculative since none of the published gonadotropin receptor antagonists has progressed into clinical development.
4. CONCLUSIONS AND FUTURE PROSPECTS The pioneering work in the late 1990s to find non-peptide ligands for protein-binding gonadotropin receptors using high-throughput
Non-Peptide Ligands for the Gonadotropin Receptors
185
screening technologies has induced a paradigm shift in the science of reproduction. Small heterocyclic molecules were identified that completely mimic the action of the endogenous glycoproteins but effect cellular signaling through allosteric receptor-binding sites. At the same time, turning these interesting starting points into bioavailable drug candidates presents a challenging task that requires years of intensive optimization. The past 4–5 years have yielded several new interesting series of LMW ligands for both the LHR and the FSHR that show promise as drug candidates. For LHR agonists, clinical results with Org 43553 indicate that it is possible to mimic the action of the endogenous hormone with an orally available small molecule drug candidate. Although ovulation induction can be regarded as proof of principle, it remains to be established whether this will indeed result in the ultimate proof of concept, for example, induction of pregnancy and live birth. FSHR agonists and antagonists are still early in the clinical development process. Whereas for the LHR agonists in vivo activity has been confirmed in both animal models and humans, translation of the available in vitro and ex vivo results for the FSHR ligands to more relevant animal and clinical models is still a subject of discovery research. In summary, strategies employing screening of large chemical libraries and subsequent hit and lead optimization have resulted in the identification of new chemical entities that mimic or modulate the activity of endogenous gonadotropins. The availability of orally active drugs for the gonadotropin receptors will certainly be of great added value to the current portfolio of parenteral infertility drugs and hormonal, non-gonad-specific contraceptives. The coming decade will reveal whether these scientific promises can be realized.
REFERENCES [1] [2] [3] [4] [5]
[6] [7] [8]
[9]
J. G. Pierce and T. F. Parsons, Ann. Rev. Biochem., 1981, 50, 465. T. Guo, Expert Opin. Ther. Patents, 2005, 15, 1555. L. H. Heitman and A. P. IJzerman, Med. Res. Reviews, 2008, 28, 975. M. Hage-van Noort, W. C. Puijk and R. H. Meloen, WO Patent Application 1992/02542, 1992. C. J. van Koppen, G. J. R. Zaman, C. M. Timmers, J. Kelder, S. Mosselman, R. v. d. Lagemaat, M. J. Smit and R. G. J. M. Hanssen, Naunyn Schmiedeberg’s Arch. Pharmacol., 2008, 378, 503. B. J. Arey, Endocrine, 2008, 34, 1. G. G. Gerritsma, N. C. R. van Straten and A. E. P. Adang, WO Patent Application 2000/ 61586, 2000. N. C. R. van Straten, G. G. Schoonus-Gerritsma, R. G. van Someren, J. Draaijer, A. E. P. Adang, C. M. Timmers, R. G. J. M. Hanssen and C. A. A. van Boeckel, ChemBioChem, 2002, 210, 1023. C. M. Timmers and W. F. J. Karstens, WO Patent Application 2002/24703, 2002.
186
Nicole van Straten and Marco Timmers
[10] M. C. Gershengorn, S. Neumann, C. Thomas, H. Jaeschke, S. Moore, G. Krause, B. Raaka and R. Paschke, WO Patent Application 2007/136776, 2007. [11] S. Neumann, G. Kleinau, S. Costanzi, S. Moore, J. K. Jiang, B. M. Raaka, C. J. Thomas, G. Krause and M. C. Gershengorn, Endocrinology, 2008, 149, 5945. [12] R. G. J. M. Hanssen and C. M. Timmers, WO Patent Application 2003/020726, 2003. [13] L. H. Heitman, J. Oosterom, K. M. Bonger, C. M. Timmers, P. H. G. Wiegerinck and A. P. IJzerman, Mol. Pharm., 2008, 73, 518. [14] R. v. d. Lagemaat, C. M. Timmers, J. Kelder, C. van Koppen, S. Mosselman and R. G. J. M. Hanssen, Hum. Reprod., 2009, 24, 640. [15] R. G. J. M. Hanssen, C. M. Timmers and J. Kelder, WO Patent Application 2003/020727, 2003. [16] H. Shroff, A. P. Reddy, N. El Tayer, N. Brugger and C. Jorand-Lebrun, WO Patent Application 2001/87287, 2001. [17] C. Jorand-Lebrun, B. Brondyk, J. Ling, S. Magar, R. Murray, A. Reddy, H. Shroff, G. Wands, W. Weiser, Q. Xu, S. McKenna and N. Brugger, Bioorg. Med. Chem. Lett., 2007, 17, 2080. [18] C. Grøndahl, WO Patent Application 1999/20223, 1999. [19] N. El tayer, A. Reddy, D. Buckler and S. Magar, WO Patent Application 2000/08015, 2000. [20] R. A. Scheuerman, S. D. Yanofsky, C. P. Holmes, D. Maclean, B. Ruhland, R. W. Barrett, J. E. Wrobel, W. Kao, A. Gopalsamy and F. Sum, WO Patent Application 2002/09706, 2002. [21] D. MacLean, F. Holden, A. M. Davis, R. A. Scheuerman, S. Yanofsky, C. P. Holmes, W. L. Fitch, K. Tsutsui, R. W. Barrett and M. A. Gallop, J. Comb. Chem., 2004, 6, 196. [22] J. Wrobel, J. Jetter, W. Kao, J. Rogers, L. Di, J. Chi, M. C. Pere´z, G.-C. Chen and E. S. Shen, Bioorg. Med. Chem., 2006, 14, 5729. [23] J. C. Pelletier, J. Rogers, J. Wrobel, M. C. Pere´z and E. S. Chen, Bioorg. Med. Chem., 2005, 13, 5986. [24] S. D. Yanofsky, E. S. Shen, F. Holden, E. Whitehorn, B. Aguilar, E. Tate, C. P. Holmes, R. Scheuerman, D. MacLean, M. M. Wu, D. E. Frail, F. J. Lo´pez, R. Winneker, B. J. Arey and R. W. Barrett, J. Biol. Chem., 2006, 19, 13226. [25] T. Guo, A. E. P. Adang, R. E. Dolle, G. Dong, D. Fitzpatrick, P. Geng, K.-K. Ho, S. G. Kultgen, R. Liu, E. McDonald, B. F. McGuinness, K. W. Saionz, K. J. Valenzano, N. C. R. van Straten, D. Xie and M. L. Webb, Bioorg. Med. Chem. Lett., 2004, 14, 1713. [26] T. Guo, A. E. P. Adang, G. Dong, D. Fitzpatrick, P. Geng, K.-K. Ho, C. H. Jilibian, S. G. Kultgen, R. Liu, E. McDonald, K. W. Saionz, K. J. Valenzano, N. C. R. van Straten and M. L. Webb, Bioorg. Med. Chem. Lett., 2004, 14, 1717. [27] T. Guo, K.-K. Ho, E. McDonald, R. E. Dolle, K.W. Saionz, S. G. Kultgen, R. Liu, G. Dong, P. Geng, A. E. P. Adang and N. C. R. van Straten, WO Patent Application 2002/070493, 2002. [28] S. Magar, A. Goutopoulos, M. Schwarz and T. J. Russell, WO Patent Application 2004/ 031182, 2004. [29] N. C. R. van Straten, R. G. van Someren and J. Schulz, WO Patent Application 2003/ 004028, 2003. [30] N. C. R. van Straten, T. H. J. van Berkel, D. R. Demont, W. F. J. Karstens, R. Merkx, J. Oosterom, J. Schulz, R. G. van Someren, C. M. Timmers and P. M. van Zandvoort, J. Med. Chem., 2005, 48, 1697. [31] C. M. Timmers and W. F. J. Karstens, WO Patent Application 2004/056779, 2004. [32] C. M. Timmers and W. F. J. Karstens, WO Patent Application 2004/056780, 2004. [33] V. J. Santora, J. A. Covel, R. Hayashi and R. R. Webb, WO Patent Application 2005/ 087765, 2005.
Non-Peptide Ligands for the Gonadotropin Receptors
187
[34] N. C. R. van Straten, G. G. Gerritsma and L. A. van der Veen, WO Patent Application 2006/117023, 2006. [35] P. M. Grima Poveda, W. F. J. Karstens and C. M. Timmers, WO Patent Application 2006/ 117368, 2006. [36] C. M. Timmers, W. F. J. Karstens and P. M. Grima Poveda, WO Patent Application 2006/ 117370, 2006. [37] W. F. J. Karstens and C. M. Timmers, WO Patent Application 2006/117371, 2006. [38] R. L. Daugherty, A. T. K. Cockett, S. R. Schoen and P. M. Sluss, J. Urol., 1992, 147, 727. [39] J. E. Wrobel, J. F. Rogers and W. Kao, WO Patent Application 2000/58276, 2000. [40] J. E. Wrobel, J. F. Rogers, D. M. Green, W. Kao and J. W. Winfield, WO Patent Application 2000/58277, 2000. [41] J. Wrobel, D. Green, J. jetter, W. Kao, J. Rogers, M. C. Pe´rez, J. Hardenburg, D. C. Deecher, F. J. Lo´pez, B. J. Arey and E. S. Shen, Bioorg. Med. Chem., 2002, 10, 639. [42] B. J. Arey, D. C. Deecher, E. S. Shen, P. E. Stevis, E. H. Meade, Jr., J. Wrobel, D. E. Frail and F. J. Lo´pez, Endocrinology, 2002, 143, 3822. [43] R. A. Scheuerman, S. D. Yanofsky, C. P. Holmes, D. Maclean, B. Ruhland, R. W. Barrett, J. E. Wrobel and A. Gopalsamy, WO Patent Application 2002/09705, 2002. [44] S. J. Coats, D. J. Hlasta, C. L. Carolina, M. J. Macielag, R. Rivero, L. J. Fitzpatrick and K. Pan, WO Patent Application 2001/47875, 2001. [45] A. Failli, G. D. Heffernan, A. A. Santilli, D. A. Quagliato, R. D. Coghlan, P. M. Andrae, S. C. Croce, E. S. Shen and E. J. Trybulski, WO Patent Application 2006/135687, 2006. [46] A. A. Failli, D. Quagliato, P. Andrae, G. D. Heffernan, R. D. Coghlan and E. S. Shen, US Patent Application 2006/0199806, 2006. [47] A. A. Failli, A. A. Santilli, D. A. Quagliato and E. S. Shen, US Patent Application 2006/ 0258644, 2006. [48] A. A. Failli, D. A. Quagliato, G. Heffernan, R. D. Coghlan and E. S. Shen, US Patent Application 2006/0258645, 2006. [49] A. A. Failli, J. S. Shumsky, T. J. Caggiano, J. P. Sabatucci, K. A. Memoli and E. J. Trybulski, WO Patent Application 2002/083683, 2002. [50] L. Wortmann, A. Cleve, H. P. Muhn, G. Langer, A. Schrey, R. Ku¨hne, B. Menzenbach, M. Koppitz and D. Kosemund, WO Patent Application 2007/017289, 2007. [51] L. Wortmann, H. P. Muhn, B. Menzenbach, A. Schrey, R. Ku¨hne, D. Kosemund and M. Koppitz, EP Patent Application 1932831A1, 2008. [52] L. Wortmann, M. Koppitz, H.-P. Muhn, T. Frenzel, F. P. Liesener, A. K. Schrey and R. Ku¨hne, WO Patent Application 2009/013333, 2009. [53] L. Wortmann, M. Koppitz, H.-P. Muhn, T. Frenzel, F. P. Liesener, A. K. Schrey and R. Ku¨hne, WO Patent Application 2009/016253, 2009. [54] L. Wortmann, M. Koppitz, H.-P. Muhn, A. K. Schrey and R. Kuehne, WO Patent Application 2009/021980, 2009. [55] L. Wortmann, H. P. Muhn, B. Menzenbach, A. Schrey, R. Ku¨hne, D. Kosemund and M. Koppitz, WO Patent Application 2008/071453, 2008. [56] L. Wortmann, B. Menzenbach, M. Koppitz, D. Kosemund, H. P. Muhn, A. Schrey, R. Ku¨hne, T. Frenzel and F. P. Liesener, WO Patent Application 2008/071455, 2008. [57] L. Wortmann, B. Menzenbach, M. Koppitz, D. Kosemund, H. P. Muhn, A. Schrey, R. Ku¨hne, T. Frenzel and F. P. Liesener, EP Patent Application 1956016A1, 2008. [58] L. Wortmann, M. Koppitz, H. P. Muhn, T. Frenzel, F. P. Liesener, A. Schrey and R. Ku¨hne, WO Patent Application 2008/0116671, 2008. [59] L. Wortmann, M. Koppitz, H. P. Muhn, T. Frenzel, F. P. Liesener, A. Schrey and R. Ku¨hne, EP Patent Application 1975159A1, 2008. [60] L. Wortmann, M. Koppitz, B. Menzenbach, D. Kosemund, N. Schmees, H.-P. Muhn, T. Frenzel, F. P. Liesener, A. K. Schrey and R. Ku¨hne, WO Patent Application 2009/ 013354, 2009.
188 [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76]
Nicole van Straten and Marco Timmers
Datamonitor, Commercial and pipeline insight: Infertility, October, 2007. M. M. Matzuk and D. J. Lamb, Nat. Med., 2008, 14, 1197. B. Mannaerts, in Proc. 4th World Congress on Ovulation (ed. M. Filicori), p. 157. Global Health Council, 2008, http://www.globalhealth.org/view_top.php3?id ¼ 225. M. A. Economidis and D. R. Mishell, Jr., Exp. Opin. Invest. Drugs, 2005, 14, 449. ESHRE Capri Workshop Group., Hum. Reprod. Update, 2008, 14, 197. F. J. M. E. Roumen, D. Apter, T. M. T. Mulders and T. O. M. Dieben, Human Reprod, 2001, 16, 469. H. B. Croxatto, Contraception, 2002, 65, 15. O. Graesslin and T. Korver, Eur. J. Contracept. Reprod. Health Care, 2008, 13(S1), 4. P. H. H. Hermkens, S. Kamp, S. Lusher and G. H. Veeneman, IDrugs, 2006, 9, 488. J. Bapst, G. Orczyk and J. Ermer, Clin. Pharm. Ther., 2005, 77(Suppl. S(44)). R. J. Aitken, M. A. Baker, G. F. Doncel, M. M. Matzuk, C. K. Mauck and M. J. K. Harper, J. Clin. Invest., 2008, 118, 1330. S. T. Page, J. K. Amory and W. J. Bremmer, Endocrine Rev, 2008, 29, 465. M. M. Matzuk and D. J. Lamb, Nat. Med, 2002, 8, S1–S49. I. Huhtaniemi, J. Reprod. Fert., 2000, 119, 173. N. R. Moughdal, M. Jeyakumar, H. N. Krishnamurthy, S. Sridhar, H. Krishnamurthy and F. Martin, Hum. Reprod. Update, 1997, 3, 335.
CHAPT ER
9 Recent Advances in Coagulation Serine Protease Inhibitors Joanne M. Smallheer and Mimi L. Quan
Contents
1. Introduction 2. Factor Xa Inhibitors 2.1 Compounds in late-stage clinical trials 2.2 Compounds in early clinical trials 2.3 Preclinical compounds 3. Thrombin Inhibitors 3.1 Compounds in clinical trials 3.2 Preclinical compounds 3.3 Dual thrombin/factor Xa inhibitors 4. Factor VIIa/TF Inhibitors 5. Factor IXa and XIa Inhibitors 6. Conclusions References
189 190 190 192 193 195 195 196 198 199 201 203 203
1. INTRODUCTION As orally bioavailable thrombin and factor Xa inhibitors advance through late-stage clinical trials and begin to gain regulatory approvals, a new era in treatment options for thromboembolic disorders may be on the horizon [1–3]. It is thought that these new highly selective inhibitors may eliminate food and drug–drug interactions and obviate the need Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543 Annual Reports in Medicinal Chemistry, Volume 44 ISSN: 0065-7743, DOI 10.1016/S0065-7743(09)04409-1
r 2009 Elsevier Inc. All rights reserved.
189
190
Joanne M. Smallheer and Mimi L. Quan
for therapeutic monitoring and dose titration that go hand-in-hand with current oral anticoagulant therapy with warfarin [4]. In addition to thrombin and factor Xa inhibitors, research continues to identify potential new therapeutic agents that target other key serine proteases in the coagulation cascade. This review will summarize recent results for several compounds in clinical trials and survey new small-molecule inhibitors reported in the literature over the past 2–3 years.
2. FACTOR Xa INHIBITORS Factor Xa has been a major focus of pharmaceutical research directed at novel antithrombotics during the past decade because of its central and unique position in the coagulation cascade. Factor Xa is a serine protease located at the junction of the intrinsic and extrinsic pathways, and its inhibition is considered to be an ideal approach to achieve strong efficacy and an improved therapeutic index compared to current therapies. Significant progress has been made in the discovery and development of orally bioavailable small-molecule factor Xa inhibitors. A few inhibitors have been advanced to phase III clinical studies, and the first factor Xa inhibitor was recently approved in Europe and Canada for the prophylaxis of venous thromboembolism (VTE) in patients after elective hip and knee replacement. Several comprehensive reviews have been published on Factor Xa inhibitors [5–7].
2.1 Compounds in late-stage clinical trials Rivaroxaban (BAY 59-7939, 1) is an oxazolidinone derivative with a Xa Ki of 0.4 nM and W10,000-fold selectivity against other related serine proteases [8]. The oral bioavailability of rivaroxaban was found to be 57–66% in rats and 60–86% in dogs with a relatively short half-life (2.3 and 0.9 h, respectively) in both species [9]. In rabbit models of thrombosis, rivaroxaban was effective in prevention and treatment of venous thrombosis [10]. In clinical studies, rivaroxaban was rapidly absorbed and displayed an oral bioavailability of 80% and a half-life of 5–9 h [11]. In a series of phase IIb studies, a range of rivaroxaban doses were found to have efficacy similar to that of standard treatment [12]. The efficacy and safety data from four phase III studies, including two randomized doubleblind trials in patients undergoing total knee arthroplasty, and two trials in patients after hip arthroplasty, have been published [13–16]. Rivaroxaban has been approved in the EU and Canada for the above indications. Phase III trials in chronic indications are ongoing, including treatment of VTE, stroke prevention in patients with atrial fibrillation (AF), and secondary prevention of acute coronary syndrome (ACS).
191
Recent Advances in Coagulation Serine Protease Inhibitors O Cl
S
HN
N O
O
N N
N
N
O
N
O HN
O NH HN
O
O
1
CONMe2
Cl
H2NOC
N O
O
S N NMe
OMe
2
3
Apixaban (BMS-562247, 2) is a second-generation pyrazole-based Xa inhibitor derived from an earlier clinical candidate, razaxaban [17]. The core structures differ in that the pyrazole ring of razaxaban is cyclized onto the amide nitrogen to form the apixaban bicyclic core [18]. Apixaban is a potent and selective Xa inhibitor with a Xa Ki of 0.08 nM and W30,000-fold selectivity over other relevant proteases. It has an excellent pharmacokinetic (PK) profile in dogs with low clearance (0.02 L/kg/h) and a low volume of distribution (0.2 L/kg). Apixaban is effective in rabbit models of thrombosis alone or in combination with aspirin, or aspirin and clopidogrel, without excessive increases in bleeding time [19,20]. Initial studies in humans suggest that apixaban is safe and well tolerated [21] and is rapidly absorbed, with a mean elimination half-life of 8–15 h and an oral bioavailability of 66% [22]. In phase II studies in patients with total knee replacement or for treatment of proximal deep vein thrombosis (DVT), apixaban had efficacy and safety similar to that of standard therapy [23,24]. Both indications are being evaluated in phase III studies, and data from one phase III trial in patients undergoing knee replacement surgery has been presented [25]. Phase II studies have also been completed in patients with recent ACS [26], and for prevention of thromboembolic events in patients with advanced cancer. Additional phase III trials are ongoing for treatment of VTE, stroke prevention in AF, and secondary prevention of ACS. The structure of edoxaban (DU-176b, 3) contains an N,N-dimethylcyclohexane carboxamide scaffold and has a chloropyridine moiety at the P1 position. Edoxaban is a potent and selective Xa inhibitor with a Ki of 0.56 nM and W10,000-fold selectivity over other relevant serine proteases [27]. Edoxaban was shown to produce a dose-dependent inhibition of thrombus formation in rat and rabbit models of thrombosis and did not significantly prolong bleeding time at an antithrombotic dose. Preliminary results from a phase II study show that edoxaban was superior to dalteparin in patients with total hip replacement in terms of incidence of VTE, with little bleeding, and could be dosed once daily [28]. In patients with total knee replacement, edoxaban produced a significant, dosedependent reduction in VTE [29]. A phase II trial of edoxaban in patients with AF showed a similar safety profile with once daily dosing compared
192
Joanne M. Smallheer and Mimi L. Quan
to standard treatment with warfarin [30]. A phase III trial in AF patients was initiated in early 2009.
2.2 Compounds in early clinical trials Eribaxaban (PD 0348292, 4) has a Xa IC50 of 0.32 nM with W1,000-fold selectivity over relevant serine proteases [31]. The oral bioavailability and half-life were 82% and 2.0 h in rats, and 41% and 4.9 h in dogs. Clearance in rats and dogs was 12 and 2.6 mL/kg/min, respectively. Eribaxaban showed a dose-dependent reduction in thrombus weight with an EC50 of 40 ng/mL in the rabbit arteriovenous (A-V) shunt model. A dose-ranging study to determine a dose of eribaxaban equivalent to enoxaparin 30 mg b.i.d. for prevention of VTE in patients undergoing total knee replacement has been completed [32]. Betrixaban (PRT54021, 5) has a Xa Ki of 0.12 nM with W86,000-fold selectivity against related serine proteases [33]. Oral bioavailability and half-life, respectively, were 24% and 8.8 h in rats, 52% and 21.2 h in dogs, and 59% and 9.6 h in monkeys. The antithrombotic efficacy of betrixaban was studied in rabbit, rat, and baboon thrombosis models to determine the target concentration required for clinical trials [34]. Early clinical studies showed that betrixaban was well tolerated across a wide range of doses. A phase II open-label VTE prevention trial showed that betrixaban was effective in preventing VTE after total knee replacement surgery [35]. A phase II trial for prevention of thromboembolic complications in patients with AF has been initiated. LY517717 (6, Xa KiB6 nM; 1,000-fold selectivity over related serine proteases) was non-inferior to enoxaparin in a phase II trial for prevention of VTE after hip or knee replacement surgery and showed similar rates of bleeding [36,37]. YM150 (Xa Ki ¼ 31 nM; low micromolar affinity for other relevant serine proteases), whose structure was not disclosed, is also in multiple phase II trials [38]. In a dose escalation study for VTE in patients undergoing hip replacement surgery, YM150 was effective, safe, and well-tolerated [39]. TAK-442 is another orally bioavailable Xa inhibitor currently in phase II clinical trials, but neither the structure nor any trial results have been disclosed.
MeO
H N N
HN
O O
MeO
F N
N H HN
NH
O N
N
4
5 Cl
Cl
N
O
O
H N
N
O
N N H
O
6
193
Recent Advances in Coagulation Serine Protease Inhibitors
2.3 Preclinical compounds Several series of pyrazole-based inhibitors have been reported. Compound 7 was derived from razaxaban [17] and was designed to prevent the potential formation of a primary aniline by replacing the amide linker with a ketone moiety [40]. Compound 7 has a Xa Ki of 0.11 nM with EC2x values of 5.2 and 5.1 mM in the prothrombin clotting time (PT) and activated partial thromboplastin time (aPTT) assays, respectively. It was found to have lower clearance and higher oral bioavailability in dogs than razaxaban. Compound 8 has a bicyclic core similar to that of apixaban with the P4 group replaced with an a-substituted phenylcyclopropyl moiety [41]. This analog has a Xa Ki of 0.035 nM and PT EC2x of 1.3 mM. Replacement of the fused piperidinone ring of apixaban with fluorophenyl afforded compounds with a 7-fluoroindazole core exemplified by 9, which has a Xa Ki of 4.4 nM and a twofold aPTT EC50 of 4.4 mM [42]. F
H2NOC N
O N
N
O
F3C N
F
H2NOC N N
N
NMe2 O
N
NMe2 N
F NH2
OMe
OMe
7
O N
8
9
Additional Xa inhibitors related to betrixaban possessing the anthranilamide scaffold and a chloropyridine P1 moiety have been reported. This is exemplified by anthranilamide 10, which also employed the P4 piperidinone moiety of apixaban [43]. Compound 10 has a Xa Ki of 0.057 nM and displayed efficacy comparable to that of apixaban in a rabbit A-V shunt thrombosis model. In compound 11 (Xa Ki ¼ 0.005 nM), the P4 phenylpiperidinone of 10 was replaced with a chlorothiophene substituted by a (methylamino(imidazol-1-yl)methyl) moiety [44]. Although this resulted in about a 10-fold improvement in Ki, the PT EC2x values of the two compounds were similar (1.5 mM for 10 and 1.2 mM for 11). Compound 11 has low clearance (4.4 mL/kg/min) and high oral bioavailability (98%) in dogs. The estimated EC50 of 11 in an intravenous (iv) rat vena cava stasis model was 0.36 mg/kg.
N H HN
O
OMe O
Cl
OMe O
Cl
N
S
N H
O HN
O
NHMe Cl
N
N 10 Cl
Cl
11
N
N
194
Joanne M. Smallheer and Mimi L. Quan
Several series of Xa inhibitors have been reported that contain a pyrrolidine core structure and a 5-chlorothiophene P1 moiety similar to that of rivaroxaban. For example, compound 12 has a Xa Ki of 3.0 nM and PT EC2x of 1.7 mM [45]. Compound 13, where a longer linker to the P1 thiophene residue was employed, is comparable in affinity (Xa IC50 ¼ 5.5 nM) [46]. Factor Xa affinity was restored in compound 14 (Kio1 nM) by incorporation of a pyrrolidinone scaffold and the basic biaryl P4 moiety present in razaxaban [47]. This analog showed clearance of 13 mL/kg/min and good oral bioavailability (52%) in rats.
H N Cl
S
H N
N
F O
O O
O
N
S
N
OMe
O
O S N H
N
Cl
12
N
13
Cl S H S N O O
N N
O
O
CH2OH S
O
NMe2
15
N
16
O N
N Me
14
Cl
N O
Cl
N
O
O O S N
F
O O S N
N
F
N
O O S
N
N
N
N N
Cl
O
17
Xa inhibitors containing piperidine and piperazine cores have also been reported. Compound 15 has a chloronaphthyl P1 group appended through a sulfonamide linkage to a 3-aminopiperidinone core to provide a potent inhibitor of Xa (Ki ¼ 0.02 nM) with PT EC2x of 1.7 mM [48]. Substitution on the nitrogen of the sulfonamide improved Xa affinity. The 6-chloronaphthylsulfonyl P1 residue of 15 in combination with a fused spirocyclic core afforded 16 that displayed a Xa IC50 of 1.2 nM [49]. Compound 16 was effective in a rat venous thrombosis model, but was
195
Recent Advances in Coagulation Serine Protease Inhibitors
less efficacious than warfarin. Another series of Xa inhibitors containing a chloronaphthylsulfonyl P1 moiety is exemplified by 17 that has a Xa IC50 of 4.8 nM with PT EC2x value of 1.0 mM and was reported to be orally bioavailable in rats and monkeys [50]. Several edoxaban analogs have been reported as Xa inhibitors. Replacement of the 5-chloropyridine P1 moiety of edoxaban with a 5-chloroindole gave 18 (Xa IC50 ¼ 2.3 nM) resulting in 10-fold loss of Xa affinity [51]. As illustrated by 19 (Xa IC50 ¼ 8.4 nM), it was possible to remove a chiral center and retain most of the Xa affinity by replacement of the cyclohexyl ring with a piperidine [52]. Cyclopentyl compound 20 includes a 4-chlorothiophene at the P1 position and a pyridone as the P4 moiety and has a Xa Ki of 0.43 nM and PT EC2x of 1.7 mM [53]. CONMe2 X O
Cl
N H
N NH H O
O
Cl S N
N
NH
S O
N H
O N 20
18, X = CH (S) 19, X = N
3. THROMBIN INHIBITORS 3.1 Compounds in clinical trials Direct inhibitors of thrombin have been the target of anticoagulant research for many years, based on the key role played by thrombin in the formation of fibrin clots [54,55]. Ximelagatran, 21, was the first orally bioavailable, active site-specific serine protease inhibitor to be approved for human use. A double prodrug, 21 is rapidly converted after oral absorption to melagatran, 22, a potent and selective direct thrombin inhibitor [56]. The data from clinical trials have been extensively reviewed [57,58]. Ximelagatran was approved in Europe in 2003 for the prevention of DVT, but failed to receive approval in the United States due to concerns relating to potential liver toxicity. This toxicity ultimate